

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/010913

International filing date: 31 March 2005 (31.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/559,275
Filing date: 01 April 2004 (01.04.2004)

Date of receipt at the International Bureau: 12 August 2005 (12.08.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1352384

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

August 02, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/559,275

FILING DATE: *April 01, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/10913*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

Abstract of the Disclosure

Provided herein are methods for identifying a risk of osteoarthritis in a subject, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating osteoarthritis, and therapeutic and preventative methods applicable to osteoarthritis. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

Application Data Sheet

Application Information

Application Type::	Provisional
Subject Matter::	Utility
Suggested Group Art Unit::	Not Yet Assigned
CD-ROM or CD-R?::	None
Sequence submission?::	None
Computer Readable Form (CRF)?::	No
Title::	METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF
Attorney Docket Number::	524593009000
Request for Early Publication?::	No
Request for Non-Publication?::	No
Total Drawing Sheets?::	3
Small Entity?::	Yes
Petition included?::	No
Secrecy Order in Parent Appl.?::	No

Applicant Information

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity
Given Name::	Steven
Family Name::	MAH
City of Residence::	San Diego
State or Province of Residence::	CA
Country of Residence::	US
Street of mailing address::	12820 Via Nieve #74
City of mailing address::	San Diego
State or Province of mailing address::	CA

Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor
Primary Citizenship Country:: Germany
Status:: Full Capacity
Given Name:: Andreas
Family Name:: BRAUN
City of Residence:: San Diego
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 3935 Lago Di Grata Circle
City of mailing address:: San Diego
State or Province of mailing address:: CA
Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor
Primary Citizenship Country:: Germany
Status:: Full Capacity
Given Name:: Stefan
Middle Name:: M.
Family Name:: KAMMERER
City of Residence:: San Diego
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 3825 Elijah Court, Unit 334
City of mailing address:: San Diego
State or Province of mailing address:: CA
Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity

Given Name:: Matthew
Middle Name:: Roberts
Family Name:: NELSON
City of Residence:: San Marcos
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 1250 Calle Prospero
City of mailing address:: San Marcos
State or Province of mailing address:: CA
Postal or Zip Code of mailing address:: 92069

Applicant Authority Type:: Inventor
Primary Citizenship Country:: Sweden
Status:: Full Capacity
Given Name:: Rikard
Middle Name:: Henry
Family Name:: RENELAND
City of Residence:: San Diego
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 7555 Charmant Drive, #1114
City of mailing address:: San Diego
State or Province of mailing address:: CA
Postal or Zip Code of mailing address:: 92122

Applicant Authority Type:: Inventor
Primary Citizenship Country:: United Kingdom
Status:: Full Capacity
Given Name:: Maria
Middle Name:: L.
Family Name:: LANGDOWN
City of Residence:: San Diego

State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 3701 Yosemite Street
City of mailing address:: San Diego
State or Province of mailing address:: CA
Postal or Zip Code of mailing address:: 92109

Correspondence Information

Correspondence Customer Number:: 25225

Representative Information

Representative Customer Number:: 25225

What is claimed is:

1. A method for identifying a subject at risk of osteoarthritis, which comprises detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the one or more polymorphic variations are detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-4;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-4;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-4;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c);

whereby the presence of the polymorphic variation is indicative of the subject being at risk of osteoarthritis.

2. The method of claim 1, which further comprises obtaining the nucleic acid sample from the subject.

3. The method of claim 1, wherein the one or more polymorphic variations are detected within a region spanning chromosome positions 102570000 to 102583000 in human genomic DNA.

4. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions selected from the group consisting of 207, 6019, 6414, 7341, 10984, 12351, 13335, 16584, 16737, 23897, 24057, 25145, 25300, 26262, 26312, 26589, 27302, 27358, 27451, 27552, 30731, 32085, 32139, 33184, 42382, 42569, 44823, 45217, 45548, 45601, 45722, 45967, 47367, 47642, 48126, 49218, 49274, 49433, 49610, 51282, 51466, 53757, 53960, 54031, 54574, 55679, 56100, 56182, 59817, 60533, 60656, 72209, 72778, 74293, 77335, 78029, 78374, 78421, 78434, 79174, 79397, 79562, 79700, 79730, 79904, 79920, 79938, 79972, 80125, 80368, 83484, 85536, 85829, 86425, 88083, 88770, 90622, 90924, 91634, 92029, 95152, 95348, 96145, 96793, 97015, 97064, 97711, 97855 and 98708.

5. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions in SEQ ID NO: 1 selected from the group consisting of 6414, 51282, 54574, 78374, 92029 and 96793.

6. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions in linkage disequilibrium with one or more positions in claim 3, 4 or 5.

7. The method of claim 1, wherein detecting the presence or absence of the one or more polymorphic variations comprises:

hybridizing an oligonucleotide to the nucleic acid sample, wherein the oligonucleotide is complementary to a nucleotide sequence in the nucleic acid and hybridizes to a region adjacent to the polymorphic variation;

extending the oligonucleotide in the presence of one or more nucleotides, yielding extension products; and

detecting the presence or absence of a polymorphic variation in the extension products.

8. The method of claim 1, wherein the subject is a human.

9. The method of claim 8, wherein the subject is a human female.

10. The method of claim 8, wherein the subject is a human male.

11. A method for identifying a polymorphic variation associated with osteoarthritis proximal to an incident polymorphic variation associated with osteoarthritis, which comprises:

identifying a polymorphic variation proximal to the incident polymorphic variation associated with osteoarthritis, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-4;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-4;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-4;

(d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation;

determining the presence or absence of an association of the proximal polymorphic variant with osteoarthritis.

12. The method of claim 11, wherein the incident polymorphic variation is at one or more positions in claim 3, 4 or 5.

13. The method of claim 11, wherein the proximal polymorphic variation is within a region between about 5 kb 5' of the incident polymorphic variation and about 5 kb 3' of the incident polymorphic variation.

14. The method of claim 11, which further comprises determining whether the proximal polymorphic variation is in linkage disequilibrium with the incident polymorphic variation.

15. The method of claim 11, which further comprises identifying a second polymorphic variation proximal to the identified proximal polymorphic variation associated with osteoarthritis and determining if the second proximal polymorphic variation is associated with osteoarthritis.

16. The method of claim 15, wherein the second proximal polymorphic variant is within a region between about 5 kb 5' of the incident polymorphic variation and about 5 kb 3' of the proximal polymorphic variation associated with osteoarthritis.

17. An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-4;
 - (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-4;
 - (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-4;
 - (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and
 - (e) a nucleotide sequence complementary to the nucleotide sequences of (a), (b), (c), or (d);
- wherein the nucleotide sequence comprises a polymorphic variation associated with osteoarthritis selected from the group consisting of an adenine at position 6414, an adenine at position 51282, a cytosine at position 54574, a thymine at position 92029 and an adenine at position 96793.

18. An oligonucleotide comprising a nucleotide sequence complementary to a portion of the nucleotide sequence of (a), (b), (c), or (d) in claim 17, wherein the 3' end of the oligonucleotide is adjacent to a polymorphic variation associated with osteoarthritis.

19. A microarray comprising an isolated nucleic acid of claim 17 linked to a solid support.

20. An isolated polypeptide encoded by the isolated nucleic acid sequence of claim 17.
21. A method for identifying a candidate therapeutic for treating osteoarthritis, which comprises:
- (a) introducing a test molecule to a system which comprises a nucleic acid comprising a nucleotide sequence selected from the group consisting of:
 - (i) a nucleotide sequence in SEQ ID NO: 1-4;
 - (ii) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-4;
 - (iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-4;
 - (iv) a fragment of a nucleotide sequence of (a), (b), or (c); orintroducing a test molecule to a system which comprises a protein encoded by a nucleotide sequence of (i), (ii), (iii), or (iv); and
 - (b) determining the presence or absence of an interaction between the test molecule and the nucleic acid or protein,
- whereby the presence of an interaction between the test molecule and the nucleic acid or protein identifies the test molecule as a candidate therapeutic for treating osteoarthritis.
22. The method of claim 21, wherein the system is an animal.
23. The method of claim 21, wherein the system is a cell.
24. The method of claim 21, wherein the nucleotide sequence comprises one or more polymorphic variations associated with osteoarthritis.
25. The method of claim 24, wherein the one or more polymorphic variations associated with osteoarthritis are at one or more positions in claim 3, 4 or 5.
26. A method for treating osteoarthritis in a subject, which comprises contacting one or more cells of a subject in need thereof with a nucleic acid, wherein the nucleic acid comprises a nucleotide sequence selected from the group consisting of:
- (a) a nucleotide sequence in SEQ ID NO: 1-4;
 - (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-4;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-4;
(d) a fragment of a nucleotide sequence of (a), (b), or (c); and
(e) a nucleotide sequence complementary to the nucleotide sequences of (a), (b), (c), or (d);
whereby contacting the one or more cells of the subject with the nucleic acid treats the osteoarthritis in the subject.

27. The method of claim 26, wherein the nucleic acid is RNA or PNA.

28. The method of claim 27, wherein the nucleic acid is duplex RNA.

29. A method for treating osteoarthritis in a subject, which comprises contacting one or more cells of a subject in need thereof with a protein, wherein the protein is encoded by a nucleotide sequence which comprises a polynucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-4;
(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-4;
(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-4;
(d) a fragment of a nucleotide sequence of (a), (b), or (c);
whereby contacting the one or more cells of the subject with the protein treats the osteoarthritis in the subject.

30. A method for treating osteoarthritis in a subject, which comprises:
detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the one or more polymorphic variation are detected in a nucleotide sequence selected from the group consisting of:
(a) a nucleotide sequence in SEQ ID NO: 1-4;
(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-4;
(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-4;
(d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

administering an osteoarthritis treatment to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

31. The method of claim 30, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

32. The method of claim 30, wherein the treatment is selected from the group consisting of administering a corticosteroid, a corticosteroid, a nonsteroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) inhibitor, an antibody, a glucocorticoid, hyaluronic acid, chondrotin sulfate, glucosamine or acetaminophen; prescribing a heat/cold regimen or a joint protection regimen; performing joint surgery; prescribing a weight control regimen; and combinations of the foregoing.

33. A method for detecting or preventing osteoarthritis in a subject, which comprises:
detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-4;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-4;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-4;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

administering an osteoarthritis prevention or detection procedure to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

34. The method of claim 33, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

35. The method of claim 33, wherein the osteoarthritis prevention is selected from the group consisting of administering a corticosteroid, a nonsteroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) inhibitor, an antibody, a glucocorticoid, hyaluronic acid, chondrotin sulfate, glucosamine or acetaminophen; prescribing a heat/cold regimen or a joint protection regimen; performing joint surgery; prescribing a weight control regimen; and combinations of the foregoing.

36. A method of targeting information for preventing or treating osteoarthritis to a subject in need thereof, which comprises:

detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-4;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-4;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-4;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

directing information for preventing or treating osteoarthritis to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

37. The method of claim 36, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

38. A composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and an antibody that specifically binds to a protein, polypeptide or peptide encoded by a nucleotide sequence identical to or 90% or more identical to a nucleotide sequence in SEQ ID NO: 1-4.

39. A composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and a RNA, DNA, PNA or ribozyme molecule comprising a nucleotide sequence identical to or 90% or more identical to a portion of a nucleotide sequence in SEQ ID NO: 1-4.

40. The composition of claim 39, wherein the RNA molecule is a short inhibitory RNA molecule.

FIGURE 1




FIGURE 2

IL1RL1 isoform expression (SW1353 monolayers)




FIGURE 3A

IL1RL1 isoform expression (3-D alginate)





FIGURE 3B

IL1RL1 isoform expression (3-D alginate)



METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF

Field of the Invention

[0001] The invention relates to genetic methods for identifying risk of osteoarthritis and treatments that specifically target such diseases.

Background

[0002] Osteoarthritis (OA) is a chronic disease usually affecting weight-bearing synovial joints. There are approximately 20 million Americans affected by OA and it is the leading cause of disability in the United States. In addition to extensive human suffering, OA also accounts for nearly all knee replacements and more than half of all hip replacements in the United States. Despite its prevalence, OA is poorly understood and there are few treatments available besides anti-inflammatory drugs and joint replacement.

[0003] Most commonly affecting middle-aged and older people, OA can range from very mild to very severe. It affects hands and weight-bearing joints such as knees, hips, feet and the back. Knee OA can be as disabling as any cardiovascular disease except stroke.

[0004] OA is characterized by the breakdown of cartilage in joints. Cartilage in joints cushions the ends of bones, and cartilage breakdown causes bones to rub against each other, causing pain and loss of movement. Type II collagen is the main component of cartilage, comprising 15-25% of the wet weight, approximately half the dry weight, and representing 90-95% of the total collagen content in the tissue. It forms fibrils that endow cartilage with tensile strength (Mayne, R. Arthritis Rheum. 32:241-246 (1989)).

Summary

[0005] It has been discovered that certain polymorphic variations in human genomic DNA are associated with osteoarthritis. In particular, polymorphic variants in a locus containing a *IL1RL1* region in human genomic DNA have been associated with risk of osteoarthritis.

[0006] Thus, featured herein are methods for identifying a subject at risk of osteoarthritis and/or a risk of osteoarthritis in a subject, which comprise detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in or around the loci described herein in a human nucleic acid sample. In an embodiment, two or more polymorphic variations are detected in two or more regions of which one is the *IL1RL1* region. In certain embodiments, 3 or more, or 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more polymorphic variants are detected.

[0007] Also featured are nucleic acids that include one or more polymorphic variations associated with occurrence of osteoarthritis, as well as polypeptides encoded by these nucleic acids. In addition, provided are methods for identifying candidate therapeutic molecules for treating osteoarthritis, as well as methods for treating osteoarthritis in a subject by identifying a subject at risk of osteoarthritis and treating the subject with a suitable prophylactic, treatment or therapeutic molecule.

[0008] Also provided are compositions comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and/or a *IL1RL1* nucleic acid, with a RNAi, siRNA, antisense DNA or RNA, or ribozyme nucleic acid designed from a *IL1RL1* nucleotide sequence. In an embodiment, the RNAi, siRNA, antisense DNA or RNA, or ribozyme nucleic acid is designed from a *IL1RL1* nucleotide sequence that includes one or more polymorphic variations associated with osteoarthritis, and in some instances, specifically interacts with such a nucleotide sequence. Further, provided are arrays of nucleic acids bound to a solid surface, in which one or more nucleic acid molecules of the array have a *IL1RL1* nucleotide sequence, or a fragment or substantially identical nucleic acid thereof, or a complementary nucleic acid of the foregoing. Featured also are compositions comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and/or a *IL1RL1* polypeptide, with an antibody that specifically binds to the polypeptide. Thus, featured is an antibody that specifically binds to an epitope in the polypeptide that includes an amino acid encoded by a polymorphic site associated with osteoarthritis. In certain embodiments, the antibody specifically binds to an epitope comprising a glutamate or alanine encoded by rs1041973 (e.g., an antibody that binds to an epitope comprising an alanine at position 78 in an *IL1RL1* polypeptide) An alanine at position 78 is associated with increased risk of osteoarthritis.

Brief Description of the Drawings

[0009] Figure 1 shows proximal SNPs in a *IL1RL1* region in genomic DNA. The position of each SNP in the chromosome is shown on the x-axis and the y-axis provides the negative logarithm of the p-value comparing the estimated allele to that of the control group. Also shown in the figure are exons and introns of the gene in the approximate chromosomal positions.

[0010] Figure 2 shows expression profiling results for *IL1RL1*.

[0011] Figures 3A and 3B show *IL1RL1* expression modulation in a human chondrocyte cell line model.

Detailed Description

[0012] It has been discovered that a polymorphic variant in a locus containing a *IL1RL1* region is associated with occurrence of osteoarthritis in subjects. Thus, detecting genetic determinants associated with an increased risk of osteoarthritis occurrence can lead to early identification of a predisposition to osteoarthritis and early prescription of preventative measures. Also, associating a *IL1RL1* polymorphic

variant with osteoarthritis has provided new targets for screening molecules useful in treatments of osteoarthritis.

Osteoarthritis and Sample Selection

[0013] Osteoarthritis (OA), or degenerative joint disease, is one of the oldest and most common types of arthritis. It is characterized by the breakdown of the joint's cartilage. Cartilage is the part of the joint that cushions the ends of bones, and its breakdown causes bones to rub against each other, causing pain and loss of movement. Type II collagen is the main component of cartilage, comprising 15-25% of the wet weight, approximately half the dry weight, and representing 90-95% of the total collagen content in the tissue. It forms fibrils that endow cartilage with tensile strength (Mayne, R. Arthritis Rheum. 32:241-246 (1989)).

[0014] Most commonly affecting middle-aged and older people, OA can range from very mild to very severe. It affects hands and weight-bearing joints such as knees, hips, feet and the back. Knee OA can be as disabling as any cardiovascular disease except stroke.

[0015] Osteoarthritis affects an estimated 20.7 million Americans, mostly after age 45, with women more commonly affected than men. Physicians make a diagnosis of OA based on a physical exam and history of symptoms. X-rays are used to confirm diagnosis. Most people over 60 reflect the disease on X-ray, and about one-third have actual symptoms.

[0016] There are many factors that can cause OA. Obesity may lead to osteoarthritis of the knees. In addition, people with joint injuries due to sports, work-related activity or accidents may be at increased risk of developing OA.

[0017] Genetics has a role in the development of OA. Some people may be born with defective cartilage or with slight defects in the way that joints fit together. As a person ages, these defects may cause early cartilage breakdown in the joint or the inability to repair damaged or deteriorated cartilage in the joint.

[0018] Inclusion or exclusion of samples for an osteoarthritis pool may be based upon the following criteria: ethnicity (e.g., samples derived from an individual characterized as Caucasian); parental ethnicity (e.g., samples derived from an individual of British paternal and maternal descent); relevant phenotype information for the individual (e.g., case samples derived from individuals diagnosed with specific knee osteoarthritis (OA) and were recruited from an OA knee replacement clinic). Control samples may be selected based on relevant phenotype information for the individual (e.g., derived from individuals free of OA at several sites (knee, hand, hip etc)); and no family history of OA and/or rheumatoid arthritis. Additional phenotype information collected for both cases and controls may include age of the individual, gender, family history of OA, diagnosis with osteoarthritis (joint location of OA, date of primary diagnosis, age of individual as of primary diagnosis), knee history (current symptoms,

any major knee injury, meniscectomy, knee replacement surgery, age of surgery), HRT history, osteoporosis diagnosis.

[0019] Based in part upon selection criteria set forth above, individuals having osteoarthritis can be selected for genetic studies. Also, individuals having no history of osteoarthritis often are selected for genetic studies, as described hereafter.

Polymorphic Variants Associated with Osteoarthritis

[0020] A genetic analysis provided herein linked osteoarthritis with polymorphic variant nucleic acid sequences in the human genome. As used herein, the term “polymorphic site” refers to a region in a nucleic acid at which two or more alternative nucleotide sequences are observed in a significant number of nucleic acid samples from a population of individuals. A polymorphic site may be a nucleotide sequence of two or more nucleotides, an inserted nucleotide or nucleotide sequence, a deleted nucleotide or nucleotide sequence, or a microsatellite, for example. A polymorphic site that is two or more nucleotides in length may be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more, 20 or more, 30 or more, 50 or more, 75 or more, 100 or more, 500 or more, or about 1000 nucleotides in length, where all or some of the nucleotide sequences differ within the region. A polymorphic site is often one nucleotide in length, which is referred to herein as a “single nucleotide polymorphism” or a “SNP.”

[0021] Where there are two, three, or four alternative nucleotide sequences at a polymorphic site, each nucleotide sequence is referred to as a “polymorphic variant” or “nucleic acid variant.” Where two polymorphic variants exist, for example, the polymorphic variant represented in a minority of samples from a population is sometimes referred to as a “minor allele” and the polymorphic variant that is more prevalently represented is sometimes referred to as a “major allele.” Many organisms possess a copy of each chromosome (*e.g.*, humans), and those individuals who possess two major alleles or two minor alleles are often referred to as being “homozygous” with respect to the polymorphism, and those individuals who possess one major allele and one minor allele are normally referred to as being “heterozygous” with respect to the polymorphism. Individuals who are homozygous with respect to one allele are sometimes predisposed to a different phenotype as compared to individuals who are heterozygous or homozygous with respect to another allele.

[0022] In genetic analysis that associate polymorphic variants with osteoarthritis, samples from individuals having osteoarthritis and individuals not having osteoarthritis often are allelotyped and/or genotyped. The term “allelotype” as used herein refers to a process for determining the allele frequency for a polymorphic variant in pooled DNA samples from cases and controls. By pooling DNA from each group, an allele frequency for each SNP in each group is calculated. These allele frequencies are then compared to one another. The term “genotyped” as used herein refers to a process for determining a

genotype of one or more individuals, where a “genotype” is a representation of one or more polymorphic variants in a population.

[0023] A genotype or polymorphic variant may be expressed in terms of a “haplotype,” which as used herein refers to two or more polymorphic variants occurring within genomic DNA in a group of individuals within a population. For example, two SNPs may exist within a gene where each SNP position includes a cytosine variation and an adenine variation. Certain individuals in a population may carry one allele (heterozygous) or two alleles (homozygous) having the gene with a cytosine at each SNP position. As the two cytosines corresponding to each SNP in the gene travel together on one or both alleles in these individuals, the individuals can be characterized as having a cytosine/cytosine haplotype with respect to the two SNPs in the gene.

[0024] As used herein, the term “phenotype” refers to a trait which can be compared between individuals, such as presence or absence of a condition, a visually observable difference in appearance between individuals, metabolic variations, physiological variations, variations in the function of biological molecules, and the like. An example of a phenotype is occurrence of osteoarthritis.

[0025] Researchers sometimes report a polymorphic variant in a database without determining whether the variant is represented in a significant fraction of a population. Because a subset of these reported polymorphic variants are not represented in a statistically significant portion of the population, some of them are sequencing errors and/or not biologically relevant. Thus, it is often not known whether a reported polymorphic variant is statistically significant or biologically relevant until the presence of the variant is detected in a population of individuals and the frequency of the variant is determined. Methods for detecting a polymorphic variant in a population are described herein, specifically in Example 2. A polymorphic variant is statistically significant and often biologically relevant if it is represented in 5% or more of a population, sometimes 10% or more, 15% or more, or 20% or more of a population, and often 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more of a population.

[0026] A polymorphic variant may be detected on either or both strands of a double-stranded nucleic acid. Also, a polymorphic variant may be located within an intron or exon of a gene or within a portion of a regulatory region such as a promoter, a 5′ untranslated region (UTR), a 3′ UTR, and in DNA (*e.g.*, genomic DNA (gDNA) and complementary DNA (cDNA)), RNA (*e.g.*, mRNA, tRNA, and rRNA), or a polypeptide. Polymorphic variations may or may not result in detectable differences in gene expression, polypeptide structure, or polypeptide function.

[0027] It was determined that polymorphic variations associated with an increased risk of osteoarthritis existed in a *IL1RL1* region in SEQ ID NO: 1. In certain embodiments, a polymorphic variant at position rs1041973 in the human genome was associated with an increased risk of osteoarthritis, and in a specific embodiment, a cytosine at position rs1041973 was associated with an increased risk of osteoarthritis.

[0028] Polymorphic variants in and around the *IL1RL1* locus were tested for association with osteoarthritis. These include polymorphic variants at positions in SEQ ID NO: 1 selected from the group consisting of 207, 6019, 6414, 7341, 10984, 12351, 13335, 16584, 16737, 23897, 24057, 25145, 25300, 26262, 26312, 26589, 27302, 27358, 27451, 27552, 30731, 32085, 32139, 33184, 42382, 42569, 44823, 45217, 45548, 45601, 45722, 45967, 47367, 47642, 48126, 49218, 49274, 49433, 49610, 51282, 51466, 53757, 53960, 54031, 54574, 55679, 56100, 56182, 59817, 60533, 60656, 72209, 72778, 74293, 77335, 78029, 78374, 78421, 78434, 79174, 79397, 79562, 79700, 79730, 79904, 79920, 79938, 79972, 80125, 80368, 83484, 85536, 85829, 86425, 88083, 88770, 90622, 90924, 91634, 92029, 95152, 95348, 96145, 96793, 97015, 97064, 97711, 97855 and 98708. Polymorphic variants at the following positions in SEQ ID NO: 1 in particular were associated with an increased risk of osteoarthritis: 6414, 51282, 54574, 78374, 92029 and 96793, where specific embodiments are directed to position 54574. In particular, the following polymorphic variants in SEQ ID NO: 1 were associated with risk of osteoarthritis: an adenine at position 6414, an adenine at position 51282, a cytosine at position 54574, a thymine at position 92029 and an adenine at position 96793.

[0029] Based in part upon analyses summarized in Figure 1, a region with significant association has been identified in a locus associated with osteoarthritis. Any polymorphic variants associated with osteoarthritis in a region of significant association can be utilized for embodiments described herein. For example, polymorphic variants in a region spanning chromosome positions 102570000 to 102583000 (approximately 13,000 nucleotides in length) in a *IL1RL1* locus have significant association (chromosome positions are within NCBI's Genome build 34).

Additional Polymorphic Variants Associated with Osteoarthritis

[0030] Also provided is a method for identifying polymorphic variants proximal to an incident, founder polymorphic variant associated with osteoarthritis. Thus, featured herein are methods for identifying a polymorphic variation associated with osteoarthritis that is proximal to an incident polymorphic variation associated with osteoarthritis, which comprises identifying a polymorphic variant proximal to the incident polymorphic variant associated with osteoarthritis, where the incident polymorphic variant is in a *IL1RL1* nucleotide sequence. The nucleotide sequence often comprises a polynucleotide sequence selected from the group consisting of (a) a polynucleotide sequence of SEQ ID NO: 1-4; (b) a polynucleotide sequence that encodes a polypeptide having an amino acid sequence encoded by a polynucleotide sequence of SEQ ID NO: 1-4; and (c) a polynucleotide sequence that encodes a polypeptide having an amino acid sequence that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-4 or a polynucleotide sequence 90% or more identical to the polynucleotide sequence of SEQ ID NO: 1-4. The presence or absence of an association of the proximal polymorphic variant with osteoarthritis then is determined using a known

association method, such as a method described in the Examples hereafter. In an embodiment, the incident polymorphic variant is a polymorphic variant associated with osteoarthritis described herein. In another embodiment, the proximal polymorphic variant identified sometimes is a publicly disclosed polymorphic variant, which for example, sometimes is published in a publicly available database. In other embodiments, the polymorphic variant identified is not publicly disclosed and is discovered using a known method, including, but not limited to, sequencing a region surrounding the incident polymorphic variant in a group of nucleic samples. Thus, multiple polymorphic variants proximal to an incident polymorphic variant are associated with osteoarthritis using this method.

[0031] The proximal polymorphic variant often is identified in a region surrounding the incident polymorphic variant. In certain embodiments, this surrounding region is about 50 kb flanking the first polymorphic variant (*e.g.* about 50 kb 5' of the first polymorphic variant and about 50 kb 3' of the first polymorphic variant), and the region sometimes is composed of shorter flanking sequences, such as flanking sequences of about 40 kb, about 30 kb, about 25 kb, about 20 kb, about 15 kb, about 10 kb, about 7 kb, about 5 kb, or about 2 kb 5' and 3' of the incident polymorphic variant. In other embodiments, the region is composed of longer flanking sequences, such as flanking sequences of about 55 kb, about 60 kb, about 65 kb, about 70 kb, about 75 kb, about 80 kb, about 85 kb, about 90 kb, about 95 kb, or about 100 kb 5' and 3' of the incident polymorphic variant.

[0032] In certain embodiments, polymorphic variants associated with osteoarthritis are identified iteratively. For example, a first proximal polymorphic variant is associated with osteoarthritis using the methods described above and then another polymorphic variant proximal to the first proximal polymorphic variant is identified (*e.g.*, publicly disclosed or discovered) and the presence or absence of an association of one or more other polymorphic variants proximal to the first proximal polymorphic variant with osteoarthritis is determined.

[0033] The methods described herein are useful for identifying or discovering additional polymorphic variants that may be used to further characterize a gene, region or loci associated with a condition, a disease (*e.g.*, osteoarthritis), or a disorder. For example, allelotyping or genotyping data from the additional polymorphic variants may be used to identify a functional mutation or a region of linkage disequilibrium. In certain embodiments, polymorphic variants identified or discovered within a region comprising the first polymorphic variant associated with osteoarthritis are genotyped using the genetic methods and sample selection techniques described herein, and it can be determined whether those polymorphic variants are in linkage disequilibrium with the first polymorphic variant. The size of the region in linkage disequilibrium with the first polymorphic variant also can be assessed using these genotyping methods. Thus, provided herein are methods for determining whether a polymorphic variant is in linkage disequilibrium with a first polymorphic variant associated with osteoarthritis, and such information can be used in prognosis/diagnosis methods described herein.

Isolated Nucleic Acids

[0034] Featured herein are isolated *IL1RL1* nucleic acid variants depicted in SEQ ID NO: 1-4, and substantially identical nucleic acids thereof. A nucleic acid variant may be represented on one or both strands in a double-stranded nucleic acid or on one chromosomal complement (heterozygous) or both chromosomal complements (homozygous).

[0035] As used herein, the term “nucleic acid” includes DNA molecules (*e.g.*, a complementary DNA (cDNA) and genomic DNA (gDNA)) and RNA molecules (*e.g.*, mRNA, rRNA, siRNA and tRNA) and analogs of DNA or RNA, for example, by use of nucleotide analogs. The nucleic acid molecule can be single-stranded and it is often double-stranded. The term “isolated or purified nucleic acid” refers to nucleic acids that are separated from other nucleic acids present in the natural source of the nucleic acid. For example, with regard to genomic DNA, the term “isolated” includes nucleic acids which are separated from the chromosome with which the genomic DNA is naturally associated. An “isolated” nucleic acid is often free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and/or 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of 5' and/or 3' nucleotide sequences which flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. As used herein, the term “gene” refers to a nucleotide sequence that encodes a polypeptide.

[0036] Also included herein are nucleic acid fragments. These fragments often have a nucleotide sequence identical to a nucleotide sequence of SEQ ID NO: 1-4, a nucleotide sequence substantially identical to a nucleotide sequence of SEQ ID NO: 1-4, or a nucleotide sequence that is complementary to the foregoing. The nucleic acid fragment may be identical, substantially identical or homologous to a nucleotide sequence in an exon or an intron in a nucleotide sequence of SEQ ID NO: 1-4, and may encode a domain or part of a domain of a polypeptide. Sometimes, the fragment will comprises one or more of the polymorphic variations described herein as being associated with osteoarthritis. The nucleic acid fragment is often 50, 100, or 200 or fewer base pairs in length, and is sometimes about 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 2000, 3000, 4000, 5000, 10000, 15000, or 20000 base pairs in length. A nucleic acid fragment that is complementary to a nucleotide sequence identical or substantially identical to a nucleotide sequence in SEQ ID NO: 1-4 and hybridizes to such a nucleotide sequence under stringent conditions is often referred to as a “probe.” Nucleic acid fragments often include one or more polymorphic sites, or sometimes have an end that is adjacent to a polymorphic site as described hereafter.

[0037] An example of a nucleic acid fragment is an oligonucleotide. As used herein, the term “oligonucleotide” refers to a nucleic acid comprising about 8 to about 50 covalently linked nucleotides, often comprising from about 8 to about 35 nucleotides, and more often from about 10 to about 25 nucleotides. The backbone and nucleotides within an oligonucleotide may be the same as those of naturally occurring nucleic acids, or analogs or derivatives of naturally occurring nucleic acids, provided that oligonucleotides having such analogs or derivatives retain the ability to hybridize specifically to a nucleic acid comprising a targeted polymorphism. Oligonucleotides described herein may be used as hybridization probes or as components of prognostic or diagnostic assays, for example, as described herein.

[0038] Oligonucleotides are typically synthesized using standard methods and equipment, such as the ABI™3900 High Throughput DNA Synthesizer and the EXPEDITE™ 8909 Nucleic Acid Synthesizer, both of which are available from Applied Biosystems (Foster City, CA). Analogs and derivatives are exemplified in U.S. Pat. Nos. 4,469,863; 5,536,821; 5,541,306; 5,637,683; 5,637,684; 5,700,922; 5,717,083; 5,719,262; 5,739,308; 5,773,601; 5,886,165; 5,929,226; 5,977,296; 6,140,482; WO 00/56746; WO 01/14398, and related publications. Methods for synthesizing oligonucleotides comprising such analogs or derivatives are disclosed, for example, in the patent publications cited above and in U.S. Pat. Nos. 5,614,622; 5,739,314; 5,955,599; 5,962,674; 6,117,992; in WO 00/75372; and in related publications.

[0039] Oligonucleotides may also be linked to a second moiety. The second moiety may be an additional nucleotide sequence such as a tail sequence (*e.g.*, a polyadenosine tail), an adapter sequence (*e.g.*, phage M13 universal tail sequence), and others. Alternatively, the second moiety may be a non-nucleotide moiety such as a moiety which facilitates linkage to a solid support or a label to facilitate detection of the oligonucleotide. Such labels include, without limitation, a radioactive label, a fluorescent label, a chemiluminescent label, a paramagnetic label, and the like. The second moiety may be attached to any position of the oligonucleotide, provided the oligonucleotide can hybridize to the nucleic acid comprising the polymorphism.

Uses for Nucleic Acid Sequence

[0040] Nucleic acid coding sequences may be used for diagnostic purposes for detection and control of polypeptide expression. Also, included herein are oligonucleotide sequences such as antisense RNA, small-interfering RNA (siRNA) and DNA molecules and ribozymes that function to inhibit translation of a polypeptide. Antisense techniques and RNA interference techniques are known in the art and are described herein.

[0041] Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme

molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, hammerhead motif ribozyme molecules may be engineered that specifically and efficiently catalyze endonucleolytic cleavage of RNA sequences corresponding to or complementary to *ILIRLI* nucleotide sequences. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between fifteen (15) and twenty (20) ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

[0042] Antisense RNA and DNA molecules, siRNA and ribozymes may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

[0043] DNA encoding a polypeptide also may have a number of uses for the diagnosis of diseases, including osteoarthritis, resulting from aberrant expression of a target gene described herein. For example, the nucleic acid sequence may be used in hybridization assays of biopsies or autopsies to diagnose abnormalities of expression or function (*e.g.*, Southern or Northern blot analysis, *in situ* hybridization assays).

[0044] In addition, the expression of a polypeptide during embryonic development may also be determined using nucleic acid encoding the polypeptide. As addressed, *infra*, production of functionally impaired polypeptide is the cause of various disease states, such as osteoarthritis. *In situ* hybridizations using polypeptide as a probe may be employed to predict problems related to osteoarthritis. Further, as indicated, *infra*, administration of human active polypeptide, recombinantly produced as described herein, may be used to treat disease states related to functionally impaired polypeptide. Alternatively, gene therapy approaches may be employed to remedy deficiencies of functional polypeptide or to replace or compete with dysfunctional polypeptide.

Expression Vectors, Host Cells, and Genetically Engineered Cells

[0045] Provided herein are nucleic acid vectors, often expression vectors, which contain a *ILIRLI* nucleotide sequence, or a substantially identical sequence thereof. As used herein, the term “vector”

refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked and can include a plasmid, cosmid, or viral vector. The vector can be capable of autonomous replication or it can integrate into a host DNA. Viral vectors may include replication defective retroviruses, adenoviruses and adeno-associated viruses for example.

[0046] A vector can include a *ILIRLI* nucleotide sequence in a form suitable for expression of an encoded target polypeptide or target nucleic acid in a host cell. A “target polypeptide” is a polypeptide encoded by a *ILIRLI* nucleotide sequence, or a substantially identical nucleotide sequence thereof. The recombinant expression vector typically includes one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. The term “regulatory sequence” includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence, as well as tissue-specific regulatory and/or inducible sequences. The design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of polypeptide desired, and the like. Expression vectors can be introduced into host cells to produce target polypeptides, including fusion polypeptides.

[0047] Recombinant expression vectors can be designed for expression of target polypeptides in prokaryotic or eukaryotic cells. For example, target polypeptides can be expressed in *E. coli*, insect cells (e.g., using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology 185*, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

[0048] Expression of polypeptides in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion polypeptides. Fusion vectors add a number of amino acids to a polypeptide encoded therein, usually to the amino terminus of the recombinant polypeptide. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant polypeptide; 2) to increase the solubility of the recombinant polypeptide; and 3) to aid in the purification of the recombinant polypeptide by acting as a ligand in affinity purification. Often, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant polypeptide to enable separation of the recombinant polypeptide from the fusion moiety subsequent to purification of the fusion polypeptide. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith & Johnson, *Gene* 67: 31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding polypeptide, or polypeptide A, respectively, to the target recombinant polypeptide.

[0049] Purified fusion polypeptides can be used in screening assays and to generate antibodies specific for target polypeptides. In a therapeutic embodiment, fusion polypeptide expressed in a retroviral expression vector is used to infect bone marrow cells that are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (*e.g.*, six (6) weeks).

[0050] Expressing the polypeptide in host bacteria with an impaired capacity to proteolytically cleave the recombinant polypeptide is often used to maximize recombinant polypeptide expression (Gottesman, S., *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, California 185: 119-128 (1990)). Another strategy is to alter the nucleotide sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, *Nucleic Acids Res.* 20: 2111-2118 (1992)). Such alteration of nucleotide sequences can be carried out by standard DNA synthesis techniques.

[0051] When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. Recombinant mammalian expression vectors are often capable of directing expression of the nucleic acid in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Non-limiting examples of suitable tissue-specific promoters include an albumin promoter (liver-specific; Pinkert *et al.*, *Genes Dev.* 1: 268-277 (1987)), lymphoid-specific promoters (Calame & Eaton, *Adv. Immunol.* 43: 235-275 (1988)), promoters of T cell receptors (Winoto & Baltimore, *EMBO J.* 8: 729-733 (1989)) promoters of immunoglobulins (Banerji *et al.*, *Cell* 33: 729-740 (1983); Queen & Baltimore, *Cell* 33: 741-748 (1983)), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne & Ruddle, *Proc. Natl. Acad. Sci. USA* 86: 5473-5477 (1989)), pancreas-specific promoters (Edlund *et al.*, *Science* 230: 912-916 (1985)), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are sometimes utilized, for example, the murine hox promoters (Kessel & Gruss, *Science* 249: 374-379 (1990)) and the α -fetopolypeptide promoter (Campes & Tilghman, *Genes Dev.* 3: 537-546 (1989)).

[0052] A *ILIRL1* nucleic acid also may be cloned into an expression vector in an antisense orientation. Regulatory sequences (*e.g.*, viral promoters and/or enhancers) operatively linked to a *ILIRL1* nucleic acid cloned in the antisense orientation can be chosen for directing constitutive, tissue specific or cell type specific expression of antisense RNA in a variety of cell types. Antisense expression vectors can be in the form of a recombinant plasmid, phagemid or attenuated virus. For a discussion of the regulation of gene expression using antisense genes *see, e.g.*, Weintraub *et al.*, *Antisense RNA as a molecular tool for genetic analysis*, *Reviews - Trends in Genetics*, Vol. 1(1) (1986).

[0053] Also provided herein are host cells that include a *IL1RL1* nucleotide sequence within a recombinant expression vector or a fragment of such a nucleotide sequence which facilitate homologous recombination into a specific site of the host cell genome. The terms “host cell” and “recombinant host cell” are used interchangeably herein. Such terms refer not only to the particular subject cell but rather also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. A host cell can be any prokaryotic or eukaryotic cell. For example, a target polypeptide can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

[0054] Vectors can be introduced into host cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, transduction/infection, DEAE-dextran-mediated transfection, lipofection, or electroporation.

[0055] A host cell provided herein can be used to produce (*i.e.*, express) a target polypeptide or a substantially identical polypeptide thereof. Accordingly, further provided are methods for producing a target polypeptide using host cells described herein. In one embodiment, the method includes culturing host cells into which a recombinant expression vector encoding a target polypeptide has been introduced in a suitable medium such that a target polypeptide is produced. In another embodiment, the method further includes isolating a target polypeptide from the medium or the host cell.

[0056] Also provided are cells or purified preparations of cells which include a *IL1RL1* transgene, or which otherwise misexpress target polypeptide. Cell preparations can consist of human or non-human cells, *e.g.*, rodent cells, *e.g.*, mouse or rat cells, rabbit cells, or pig cells. In preferred embodiments, the cell or cells include a *IL1RL1* transgene (*e.g.*, a heterologous form of a *IL1RL1* gene, such as a human gene expressed in non-human cells). The transgene can be misexpressed, *e.g.*, overexpressed or underexpressed. In other preferred embodiments, the cell or cells include a gene which misexpress an endogenous target polypeptide (*e.g.*, expression of a gene is disrupted, also known as a knockout). Such cells can serve as a model for studying disorders which are related to mutated or mis-expressed alleles or for use in drug screening. Also provided are human cells (*e.g.*, a hematopoietic stem cells) transfected with a *IL1RL1* nucleic acid.

[0057] Also provided are cells or a purified preparation thereof (*e.g.*, human cells) in which an endogenous *IL1RL1* nucleic acid is under the control of a regulatory sequence that does not normally control the expression of the endogenous gene. The expression characteristics of an endogenous gene within a cell (*e.g.*, a cell line or microorganism) can be modified by inserting a heterologous DNA

regulatory element into the genome of the cell such that the inserted regulatory element is operably linked to the corresponding endogenous gene. For example, an endogenous corresponding gene (*e.g.*, a gene which is “transcriptionally silent,” not normally expressed, or expressed only at very low levels) may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell. Techniques such as targeted homologous recombinations, can be used to insert the heterologous DNA as described in, *e.g.*, Chappel, US 5,272,071; WO 91/06667, published on May 16, 1991.

Transgenic Animals

[0058] Non-human transgenic animals that express a heterologous target polypeptide (*e.g.*, expressed from a *ILIRL1* nucleic acid or substantially identical sequence thereof) can be generated. Such animals are useful for studying the function and/or activity of a target polypeptide and for identifying and/or evaluating modulators of the activity of *ILIRL1* nucleic acids and encoded polypeptides. As used herein, a “transgenic animal” is a non-human animal such as a mammal (*e.g.*, a non-human primate such as chimpanzee, baboon, or macaque; an ungulate such as an equine, bovine, or caprine; or a rodent such as a rat, a mouse, or an Israeli sand rat), a bird (*e.g.*, a chicken or a turkey), an amphibian (*e.g.*, a frog, salamander, or newt), or an insect (*e.g.*, *Drosophila melanogaster*), in which one or more of the cells of the animal includes a transgene. A transgene is exogenous DNA or a rearrangement (*e.g.*, a deletion of endogenous chromosomal DNA) that is often integrated into or occurs in the genome of cells in a transgenic animal. A transgene can direct expression of an encoded gene product in one or more cell types or tissues of the transgenic animal, and other transgenes can reduce expression (*e.g.*, a knockout). Thus, a transgenic animal can be one in which an endogenous nucleic acid homologous to a *ILIRL1* nucleic acid has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal (*e.g.*, an embryonic cell of the animal) prior to development of the animal.

[0059] Intronic sequences and polyadenylation signals can also be included in the transgene to increase expression efficiency of the transgene. One or more tissue-specific regulatory sequences can be operably linked to a *ILIRL1* nucleotide sequence to direct expression of an encoded polypeptide to particular cells. A transgenic founder animal can be identified based upon the presence of a *ILIRL1* nucleotide sequence in its genome and/or expression of encoded mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a *ILIRL1* nucleotide sequence can further be bred to other transgenic animals carrying other transgenes.

[0060] Target polypeptides can be expressed in transgenic animals or plants by introducing, for example, a *ILIRL1* nucleic acid into the genome of an animal that encodes the target polypeptide. In

preferred embodiments the nucleic acid is placed under the control of a tissue specific promoter, *e.g.*, a milk or egg specific promoter, and recovered from the milk or eggs produced by the animal. Also included is a population of cells from a transgenic animal.

Target Polypeptides

[0061] Also featured herein are isolated target polypeptides, which are encoded by a *IL1RL1* nucleotide sequence (*e.g.*, SEQ ID NO: 1-4), or a substantially identical nucleotide sequence thereof. Examples of *IL1RL1* polypeptides are set forth in SEQ ID NO: 5-7. The term “polypeptide” as used herein includes proteins and peptides. An “isolated” or “purified” polypeptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. In one embodiment, the language “substantially free” means preparation of a target polypeptide having less than about 30%, 20%, 10% and more preferably 5% (by dry weight), of non-target polypeptide (also referred to herein as a “contaminating protein”), or of chemical precursors or non-target chemicals. When the target polypeptide or a biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, specifically, where culture medium represents less than about 20%, sometimes less than about 10%, and often less than about 5% of the volume of the polypeptide preparation. Isolated or purified target polypeptide preparations are sometimes 0.01 milligrams or more or 0.1 milligrams or more, and often 1.0 milligrams or more and 10 milligrams or more in dry weight.

[0062] Further included herein are target polypeptide fragments. The polypeptide fragment may be a domain or part of a domain of a target polypeptide. The polypeptide fragment may have increased, decreased or unexpected biological activity. The polypeptide fragment is often 50 or fewer, 100 or fewer, or 200 or fewer amino acids in length, and is sometimes 300, 400, 500, 600, 700, or 900 or fewer amino acids in length.

[0063] Interleukin 1 receptor-like 1 isoform 1 (SEQ ID NO: 5) is a member of the interleukin 1 receptor family with no known ligand (orphan receptor). *IL1RL1* exists in soluble (SEQ ID NO: 6-7) and transmembrane forms, suggesting that it may have ligand or ligand scavenging activity. In an embodiment, *IL1RL1* protein agents may be administered to treat or prevent the occurrence of OA. *IL1RL1* protein agents include *IL1RL1* polypeptides or fragments thereof that have *IL1RL1* ligand activity (*e.g.*, recombinant polypeptides of SEQ ID NO: 6-7). In a related embodiment, *IL1RL1* protein agents include *IL1RL1* polypeptides or fragments thereof that have *IL1RL1* ligand scavenging activity (*e.g.*, recombinant polypeptide of SEQ ID NO: 5). Isolated *IL1RL1* polypeptides featured herein include the full-length polypeptide, the mature polypeptide (*i.e.*, the polypeptide without the signal sequence

MGFWILAILTILMYSTAA) or a polypeptide fragment containing a domain or part of a *ILIRLI* domain. The polypeptide fragment may have increased, decreased or unexpected biological activity.

[0064] Substantially identical target polypeptides may depart from the amino acid sequences of target polypeptides in different manners. For example, conservative amino acid modifications may be introduced at one or more positions in the amino acid sequences of target polypeptides. A “conservative amino acid substitution” is one in which the amino acid is replaced by another amino acid having a similar structure and/or chemical function. Families of amino acid residues having similar structures and functions are well known. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Also, essential and non-essential amino acids may be replaced. A “non-essential” amino acid is one that can be altered without abolishing or substantially altering the biological function of a target polypeptide, whereas altering an “essential” amino acid abolishes or substantially alters the biological function of a target polypeptide. Amino acids that are conserved among target polypeptides are typically essential amino acids. In certain embodiments, the polypeptide includes one or more non-synonymous polymorphic variants associated with osteoarthritis.

[0065] Also, target polypeptides may exist as chimeric or fusion polypeptides. As used herein, a target “chimeric polypeptide” or target “fusion polypeptide” includes a target polypeptide linked to a non-target polypeptide. A “non-target polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a polypeptide which is not substantially identical to the target polypeptide, which includes, for example, a polypeptide that is different from the target polypeptide and derived from the same or a different organism. The target polypeptide in the fusion polypeptide can correspond to an entire or nearly entire target polypeptide or a fragment thereof. The non-target polypeptide can be fused to the N-terminus or C-terminus of the target polypeptide.

[0066] Fusion polypeptides can include a moiety having high affinity for a ligand. For example, the fusion polypeptide can be a GST-target fusion polypeptide in which the target sequences are fused to the C-terminus of the GST sequences, or a polyhistidine-target fusion polypeptide in which the target polypeptide is fused at the N- or C-terminus to a string of histidine residues. Such fusion polypeptides can facilitate purification of recombinant target polypeptide. Expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide), and a nucleotide sequence in SEQ ID NO: 1-4, or a substantially identical nucleotide sequence thereof, can be cloned into an expression vector such that the fusion moiety is linked in-frame to the target polypeptide. Further, the fusion polypeptide can be a target polypeptide containing a heterologous signal sequence at its N-

terminus. In certain host cells (*e.g.*, mammalian host cells), expression, secretion, cellular internalization, and cellular localization of a target polypeptide can be increased through use of a heterologous signal sequence. Fusion polypeptides can also include all or a part of a serum polypeptide (*e.g.*, an IgG constant region or human serum albumin).

[0067] Target polypeptides can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. Administration of these target polypeptides can be used to affect the bioavailability of a substrate of the target polypeptide and may effectively increase target polypeptide biological activity in a cell. Target fusion polypeptides may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding a target polypeptide; (ii) misregulation of the gene encoding the target polypeptide; and (iii) aberrant post-translational modification of a target polypeptide. Also, target polypeptides can be used as immunogens to produce anti-target antibodies in a subject, to purify target polypeptide ligands or binding partners, and in screening assays to identify molecules which inhibit or enhance the interaction of a target polypeptide with a substrate.

[0068] In addition, polypeptides can be chemically synthesized using techniques known in the art (See, *e.g.*, Creighton, 1983 *Proteins*. New York, N.Y.: W. H. Freeman and Company; and Hunkapiller et al., (1984) *Nature* July 12 -18;310(5973):105-111). For example, a relative short fragment can be synthesized by use of a peptide synthesizer. Furthermore, if desired, non-classical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the fragment sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ -Abu, ϵ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoroamino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

[0069] Polypeptides and polypeptide fragments sometimes are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; and the like. Additional post-translational modifications include, for example, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell

expression. The polypeptide fragments may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the polypeptide.

[0070] Also provided are chemically modified derivatives of polypeptides that can provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (*see e.g.*, U.S. Pat. No: 4,179,337. The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

[0071] The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term “about” indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

[0072] The polymers should be attached to the polypeptide with consideration of effects on functional or antigenic domains of the polypeptide. There are a number of attachment methods available to those skilled in the art (*e.g.*, EP 0 401 384 (coupling PEG to G-CSF) and Malik et al. (1992) Exp Hematol. September;20(8):1028-35 (pegylation of GM-CSF using tresyl chloride)). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues, glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. For therapeutic purposes, the attachment sometimes is at an amino group, such as attachment at the N-terminus or lysine group.

[0073] Proteins can be chemically modified at the N-terminus. Using polyethylene glycol as an illustration of such a composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, and the like), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus may be accomplished by

reductive alkylation, which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

Substantially Identical Nucleic Acids and Polypeptides

[0074] Nucleotide sequences and polypeptide sequences that are substantially identical to a *ILIRLI* nucleotide sequence and the target polypeptide sequences encoded by those nucleotide sequences, respectively, are included herein. The term “substantially identical” as used herein refers to two or more nucleic acids or polypeptides sharing one or more identical nucleotide sequences or polypeptide sequences, respectively. Included are nucleotide sequences or polypeptide sequences that are 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more (each often within a 1%, 2%, 3% or 4% variability) identical to a *ILIRLI* nucleotide sequence or the encoded target polypeptide amino acid sequences. One test for determining whether two nucleic acids are substantially identical is to determine the percent of identical nucleotide sequences or polypeptide sequences shared between the nucleic acids or polypeptides.

[0075] Calculations of sequence identity are often performed as follows. Sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The length of a reference sequence aligned for comparison purposes is sometimes 30% or more, 40% or more, 50% or more, often 60% or more, and more often 70% or more, 80% or more, 90% or more, or 100% of the length of the reference sequence. The nucleotides or amino acids at corresponding nucleotide or polypeptide positions, respectively, are then compared among the two sequences. When a position in the first sequence is occupied by the same nucleotide or amino acid as the corresponding position in the second sequence, the nucleotides or amino acids are deemed to be identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, introduced for optimal alignment of the two sequences.

[0076] Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. Percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of Meyers & Miller, *CABIOS* 4: 11-17 (1989), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. Also, percent identity between two amino acid sequences can be determined using the Needleman & Wunsch, *J. Mol. Biol.* 48: 444-453 (1970) algorithm which has been incorporated into the GAP program in the GCG software package (available at

the http address www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. Percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available at http address www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A set of parameters often used is a Blossum 62 scoring matrix with a gap open penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

[0077] Another manner for determining if two nucleic acids are substantially identical is to assess whether a polynucleotide homologous to one nucleic acid will hybridize to the other nucleic acid under stringent conditions. As use herein, the term “stringent conditions” refers to conditions for hybridization and washing. Stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. , 6.3.1-6.3.6 (1989). Aqueous and non-aqueous methods are described in that reference and either can be used. An example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50°C. Another example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 55°C. A further example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C. Often, stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. More often, stringency conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C.

[0078] An example of a substantially identical nucleotide sequence to a nucleotide sequence in SEQ ID NO: 1-4 is one that has a different nucleotide sequence but still encodes the same polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO: 1-4. Another example is a nucleotide sequence that encodes a polypeptide having a polypeptide sequence that is more than 70% or more identical to, sometimes more than 75% or more, 80% or more, or 85% or more identical to, and often more than 90% or more and 95% or more identical to a polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO: 1-4.

[0079] Nucleotide sequences in SEQ ID NO: 1-4 and amino acid sequences of encoded polypeptides can be used as “query sequences” to perform a search against public databases to identify other family members or related sequences, for example. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul *et al.*, *J. Mol. Biol.* 215: 403-10 (1990). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to nucleotide sequences in SEQ ID NO: 1-4. BLAST polypeptide

searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to polypeptides encoded by the nucleotide sequences of SEQ ID NO: 1-4. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, *Nucleic Acids Res.* 25(17): 3389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used (*see* the [http](http://www.ncbi.nlm.nih.gov) address www.ncbi.nlm.nih.gov).

[0080] A nucleic acid that is substantially identical to a nucleotide sequence in SEQ ID NO: 1-4 may include polymorphic sites at positions equivalent to those described herein when the sequences are aligned. For example, using the alignment procedures described herein, SNPs in a sequence substantially identical to a sequence in SEQ ID NO: 1-4 can be identified at nucleotide positions that match (*i.e.*, align) with nucleotides at SNP positions in each nucleotide sequence in SEQ ID NO: 1-4. Also, where a polymorphic variation results in an insertion or deletion, insertion or deletion of a nucleotide sequence from a reference sequence can change the relative positions of other polymorphic sites in the nucleotide sequence.

[0081] Substantially identical nucleotide and polypeptide sequences include those that are naturally occurring, such as allelic variants (same locus), splice variants, homologs (different locus), and orthologs (different organism) or can be non-naturally occurring. Non-naturally occurring variants can be generated by mutagenesis techniques, including those applied to polynucleotides, cells, or organisms. The variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions (as compared in the encoded product). Orthologs, homologs, allelic variants, and splice variants can be identified using methods known in the art. These variants normally comprise a nucleotide sequence encoding a polypeptide that is 50% or more, about 55% or more, often about 70-75% or more or about 80-85% or more, and sometimes about 90-95% or more identical to the amino acid sequences of target polypeptides or a fragment thereof. Such nucleic acid molecules can readily be identified as being able to hybridize under stringent conditions to a nucleotide sequence in SEQ ID NO: 1-4 or a fragment of this sequence. Nucleic acid molecules corresponding to orthologs, homologs, and allelic variants of a nucleotide sequence in SEQ ID NO: 1-4 can further be identified by mapping the sequence to the same chromosome or locus as the nucleotide sequence in SEQ ID NO: 1-4.

[0082] Also, substantially identical nucleotide sequences may include codons that are altered with respect to the naturally occurring sequence for enhancing expression of a target polypeptide in a particular expression system. For example, the nucleic acid can be one in which one or more codons are altered, and often 10% or more or 20% or more of the codons are altered for optimized expression in

bacteria (*e.g.*, *E. coli.*), yeast (*e.g.*, *S. cerevisiae*), human (*e.g.*, 293 cells), insect, or rodent (*e.g.*, hamster) cells.

Methods for Identifying Risk of Osteoarthritis

[0083] Methods for prognosing and diagnosing osteoarthritis are included herein. These methods include detecting the presence or absence of one or more polymorphic variations in a nucleotide sequence associated with osteoarthritis, such as variants in or around the loci set forth herein, or a substantially identical sequence thereof, in a sample from a subject, where the presence of a polymorphic variant described herein is indicative of a risk of osteoarthritis. Determining a risk of osteoarthritis sometimes refers to determining whether an individual is at an increased risk of osteoarthritis (*e.g.*, intermediate risk or higher risk).

[0084] Thus, featured herein is a method for identifying a subject who is at risk of osteoarthritis, which comprises detecting an aberration associated with osteoarthritis in a nucleic acid sample from the subject. An embodiment is a method for detecting a risk of osteoarthritis in a subject, which comprises detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject, where the nucleotide sequence comprises a polynucleotide sequence selected from the group consisting of: (a) a nucleotide sequence of SEQ ID NO: 1-4; (b) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-4; (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-4, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-4; and (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising the polymorphic site; whereby the presence of the polymorphic variation is indicative of a predisposition to osteoarthritis in the subject. In certain embodiments, polymorphic variants at the positions described herein are detected for determining a risk of osteoarthritis, and polymorphic variants at positions in linkage disequilibrium with these positions are detected for determining a risk of osteoarthritis. As used herein, "SEQ ID NO: 1-4" refers to individual sequences in SEQ ID NO: 1, 2, 3 or 4, each sequence being separately applicable to embodiments described herein.

[0085] Risk of osteoarthritis sometimes is expressed as a probability, such as an odds ratio, percentage, or risk factor. Risk often is based upon the presence or absence of one or more polymorphic variants described herein, and also may be based in part upon phenotypic traits of the individual being tested. Methods for calculating risk based upon patient data are well known (*see, e.g.*, Agresti, *Categorical Data Analysis*, 2nd Ed. 2002. Wiley). Allelotyping and genotyping analyses may be carried out in populations other than those exemplified herein to enhance the predictive power of the prognostic

method. These further analyses are executed in view of the exemplified procedures described herein, and may be based upon the same polymorphic variations or additional polymorphic variations.

[0086] In certain embodiments, determining the presence of a combination of two or more polymorphic variants associated with osteoarthritis in one or more genetic loci (e.g., one or more genes) of the sample is determined to identify, quantify and/or estimate, risk of osteoarthritis. The risk often is the probability of having or developing osteoarthritis. The risk sometimes is expressed as a relative risk with respect to a population average risk of osteoarthritis, and sometimes is expressed as a relative risk with respect to the lowest risk group. Such relative risk assessments often are based upon penetrance values determined by statistical methods, and are particularly useful to clinicians and insurance companies for assessing risk of osteoarthritis (e.g., a clinician can target appropriate detection, prevention and therapeutic regimens to a patient after determining the patient's risk of osteoarthritis, and an insurance company can fine tune actuarial tables based upon population genotype assessments of osteoarthritis risk). Risk of osteoarthritis sometimes is expressed as an odds ratio, which is the odds of a particular person having a genotype has or will develop osteoarthritis with respect to another genotype group (e.g., the most disease protective genotype or population average). In related embodiments, the determination is utilized to identify a subject at risk of osteoarthritis. In an embodiment, two or more polymorphic variations are detected in two or more regions in human genomic DNA associated with increased risk of osteoarthritis, such as a locus containing a *ILIRLI*, for example. In certain embodiments, 3 or more, or 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more polymorphic variants are detected in the sample. In specific embodiments, polymorphic variants are detected in a *ILIRLI* region, for example. In certain embodiments, polymorphic variants are detected at other genetic loci (e.g., the polymorphic variants can be detected in *ILIRLI* in addition to other loci or only in other loci), where the other loci include but are not limited to those described in concurrently-filed patent applications having attorney docket number 524593008700, 524593008800, 524593008900, 524593009000 or 524593009200, which is incorporated herein by reference in its entirety.

[0087] Results from prognostic tests may be combined with other test results to diagnose osteoarthritis. For example, prognostic results may be gathered, a patient sample may be ordered based on a determined predisposition to osteoarthritis, the patient sample is analyzed, and the results of the analysis may be utilized to diagnose osteoarthritis. Also osteoarthritis diagnostic method can be developed from studies used to generate prognostic methods in which populations are stratified into subpopulations having different progressions of osteoarthritis. In another embodiment, prognostic results may be gathered, a patient's risk factors for developing osteoarthritis (e.g., age, weight, race, diet) analyzed, and a patient sample may be ordered based on a determined predisposition to osteoarthritis.

[0088] The nucleic acid sample typically is isolated from a biological sample obtained from a subject. For example, nucleic acid can be isolated from blood, saliva, sputum, urine, cell scrapings, and

biopsy tissue. The nucleic acid sample can be isolated from a biological sample using standard techniques, such as the technique described in Example 2. As used herein, the term “subject” refers primarily to humans but also refers to other mammals such as dogs, cats, and ungulates (*e.g.*, cattle, sheep, and swine). Subjects also include avians (*e.g.*, chickens and turkeys), reptiles, and fish (*e.g.*, salmon), as embodiments described herein can be adapted to nucleic acid samples isolated from any of these organisms. The nucleic acid sample may be isolated from the subject and then directly utilized in a method for determining the presence of a polymorphic variant, or alternatively, the sample may be isolated and then stored (*e.g.*, frozen) for a period of time before being subjected to analysis.

[0089] The presence or absence of a polymorphic variant is determined using one or both chromosomal complements represented in the nucleic acid sample. Determining the presence or absence of a polymorphic variant in both chromosomal complements represented in a nucleic acid sample from a subject having a copy of each chromosome is useful for determining the zygosity of an individual for the polymorphic variant (*i.e.*, whether the individual is homozygous or heterozygous for the polymorphic variant). Any oligonucleotide-based diagnostic may be utilized to determine whether a sample includes the presence or absence of a polymorphic variant in a sample. For example, primer extension methods, ligase sequence determination methods (*e.g.*, U.S. Pat. Nos. 5,679,524 and 5,952,174, and WO 01/27326), mismatch sequence determination methods (*e.g.*, U.S. Pat. Nos. 5,851,770; 5,958,692; 6,110,684; and 6,183,958), microarray sequence determination methods, restriction fragment length polymorphism (RFLP), single strand conformation polymorphism detection (SSCP) (*e.g.*, U.S. Pat. Nos. 5,891,625 and 6,013,499), PCR-based assays (*e.g.*, TAQMAN® PCR System (Applied Biosystems)), and nucleotide sequencing methods may be used.

[0090] Oligonucleotide extension methods typically involve providing a pair of oligonucleotide primers in a polymerase chain reaction (PCR) or in other nucleic acid amplification methods for the purpose of amplifying a region from the nucleic acid sample that comprises the polymorphic variation. One oligonucleotide primer is complementary to a region 3' of the polymorphism and the other is complementary to a region 5' of the polymorphism. A PCR primer pair may be used in methods disclosed in U.S. Pat. Nos. 4,683,195; 4,683,202, 4,965,188; 5,656,493; 5,998,143; 6,140,054; WO 01/27327; and WO 01/27329 for example. PCR primer pairs may also be used in any commercially available machines that perform PCR, such as any of the GENEAMP® Systems available from Applied Biosystems. Also, those of ordinary skill in the art will be able to design oligonucleotide primers based upon a *IL1RL1* nucleotide sequence using knowledge available in the art.

[0091] Also provided is an extension oligonucleotide that hybridizes to the amplified fragment adjacent to the polymorphic variation. As used herein, the term “adjacent” refers to the 3' end of the extension oligonucleotide being often 1 nucleotide from the 5' end of the polymorphic site, and sometimes 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides from the 5' end of the polymorphic site, in the nucleic

acid when the extension oligonucleotide is hybridized to the nucleic acid. The extension oligonucleotide then is extended by one or more nucleotides, and the number and/or type of nucleotides that are added to the extension oligonucleotide determine whether the polymorphic variant is present. Oligonucleotide extension methods are disclosed, for example, in U.S. Pat. Nos. 4,656,127; 4,851,331; 5,679,524; 5,834,189; 5,876,934; 5,908,755; 5,912,118; 5,976,802; 5,981,186; 6,004,744; 6,013,431; 6,017,702; 6,046,005; 6,087,095; 6,210,891; and WO 01/20039. Oligonucleotide extension methods using mass spectrometry are described, for example, in U.S. Pat. Nos. 5,547,835; 5,605,798; 5,691,141; 5,849,542; 5,869,242; 5,928,906; 6,043,031; and 6,194,144, and a method often utilized is described herein in Example 2.

[0092] A microarray can be utilized for determining whether a polymorphic variant is present or absent in a nucleic acid sample. A microarray may include any oligonucleotides described herein, and methods for making and using oligonucleotide microarrays suitable for diagnostic use are disclosed in U.S. Pat. Nos. 5,492,806; 5,525,464; 5,589,330; 5,695,940; 5,849,483; 6,018,041; 6,045,996; 6,136,541; 6,142,681; 6,156,501; 6,197,506; 6,223,127; 6,225,625; 6,229,911; 6,239,273; WO 00/52625; WO 01/25485; and WO 01/29259. The microarray typically comprises a solid support and the oligonucleotides may be linked to this solid support by covalent bonds or by non-covalent interactions. The oligonucleotides may also be linked to the solid support directly or by a spacer molecule. A microarray may comprise one or more oligonucleotides complementary to a polymorphic site set forth herein.

[0093] A kit also may be utilized for determining whether a polymorphic variant is present or absent in a nucleic acid sample. A kit often comprises one or more pairs of oligonucleotide primers useful for amplifying a fragment of a nucleotide sequence of SEQ ID NO: 1-4 or a substantially identical sequence thereof, where the fragment includes a polymorphic site. The kit sometimes comprises a polymerizing agent, for example, a thermostable nucleic acid polymerase such as one disclosed in U.S. Pat. Nos. 4,889,818 or 6,077,664. Also, the kit often comprises an elongation oligonucleotide that hybridizes to a *ILIRL1* nucleotide sequence in a nucleic acid sample adjacent to the polymorphic site. Where the kit includes an elongation oligonucleotide, it also often comprises chain elongating nucleotides, such as dATP, dTTP, dGTP, dCTP, and dITP, including analogs of dATP, dTTP, dGTP, dCTP and dITP, provided that such analogs are substrates for a thermostable nucleic acid polymerase and can be incorporated into a nucleic acid chain elongated from the extension oligonucleotide. Along with chain elongating nucleotides would be one or more chain terminating nucleotides such as ddATP, ddTTP, ddGTP, ddCTP, and the like. In an embodiment, the kit comprises one or more oligonucleotide primer pairs, a polymerizing agent, chain elongating nucleotides, at least one elongation oligonucleotide, and one or more chain terminating nucleotides. Kits optionally include buffers, vials, microtiter plates, and instructions for use.

[0094] An individual identified as being at risk of osteoarthritis may be heterozygous or homozygous with respect to the allele associated with a higher risk of osteoarthritis. A subject homozygous for an allele associated with an increased risk of osteoarthritis is at a comparatively high risk of osteoarthritis, a subject heterozygous for an allele associated with an increased risk of osteoarthritis is at a comparatively intermediate risk of osteoarthritis, and a subject homozygous for an allele associated with a decreased risk of osteoarthritis is at a comparatively low risk of osteoarthritis. A genotype may be assessed for a complementary strand, such that the complementary nucleotide at a particular position is detected.

[0095] Also featured are methods for determining risk of osteoarthritis and/or identifying a subject at risk of osteoarthritis by contacting a polypeptide or protein encoded by a *ILIRLI* nucleotide sequence from a subject with an antibody that specifically binds to an epitope associated with increased risk of osteoarthritis in the polypeptide (e.g., an epitope comprising an alanine at position 78 in an *ILIRLI* polypeptide).

Applications of Prognostic and Diagnostic Results to Pharmacogenomic Methods

[0096] Pharmacogenomics is a discipline that involves tailoring a treatment for a subject according to the subject's genotype as a particular treatment regimen may exert a differential effect depending upon the subject's genotype. For example, based upon the outcome of a prognostic test described herein, a clinician or physician may target pertinent information and preventative or therapeutic treatments to a subject who would be benefited by the information or treatment and avoid directing such information and treatments to a subject who would not be benefited (e.g., the treatment has no therapeutic effect and/or the subject experiences adverse side effects).

[0097] The following is an example of a pharmacogenomic embodiment. A particular treatment regimen can exert a differential effect depending upon the subject's genotype. Where a candidate therapeutic exhibits a significant interaction with a major allele and a comparatively weak interaction with a minor allele (e.g., an order of magnitude or greater difference in the interaction), such a therapeutic typically would not be administered to a subject genotyped as being homozygous for the minor allele, and sometimes not administered to a subject genotyped as being heterozygous for the minor allele. In another example, where a candidate therapeutic is not significantly toxic when administered to subjects who are homozygous for a major allele but is comparatively toxic when administered to subjects heterozygous or homozygous for a minor allele, the candidate therapeutic is not typically administered to subjects who are genotyped as being heterozygous or homozygous with respect to the minor allele.

[0098] The methods described herein are applicable to pharmacogenomic methods for preventing, alleviating or treating osteoarthritis. For example, a nucleic acid sample from an individual may be subjected to a prognostic test described herein. Where one or more polymorphic variations associated

with increased risk of osteoarthritis are identified in a subject, information for preventing or treating osteoarthritis and/or one or more osteoarthritis treatment regimens then may be prescribed to that subject.

[0099] In certain embodiments, a treatment or preventative regimen is specifically prescribed and/or administered to individuals who will most benefit from it based upon their risk of developing osteoarthritis assessed by the methods described herein. Thus, provided are methods for identifying a subject predisposed to osteoarthritis and then prescribing a therapeutic or preventative regimen to individuals identified as having a predisposition. Thus, certain embodiments are directed to a method for reducing osteoarthritis in a subject, which comprises: detecting the presence or absence of a polymorphic variant associated with osteoarthritis in a nucleotide sequence in a nucleic acid sample from a subject, where the nucleotide sequence comprises a polynucleotide sequence selected from the group consisting of: (a) a nucleotide sequence of SEQ ID NO: 1-4; (b) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-4; (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-4, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-4; and (d) a fragment of a polynucleotide sequence of (a), (b), or (c); and prescribing or administering a treatment regimen to a subject from whom the sample originated where the presence of a polymorphic variation associated with osteoarthritis is detected in the nucleotide sequence. In these methods, predisposition results may be utilized in combination with other test results to diagnose osteoarthritis.

[0100] Certain preventative treatments often are prescribed to subjects having a predisposition to osteoarthritis and where the subject is diagnosed with osteoarthritis or is diagnosed as having symptoms indicative of an early stage of osteoarthritis. The treatment sometimes is preventative (*e.g.*, is prescribed or administered to reduce the probability that osteoarthritis arises or progresses), sometimes is therapeutic, and sometimes delays, alleviates or halts the progression of osteoarthritis. Any known preventative or therapeutic treatment for alleviating or preventing the occurrence of osteoarthritis is prescribed and/or administered. For example, the treatment often is directed to decreasing pain and improving joint movement. Examples of OA treatments include exercises to keep joints flexible and improve muscle strength. Different medications to control pain, including corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs, *e.g.*, Voltaren); cyclooxygenase-2 (COX-2) inhibitors (*e.g.*, Celebrex, Vioxx, Mobic, and Bextra); monoclonal antibodies (*e.g.*, Remicade); tumor necrosis factor inhibitors (*e.g.*, Enbrel); or injections of glucocorticoids, hyaluronic acid or chondroitin sulfate into joints that are inflamed and not responsive to NSAIDs. Orally administered chondroitin sulfate also may be used as a therapeutic, as it may increase hyaluronic acid levels and viscosity of synovial fluid, and decrease collagenase levels in synovial fluid. Also, glucosamine can serve as an OA therapeutic as delivering it into joints may inhibit enzymes involved in cartilage degradation and enhance the

production of hyaluronic acid. For mild pain without inflammation, acetaminophen may be used. Other treatments include: heat/cold therapy for temporary pain relief; joint protection to prevent strain or stress on painful joints; surgery to relieve chronic pain in damaged joints; and weight control to prevent extra stress on weight-bearing joints.

[0101] As therapeutic approaches for treating osteoarthritis continue to evolve and improve, the goal of treatments for osteoarthritis related disorders is to intervene even before clinical signs first manifest. Thus, genetic markers associated with susceptibility to osteoarthritis prove useful for early diagnosis, prevention and treatment of osteoarthritis.

[0102] As osteoarthritis preventative and treatment information can be specifically targeted to subjects in need thereof (*e.g.*, those at risk of developing osteoarthritis or those in an early stage of osteoarthritis), provided herein is a method for preventing or reducing the risk of developing osteoarthritis in a subject, which comprises: (a) detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) identifying a subject with a predisposition to osteoarthritis, whereby the presence of the polymorphic variation is indicative of a predisposition to osteoarthritis in the subject; and (c) if such a predisposition is identified, providing the subject with information about methods or products to prevent or reduce osteoarthritis or to delay the onset of osteoarthritis. Also provided is a method of targeting information or advertising to a subpopulation of a human population based on the subpopulation being genetically predisposed to a disease or condition, which comprises: (a) detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) identifying the subpopulation of subjects in which the polymorphic variation is associated with osteoarthritis; and (c) providing information only to the subpopulation of subjects about a particular product which may be obtained and consumed or applied by the subject to help prevent or delay onset of the disease or condition.

[0103] Pharmacogenomics methods also may be used to analyze and predict a response to osteoarthritis treatment or a drug. For example, if pharmacogenomics analysis indicates a likelihood that an individual will respond positively to osteoarthritis treatment with a particular drug, the drug may be administered to the individual. Conversely, if the analysis indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may be defined as either the absence of an efficacious response or the presence of toxic side effects. The response to a therapeutic treatment can be predicted in a background study in which subjects in any of the following populations are genotyped: a population that responds favorably to a treatment regimen, a population that does not respond significantly to a treatment regimen, and a population that responds adversely to a treatment regimen (*e.g.*, exhibits one or more side effects). These populations are provided as examples and other populations and subpopulations may be analyzed. Based

upon the results of these analyses, a subject is genotyped to predict whether he or she will respond favorably to a treatment regimen, not respond significantly to a treatment regimen, or respond adversely to a treatment regimen.

[0104] The tests described herein also are applicable to clinical drug trials. One or more polymorphic variants indicative of response to an agent for treating osteoarthritis or to side effects to an agent for treating osteoarthritis may be identified using the methods described herein. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

[0105] Thus, another embodiment is a method of selecting an individual for inclusion in a clinical trial of a treatment or drug comprising the steps of: (a) obtaining a nucleic acid sample from an individual; (b) determining the identity of a polymorphic variation which is associated with a positive response to the treatment or the drug, or at least one polymorphic variation which is associated with a negative response to the treatment or the drug in the nucleic acid sample, and (c) including the individual in the clinical trial if the nucleic acid sample contains said polymorphic variation associated with a positive response to the treatment or the drug or if the nucleic acid sample lacks said polymorphic variation associated with a negative response to the treatment or the drug. In addition, the methods described herein for selecting an individual for inclusion in a clinical trial of a treatment or drug encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination. The polymorphic variation may be in a sequence selected individually or in any combination from the group consisting of (i) a nucleotide sequence of SEQ ID NO: 1-4; (ii) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-4; (iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-4, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-4; and (iv) a fragment of a polynucleotide sequence of (i), (ii), or (iii) comprising the polymorphic site. The including step (c) optionally comprises administering the drug or the treatment to the individual if the nucleic acid sample contains the polymorphic variation associated with a positive response to the treatment or the drug and the nucleic acid sample lacks said biallelic marker associated with a negative response to the treatment or the drug.

[0106] Also provided herein is a method of partnering between a diagnostic/prognostic testing provider and a provider of a consumable product, which comprises: (a) the diagnostic/prognostic testing provider detects the presence or absence of a polymorphic variation associated with osteoarthritis at a

polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) the diagnostic/prognostic testing provider identifies the subpopulation of subjects in which the polymorphic variation is associated with osteoarthritis; (c) the diagnostic/prognostic testing provider forwards information to the subpopulation of subjects about a particular product which may be obtained and consumed or applied by the subject to help prevent or delay onset of the disease or condition; and (d) the provider of a consumable product forwards to the diagnostic test provider a fee every time the diagnostic/prognostic test provider forwards information to the subject as set forth in step (c) above.

Compositions Comprising Osteoarthritis-Directed Molecules

[0107] Featured herein is a composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and one or more molecules specifically directed and targeted to a nucleic acid comprising a *IL1RL1* nucleotide sequence or amino acid sequence. Such directed molecules include, but are not limited to, a compound that binds to a *IL1RL1* nucleotide sequence or amino acid sequence referenced herein; a RNAi or siRNA molecule having a strand complementary or substantially complementary to a *IL1RL1* nucleotide sequence (e.g., hybridizes to a *IL1RL1* nucleotide sequence under conditions of high stringency); an antisense nucleic acid complementary or substantially complementary to an RNA encoded by a *IL1RL1* nucleotide sequence (e.g., hybridizes to a *IL1RL1* nucleotide sequence under conditions of high stringency); a ribozyme that hybridizes to a *IL1RL1* nucleotide sequence (e.g., hybridizes to a *IL1RL1* nucleotide sequence under conditions of high stringency); a nucleic acid aptamer that specifically binds a polypeptide encoded by *IL1RL1* nucleotide sequence; and an antibody that specifically binds to a polypeptide encoded by *IL1RL1* nucleotide sequence or binds to a nucleic acid having such a nucleotide sequence. In specific embodiments, the osteoarthritis directed molecule interacts with a nucleic acid or polypeptide variant associated with osteoarthritis, such as variants referenced herein. In other embodiments, the osteoarthritis directed molecule interacts with a polypeptide involved in a signal pathway of a polypeptide encoded by a *IL1RL1* nucleotide sequence, or a nucleic acid comprising such a nucleotide sequence.

[0108] Compositions sometimes include an adjuvant known to stimulate an immune response, and in certain embodiments, an adjuvant that stimulates a T-cell lymphocyte response. Adjuvants are known, including but not limited to an aluminum adjuvant (e.g., aluminum hydroxide); a cytokine adjuvant or adjuvant that stimulates a cytokine response (e.g., interleukin (IL)-12 and/or gamma-interferon cytokines); a Freund-type mineral oil adjuvant emulsion (e.g., Freund's complete or incomplete adjuvant); a synthetic lipid compound; a copolymer adjuvant (e.g., TitreMax); a saponin; Quil A; a liposome; an oil-in-water emulsion (e.g., an emulsion stabilized by Tween 80 and pluronic polyoxyethylene/polyoxypropylene block copolymer (Syntex Adjuvant Formulation); TitreMax; detoxified endotoxin (MPL) and mycobacterial cell wall components (TDW, CWS) in 2% squalene (Ribi

Adjuvant System)); a muramyl dipeptide; an immune-stimulating complex (ISCOM, e.g., an Ag-modified saponin/cholesterol micelle that forms stable cage-like structure); an aqueous phase adjuvant that does not have a depot effect (e.g., Gerbu adjuvant); a carbohydrate polymer (e.g., AdjuPrime); L-tyrosine; a manide-oleate compound (e.g., Montanide); an ethylene-vinyl acetate copolymer (e.g., Elvax 40W1,2); or lipid A, for example. Such compositions are useful for generating an immune response against osteoarthritis directed molecule (e.g., an HLA-binding subsequence within a polypeptide encoded by a *IL1RL1* nucleotide sequence). In such methods, a peptide having an amino acid subsequence of a polypeptide encoded by a *IL1RL1* nucleotide sequence is delivered to a subject, where the subsequence binds to an HLA molecule and induces a CTL lymphocyte response. The peptide sometimes is delivered to the subject as an isolated peptide or as a minigene in a plasmid that encodes the peptide. Methods for identifying HLA-binding subsequences in such polypeptides are known (see e.g., publication WO02/20616 and PCT application US98/01373 for methods of identifying such sequences).

[0109] The cell may be in a group of cells cultured *in vitro* or in a tissue maintained *in vitro* or present in an animal *in vivo* (e.g., a rat, mouse, ape or human). In certain embodiments, a composition comprises a component from a cell such as a nucleic acid molecule (e.g., genomic DNA), a protein mixture or isolated protein, for example. The aforementioned compositions have utility in diagnostic, prognostic and pharmacogenomic methods described previously and in therapeutics described hereafter. Certain osteoarthritis directed molecules are described in greater detail below.

Compounds

[0110] Compounds can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive (see, e.g., Zuckermann et al., J. Med. Chem. 37: 2678-85 (1994)); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; "one-bead one-compound" library methods; and synthetic library methods using affinity chromatography selection. Biological library and peptoid library approaches are typically limited to peptide libraries, while the other approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, Anticancer Drug Des. 12: 145, (1997)). Examples of methods for synthesizing molecular libraries are described, for example, in DeWitt et al., Proc. Natl. Acad. Sci. U.S.A. 90: 6909 (1993); Erb et al., Proc. Natl. Acad. Sci. USA 91: 11422 (1994); Zuckermann et al., J. Med. Chem. 37: 2678 (1994); Cho et al., Science 261: 1303 (1993); Carrell et al., Angew. Chem. Int. Ed. Engl. 33: 2059 (1994); Carell et al., Angew. Chem. Int. Ed. Engl. 33: 2061 (1994); and in Gallop et al., J. Med. Chem. 37: 1233 (1994).

[0111] Libraries of compounds may be presented in solution (e.g., Houghten, *Biotechniques* 13: 412-421 (1992)), or on beads (Lam, *Nature* 354: 82-84 (1991)), chips (Fodor, *Nature* 364: 555-556 (1993)), bacteria or spores (Ladner, United States Patent No. 5,223,409), plasmids (Cull et al., *Proc. Natl. Acad. Sci. USA* 89: 1865-1869 (1992)) or on phage (Scott and Smith, *Science* 249: 386-390 (1990); Devlin, *Science* 249: 404-406 (1990); Cwirla et al., *Proc. Natl. Acad. Sci.* 87: 6378-6382 (1990); Felici, *J. Mol. Biol.* 222: 301-310 (1991); Ladner *supra*).

[0112] A compound sometimes alters expression and sometimes alters activity of a polypeptide target and may be a small molecule. Small molecules include, but are not limited to, peptides, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

Antisense Nucleic Acid Molecules, Ribozymes, RNAi, siRNA and Modified Nucleic Acid Molecules

[0113] An “antisense” nucleic acid refers to a nucleotide sequence complementary to a “sense” nucleic acid encoding a polypeptide, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. The antisense nucleic acid can be complementary to an entire coding strand, or to a portion thereof or a substantially identical sequence thereof. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence (e.g., 5' and 3' untranslated regions in SEQ ID NO: 1).

[0114] An antisense nucleic acid can be designed such that it is complementary to the entire coding region of an mRNA encoded by a nucleotide sequence (e.g., SEQ ID NO: 1), and often the antisense nucleic acid is an oligonucleotide antisense to only a portion of a coding or noncoding region of the mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the mRNA, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of interest. An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length. The antisense nucleic acids, which include the ribozymes described hereafter, can be designed to target a *ILIRLI* nucleotide sequence, often a variant associated with osteoarthritis, or a substantially identical sequence thereof. Among the variants, minor alleles and major alleles can be targeted, and those associated with a higher risk of osteoarthritis are often designed, tested, and administered to subjects.

[0115] An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using standard procedures. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0116] When utilized as therapeutics, antisense nucleic acids typically are administered to a subject (e.g., by direct injection at a tissue site) or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a polypeptide and thereby inhibit expression of the polypeptide, for example, by inhibiting transcription and/or translation. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then are administered systemically. For systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, for example, by linking antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. Antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. Sufficient intracellular concentrations of antisense molecules are achieved by incorporating a strong promoter, such as a pol II or pol III promoter, in the vector construct.

[0117] Antisense nucleic acid molecules sometimes are alpha-anomeric nucleic acid molecules. An alpha-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual beta-units, the strands run parallel to each other (Gaultier et al., Nucleic Acids. Res. 15: 6625-6641 (1987)). Antisense nucleic acid molecules can also comprise a 2'-O-methylribonucleotide (Inoue et al., Nucleic Acids Res. 15: 6131-6148 (1987)) or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215: 327-330 (1987)). Antisense nucleic acids sometimes are composed of DNA or PNA or any other nucleic acid derivatives described previously.

[0118] In another embodiment, an antisense nucleic acid is a ribozyme. A ribozyme having specificity for a *IL1RL1* nucleotide sequence can include one or more sequences complementary to such a nucleotide sequence, and a sequence having a known catalytic region responsible for mRNA cleavage (see e.g., U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach, Nature 334: 585-591 (1988)). For example, a derivative of a Tetrahymena L-19 IVS RNA is sometimes utilized in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a mRNA (see e.g., Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742). Also, target mRNA sequences

can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules (see e.g., Bartel & Szostak, *Science* 261: 1411-1418 (1993)).

[0119] Osteoarthritis directed molecules include in certain embodiments nucleic acids that can form triple helix structures with a *ILIRLI* nucleotide sequence, or a substantially identical sequence thereof, especially one that includes a regulatory region that controls expression of a polypeptide. Gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of a nucleotide sequence referenced herein or a substantially identical sequence (e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of a gene in target cells (see e.g., Helene, *Anticancer Drug Des.* 6(6): 569-84 (1991); Helene et al., *Ann. N.Y. Acad. Sci.* 660: 27-36 (1992); and Maher, *Bioassays* 14(12): 807-15 (1992). Potential sequences that can be targeted for triple helix formation can be increased by creating a so-called “switchback” nucleic acid molecule. Switchback molecules are synthesized in an alternating 5’-3’, 3’-5’ manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

[0120] Osteoarthritis directed molecules include RNAi and siRNA nucleic acids. Gene expression may be inhibited by the introduction of double-stranded RNA (dsRNA), which induces potent and specific gene silencing, a phenomenon called RNA interference or RNAi. See, e.g., Fire et al., US Patent Number 6,506,559; Tuschl et al. PCT International Publication No. WO 01/75164; Kay et al. PCT International Publication No. WO 03/010180A1; or Boshier JM, Labouesse, *Nat Cell Biol* 2000 Feb;2(2):E31-6. This process has been improved by decreasing the size of the double-stranded RNA to 20-24 base pairs (to create small-interfering RNAs or siRNAs) that “switched off” genes in mammalian cells without initiating an acute phase response, i.e., a host defense mechanism that often results in cell death (see, e.g., Caplen et al. *Proc Natl Acad Sci U S A.* 2001 Aug 14;98(17):9742-7 and Elbashir et al. *Methods* 2002 Feb;26(2):199-213). There is increasing evidence of post-transcriptional gene silencing by RNA interference (RNAi) for inhibiting targeted expression in mammalian cells at the mRNA level, in human cells. There is additional evidence of effective methods for inhibiting the proliferation and migration of tumor cells in human patients, and for inhibiting metastatic cancer development (see, e.g., U.S. Patent Application No. US2001000993183; Caplen et al. *Proc Natl Acad Sci U S A*; and Abderrahmani et al. *Mol Cell Biol* 2001 Nov21(21):7256-67).

[0121] An “siRNA” or “RNAi” refers to a nucleic acid that forms a double stranded RNA and has the ability to reduce or inhibit expression of a gene or target gene when the siRNA is delivered to or expressed in the same cell as the gene or target gene. “siRNA” refers to short double-stranded RNA formed by the complementary strands. Complementary portions of the siRNA that hybridize to form the double stranded molecule often have substantial or complete identity to the target molecule sequence. In

one embodiment, an siRNA refers to a nucleic acid that has substantial or complete identity to a target gene and forms a double stranded siRNA.

[0122] When designing the siRNA molecules, the targeted region often is selected from a given DNA sequence beginning 50 to 100 nucleotides downstream of the start codon. See, e.g., Elbashir et al., *Methods* 26:199-213 (2002). Initially, 5' or 3' UTRs and regions nearby the start codon were avoided assuming that UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. Sometimes regions of the target 23 nucleotides in length conforming to the sequence motif AA(N19)TT (N, an nucleotide), and regions with approximately 30% to 70% G/C-content (often about 50% G/C-content) often are selected. If no suitable sequences are found, the search often is extended using the motif NA(N21). The sequence of the sense siRNA sometimes corresponds to (N19) TT or N21 (position 3 to 23 of the 23-nt motif), respectively. In the latter case, the 3' end of the sense siRNA often is converted to TT. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense 3' overhangs. The antisense siRNA is synthesized as the complement to position 1 to 21 of the 23-nt motif. Because position 1 of the 23-nt motif is not recognized sequence-specifically by the antisense siRNA, the 3'-most nucleotide residue of the antisense siRNA can be chosen deliberately. However, the penultimate nucleotide of the antisense siRNA (complementary to position 2 of the 23-nt motif) often is complementary to the targeted sequence. For simplifying chemical synthesis, TT often is utilized. siRNAs corresponding to the target motif NAR(N17)YNN, where R is purine (A,G) and Y is pyrimidine (C,U), often are selected. Respective 21 nucleotide sense and antisense siRNAs often begin with a purine nucleotide and can also be expressed from pol III expression vectors without a change in targeting site. Expression of RNAs from pol III promoters often is efficient when the first transcribed nucleotide is a purine.

[0123] The sequence of the siRNA can correspond to the full length target gene, or a subsequence thereof. Often, the siRNA is about 15 to about 50 nucleotides in length (e.g., each complementary sequence of the double stranded siRNA is 15-50 nucleotides in length, and the double stranded siRNA is about 15-50 base pairs in length, sometimes about 20-30 nucleotides in length or about 20-25 nucleotides in length, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. The siRNA sometimes is about 21 nucleotides in length. Methods of using siRNA are well known in the art, and specific siRNA molecules may be purchased from a number of companies including Dharmacon Research, Inc.

[0124] Antisense, ribozyme, RNAi and siRNA nucleic acids can be altered to form modified nucleic acid molecules. The nucleic acids can be altered at base moieties, sugar moieties or phosphate backbone moieties to improve stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup et al., *Bioorganic & Medicinal Chemistry* 4 (1): 5-23 (1996)). As used herein, the terms "peptide

nucleic acid” or “PNA” refers to a nucleic acid mimic such as a DNA mimic, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of a PNA can allow for specific hybridization to DNA and RNA under conditions of low ionic strength. Synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described, for example, in Hyrup et al., (1996) supra and Perry-O’Keefe et al., Proc. Natl. Acad. Sci. 93: 14670-675 (1996).

[0125] PNA nucleic acids can be used in prognostic, diagnostic, and therapeutic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNA nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR clamping); as “artificial restriction enzymes” when used in combination with other enzymes, (e.g., S1 nucleases (Hyrup (1996) supra)); or as probes or primers for DNA sequencing or hybridization (Hyrup et al., (1996) supra; Perry-O’Keefe supra).

[0126] In other embodiments, oligonucleotides may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across cell membranes (see e.g., Letsinger et al., Proc. Natl. Acad. Sci. USA 86: 6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci. USA 84: 648-652 (1987); PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, e.g., Krol et al., Bio-Techniques 6: 958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res. 5: 539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

[0127] Also included herein are molecular beacon oligonucleotide primer and probe molecules having one or more regions complementary to a *IL1RL1* nucleotide sequence, or a substantially identical sequence thereof, two complementary regions one having a fluorophore and one a quencher such that the molecular beacon is useful for quantifying the presence of the nucleic acid in a sample. Molecular beacon nucleic acids are described, for example, in Lizardi et al., U.S. Patent No. 5,854,033; Nazarenko et al., U.S. Patent No. 5,866,336, and Livak et al., U.S. Patent 5,876,930.

Antibodies

[0128] The term “antibody” as used herein refers to an immunoglobulin molecule or immunologically active portion thereof, i.e., an antigen-binding portion. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab’)₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. An antibody sometimes is a polyclonal, monoclonal, recombinant (e.g., a chimeric or humanized), fully human, non-human (e.g.,

murine), or a single chain antibody. An antibody may have effector function and can fix complement, and is sometimes coupled to a toxin or imaging agent.

[0129] A full-length polypeptide or antigenic peptide fragment encoded by a nucleotide sequence referenced herein can be used as an immunogen or can be used to identify antibodies made with other immunogens, e.g., cells, membrane preparations, and the like. An antigenic peptide often includes at least 8 amino acid residues of the amino acid sequences encoded by a nucleotide sequence referenced herein, or substantially identical sequence thereof, and encompasses an epitope. Antigenic peptides sometimes include 10 or more amino acids, 15 or more amino acids, 20 or more amino acids, or 30 or more amino acids. Hydrophilic and hydrophobic fragments of polypeptides sometimes are used as immunogens.

[0130] Epitopes encompassed by the antigenic peptide are regions located on the surface of the polypeptide (e.g., hydrophilic regions) as well as regions with high antigenicity. For example, an Emini surface probability analysis of the human polypeptide sequence can be used to indicate the regions that have a particularly high probability of being localized to the surface of the polypeptide and are thus likely to constitute surface residues useful for targeting antibody production. The antibody may bind an epitope on any domain or region on polypeptides described herein.

[0131] Also, chimeric, humanized, and completely human antibodies are useful for applications which include repeated administration to subjects. Chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, can be made using standard recombinant DNA techniques. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al International Application No. PCT/US86/02269; Akira, et al European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al European Patent Application 173,494; Neuberger et al PCT International Publication No. WO 86/01533; Cabilly et al U.S. Patent No. 4,816,567; Cabilly et al European Patent Application 125,023; Better et al., Science 240: 1041-1043 (1988); Liu et al., Proc. Natl. Acad. Sci. USA 84: 3439-3443 (1987); Liu et al., J. Immunol. 139: 3521-3526 (1987); Sun et al., Proc. Natl. Acad. Sci. USA 84: 214-218 (1987); Nishimura et al., Canc. Res. 47: 999-1005 (1987); Wood et al., Nature 314: 446-449 (1985); and Shaw et al., J. Natl. Cancer Inst. 80: 1553-1559 (1988); Morrison, S. L., Science 229: 1202-1207 (1985); Oi et al., BioTechniques 4: 214 (1986); Winter U.S. Patent 5,225,539; Jones et al., Nature 321: 552-525 (1986); Verhoeyan et al., Science 239: 1534; and Beidler et al., J. Immunol. 141: 4053-4060 (1988).

[0132] Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. See, for example, Lonberg and Huszar, Int. Rev. Immunol. 13: 65-93 (1995); and U.S.

Patent Nos. 5,625,126; 5,633,425; 5,569,825; 5,661,016; and 5,545,806. In addition, companies such as Abgenix, Inc. (Fremont, CA) and Medarex, Inc. (Princeton, NJ), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above. Completely human antibodies that recognize a selected epitope also can be generated using a technique referred to as “guided selection.” In this approach a selected non-human monoclonal antibody (e.g., a murine antibody) is used to guide the selection of a completely human antibody recognizing the same epitope. This technology is described for example by Jespers et al., *Bio/Technology* 12: 899-903 (1994).

[0133] An antibody can be a single chain antibody. A single chain antibody (scFV) can be engineered (see, e.g., Colcher et al., *Ann. N Y Acad. Sci.* 880: 263-80 (1999); and Reiter, *Clin. Cancer Res.* 2: 245-52 (1996)). Single chain antibodies can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target polypeptide.

[0134] Antibodies also may be selected or modified so that they exhibit reduced or no ability to bind an Fc receptor. For example, an antibody may be an isotype or subtype, fragment or other mutant, which does not support binding to an Fc receptor (e.g., it has a mutagenized or deleted Fc receptor binding region).

[0135] Also, an antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1 dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thiotepa chlorambucil, melphalan, carmustine (BCNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0136] Antibody conjugates can be used for modifying a given biological response. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, gamma-interferon, alpha-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 (“IL-1”), interleukin-2 (“IL-2”), interleukin-6 (“IL-6”), granulocyte macrophage colony stimulating factor (“GM-CSF”), granulocyte colony stimulating factor (“G-CSF”), or

other growth factors. Also, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, for example.

[0137] An antibody (e.g., monoclonal antibody) can be used to isolate target polypeptides by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, an antibody can be used to detect a target polypeptide (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. Antibodies can be used diagnostically to monitor polypeptide levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance (i.e., antibody labeling). Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H . Also, an antibody can be utilized as a test molecule for determining whether it can treat osteoarthritis, and as a therapeutic for administration to a subject for treating osteoarthritis.

[0138] An antibody can be made by immunizing with a purified antigen, or a fragment thereof, e.g., a fragment described herein, a membrane associated antigen, tissues, e.g., crude tissue preparations, whole cells, preferably living cells, lysed cells, or cell fractions.

[0139] Included herein are antibodies which bind only a native polypeptide, only denatured or otherwise non-native polypeptide, or which bind both, as well as those having linear or conformational epitopes. Conformational epitopes sometimes can be identified by selecting antibodies that bind to native but not denatured polypeptide. Also featured are antibodies that specifically bind to a polypeptide variant associated with osteoarthritis.

Methods for Identifying Candidate Therapeutics for Treating Osteoarthritis

[0140] Current therapies for the treatment of osteoarthritis have limited efficacy, limited tolerability and significant mechanism-based side effects, and few of the available therapies adequately address underlying defects. Current therapeutic approaches were largely developed in the absence of defined molecular targets or even a solid understanding of disease pathogenesis. Therefore, provided are methods of identifying candidate therapeutics that target biochemical pathways related to the development of osteoarthritis.

[0141] Thus, featured herein are methods for identifying a candidate therapeutic for treating osteoarthritis. The methods comprise contacting a test molecule with a target molecule in a system. A “target molecule” as used herein refers to a *ILIRLI* nucleic acid, a substantially identical nucleic acid thereof, or a fragment thereof, and an encoded polypeptide of the foregoing. The methods also comprise determining the presence or absence of an interaction between the test molecule and the target molecule, where the presence of an interaction between the test molecule and the nucleic acid or polypeptide identifies the test molecule as a candidate osteoarthritis therapeutic. The interaction between the test molecule and the target molecule may be quantified.

[0142] Test molecules and candidate therapeutics include, but are not limited to, compounds, antisense nucleic acids, siRNA molecules, ribozymes, polypeptides or proteins encoded by a *ILIRLI* nucleotide sequence, or a substantially identical sequence or fragment thereof, and immunotherapeutics (e.g., antibodies and HLA-presented polypeptide fragments). A test molecule or candidate therapeutic may act as a modulator of target molecule concentration or target molecule function in a system. A “modulator” may agonize (i.e., up-regulates) or antagonize (i.e., down-regulates) a target molecule concentration partially or completely in a system by affecting such cellular functions as DNA replication and/or DNA processing (e.g., DNA methylation or DNA repair), RNA transcription and/or RNA processing (e.g., removal of intronic sequences and/or translocation of spliced mRNA from the nucleus), polypeptide production (e.g., translation of the polypeptide from mRNA), and/or polypeptide post-translational modification (e.g., glycosylation, phosphorylation, and proteolysis of pro-polypeptides). A modulator may also agonize or antagonize a biological function of a target molecule partially or completely, where the function may include adopting a certain structural conformation, interacting with one or more binding partners, ligand binding, catalysis (e.g., phosphorylation, dephosphorylation, hydrolysis, methylation, and isomerization), and an effect upon a cellular event (e.g., effecting progression of osteoarthritis).

[0143] As used herein, the term “system” refers to a cell free *in vitro* environment and a cell-based environment such as a collection of cells, a tissue, an organ, or an organism. A system is “contacted” with a test molecule in a variety of manners, including adding molecules in solution and allowing them to interact with one another by diffusion, cell injection, and any administration routes in an animal. As used herein, the term “interaction” refers to an effect of a test molecule on test molecule, where the effect sometimes is binding between the test molecule and the target molecule, and sometimes is an observable change in cells, tissue, or organism.

[0144] There are many standard methods for detecting the presence or absence of interaction between a test molecule and a target molecule. For example, titrametric, acidimetric, radiometric, NMR, monolayer, polarographic, spectrophotometric, fluorescent, and ESR assays probative of a target molecule interaction may be utilized.

[0145] Test molecule/target molecule interactions can be detected and/or quantified using assays known in the art. For example, an interaction can be determined by labeling the test molecule and/or the target molecule, where the label is covalently or non-covalently attached to the test molecule or target molecule. The label is sometimes a radioactive molecule such as ^{125}I , ^{131}I , ^{35}S or ^3H , which can be detected by direct counting of radioemission or by scintillation counting. Also, enzymatic labels such as horseradish peroxidase, alkaline phosphatase, or luciferase may be utilized where the enzymatic label can be detected by determining conversion of an appropriate substrate to product. In addition, presence or absence of an interaction can be determined without labeling. For example, a microphysiometer (*e.g.*, Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indication of an interaction between a test molecule and target molecule (McConnell, H. M. *et al.*, *Science* 257: 1906-1912 (1992)).

[0146] In cell-based systems, cells typically include a *IL1RL1* nucleic acid, an encoded polypeptide, or substantially identical nucleic acid or polypeptide thereof, and are often of mammalian origin, although the cell can be of any origin. Whole cells, cell homogenates, and cell fractions (*e.g.*, cell membrane fractions) can be subjected to analysis. Where interactions between a test molecule with a target polypeptide are monitored, soluble and/or membrane bound forms of the polypeptide may be utilized. Where membrane-bound forms of the polypeptide are used, it may be desirable to utilize a solubilizing agent. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.

[0147] An interaction between a test molecule and target molecule also can be detected by monitoring fluorescence energy transfer (FET) (*see, e.g.*, Lakowicz *et al.*, U.S. Patent No. 5,631,169; Stavrianopoulos *et al.* U.S. Patent No. 4,868,103). A fluorophore label on a first, “donor” molecule is selected such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, “acceptor” molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the “donor” polypeptide molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the “acceptor” molecule label may be differentiated from that of the “donor”. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the

“acceptor” molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (*e.g.*, using a fluorimeter).

[0148] In another embodiment, determining the presence or absence of an interaction between a test molecule and a target molecule can be effected by monitoring surface plasmon resonance (*see, e.g.*, Sjolander & Urbanicz, *Anal. Chem.* 63: 2338-2345 (1991) and Szabo *et al.*, *Curr. Opin. Struct. Biol.* 5: 699-705 (1995)). “Surface plasmon resonance” or “biomolecular interaction analysis (BIA)” can be utilized to detect biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

[0149] In another embodiment, the target molecule or test molecules are anchored to a solid phase, facilitating the detection of target molecule/test molecule complexes and separation of the complexes from free, uncomplexed molecules. The target molecule or test molecule is immobilized to the solid support. In an embodiment, the target molecule is anchored to a solid surface, and the test molecule, which is not anchored, can be labeled, either directly or indirectly, with detectable labels discussed herein.

[0150] It may be desirable to immobilize a target molecule, an anti-target molecule antibody, and/or test molecules to facilitate separation of target molecule/test molecule complexes from uncomplexed forms, as well as to accommodate automation of the assay. The attachment between a test molecule and/or target molecule and the solid support may be covalent or non-covalent (*see, e.g.*, U.S. Patent No. 6,022,688 for non-covalent attachments). The solid support may be one or more surfaces of the system, such as one or more surfaces in each well of a microtiter plate, a surface of a silicon wafer, a surface of a bead (*see, e.g.*, Lam, *Nature* 354: 82-84 (1991)) that is optionally linked to another solid support, or a channel in a microfluidic device, for example. Types of solid supports, linker molecules for covalent and non-covalent attachments to solid supports, and methods for immobilizing nucleic acids and other molecules to solid supports are well known (*see, e.g.*, U.S. Patent Nos. 6,261,776; 5,900,481; 6,133,436; and 6,022,688; and WIPO publication WO 01/18234).

[0151] In an embodiment, target molecule may be immobilized to surfaces via biotin and streptavidin. For example, biotinylated target polypeptide can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In another embodiment, a target polypeptide can be prepared as a fusion polypeptide. For example, glutathione-S-transferase/target polypeptide fusion can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivitized microtiter plates, which are then combined with a test molecule

under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, or the matrix is immobilized in the case of beads, and complex formation is determined directly or indirectly as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of target molecule binding or activity is determined using standard techniques.

[0152] In an embodiment, the non-immobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (*e.g.*, by washing) under conditions such that a significant percentage of complexes formed will remain immobilized to the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of manners. Where the previously non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface, *e.g.*, by adding a labeled antibody specific for the immobilized component, where the antibody, in turn, can be directly labeled or indirectly labeled with, *e.g.*, a labeled anti-Ig antibody.

[0153] In another embodiment, an assay is performed utilizing antibodies that specifically bind target molecule or test molecule but do not interfere with binding of the target molecule to the test molecule. Such antibodies can be derivitized to a solid support, and unbound target molecule may be immobilized by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

[0154] Cell free assays also can be conducted in a liquid phase. In such an assay, reaction products are separated from unreacted components, by any of a number of standard techniques, including but not limited to: differential centrifugation (*see, e.g.*, Rivas, G., and Minton, *Trends Biochem Sci Aug; 18(8): 284-7 (1993)*); chromatography (gel filtration chromatography, ion-exchange chromatography); electrophoresis (*see, e.g.*, Ausubel *et al.*, eds. *Current Protocols in Molecular Biology*, J. Wiley: New York (1999)); and immunoprecipitation (*see, e.g.*, Ausubel *et al.*, eds., *supra*). Media and chromatographic techniques are known to one skilled in the art (*see, e.g.*, Heegaard, *J Mol. Recognit. Winter; 11(1-6): 141-8 (1998)*; Hage & Tweed, *J. Chromatogr. B Biomed. Sci. Appl. Oct 10; 699 (1-2): 499-525 (1997)*). Further, fluorescence energy transfer may also be conveniently utilized, as described herein, to detect binding without further purification of the complex from solution.

[0155] In another embodiment, modulators of target molecule expression are identified. For example, a cell or cell free mixture is contacted with a candidate compound and the expression of target mRNA or target polypeptide is evaluated relative to the level of expression of target mRNA or target

polypeptide in the absence of the candidate compound. When expression of target mRNA or target polypeptide is greater in the presence of the candidate compound than in its absence, the candidate compound is identified as an agonist of target mRNA or target polypeptide expression. Alternatively, when expression of target mRNA or target polypeptide is less (*e.g.*, less with statistical significance) in the presence of the candidate compound than in its absence, the candidate compound is identified as an antagonist or inhibitor of target mRNA or target polypeptide expression. The level of target mRNA or target polypeptide expression can be determined by methods described herein.

[0156] In another embodiment, binding partners that interact with a target molecule are detected. The target molecules can interact with one or more cellular or extracellular macromolecules, such as polypeptides *in vivo*, and these interacting molecules are referred to herein as “binding partners.” Binding partners can agonize or antagonize target molecule biological activity. Also, test molecules that agonize or antagonize interactions between target molecules and binding partners can be useful as therapeutic molecules as they can up-regulate or down-regulated target molecule activity *in vivo* and thereby treat osteoarthritis.

[0157] Binding partners of target molecules can be identified by methods known in the art. For example, binding partners may be identified by lysing cells and analyzing cell lysates by electrophoretic techniques. Alternatively, a two-hybrid assay or three-hybrid assay can be utilized (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos *et al.*, *Cell* 72:223-232 (1993); Madura *et al.*, *J. Biol. Chem.* 268: 12046-12054 (1993); Bartel *et al.*, *Biotechniques* 14: 920-924 (1993); Iwabuchi *et al.*, *Oncogene* 8: 1693-1696 (1993); and Brent WO94/10300). A two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. The assay often utilizes two different DNA constructs. In one construct, a *ILIRLI* nucleic acid (sometimes referred to as the “bait”) is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In another construct, a DNA sequence from a library of DNA sequences that encodes a potential binding partner (sometimes referred to as the “prey”) is fused to a gene that encodes an activation domain of the known transcription factor. Sometimes, a *ILIRLI* nucleic acid can be fused to the activation domain. If the “bait” and the “prey” molecules interact *in vivo*, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to identify the potential binding partner.

[0158] In an embodiment for identifying test molecules that antagonize or agonize complex formation between target molecules and binding partners, a reaction mixture containing the target molecule and the binding partner is prepared, under conditions and for a time sufficient to allow complex formation. The reaction mixture often is provided in the presence or absence of the test molecule. The

test molecule can be included initially in the reaction mixture, or can be added at a time subsequent to the addition of the target molecule and its binding partner. Control reaction mixtures are incubated without the test molecule or with a placebo. Formation of any complexes between the target molecule and the binding partner then is detected. Decreased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture indicates that the molecule antagonizes target molecule/binding partner complex formation. Alternatively, increased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture indicates that the molecule agonizes target molecule/binding partner complex formation. In another embodiment, complex formation of target molecule/binding partner can be compared to complex formation of mutant target molecule/binding partner (*e.g.*, amino acid modifications in a target polypeptide). Such a comparison can be important in those cases where it is desirable to identify test molecules that modulate interactions of mutant but not non-mutated target gene products.

[0159] The assays can be conducted in a heterogeneous or homogeneous format. In heterogeneous assays, target molecule and/or the binding partner are immobilized to a solid phase, and complexes are detected on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the molecules being tested. For example, test compounds that agonize target molecule/binding partner interactions can be identified by conducting the reaction in the presence of the test molecule in a competition format. Alternatively, test molecules that agonize preformed complexes, *e.g.*, molecules with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed.

[0160] In a heterogeneous assay embodiment, the target molecule or the binding partner is anchored onto a solid surface (*e.g.*, a microtiter plate), while the non-anchored species is labeled, either directly or indirectly. The anchored molecule can be immobilized by non-covalent or covalent attachments. Alternatively, an immobilized antibody specific for the molecule to be anchored can be used to anchor the molecule to the solid surface. The partner of the immobilized species is exposed to the coated surface with or without the test molecule. After the reaction is complete, unreacted components are removed (*e.g.*, by washing) such that a significant portion of any complexes formed will remain immobilized on the solid surface. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface is indicative of complex. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored to the surface; *e.g.*, by using a labeled antibody specific for the initially non-immobilized species. Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or that disrupt preformed complexes can be detected.

[0161] In another embodiment, the reaction can be conducted in a liquid phase in the presence or absence of test molecule, where the reaction products are separated from unreacted components, and the complexes are detected (*e.g.*, using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes). Again, depending upon the order of addition of reactants to the liquid phase, test compounds that inhibit complex or that disrupt preformed complexes can be identified.

[0162] In an alternate embodiment, a homogeneous assay can be utilized. For example, a preformed complex of the target gene product and the interactive cellular or extracellular binding partner product is prepared. One or both of the target molecule or binding partner is labeled, and the signal generated by the label(s) is quenched upon complex formation (*e.g.*, U.S. Patent No. 4,109,496 that utilizes this approach for immunoassays). Addition of a test molecule that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances that disrupt target molecule/binding partner complexes can be identified.

[0163] Candidate therapeutics for treating osteoarthritis are identified from a group of test molecules that interact with a target molecule. Test molecules are normally ranked according to the degree with which they modulate (*e.g.*, agonize or antagonize) a function associated with the target molecule (*e.g.*, DNA replication and/or processing, RNA transcription and/or processing, polypeptide production and/or processing, and/or biological function/activity), and then top ranking modulators are selected. Also, pharmacogenomic information described herein can determine the rank of a modulator. The top 10% of ranked test molecules often are selected for further testing as candidate therapeutics, and sometimes the top 15%, 20%, or 25% of ranked test molecules are selected for further testing as candidate therapeutics. Candidate therapeutics typically are formulated for administration to a subject.

Therapeutic Formulations

[0164] Formulations and pharmaceutical compositions typically include in combination with a pharmaceutically acceptable carrier one or more target molecule modulators. The modulator often is a test molecule identified as having an interaction with a target molecule by a screening method described above. The modulator may be a compound, an antisense nucleic acid, a ribozyme, an antibody, or a binding partner. Also, formulations may comprise a target polypeptide or fragment thereof in combination with a pharmaceutically acceptable carrier.

[0165] As used herein, the term “pharmaceutically acceptable carrier” includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions. Pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0166] A pharmaceutical composition typically is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0167] Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, *e.g.*, gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0168] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in

the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0169] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0170] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

[0171] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. Molecules can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0172] In one embodiment, active molecules are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0173] It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity

of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

[0174] Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Molecules which exhibit high therapeutic indices are preferred. While molecules that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0175] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such molecules lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any molecules used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0176] As defined herein, a therapeutically effective amount of protein or polypeptide (*i.e.*, an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, sometimes about 0.01 to 25 mg/kg body weight, often about 0.1 to 20 mg/kg body weight, and more often about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The protein or polypeptide can be administered one time per week for between about 1 to 10 weeks, sometimes between 2 to 8 weeks, often between about 3 to 7 weeks, and more often for about 4, 5, or 6 weeks. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.

[0177] With regard to polypeptide formulations, featured herein is a method for treating osteoarthritis in a subject, which comprises contacting one or more cells in the subject with a first polypeptide, where the subject comprises a second polypeptide having one or more polymorphic variations associated with cancer, and where the first polypeptide comprises fewer polymorphic

variations associated with cancer than the second polypeptide. The first and second polypeptides are encoded by a nucleic acid which comprises a nucleotide sequence in SEQ ID NO: 1-4; a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence referenced in SEQ ID NO: 1-4; a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-4 and a nucleotide sequence 90% or more identical to a nucleotide sequence in SEQ ID NO: 1-4. The subject often is a human.

[0178] For antibodies, a dosage of 0.1 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg) is often utilized. If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is often appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (*e.g.*, into the brain). A method for lipidation of antibodies is described by Cruikshank *et al.*, *J. Acquired Immune Deficiency Syndromes and Human Retrovirology* 14:193 (1997).

[0179] Antibody conjugates can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors. Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

[0180] For compounds, exemplary doses include milligram or microgram amounts of the compound per kilogram of subject or sample weight, for example, about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. When one or more of these small molecules is to be administered to an animal (*e.g.*, a human) in order to modulate expression or activity of a polypeptide or nucleic acid described herein, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of

factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

[0181] With regard to nucleic acid formulations, gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.*, U.S. Patent 5,328,470) or by stereotactic injection (*see e.g.*, Chen *et al.*, (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). Pharmaceutical preparations of gene therapy vectors can include a gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells (*e.g.*, retroviral vectors) the pharmaceutical preparation can include one or more cells which produce the gene delivery system. Examples of gene delivery vectors are described herein.

Therapeutic Methods

[0182] A therapeutic formulation described above can be administered to a subject in need of a therapeutic for inducing a desired biological response.. Therapeutic formulations can be administered by any of the paths described herein. With regard to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from pharmacogenomic analyses described herein.

[0183] As used herein, the term “treatment” is defined as the application or administration of a therapeutic formulation to a subject, or application or administration of a therapeutic agent to an isolated tissue or cell line from a subject with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect osteoarthritis, symptoms of osteoarthritis or a predisposition towards osteoarthritis. A therapeutic formulation includes, but is not limited to, small molecules, peptides, antibodies, ribozymes and antisense oligonucleotides. Administration of a therapeutic formulation can occur prior to the manifestation of symptoms characteristic of osteoarthritis, such that osteoarthritis is prevented or delayed in its progression. The appropriate therapeutic composition can be determined based on screening assays described herein.

[0184] As discussed, successful treatment of osteoarthritis can be brought about by techniques that serve to agonize target molecule expression or function, or alternatively, antagonize target molecule expression or function. These techniques include administration of modulators that include, but are not limited to, small organic or inorganic molecules; antibodies (including, for example, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab')₂ and Fab expression library fragments, scFV molecules, and epitope-binding fragments thereof); and peptides, phosphopeptides, or polypeptides.

[0185] Further, antisense and ribozyme molecules that inhibit expression of the target gene can also be used to reduce the level of target gene expression, thus effectively reducing the level of target gene activity. Still further, triple helix molecules can be utilized in reducing the level of target gene activity. Antisense, ribozyme and triple helix molecules are discussed above. It is possible that the use of antisense, ribozyme, and/or triple helix molecules to reduce or inhibit mutant gene expression can also reduce or inhibit the transcription (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles, such that the concentration of normal target gene product present can be lower than is necessary for a normal phenotype. In such cases, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal target gene activity can be introduced into cells via gene therapy method. Alternatively, in instances in that the target gene encodes an extracellular polypeptide, it can be preferable to co-administer normal target gene polypeptide into the cell or tissue in order to maintain the requisite level of cellular or tissue target gene activity.

[0186] Another method by which nucleic acid molecules may be utilized in treating or preventing osteoarthritis is use of aptamer molecules specific for target molecules. Aptamers are nucleic acid molecules having a tertiary structure which permits them to specifically bind to ligands (*see, e.g., Osborne, et al., Curr. Opin. Chem. Biol.* 1(1): 5-9 (1997); and Patel, D. J., *Curr. Opin. Chem. Biol. Jun; 1(1): 32-46 (1997)*).

[0187] Yet another method of utilizing nucleic acid molecules for osteoarthritis treatment is gene therapy, which can also be referred to as allele therapy. Provided herein is a gene therapy method for treating osteoarthritis in a subject, which comprises contacting one or more cells in the subject or from the subject with a nucleic acid having a first nucleotide sequence (e.g., the first nucleotide sequence is identical to or substantially identical to a nucleotide sequence of SEQ ID NO: 1-4). Genomic DNA in the subject comprises a second nucleotide sequence having one or more polymorphic variations associated with osteoarthritis (e.g., the second nucleotide sequence is identical to or substantially identical to a nucleotide sequence of SEQ ID NO: 1). The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence comprises fewer polymorphic variations associated with osteoarthritis than the second nucleotide sequence. The first nucleotide sequence may comprise a gene sequence that encodes a full-length polypeptide or a fragment thereof. The subject is often a human. Allele therapy methods often are utilized in conjunction with a method of first determining whether a subject has genomic DNA that includes polymorphic variants associated with osteoarthritis.

[0188] In another allele therapy embodiment, provided herein is a method which comprises contacting one or more cells in the subject or from the subject with a polypeptide encoded by a nucleic acid having a first nucleotide sequence (e.g., the first nucleotide sequence is identical to or substantially identical to the nucleotide sequence of SEQ ID NO: 1-4). Genomic DNA in the subject comprises a

second nucleotide sequence having one or more polymorphic variations associated with osteoarthritis (e.g., the second nucleotide sequence is identical to or substantially identical to a nucleotide sequence of SEQ ID NO: 1). The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence comprises fewer polymorphic variations associated with osteoarthritis than the second nucleotide sequence. The first nucleotide sequence may comprise a gene sequence that encodes a full-length polypeptide or a fragment thereof. The subject is often a human.

[0189] For antibody-based therapies, antibodies can be generated that are both specific for target molecules and that reduce target molecule activity. Such antibodies may be administered in instances where antagonizing a target molecule function is appropriate for the treatment of osteoarthritis.

[0190] In circumstances where stimulating antibody production in an animal or a human subject by injection with a target molecule is harmful to the subject, it is possible to generate an immune response against the target molecule by use of anti-idiotypic antibodies (*see, e.g., Herlyn, Ann. Med.; 31(1): 66-78 (1999); and Bhattacharya-Chatterjee & Foon, Cancer Treat. Res.; 94: 51-68 (1998)*). Introducing an anti-idiotypic antibody to a mammal or human subject often stimulates production of anti-anti-idiotypic antibodies, which typically are specific to the target molecule. Vaccines directed to osteoarthritis also may be generated in this fashion.

[0191] In instances where the target molecule is intracellular and whole antibodies are used, internalizing antibodies may be preferred. Lipofectin or liposomes can be used to deliver the antibody or a fragment of the Fab region that binds to the target antigen into cells. Where fragments of the antibody are used, the smallest inhibitory fragment that binds to the target antigen is preferred. For example, peptides having an amino acid sequence corresponding to the Fv region of the antibody can be used. Alternatively, single chain neutralizing antibodies that bind to intracellular target antigens can also be administered. Such single chain antibodies can be administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell population (*see, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA 90: 7889-7893 (1993)*).

[0192] Modulators can be administered to a patient at therapeutically effective doses to treat osteoarthritis. A therapeutically effective dose refers to an amount of the modulator sufficient to result in amelioration of symptoms of osteoarthritis. Toxicity and therapeutic efficacy of modulators can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.,* for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Modulators that exhibit large therapeutic indices are preferred. While modulators that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such molecules to the site of affected tissue in order to minimize potential damage to uninfected cells, thereby reducing side effects.

[0193] Data obtained from cell culture assays and animal studies can be used in formulating a range of dosages for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED_{50} with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC_{50} (*i.e.*, the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

[0194] Another example of effective dose determination for an individual is the ability to directly assay levels of “free” and “bound” compound in the serum of the test subject. Such assays may utilize antibody mimics and/or “biosensors” that have been created through molecular imprinting techniques. Molecules that modulate target molecule activity are used as a template, or “imprinting molecule”, to spatially organize polymerizable monomers prior to their polymerization with catalytic reagents. The subsequent removal of the imprinted molecule leaves a polymer matrix which contains a repeated “negative image” of the compound and is able to selectively rebind the molecule under biological assay conditions. A detailed review of this technique can be seen in Ansell *et al.*, *Current Opinion in Biotechnology* 7: 89-94 (1996) and in Shea, *Trends in Polymer Science* 2: 166-173 (1994). Such “imprinted” affinity matrixes are amenable to ligand-binding assays, whereby the immobilized monoclonal antibody component is replaced by an appropriately imprinted matrix. An example of the use of such matrixes in this way can be seen in Vlatakis, *et al.*, *Nature* 361: 645-647 (1993). Through the use of isotope-labeling, the “free” concentration of compound which modulates target molecule expression or activity readily can be monitored and used in calculations of IC_{50} . Such “imprinted” affinity matrixes can also be designed to include fluorescent groups whose photon-emitting properties measurably change upon local and selective binding of target compound. These changes readily can be assayed in real time using appropriate fiberoptic devices, in turn allowing the dose in a test subject to be quickly optimized based on its individual IC_{50} . An example of such a “biosensor” is discussed in Kriz *et al.*, *Analytical Chemistry* 67: 2142-2144 (1995).

[0195] The examples set forth below are intended to illustrate but not limit the invention.

Examples

[0196] In the following studies a group of subjects was selected according to specific parameters relating to osteoarthritis. Nucleic acid samples obtained from individuals in the study group were subjected to genetic analysis, which identified associations between osteoarthritis and a polymorphism in

the *IL1RL1* gene on chromosome two. The polymorphism was genotyped again in two replication cohorts consisting of individuals selected for OA. In addition, SNPs proximal to the incident polymorphism were identified and allelotyped in OA case and control pools. Methods are described for producing *IL1RL1* polypeptide and *IL1RL1* polypeptide variants *in vitro* or *in vivo*, *IL1RL1* nucleic acids or polypeptides and variants thereof are utilized for screening test molecules for those that interact with *IL1RL1* molecules. Test molecules identified as interactors with *IL1RL1* molecules and *IL1RL1* variants are further screened *in vivo* to determine whether they treat osteoarthritis.

Example 1

Samples and Pooling Strategies

Sample Selection

[0197] Blood samples were collected from individuals diagnosed with knee osteoarthritis, which were referred to as case samples. Also, blood samples were collected from individuals not diagnosed with knee osteoarthritis as gender and age-matched controls. A database was created that listed all phenotypic trait information gathered from individuals for each case and control sample. Genomic DNA was extracted from each of the blood samples for genetic analyses.

DNA Extraction from Blood Samples

[0198] Six to ten milliliters of whole blood was transferred to a 50 ml tube containing 27 ml of red cell lysis solution (RCL). The tube was inverted until the contents were mixed. Each tube was incubated for 10 minutes at room temperature and inverted once during the incubation. The tubes were then centrifuged for 20 minutes at 3000 x g and the supernatant was carefully poured off. 100-200 µl of residual liquid was left in the tube and was pipetted repeatedly to resuspend the pellet in the residual supernatant. White cell lysis solution (WCL) was added to the tube and pipetted repeatedly until completely mixed. While no incubation was normally required, the solution was incubated at 37°C or room temperature if cell clumps were visible after mixing until the solution was homogeneous. 2 ml of protein precipitation was added to the cell lysate. The mixtures were vortexed vigorously at high speed for 20 sec to mix the protein precipitation solution uniformly with the cell lysate, and then centrifuged for 10 minutes at 3000 x g. The supernatant containing the DNA was then poured into a clean 15 ml tube, which contained 7 ml of 100% isopropanol. The samples were mixed by inverting the tubes gently until white threads of DNA were visible. Samples were centrifuged for 3 minutes at 2000 x g and the DNA was visible as a small white pellet. The supernatant was decanted and 5 ml of 70% ethanol was added to each tube. Each tube was inverted several times to wash the DNA pellet, and then centrifuged for 1 minute at 2000 x g. The ethanol was decanted and each tube was drained on clean absorbent paper. The

DNA was dried in the tube by inversion for 10 minutes, and then 1000 µl of 1X TE was added. The size of each sample was estimated, and less TE buffer was added during the following DNA hydration step if the sample was smaller. The DNA was allowed to rehydrate overnight at room temperature, and DNA samples were stored at 2-8°C.

[0199] DNA was quantified by placing samples on a hematology mixer for at least 1 hour. DNA was serially diluted (typically 1:80, 1:160, 1:320, and 1:640 dilutions) so that it would be within the measurable range of standards. 125 µl of diluted DNA was transferred to a clear U-bottom microtitre plate, and 125 µl of 1X TE buffer was transferred into each well using a multichannel pipette. The DNA and 1X TE were mixed by repeated pipetting at least 15 times, and then the plates were sealed. 50 µl of diluted DNA was added to wells A5-H12 of a black flat bottom microtitre plate. Standards were inverted six times to mix them, and then 50 µl of 1X TE buffer was pipetted into well A1, 1000 ng/ml of standard was pipetted into well A2, 500 ng/ml of standard was pipetted into well A3, and 250 ng/ml of standard was pipetted into well A4. PicoGreen (Molecular Probes, Eugene, Oregon) was thawed and freshly diluted 1:200 according to the number of plates that were being measured. PicoGreen was vortexed and then 50µl was pipetted into all wells of the black plate with the diluted DNA. DNA and PicoGreen were mixed by pipetting repeatedly at least 10 times with the multichannel pipette. The plate was placed into a Fluoroskan Ascent Machine (microplate fluorometer produced by Labsystems) and the samples were allowed to incubate for 3 minutes before the machine was run using filter pairs 485 nm excitation and 538 nm emission wavelengths. Samples having measured DNA concentrations of greater than 450 ng/µl were re-measured for conformation. Samples having measured DNA concentrations of 20 ng/µl or less were re-measured for confirmation.

Pooling Strategies – Discovery Cohort

[0200] Samples were derived from the Nottingham knee OA family study (UK) where index cases were identified through a knee replacement registry. Siblings were approached and assessed with knee x-rays and assigned status as affected or unaffected. In all 1,157 individuals were available. In order to create same-sex pools of appropriate sizes, 335 unrelated female individuals with OA from the Nottingham OA sample were selected for the case pool. The control pool was made up of unrelated female individuals from the St. Thomas twin study (England) with normal knee x-rays and without other indications of OA, regardless of anatomical location, as well as lacking family history of OA. The St. Thomas twin study consists of Caucasian, female participants from the St. Thomas' Hospital, London, adult-twin registry, which is a voluntary registry of >4,000 twin pairs ranging from 18 to 76 years of age. The female case samples and female control samples are described further in Table 1 below.

[0201] A select set of samples from each group were utilized to generate pools, and one pool was created for each group. Each individual sample in a pool was represented by an equal amount of genomic DNA. For example, where 25 ng of genomic DNA was utilized in each PCR reaction and there were 200 individuals in each pool, each individual would provide 125 pg of genomic DNA. Inclusion or exclusion of samples for a pool was based upon the following criteria: the sample was derived from an individual characterized as Caucasian; the sample was derived from an individual of British paternal and maternal descent; case samples were derived from individuals diagnosed with specific knee osteoarthritis (OA) and were recruited from an OA knee replacement clinic. Control samples were derived from individuals free of OA, family history of OA, and rheumatoid arthritis. Also, sufficient genomic DNA was extracted from each blood sample for all allelotyping and genotyping reactions performed during the study. Phenotype information from each individual was collected and included age of the individual, gender, family history of OA, general medical information (e.g., height, weight, thyroid disease, diabetes, psoriasis, hysterectomy), joint history (previous and current symptoms, joint-related operations, age at onset of symptoms, date of primary diagnosis, age of individual as of primary diagnosis and order of involvement), and knee-related findings (crepitus, restricted passive movement, bony swelling/deformity). Additional knee information included knee history, current symptoms, any major knee injury, meniscectomy, knee replacement surgery, age of surgery, and treatment history (including hormone replace therapy (HRT)). Samples that met these criteria were added to appropriate pools based on disease status.

[0202] The selection process yielded the pools set forth in Table 1, which were used in the studies that follow:

TABLE 1

	Female case	Female control
Pool size (Number)	335	335
Pool Criteria (ex: case/control)	control	case
Mean Age (ex: years)	57.21	69.95

Example 2

Association of Polymorphic Variants with Osteoarthritis

[0203] A whole-genome screen was performed to identify particular SNPs associated with occurrence of osteoarthritis. As described in Example 1, two sets of samples were utilized, which included samples from female individuals having knee osteoarthritis (osteoarthritis cases), and samples

from female individuals not having knee osteoarthritis (female controls). The initial screen of each pool was performed in an allelotyping study, in which certain samples in each group were pooled. By pooling DNA from each group, an allele frequency for each SNP in each group was calculated. These allele frequencies were then compared to one another. Particular SNPs were considered as being associated with osteoarthritis when allele frequency differences calculated between case and control pools were statistically significant. SNP disease association results obtained from the allelotyping study were then validated by genotyping each associated SNP across all samples from each pool. The results of the genotyping then were analyzed, allele frequencies for each group were calculated from the individual genotyping results, and a p-value was calculated to determine whether the case and control groups had statistically significant differences in allele frequencies for a particular SNP. When the genotyping results agreed with the original allelotyping results, the SNP disease association was considered validated at the genetic level.

SNP Panel Used for Genetic Analyses

[0204] A whole-genome SNP screen began with an initial screen of approximately 25,000 SNPs over each set of disease and control samples using a pooling approach. The pools studied in the screen are described in Example 1. The SNPs analyzed in this study were part of a set of 25,488 SNPs confirmed as being statistically polymorphic as each is characterized as having a minor allele frequency of greater than 10%. The SNPs in the set reside in genes or in close proximity to genes, and many reside in gene exons. Specifically, SNPs in the set are located in exons, introns, and within 5,000 base-pairs upstream of a transcription start site of a gene. In addition, SNPs were selected according to the following criteria: they are located in ESTs; they are located in Locuslink or Ensembl genes; and they are located in Genomatix promoter predictions. SNPs in the set were also selected on the basis of even spacing across the genome, as depicted in Table 2.

[0205] A case-control study design using a whole genome association strategy involving approximately 28,000 single nucleotide polymorphisms (SNPs) was employed. Approximately 25,000 SNPs were evenly spaced in gene-based regions of the human genome with a median inter-marker distance of about 40,000 base pairs. Additionally, approximately 3,000 SNPs causing amino acid substitutions in genes described in the literature as candidates for various diseases were used. The case-control study samples were of female Caucasian origin (British paternal and maternal descent) 670 individuals were equally distributed in two groups: female controls and female cases. The whole genome association approach was first conducted on 2 DNA pools representing the 2 groups. Significant markers were confirmed by individual genotyping.

TABLE 2

<u>General Statistics</u>		<u>Spacing Statistics</u>	
Total # of SNPs	25,488	Median	37,058 bp
# of Exonic SNPs	>4,335 (17%)	Minimum*	1,000 bp
# SNPs with refSNP ID	20,776 (81%)	Maximum*	3,000,000 bp
Gene Coverage	>10,000	Mean	122,412 bp
Chromosome Coverage	All	Std Deviation	373,325 bp
		<i>*Excludes outliers</i>	

Allelotyping and Genotyping Results

[0206] The genetic studies summarized above and described in more detail below identified an allelic variant in the IL1RL1 gene that is associated with osteoarthritis.

Assay for Verifying, Allelotyping, and Genotyping SNPs

[0207] A MassARRAY™ system (Sequenom, Inc.) was utilized to perform SNP genotyping in a high-throughput fashion. This genotyping platform was complemented by a homogeneous, single-tube assay method (hMET™ or homogeneous MassEXTEND™ (Sequenom, Inc.)) in which two genotyping primers anneal to and amplify a genomic target surrounding a polymorphic site of interest. A third primer (the MassEXTEND™ primer), which is complementary to the amplified target up to but not including the polymorphism, was then enzymatically extended one or a few bases through the polymorphic site and then terminated.

[0208] For each polymorphism, SpectroDESIGNER™ software (Sequenom, Inc.) was used to generate a set of PCR primers and a MassEXTEND™ primer which were used to genotype the polymorphism. Other primer design software could be used or one of ordinary skill in the art could manually design primers based on his or her knowledge of the relevant factors and considerations in designing such primers. Table 3 shows PCR primers and Table 4 shows extension primers used for analyzing polymorphisms. The initial PCR amplification reaction was performed in a 5 µl total volume containing 1X PCR buffer with 1.5 mM MgCl₂ (Qiagen), 200 µM each of dATP, dGTP, dCTP, dTTP (Gibco-BRL), 2.5 ng of genomic DNA, 0.1 units of HotStar DNA polymerase (Qiagen), and 200 nM each of forward and reverse PCR primers specific for the polymorphic region of interest.

TABLE 3: PCR Primers

SNP Reference	Forward PCR primer	Reverse PCR primer
rs1041973	ACGTTGGATGGGGACTTCTGACAATACAGG	ACGTTGGATGAATCGTGTGTTTGCCTCAGG

[0209] Samples were incubated at 95°C for 15 minutes, followed by 45 cycles of 95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 1 minute, finishing with a 3 minute final extension at 72°C. Following amplification, shrimp alkaline phosphatase (SAP) (0.3 units in a 2 µl volume) (Amersham Pharmacia) was added to each reaction (total reaction volume was 7 µl) to remove any residual dNTPs that were not consumed in the PCR step. Samples were incubated for 20 minutes at 37°C, followed by 5 minutes at 85°C to denature the SAP.

[0210] Once the SAP reaction was complete, a primer extension reaction was initiated by adding a polymorphism-specific MassEXTEND™ primer cocktail to each sample. Each MassEXTEND™ cocktail included a specific combination of dideoxynucleotides (ddNTPs) and deoxynucleotides (dNTPs) used to distinguish polymorphic alleles from one another. Methods for verifying, allelotyping and genotyping SNPs are disclosed, for example, in U.S. Pat. No. 6,258,538, the content of which is hereby incorporated by reference. In Table 4, ddNTPs are shown and the fourth nucleotide not shown is the dNTP.

TABLE 4: Extension Primers

SNP Reference	Extend Probe	Termination Mix
rs1041973	ATACCAGAATCAGCAACT	ACT

[0211] The MassEXTEND™ reaction was performed in a total volume of 9 µl, with the addition of 1X ThermoSequenase buffer, 0.576 units of ThermoSequenase (Amersham Pharmacia), 600 nM MassEXTEND™ primer, 2 mM of ddATP and/or ddCTP and/or ddGTP and/or ddTTP, and 2 mM of dATP or dCTP or dGTP or dTTP. The deoxy nucleotide (dNTP) used in the assay normally was complementary to the nucleotide at the polymorphic site in the amplicon. Samples were incubated at 94°C for 2 minutes, followed by 55 cycles of 5 seconds at 94°C, 5 seconds at 52°C, and 5 seconds at 72°C.

[0212] Following incubation, samples were desalted by adding 16 µl of water (total reaction volume was 25 µl), 3 mg of SpectroCLEAN™ sample cleaning beads (Sequenom, Inc.) and allowed to incubate for 3 minutes with rotation. Samples were then robotically dispensed using a piezoelectric dispensing device (SpectroJET™ (Sequenom, Inc.)) onto either 96-spot or 384-spot silicon chips containing a matrix that crystallized each sample (SpectroCHIP™ (Sequenom, Inc.)). Subsequently, MALDI-TOF mass spectrometry (Biflex and Autoflex MALDI-TOF mass spectrometers (Bruker Daltonics) can be used) and SpectroTYPER RT™ software (Sequenom, Inc.) were used to analyze and interpret the SNP genotype for each sample.

Genetic Analysis

[0213] Minor allelic frequencies for the polymorphisms set forth in Table A were verified as being 10% or greater using the extension assay described above in a group of samples isolated from 92 individuals originating from the state of Utah in the United States, Venezuela and France (Coriell cell repositories).

[0214] Genotyping results are shown for female pools in Table 5. In Table 5, "AF" refers to allelic frequency; and "F case" and "F control" refer to female case and female control groups, respectively.

TABLE 5: Genotyping Results

SNP Reference	AF F case	AF F control	p-value
rs1041973	A = 0.189 C = 0.811	A = 0.233 C = 0.767	0.0539

[0215] All of the single marker alleles set forth in Table A were considered validated, since the genotyping data agreed with the allelotyping data and each SNP significantly associated with osteoarthritis. Particularly significant associations with osteoarthritis are indicated by a calculated p-value of less than 0.05 for genotype results. SNP rs1041973 has a calculated p-value of greater than 0.05 (0.0539), but was included because it is an exonic SNP located in the IL1RL1 gene, which plays a role in inflammation and is a compelling target for osteoarthritis.

Example 3

Association of Polymorphic Variants with Osteoarthritis in Replication Cohorts

[0216] The single marker polymorphism set forth in Table A was genotyped again in two replication cohorts consisting of individuals selected for OA.

Sample Selection and Pooling Strategies – Replication Sample 1

[0217] A second case control sample (replication sample #1) was created by using 100 Caucasian female cases from Chingford, UK, and 148 unrelated female cases from the St. Thomas twin study. Cases were defined as having Kellgren-Lawrence (KL) scores of at least 2 in at least one knee x-ray. In addition, 199 male knee replacement cases from Nottingham were included. (For a cohort description, see the Nottingham description provided in Example 1). The control pool was made up of unrelated female individuals from the St. Thomas twin study (England) with normal knee x-rays and without other indications of OA, regardless of anatomical location, as well as lacking family history of OA. The St. Thomas twin study consists of Caucasian, female participants from the St. Thomas' Hospital, London, adult-twin registry, which is a voluntary registry of >4,000 twin pairs ranging from 18 to 76 years of age.

The replication sample 1 cohort was used to replicate the initial results. Table 6 below summarizes the selected phenotype data collected from the case and control individuals.

TABLE 6

Phenotype	Female cases (n=248): median (range)/ (n,%)	Male cases (n=199): median (range)/ (n,%)	Female controls (n=313): mean (range)/ (n,%)
Age	59 (39- 73)	66 (45- 73)	55 (50- 72)
Height (cm)	162 (141- 178)	175 (152- 198)	162 (141- 176)
Weight (kg)	68 (51- 123)	86 (62- 127)	64 (40- 111)
Body mass index (kg/m ²)	26 (18- 44)	29 (21- 41)	24 (18- 46)
Kellgren- Lawrence* left knee	0 (63, 26%), 1 (20, 8%), 2 (105, 43%), 3 (58, 23%), 4 (1, 0%)	NA	NA
Kellgren- Lawrence* right knee	0 (43, 7%), 1 (18, 7%), 2 (127, 52%), 3 (57, 23%), 4 (1, 0%)	NA	NA
KL* >2 both knees	No (145, 59%), Yes (101, 41%)	NA	NA
KL* >2 either knee	No (0, 0%), Yes (248, 100%)	NA	NA

* 0: normal, 1: doubtful, 2: definite osteophyte (bony protuberance), 3: joint space narrowing (with or without osteophyte), 4: joint deformity

Sample Selection and Pooling Strategies – Replication Sample 2

[0218] A third case control sample (replication sample #2) was created by using individuals with symptoms of OA from Newfoundland, Canada. These individuals were recruited and examined by rheumatologists. Affected joints were x-rayed and a final diagnosis of definite or probable OA was made according to American College of Rheumatology criteria by a single rheumatologist to avoid any inter-examiner diagnosis variability. Controls were recruited from volunteers without any symptoms from the musculoskeletal system based on a normal joint exam performed by a rheumatologist. Only cases with a diagnosis of definite OA were included in the study. Only individuals of Caucasian origin were included. The cases consisted of 228 individuals with definite knee OA, 106 individuals with definite hip OA, and 74 individuals with hip OA.

TABLE 7

Phenotype	Case	Control
Age at Visit	62.7	52.5

Phenotype	Case	Control
Sex (Female/Male)	227/119	174/101
Knee OA Xray: No	35% (120)	80% (16)
Unknown	1% (4)	0% (0)
Yes	64% (221)	20% (4)
Hip OA Xray: No	63% (215)	80% (16)
Unknown	2% (7)	0% (0)
Yes	35% (121)	20% (4)

Assay for Verifying, Allelotyping, and Genotyping SNPs

[0219] Genotyping of the replication cohorts described in Tables 6 and 7 was performed using the same methods used for the original genotyping, as described herein. A MassARRAY™ system (Sequenom, Inc.) was utilized to perform SNP genotyping in a high-throughput fashion. This genotyping platform was complemented by a homogeneous, single-tube assay method (hMET™ or homogeneous MassEXTEND™ (Sequenom, Inc.)) in which two genotyping primers anneal to and amplify a genomic target surrounding a polymorphic site of interest. A third primer (the MassEXTEND™ primer), which is complementary to the amplified target up to but not including the polymorphism, was then enzymatically extended one or a few bases through the polymorphic site and then terminated.

[0220] For each polymorphism, SpectroDESIGNER™ software (Sequenom, Inc.) was used to generate a set of PCR primers and a MassEXTEND™ primer which were used to genotype the polymorphism. Other primer design software could be used or one of ordinary skill in the art could manually design primers based on his or her knowledge of the relevant factors and considerations in designing such primers. Table 3 shows PCR primers and Table 4 shows extension probes used for analyzing (e.g., genotyping) polymorphisms in the replication cohorts. The initial PCR amplification reaction was performed in a 5 µl total volume containing 1X PCR buffer with 1.5 mM MgCl₂ (Qiagen), 200 µM each of dATP, dGTP, dCTP, dTTP (Gibco-BRL), 2.5 ng of genomic DNA, 0.1 units of HotStar DNA polymerase (Qiagen), and 200 nM each of forward and reverse PCR primers specific for the polymorphic region of interest.

[0221] Samples were incubated at 95°C for 15 minutes, followed by 45 cycles of 95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 1 minute, finishing with a 3 minute final extension at 72°C. Following amplification, shrimp alkaline phosphatase (SAP) (0.3 units in a 2 µl volume) (Amersham Pharmacia) was added to each reaction (total reaction volume was 7 µl) to remove any residual dNTPs

that were not consumed in the PCR step. Samples were incubated for 20 minutes at 37°C, followed by 5 minutes at 85°C to denature the SAP.

[0222] Once the SAP reaction was complete, a primer extension reaction was initiated by adding a polymorphism-specific MassEXTEND™ primer cocktail to each sample. Each MassEXTEND™ cocktail included a specific combination of dideoxynucleotides (ddNTPs) and deoxynucleotides (dNTPs) used to distinguish polymorphic alleles from one another. Methods for verifying, allelotyping and genotyping SNPs are disclosed, for example, in U.S. Pat. No. 6,258,538, the content of which is hereby incorporated by reference. In Table 7, ddNTPs are shown and the fourth nucleotide not shown is the dNTP.

[0223] The MassEXTEND™ reaction was performed in a total volume of 9 µl, with the addition of 1X ThermoSequenase buffer, 0.576 units of ThermoSequenase (Amersham Pharmacia), 600 nM MassEXTEND™ primer, 2 mM of ddATP and/or ddCTP and/or ddGTP and/or ddTTP, and 2 mM of dATP or dCTP or dGTP or dTTP. The deoxy nucleotide (dNTP) used in the assay normally was complementary to the nucleotide at the polymorphic site in the amplicon. Samples were incubated at 94°C for 2 minutes, followed by 55 cycles of 5 seconds at 94°C, 5 seconds at 52°C, and 5 seconds at 72°C.

[0224] Following incubation, samples were desalted by adding 16 µl of water (total reaction volume was 25 µl), 3 mg of SpectroCLEAN™ sample cleaning beads (Sequenom, Inc.) and allowed to incubate for 3 minutes with rotation. Samples were then robotically dispensed using a piezoelectric dispensing device (SpectroJET™ (Sequenom, Inc.)) onto either 96-spot or 384-spot silicon chips containing a matrix that crystallized each sample (SpectroCHIP™ (Sequenom, Inc.)). Subsequently, MALDI-TOF mass spectrometry (Biflex and Autoflex MALDI-TOF mass spectrometers (Bruker Daltonics) can be used) and SpectroTYPER RT™ software (Sequenom, Inc.) were used to analyze and interpret the SNP genotype for each sample.

Genetic Analysis

[0225] Genotyping results for replication cohorts #1 and #2 are provided in Tables 8 and 9, respectively.

TABLE 8

rsID	Replication #1 (Mixed Male/Female cases and Female controls)				Meta-analysis Disc. + Rep #1
	AF OA Con	AF OA Cas	Delta	P-value	P-value
rs1041973	0.77	0.79	-0.02	0.357	NA

TABLE 9

rsID	Replication #2 (Newfoundland) (Male/Female cases and controls)				Meta-analysis Disc. + Rep #2 Not Done
	AF OA Con	AF OA Cas	Delta	P-value	
rs1041973	0.78	0.79	-0.016	0.510	

[0226] To combine the evidence for association from multiple sample collections, a meta-analysis procedure was employed. The allele frequencies were compared between cases and controls within the discovery sample, as well as within the replication cohort #1 using the DerSimonian-Laird approach (DerSimonian, R. and N. Laird. 1986. Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.)

[0227] The absence of a statistically significant association in one or more of the replication cohorts should not be interpreted as minimizing the value of the original finding. There are many reasons why a biologically derived association identified in a sample from one population would not replicate in a sample from another population. The most important reason is differences in population history. Due to bottlenecks and founder effects, there may be common disease predisposing alleles present in one population that are relatively rare in another, leading to a lack of association in the candidate region. Also, because common diseases such as arthritis-related disorders are the result of susceptibilities in many genes and many environmental risk factors, differences in population-specific genetic and environmental backgrounds could mask the effects of a biologically relevant allele. For these and other reasons, statistically strong results in the original, discovery sample that did not replicate in one or more of the replication samples may be further evaluated in additional replication cohorts and experimental systems.

Example 4

IL1RL1 Region Proximal SNPs

[0228] It has been discovered that SNP rs1041973 in Interleukin 1 receptor-like 1 isoform 1 (*IL1RL1*) is associated with occurrence of osteoarthritis in subjects. Interleukin 1 receptor-like 1 isoform 1 is a member of the interleukin 1 receptor family with no known ligand (orphan receptor). IL1RL1 exists in both a soluble and transmembrane form, suggesting that it may have ligand or ligand scavenging activity. Studies of the similar gene in mouse suggested that this receptor can be induced by proinflammatory stimuli. This gene and four other interleukin 1 receptor family genes, including interleukin 1 receptor, type I (IL1R1), interleukin 1 receptor, type II (IL1R2), interleukin 1 receptor-like 2 (IL1RL2), and interleukin 18 receptor 1 (IL18R1), form a cytokine receptor gene cluster.

[0229] Ninety-one additional allelic variants proximal to rs1041973 were identified and subsequently allelotyped in osteoarthritis case and control sample sets as described in Examples 1 and 2.

The polymorphic variants are set forth in Table 10. The chromosome positions provided in column four of Table 10 are based on Genome “Build 34” of NCBI’s GenBank.

TABLE 10

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs884517	2	207	102527857	c/t
rs1476984	2	6019	102533669	a/g
rs951774	2	6414	102534064	a/c
rs2041737	2	7341	102534991	a/g
rs1420091	2	10984	102538634	a/g
rs2110660	2	12351	102540001	c/g
rs1362347	2	13335	102540985	a/g
rs3073968	2	16584	102544234	-/tgtg/tgtgag
rs4090473	2	16737	102544387	c/g
rs1558622	2	23897	102551547	c/t
rs1558621	2	24057	102551707	c/t
rs1558620	2	25145	102552795	a/g
rs1558619	2	25300	102552950	a/c
rs950881	2	26262	102553912	a/c
rs950880	2	26312	102553962	g/t
rs1362346	2	26589	102554239	c/t
rs1968171	2	27302	102554952	a/g
rs1813299	2	27358	102555008	a/t
rs1813298	2	27451	102555101	c/g
rs1968170	2	27552	102555202	c/t
rs974389	2	30731	102558381	c/t
rs971764	2	32085	102559735	a/g
rs1420089	2	32139	102559789	a/g
rs1420088	2	33184	102560834	a/g
rs1420103	2	42382	102570032	g/t
rs1420102	2	42569	102570219	a/g
rs1997467	2	44823	102572473	c/t
rs1997466	2	45217	102572867	c/g
rs1362350	2	45548	102573198	c/g
rs2310220	2	45601	102573251	a/g
rs1362349	2	45722	102573372	c/g
rs3755278	2	45967	102573617	a/g
rs3771180	2	47367	102575017	a/c
rs3771179	2	47642	102575292	a/c
rs985523	2	48126	102575776	c/t
rs1041973	2	49218	102576868	a/c
rs3214363	2	49274	102576924	-/a
rs873022	2	49433	102577083	g/t
rs3771177	2	49610	102577260	a/c
rs3732129	2	51282	102578932	a/g
rs1420101	2	51466	102579116	a/g
rs12905	2	53757	102581407	a/g

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs3771175	2	53960	102581610	a/t
rs3821204	2	54031	102581681	c/g
rs2160203	2	54574	102582224	c/t
rs1946131	2	55679	102583329	a/g
rs1054096	2	56100	102583750	c/t
rs2287038	2	56182	102583832	c/t
rs1921622	2	59817	102587467	a/g
rs1861246	2	60533	102588183	a/g
rs1861245	2	60656	102588306	a/g
rs3755276	2	72209	102599859	a/g
rs2287037	2	72778	102600428	a/g
rs1420099	2	74293	102601943	c/g
rs3771174	2	77335	102604985	a/g
rs1420098	2	78029	102605679	a/g
rs1362348	2	78374	102606024	c/g
rs1882348	2	78421	102606071	a/t
rs1558627	2	78434	102606084	c/t
rs2058622	2	79174	102606824	c/t
rs3836110	2	79397	102607047	-/g
rs3771172	2	79562	102607212	a/g
rs3771171	2	79700	102607350	a/g
rs3771170	2	79730	102607380	a/t
rs2160202	2	79904	102607554	c/t
rs2058623	2	79920	102607570	a/g
rs3771167	2	79938	102607588	c/t
rs3771166	2	79972	102607622	c/t
rs1974675	2	80125	102607775	c/t
rs1465321	2	80368	102608018	a/g
rs2041740	2	83484	102611134	c/t
rs3771164	2	85536	102613186	a/t
rs2270298	2	85829	102613479	c/t
rs2270297	2	86425	102614075	a/g
rs2041739	2	88083	102615733	a/g
rs2080289	2	88770	102616420	c/t
rs3821203	2	90622	102618272	a/g
rs3771162	2	90924	102618574	a/t
rs3213733	2	91634	102619284	g/t
rs3213732	2	92029	102619679	c/t
rs1035130	2	95152	102622802	a/g
rs3752659	2	95348	102622998	c/t
rs3755274	2	96145	102623795	c/t
rs2241117	2	96793	102624443	a/g
rs2241116	2	97015	102624665	g/t
rs881890	2	97064	102624714	c/t
rs3771161	2	97711	102625361	g/t
rs3771160	2	97855	102625505	a/c
rs3771159	2	98708	102626358	a/g

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs1420104	2	not mapped	not mapped	c/t
rs2041738	2	not mapped	not mapped	a/c

Assay for Verifying and Allelotyping SNPs

[0230] The methods used to verify and allelotype the 91 proximal SNPs of Table 10 are the same methods described in Examples 1 and 2 herein. The primers and probes used in these assays are provided in Table 11 and Table 12, respectively.

TABLE 11

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs884517	ACGTTGGATGCATTTTCTGGTGTGACTCCC	ACGTTGGATGATGTTCCGGTCACTTGTGAGC
rs1476984	ACGTTGGATGTGAGAGAGTTGAAGAATGGG	ACGTTGGATGCCAAGAAGTGATTTCTTCC
rs951774	ACGTTGGATGTCAGCCAGAGGTCTTTACTC	ACGTTGGATGTTAGAAGTCTCTTGGGTGGG
rs2041737	ACGTTGGATGGAGATGGAGTTTCCCTCTTG	ACGTTGGATGAAACCAAGAGGTGGAGGTTG
rs1420091	ACGTTGGATGCACCCCTATTATAAAACCCAC	ACGTTGGATGACCAGAAATGGCATCTATGG
rs2110660	ACGTTGGATGTCTCTCCGAGATGAGGAATC	ACGTTGGATGGTGATCTCCTCAGTACTCTG
rs1362347	ACGTTGGATGTTCTTTGGTAATGAGGTAGG	ACGTTGGATGTGCTTGCCCTCTATTTATGG
rs3073968	ACGTTGGATGGAATGATGAGGAAGGAAGGG	ACGTTGGATGTAAAGCCACATGTTACCCCG
rs4090473	ACGTTGGATGTAGTGTGTTTCACTCTTCCC	ACGTTGGATGTCAAGCACCTCTGTAACTC
rs1558622	ACGTTGGATGATACTTCCTGGTTTTCTGGG	ACGTTGGATGGGCTCAAAGTCATCACCCAA
rs1558621	ACGTTGGATGACAGTGGCGATGCCAACATT	ACGTTGGATGCCTGTAGTAGGACCCTACTG
rs1558620	ACGTTGGATGTTGCAGGTGTCTGGTGATAG	ACGTTGGATGAGTTTGCCTTTCTTCATGGC
rs1558619	ACGTTGGATGCCCTAATTAGGATTCCGCAC	ACGTTGGATGCTCCATCACACTTTGACTGC
rs950881	ACGTTGGATGCTTATCTCAGTCTGCCAGTG	ACGTTGGATGGGTGAGTGAATTAGTCCTGG
rs950880	ACGTTGGATGTGCCAAAGACAATCAAATCC	ACGTTGGATGCACTCACCTCTGATTTCTAG
rs1362346	ACGTTGGATGTTCTCAGGTTACCAAGAG	ACGTTGGATGTCCCGAACCTCATCTCATAC
rs1968171	ACGTTGGATGAATGTTTCAGCCAGCATGG	ACGTTGGATGATCTCCTGACCTCATGATCC
rs1813299	ACGTTGGATGAATTCCAGCACTTTGGGAGG	ACGTTGGATGTTTACCCTGTTAGCCAGGA
rs1813298	ACGTTGGATGTTACTGCAAGCTCCACCTCC	ACGTTGGATGATTAAGTGGCGTGGTGGTG
rs1968170	ACGTTGGATGAGCTTGCAGTAAGCCAGAT	ACGTTGGATGTGTTAGGGTAATTACAGTGC
rs974389	ACGTTGGATGCTCTAGCCCAATATGTCTCC	ACGTTGGATGACTGGAGATGTGAACCCATC
rs971764	ACGTTGGATGGAGATGATGGAGATTAAGAGG	ACGTTGGATGAGTTGTTTGACTTCGGACTG
rs1420089	ACGTTGGATGAGACAGCACATATCAATGAC	ACGTTGGATGTATTGTGCGGTTTCGCTATAG
rs1420088	ACGTTGGATGGGATGACTGTCAAAAACATC	ACGTTGGATGTAATTTTTCAGGAGCAAGGC
rs1420103	ACGTTGGATGTCCATTGGAATATGACCTCC	ACGTTGGATGCCAGGCACATGAGCTATATC
rs1420102	ACGTTGGATGGATTGGTCAGGAACCTCAAAC	ACGTTGGATGTGGGTTGCTTCTAGCTATTG
rs1997467	ACGTTGGATGTGAATTTCAAGTGTGAGTCAGGC	ACGTTGGATGTGAGGGGAAAAAATCATCC
rs1997466	ACGTTGGATGATAGGCACATACAGGATTTT	ACGTTGGATGCTCCCTTTTTCAGATTAATCTC
rs1362350	ACGTTGGATGGAGAACATTCTCTATACCAG	ACGTTGGATGTGCCTGAATAGTGAGAAGCC
rs2310220	ACGTTGGATGGGTTGAAACCAGACTTGCTG	ACGTTGGATGCAGCCTAATCTCTGGTATAG
rs1362349	ACGTTGGATGCAATACTCTGTGGTACTTATC	ACGTTGGATGTAAACAGTCTTATCCTTGGG
rs3755278	ACGTTGGATGAGTGCTGAATAGGTTTGTTT	ACGTTGGATGGCCTAGTTTAAAGATGAATGC

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs3771180	ACGTTGGATGGTCAACATCAAGAATTCTTAG	ACGTTGGATGCCTGAAATTTGATTTGTGGC
rs3771179	ACGTTGGATGGTCTTCATAATTCATGATTG	ACGTTGGATGTCTTAAATATAAGGGGAAG
rs985523	ACGTTGGATGTCTTATGGAAGTTTTGGGTC	ACGTTGGATGCTGCGAAGTAGCATGATAAC
rs1041973	ACGTTGGATGGGGACTTCTGACAATACAGG	ACGTTGGATGAATCGTGTGTTTGCCTCAGG
rs3214363	ACGTTGGATGCAGGCAATCAACCACTGAAG	ACGTTGGATGCTGCAGTTGCTGATTCTGGT
rs873022	ACGTTGGATGCCTAGTCCTTTCTGGAACAG	ACGTTGGATGATCCCTGCAACTGTAAATCC
rs3771177	ACGTTGGATGAAGGTTAGAAGCCCCCTTTTC	ACGTTGGATGGGCTGGAATTAAGAACAAAC
rs3732129	ACGTTGGATGCTAATTCAAAGCCACATCTG	ACGTTGGATGTAAGTTAGCATTGAGATTGC
rs1420101	ACGTTGGATGCAACATTTATGTACACCATAG	ACGTTGGATGTTAGTAATACTCATTGGATT
rs12905	ACGTTGGATGCTCCCAGCAAACAGGAACAG	ACGTTGGATGATCAAGACAATGGGAATGSC
rs3771175	ACGTTGGATGAAAGAGCACAAAAGAACACG	ACGTTGGATGTTATGAACCTCCCTCTGTGTC
rs3821204	ACGTTGGATGCATGTTGTAAGCATGGTCCG	ACGTTGGATGACTTTACCACCCTCGCTAAC
rs2160203	ACGTTGGATGACACAGACCCAAACCATACC	ACGTTGGATGTTCCCGTGTGTTCCATGTAC
rs1946131	ACGTTGGATGGGGAAGTCAAGGTTTAACAC	ACGTTGGATGTACACTCATCACTCCTCAGG
rs1054096	ACGTTGGATGATCAAGGTGCTATGTGAGGG	ACGTTGGATGAAAGCAGGAGTACACAAGGG
rs2287038	ACGTTGGATGAATGTCCCTGGTTACCTATG	ACGTTGGATGACAAATAAGCTAGAAGGAGC
rs1921622	ACGTTGGATGGCCAATTCTTAATTCTGTCC	ACGTTGGATGATTCAGCTAGTGCCTATGG
rs1861246	ACGTTGGATGCACAAGCTCTTCACCTCTTC	ACGTTGGATGTGGCTGAGGAGAAGTGTAAC
rs1861245	ACGTTGGATGTGCTGCCTTCAATGTGTGAC	ACGTTGGATGAGGAAAGGTCAGAGGACATG
rs3755276	ACGTTGGATGCCAGCACTCACTAACATGTG	ACGTTGGATGAAACTCATATGGGCAGCCAC
rs2287037	ACGTTGGATGCAGATTCAGCCAAAGCTTTC	ACGTTGGATGAAAAATCTGTGTGCCAGAAG
rs1420099	ACGTTGGATGTTACACACTCTCCAGAGGTG	ACGTTGGATGAAAGCTTCTAGCTGCCTGAG
rs3771174	ACGTTGGATGACCCAGATTCTCTGGCTTTG	ACGTTGGATGTACCACAAGTGCCGAAAGAG
rs1420098	ACGTTGGATGGGGACGTGAAGTACAAGAT	ACGTTGGATGGGAGACCAAAAAAAGTTACC
rs1362348	ACGTTGGATGCATGTCATAGGAAGAGTAGG	ACGTTGGATGTCAGCAACTCAAATATGCAG
rs1882348	ACGTTGGATGCCTACTCTTCCTATGACATG	ACGTTGGATGCCCTAAAAGGAAATCCTATC
rs1558627	ACGTTGGATGCCCTAAAAGGAAATCCTATC	ACGTTGGATGCCTACTCTTCCTATGACATG
rs2058622	ACGTTGGATGCTGTGAAACCTTGAGTACAC	ACGTTGGATGTTTCTGATGCCTGGGAGTTC
rs3836110	ACGTTGGATGACTCACAAATGGGGTAAAGG	ACGTTGGATGTGCCTTCATTCAATCAGGAG
rs3771172	ACGTTGGATGCAGAAGCAAATGGCATTGGC	ACGTTGGATGCCATTGTTGCTTCCTAAGCC
rs3771171	ACGTTGGATGAGGGTAGCAGATAGGAGATG	ACGTTGGATGAAGCTGCTTCTCTCCTCATC
rs3771170	ACGTTGGATGCAAGGCCATTGTCAAAGCTG	ACGTTGGATGGTGTCCAGAGTGGATATTG
rs2160202	ACGTTGGATGAGCAGTATTTACTGCAGATG	ACGTTGGATGCCACATCAAAGTCAAAGG
rs2058623	ACGTTGGATGATTTACTGCAGATGTGTGTG	ACGTTGGATGTGTTCACTGATAGATCCAC
rs3771167	ACGTTGGATGCTAACTTAAGTGTGTAACCC	ACGTTGGATGCTAACGGGAAATTTTCAGGTG
rs3771166	ACGTTGGATGGTGAACAGACTTTACACCTG	ACGTTGGATGCCTCAGTGGCATTGATTAT
rs1974675	ACGTTGGATGACTAAGAAGGAAGGGGATAC	ACGTTGGATGGTACATTTCCCTCTACCTTC
rs1465321	ACGTTGGATGTCACAGCTTTGGGTCAGTTG	ACGTTGGATGTCAACAACACACTGCACCTG
rs2041740	ACGTTGGATGCATCCATGTCCCTACAAAAG	ACGTTGGATGAAAGCTCTTATACACCATGG
rs3771164	ACGTTGGATGCCTGTGACATGTATGGAAATG	ACGTTGGATGTCAAATCCATAGGTACACTC
rs2270298	ACGTTGGATGTGAAGTAGTGTCTCTCTC	ACGTTGGATGAATATGAGCACTGTAGCTGC
rs2270297	ACGTTGGATGTTTCTGCCAAAAAGAAAGG	ACGTTGGATGGACCACACCACTAGTTCAA
rs2041739	ACGTTGGATGTAGACCCTGAAGTTTCCAC	ACGTTGGATGCACCTAGAGGTTCTTTTGC
rs2080289	ACGTTGGATGTGGAGAATGTCAACTGAGTC	ACGTTGGATGATACAAACAAGAGGCCATGG
rs3821203	ACGTTGGATGTCAAAGACAAAGGGCAGGAG	ACGTTGGATGGGATCCAGAGAAAGGTAGTC
rs3771162	ACGTTGGATGTGAGTGGAGTACAGTGAGAC	ACGTTGGATGTGGCACTGCACCTTCTGAGA
rs3213733	ACGTTGGATGTGAAAGCACCTTGATCTGG	ACGTTGGATGCATCTTCTCTGCCCTTTAG

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs3213732	ACGTTGGATGGTCAGGTTAAAGTGGCAAC	ACGTTGGATGTGACACTGGATACACATTTTC
rs1035130	ACGTTGGATGTTAGGATCCGATCCATTTTC	ACGTTGGATGCTCTGCTTTGCTGAATGAAG
rs3752659	ACGTTGGATGTGCATAATGCGTCCACCTAG	ACGTTGGATGGGCTGATGTGTATTTTGGGC
rs3755274	ACGTTGGATGTATCAAAGGTGTGTGCACCC	ACGTTGGATGAGGGGTAGAAAACACAGTG
rs2241117	ACGTTGGATGTGGCTGGAAGATCATGATGC	ACGTTGGATGCCCCAAGTTGTTAGGAAGAG
rs2241116	ACGTTGGATGAATGCAGGCAACATCACAGC	ACGTTGGATGAGTAGGCTCTGTTCTGTTACC
rs881890	ACGTTGGATGATGCCATTTGCCTTCTGGAG	ACGTTGGATGTCTCAGGGTAACGAACAGAG
rs3771161	ACGTTGGATGCCATCAGGTGAGCACTGAAA	ACGTTGGATGTCATTGCCTCCTGAACTTGG
rs3771160	ACGTTGGATGAGAAAATGGCTGTGACTGGAG	ACGTTGGATGTATCCAGGGAGTTGATGGTG
rs3771159	ACGTTGGATGCAGGTGATGGTCCAACAAAG	ACGTTGGATGTGCTGTGGTCCACTCACTTG
rs1420104	ACGTTGGATGTATTCTGGAGGCTGAGGTGG	ACGTTGGATGTGGAGTGCAGTGGTGTGATC
rs2041738	ACGTTGGATGTGGTGAAACCCCATCTCTAC	ACGTTGGATGTTCAAGCTATTCTCCTGCC

TABLE 12

dbSNP rs#	Extend Primer	Term Mix
rs884517	GGTGTGACTCCCAGACCAA	ACT
rs1476984	ATGGGTAGTTAATGGTGGAATTT	ACT
rs951774	CAAAGTAGTTGACTTGTCTTTCT	ACT
rs2041737	CCAGGCTAGTGCAGTGGC	ACT
rs1420091	CCCACATTATATTGTCATTACTTT	ACG
rs2110660	ATGAGGAATCAGAGCTGGGA	ACT
rs1362347	GTAATGAGGTAGGAATAATATTG	ACT
rs3073968	GGCAATTGTGTGTGTGTGTG	CGT
rs4090473	CTTACTCCTATTCCAAAGTTCA	ACT
rs1558622	ACTGCAAGGGAGAGCCCC	ACT
rs1558621	AGTGTGTGTGTGTGCGTGC	ACT
rs1558620	GTCTGGTGATAGTTGGGTGC	ACG
rs1558619	GATTCCGCACATCCTATGCCT	ACT
rs950881	GATGGTTTGTGCCTCTGGTC	ACT
rs950880	ATTTAAGAATGCTTTCGTCATAAG	ACT
rs1362346	GAATATCTATGCCACCAGAT	ACG
rs1968171	GCCCAGCATGGTGGCTCA	ACG
rs1813299	GTGGATCATGAGGTCAGGAG	CGT
rs1813298	GCCTCAGCCTCCCGAGTA	ACT
rs1968170	AGCCTGGGTGACAGAGCC	ACT
rs974389	GTCTCCTGAATTTCAGAAGCA	ACT
rs971764	GTCAAGGTAAAAACATTATTGTG	ACG
rs1420089	GCACATATCAATGACAAGACTA	ACT
rs1420088	CATGTTATGTAACCTCTGAGTTC	ACT
rs1420103	GAATATGACCTCCAGAAGGCAA	ACT
rs1420102	GAACTCAAACAAATACTTGGACAC	ACG
rs1997467	TTCAGTGACTCTCACAATAAGC	ACG
rs1997466	AAGAAAAAGCTGGTTCAATGAG	ACT
rs1362350	ACATTCTCTATACCAGAGATTAGG	ACT

dbSNP rs#	Extend Primer	Term Mix
rs2310220	CTGAACTTCAAAGTCAAGCTTTT	ACG
rs1362349	CTGTGGTACTTATCATTAAACATCA	ACT
rs3755278	ACTCGGAATTCTTTTACATTTGGT	ACT
rs3771180	CATCAAGAATTCTTAGTACATGAT	ACT
rs3771179	TATGTTAGTAAATTTCTATGTTGG	ACT
rs985523	CATATAGCTTTCACAATGATCATG	ACG
rs1041973	ATACCAGAATCAGCAACT	ACT
rs3214363	GAGCAGGGTGAAAGAAGATGGG	ACT
rs873022	TTCTAGGAATACTATCAGGTTGA	ACT
rs3771177	TTTTACCTACTAGAGGCC	CGT
rs3732129	GCCACATCTGTTCTTTATTCTTT	ACG
rs1420101	CCATCACAAGCCTCTCATT	ACT
rs12905	AGACAGCAAACAACATCC	ACG
rs3771175	CACAAAAGAACACGTTCAGTTT	CGT
rs3821204	TAAGCATGGTCCGTTCTATAC	ACT
rs2160203	CCACACACATTATCATTGTTA	ACT
rs1946131	TTAACTCTTTGGCTATTTGACA	ACT
rs1054096	TCCATCCAGCCTGCCCAC	ACG
rs2287038	TACCTATGTGTTTGAATTATCTTC	ACT
rs1921622	GAAAGAGGACTTAAAAATTGATGA	ACT
rs1861246	CTTCACCTCTTCTTTTTCAGTC	ACG
rs1861245	CTGGAATGGTTTTCTACTTCC	ACG
rs3755276	GTGTGTATGCATGTGTTTCGC	ACT
rs2287037	ACAAAAGTGTGCCTATCTTATGAA	ACT
rs1420099	GGTGGGAGGTTGATAATTGAAA	ACT
rs3771174	CTGACCATCATCTACCCAGG	ACT
rs1420098	ACGTGAAGTACAAGATTCTTCA	ACT
rs1362348	GAGTAGGAAAGAAAAGGATGTG	ACT
rs1882348	TCCTATGACATGAAATACATTCT	CGT
rs1558627	AAGCAGAGAGAGATAAACTTATT	ACG
rs2058622	AAACCTTGGTAGCACTTCTGT	ACT
rs3836110	AACAAACACCGCCCCCCC	CGT
rs3771172	GCATTGCCATCTTTCTGATA	ACG
rs3771171	GAGGTGTCCAGAGTGGATA	ACG
rs3771170	CAAAGCTGCTTCTCTCTCA	CGT
rs2160202	TATACACATATGTGTTCTAACTTA	ACT
rs2058623	ACTTAGGTGTGTAACCCTTTG	ACG
rs3771167	CTTTGTAGTTTGTATGTGGGATCT	ACT
rs3771166	ACTTTACACCTGAAAATTTCCC	ACT
rs1974675	GAAGGGGATACAAAAGGGATA	ACT
rs1465321	CAGTTGGCCTCAGTGTTAACCC	ACG
rs2041740	GAACATCATGCTTTTTTATGGCTG	ACG
rs3771164	GACATGTATGGAATGTGTGTG	CGT
rs2270298	CTCTCTCTCTGCATGTGTGT	ACT

dbSNP rs#	Extend Primer	Term Mix
rs2270297	AGCCAAGTAGAGGAGCACC	ACT
rs2041739	CTCCTGAGTTCCTGTGAATAC	ACT
rs2080289	TCTCAGGACTCCACTCAAATGTC	ACT
rs3821203	GGCAGGAGGCAATTTCCGT	ACT
rs3771162	CAGTGAGACTCAGGAGTGC	CGT
rs3213733	TGTATCTGGTTTTCTCTCACTCA	ACT
rs3213732	CAACATTCAAAAAATGGCACTCTT	ACG
rs1035130	TCCGATCCATTTTCTTCCCC	ACT
rs3752659	CCTAGGGTATGGCCACTATAATTA	ACG
rs3755274	CACCCAACATAAAGAAAGACCTC	ACG
rs2241117	ATCATGATGCTAAGTTGAAAATAT	ACT
rs2241116	TCAAGCATTTTAAACATGTGAATT	CGT
rs881890	TGCCTTCTGGAGTCCTGTAA	ACT
rs3771161	GTGAGCACTGAAAACTTTAAGA	ACT
rs3771160	GCCAGAAAGCTGTGATTCCA	ACT
rs3771159	CCAACAAAGATTGAGCCCC	ACT
rs1420104	CTGGGAGGTGGAGACTGCA	ACT
rs2041738	AAAAATACAAAAATTAGCTGGGC	ACT

Genetic Analysis

[0231] Allelotyping results from the discovery cohort are shown for cases and controls in Table 13. The allele frequency for the A2 allele is noted in the fifth and sixth columns for osteoarthritis case pools and control pools, respectively, where “AF” is allele frequency. The allele frequency for the A1 allele can be easily calculated by subtracting the A2 allele frequency from 1 (A1 AF = 1-A2 AF). For example, the SNP rs951774 has the following case and control allele frequencies: case A1 (A) = 0.24; case A2 (C) = 0.76; control A1 (A) = 0.20; and control A2 (C) = 0.80, where the nucleotide is provided in paranthesis. Some SNPs are labeled “untyped” because of failed assays.

TABLE 13

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs884517	207	102527857	C/T			
rs1476984	6019	102533669	A/G	0.83	0.83	0.973
rs951774	6414	102534064	A/C	0.76	0.80	0.099
rs2041737	7341	102534991	A/G	0.38	0.32	0.146
rs1420091	10984	102538634	A/G	0.33	0.35	0.388
rs2110660	12351	102540001	C/G	0.41	0.40	0.753
rs1362347	13335	102540985	A/G	0.83	0.83	0.895
rs3073968	16584	102544234	/TGTG/T GTGAG	0.48	0.48	0.878
rs4090473	16737	102544387	C/G	0.42	0.43	0.633
rs1558622	23897	102551547	C/T	0.40	0.39	0.879

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs1558621	24057	102551707	C/T	0.32	0.31	0.795
rs1558620	25145	102552795	A/G	0.37	0.37	0.998
rs1558619	25300	102552950	A/C	0.46	0.47	0.556
rs950881	26262	102553912	A/C	0.75	0.74	0.636
rs950880	26312	102553962	G/T	0.45	0.48	0.285
rs1362346	26589	102554239	C/T			
rs1968171	27302	102554952	A/G	0.43	0.43	0.891
rs1813299	27358	102555008	A/T			
rs1813298	27451	102555101	C/G			
rs1968170	27552	102555202	C/T	0.65	0.65	0.941
rs974389	30731	102558381	C/T	0.41	0.42	0.734
rs971764	32085	102559735	A/G	0.45	0.44	0.738
rs1420089	32139	102559789	A/G	0.16	0.19	0.099
rs1420088	33184	102560834	A/G	0.41	0.40	0.869
rs1420103	42382	102570032	G/T	0.68	0.68	0.952
rs1420102	42569	102570219	A/G	0.48	0.46	0.349
rs1997467	44823	102572473	C/T			
rs1997466	45217	102572867	C/G	0.46	0.46	0.693
rs1362350	45548	102573198	C/G	0.48	0.46	0.475
rs2310220	45601	102573251	A/G	0.40	0.41	0.480
rs1362349	45722	102573372	C/G	0.41	0.42	0.893
rs3755278	45967	102573617	A/G	0.07	0.08	0.876
rs3771180	47367	102575017	A/C	0.91	0.90	0.669
rs3771179	47642	102575292	A/C	0.08	0.08	0.986
rs985523	48126	102575776	C/T	0.17	0.13	0.064
rs1041973	49218	102576868	A/C			
rs3214363	49274	102576924	-A			
rs873022	49433	102577083	G/T	0.53	0.56	0.321
rs3771177	49610	102577260	A/C	0.33	0.31	0.278
rs3732129	51282	102578932	A/G	0.46	0.50	0.127
rs1420101	51466	102579116	A/G	0.55	0.57	0.257
rs12905	53757	102581407	A/G	0.30	0.27	0.262
rs3771175	53960	102581610	A/T	0.84	0.82	0.174
rs3821204	54031	102581681	C/G	0.26	0.23	0.222
rs2160203	54574	102582224	C/T	0.21	0.26	0.033
rs1946131	55679	102583329	A/G	0.73	0.74	0.710
rs1054096	56100	102583750	C/T	0.69	0.65	0.137
rs2287038	56182	102583832	C/T	0.98	0.95	0.207
rs1921622	59817	102587467	A/G	0.40	0.43	0.218
rs1861246	60533	102588183	A/G	0.22	0.18	0.068
rs1861245	60656	102588306	A/G	0.35	0.37	0.377
rs3755276	72209	102599859	A/G	0.51	0.48	0.355
rs2287037	72778	102600428	A/G	0.49	0.53	0.195
rs1420099	74293	102601943	C/G	0.58	0.56	0.416
rs3771174	77335	102604985	A/G			
rs1420098	78029	102605679	A/G	0.33	0.32	0.532
rs1362348	78374	102606024	C/G	0.02	0.03	0.590
rs1882348	78421	102606071	A/T	0.36	0.35	0.596
rs1558627	78434	102606084	C/T	0.62	0.65	0.219
rs2058622	79174	102606824	C/T	0.57	0.59	0.528
rs3836110	79397	102607047	-G	0.72	0.73	0.856
rs3771172	79562	102607212	A/G	0.28	0.25	0.261
rs3771171	79700	102607350	A/G			
rs3771170	79730	102607380	A/T	0.24	0.23	0.533
rs2160202	79904	102607554	C/T	0.55	0.62	0.061
rs2058623	79920	102607570	A/G	0.67	0.68	0.631
rs3771167	79938	102607588	C/T			

dbSNP rs#	Position in SEQ ID NO: I	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs3771166	79972	102607622	C/T	0.55	0.53	0.624
rs1974675	80125	102607775	C/T	0.57	0.55	0.470
rs1465321	80368	102608018	A/G	0.27	0.26	0.614
rs2041740	83484	102611134	C/T	0.26	0.25	0.622
rs3771164	85536	102613186	A/T	0.76	0.73	0.197
rs2270298	85829	102613479	C/T	0.23	0.21	0.329
rs2270297	86425	102614075	A/G	0.60	0.60	0.900
rs2041739	88083	102615733	A/G	0.43	0.40	0.235
rs2080289	88770	102616420	C/T	0.56	0.59	0.322
rs3821203	90622	102618272	A/G	0.58	0.62	0.194
rs3771162	90924	102618574	A/T	0.30	0.28	0.260
rs3213733	91634	102619284	G/T	0.76	0.73	0.287
rs3213732	92029	102619679	C/T	0.44	0.42	0.507
rs1035130	95152	102622802	A/G	0.58	0.61	0.234
rs3752659	95348	102622998	C/T	0.80	0.80	0.957
rs3755274	96145	102623795	C/T	0.26	0.25	0.549
rs2241117	96793	102624443	A/G	0.71	0.75	0.077
rs2241116	97015	102624665	G/T	0.16	0.15	0.469
rs881890	97064	102624714	C/T			
rs3771161	97711	102625361	G/T	0.70	0.68	0.348
rs3771160	97855	102625505	A/C			
rs3771159	98708	102626358	A/G	0.38	0.40	0.294
rs1420104	not mapped	not mapped	C/T			
rs2041738	not mapped	not mapped	A/C			

[0232] The *IL1RL1* proximal SNPs were also allelotyped in the replication cohorts using the methods described herein and the primers provided in Tables 11 and 12. The replication allelotyping results for replication cohort #1 and replication cohort #2 are provided in Tables 14 and 15, respectively.

TABLE 14

dbSNP rs#	Position in SEQ ID NO: I	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs884517	207	102527857	C/T			
rs1476984	6019	102533669	A/G	0.82	0.81	0.878
rs951774	6414	102534064	A/C	0.76	0.82	0.024
rs2041737	7341	102534991	A/G	0.36	0.32	0.382
rs1420091	10984	102538634	A/G	0.32	0.35	0.340
rs2110660	12351	102540001	C/G	0.39	0.39	0.951
rs1362347	13335	102540985	A/G	0.83	0.83	0.766
rs3073968	16584	102544234	/TGTG/T GTGAG	0.47	0.48	0.822
rs4090473	16737	102544387	C/G	0.40	0.41	0.663
rs1558622	23897	102551547	C/T	0.38	0.38	0.943
rs1558621	24057	102551707	C/T	0.33	0.32	0.631
rs1558620	25145	102552795	A/G	0.34	0.34	0.957
rs1558619	25300	102552950	A/C	0.44	0.47	0.368
rs950881	26262	102553912	A/C	0.76	0.74	0.476
rs950880	26312	102553962	G/T	0.42	0.47	0.199
rs1362346	26589	102554239	C/T			
rs1968171	27302	102554952	A/G	0.43	0.44	0.641
rs1813299	27358	102555008	A/T			

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs1813298	27451	102555101	C/G			
rs1968170	27552	102555202	C/T	0.64	0.65	0.797
rs974389	30731	102558381	C/T	0.39	0.41	0.678
rs971764	32085	102559735	A/G	0.47	0.46	0.710
rs1420089	32139	102559789	A/G	0.16	0.21	0.075
rs1420088	33184	102560834	A/G	0.41	0.40	0.869
rs1420103	42382	102570032	G/T	0.69	0.72	0.268
rs1420102	42569	102570219	A/G	0.50	0.47	0.329
rs1997467	44823	102572473	C/T			
rs1997466	45217	102572867	C/G	0.49	0.47	0.675
rs1362350	45548	102573198	C/G	0.51	0.47	0.308
rs2310220	45601	102573251	A/G	0.40	0.44	0.282
rs1362349	45722	102573372	C/G	0.42	0.43	0.730
rs3755278	45967	102573617	A/G	0.08	0.08	0.902
rs3771180	47367	102575017	A/C	0.93	0.92	0.591
rs3771179	47642	102575292	A/C	0.08	0.08	0.936
rs985523	48126	102575776	C/T	0.17	0.13	0.156
rs1041973	49218	102576868	A/C			
rs3214363	49274	102576924	-/A			
rs873022	49433	102577083	G/T	0.51	0.56	0.138
rs3771177	49610	102577260	A/C	0.36	0.32	0.125
rs3732129	51282	102578932	A/G	0.43	0.50	0.048
rs1420101	51466	102579116	A/G	0.50	0.55	0.132
rs12905	53757	102581407	A/G	0.33	0.28	0.127
rs3771175	53960	102581610	A/T	0.86	0.83	0.217
rs3821204	54031	102581681	C/G	0.29	0.23	0.071
rs2160203	54574	102582224	C/T	0.19	0.26	0.016
rs1946131	55679	102583329	A/G	0.72	0.73	0.771
rs1054096	56100	102583750	C/T	0.70	0.65	0.079
rs2287038	56182	102583832	C/T	0.93	NA	0.975
rs1921622	59817	102587467	A/G	0.37	0.41	0.260
rs1861246	60533	102588183	A/G	0.22	0.15	0.031
rs1861245	60656	102588306	A/G	0.34	0.39	0.149
rs3755276	72209	102599859	A/G	0.53	0.46	0.072
rs2287037	72778	102600428	A/G	0.45	0.51	0.069
rs1420099	74293	102601943	C/G	0.59	0.55	0.312
rs3771174	77335	102604985	A/G			
rs1420098	78029	102605679	A/G	0.35	0.32	0.328
rs1362348	78374	102606024	C/G	0.02	NA	0.025
rs1882348	78421	102606071	A/T	0.40	0.37	0.399
rs1558627	78434	102606084	C/T	0.64	0.69	0.118
rs2058622	79174	102606824	C/T	0.59	0.62	0.491
rs3836110	79397	102607047	-/G	0.74	0.75	0.625
rs3771172	79562	102607212	A/G	0.31	0.27	0.200
rs3771171	79700	102607350	A/G			
rs3771170	79730	102607380	A/T	0.22	0.20	0.346
rs2160202	79904	102607554	C/T	0.55	0.60	0.217
rs2058623	79920	102607570	A/G	0.69	0.72	0.266
rs3771167	79938	102607588	C/T			
rs3771166	79972	102607622	C/T	0.57	untyped	NA
rs1974675	80125	102607775	C/T	0.58	0.54	0.297
rs1465321	80368	102608018	A/G	0.25	0.23	0.471
rs2041740	83484	102611134	C/T	0.25	0.22	0.450
rs3771164	85536	102613186	A/T	0.77	0.72	0.073
rs2270298	85829	102613479	C/T	0.25	0.22	0.324
rs2270297	86425	102614075	A/G	0.63	0.64	0.589
rs2041739	88083	102615733	A/G	0.44	0.40	0.157

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs2080289	88770	102616420	C/T	0.53	0.58	0.114
rs3821203	90622	102618272	A/G	0.55	0.61	0.104
rs3771162	90924	102618574	A/T	0.34	0.29	0.261
rs3213733	91634	102619284	G/T	0.77	0.73	0.260
rs3213732	92029	102619679	C/T	0.48	0.41	0.026
rs1035130	95152	102622802	A/G	0.55	0.60	0.152
rs3752659	95348	102622998	C/T	0.81	0.80	0.760
rs3755274	96145	102623795	C/T	0.25	0.22	0.319
rs2241117	96793	102624443	A/G	0.72	0.80	0.024
rs2241116	97015	102624665	G/T	0.18	NA	NA
rs881890	97064	102624714	C/T			
rs3771161	97711	102625361	G/T	0.71	0.66	0.146
rs3771160	97855	102625505	A/C			
rs3771159	98708	102626358	A/G	0.38	0.42	0.175
rs1420104	not mapped	not mapped	C/T			
rs2041738	not mapped	not mapped	A/C			

TABLE 15

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs884517	207	102527857	C/T			
rs1476984	6019	102533669	A/G	0.84	0.85	0.759
rs951774	6414	102534064	A/C	0.77	0.75	0.730
rs2041737	7341	102534991	A/G	0.40	NA	
rs1420091	10984	102538634	A/G	0.34	0.35	0.819
rs2110660	12351	102540001	C/G	0.43	0.42	0.665
rs1362347	13335	102540985	A/G	0.82	0.83	0.576
rs3073968	16584	102544234	- /TGTG/T GTGAG	0.49	0.49	0.997
rs4090473	16737	102544387	C/G	0.44	0.45	0.732
rs1558622	23897	102551547	C/T	0.42	0.42	0.976
rs1558621	24057	102551707	C/T	0.31	0.31	0.926
rs1558620	25145	102552795	A/G	0.42	0.42	0.867
rs1558619	25300	102552950	A/C	0.48	0.48	0.930
rs950881	26262	102553912	A/C	0.73	0.73	0.955
rs950880	26312	102553962	G/T	0.48	0.49	0.919
rs1362346	26589	102554239	C/T			
rs1968171	27302	102554952	A/G	0.43	0.42	0.717
rs1813299	27358	102555008	A/T			
rs1813298	27451	102555101	C/G			
rs1968170	27552	102555202	C/T	0.67	0.66	0.830
rs974389	30731	102558381	C/T	0.44	0.45	0.857
rs971764	32085	102559735	A/G	0.43	0.42	0.845
rs1420089	32139	102559789	A/G	0.15	0.16	0.809
rs1420088	33184	102560834	A/G			
rs1420103	42382	102570032	G/T	0.68	0.63	0.178
rs1420102	42569	102570219	A/G	0.45	0.44	0.722
rs1997467	44823	102572473	C/T			
rs1997466	45217	102572867	C/G	0.44	0.43	0.805
rs1362350	45548	102573198	C/G	0.45	0.46	0.890
rs2310220	45601	102573251	A/G	0.38	0.37	0.661
rs1362349	45722	102573372	C/G	0.41	0.40	0.762
rs3755278	45967	102573617	A/G	0.07	0.07	0.984

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs3771180	47367	102575017	A/C	0.88	0.87	0.812
rs3771179	47642	102575292	A/C	0.07	0.07	0.868
rs985523	48126	102575776	C/T	0.16	0.13	0.270
rs1041973	49218	102576868	A/C			
rs3214363	49274	102576924	-/A			
rs873022	49433	102577083	G/T	0.57	0.56	0.868
rs3771177	49610	102577260	A/C	0.29	0.29	0.988
rs3732129	51282	102578932	A/G	0.51	0.52	0.795
rs1420101	51466	102579116	A/G	0.60	0.61	0.864
rs12905	53757	102581407	A/G	0.26	0.26	0.994
rs3771175	53960	102581610	A/T	0.82	0.80	0.444
rs3821204	54031	102581681	C/G	0.22	0.23	0.769
rs2160203	54574	102582224	C/T	0.23	0.25	0.732
rs1946131	55679	102583329	A/G	0.75	0.77	0.723
rs1054096	56100	102583750	C/T	0.66	0.65	0.807
rs2287038	56182	102583832	C/T	0.97	0.00	
rs1921622	59817	102587467	A/G	0.44	0.46	0.472
rs1861246	60533	102588183	A/G	0.23	0.24	0.824
rs1861245	60656	102588306	A/G	0.36	0.34	0.590
rs3755276	72209	102599859	A/G	0.48	0.51	0.423
rs2287037	72778	102600428	A/G	0.55	0.54	0.941
rs1420099	74293	102601943	C/G	0.58	0.58	0.904
rs3771174	77335	102604985	A/G			
rs1420098	78029	102605679	A/G	0.30	0.31	0.827
rs1362348	78374	102606024	C/G	0.04	-0.01	
rs1882348	78421	102606071	A/T	0.31	0.31	0.968
rs1558627	78434	102606084	C/T	0.60	0.59	0.839
rs2058622	79174	102606824	C/T	0.56	0.55	0.961
rs3836110	79397	102607047	-/G	0.70	0.69	0.643
rs3771172	79562	102607212	A/G	0.24	0.22	0.675
rs3771171	79700	102607350	A/G			
rs3771170	79730	102607380	A/T	0.26	0.27	0.700
rs2160202	79904	102607554	C/T	untyped	0.64	NA
rs2058623	79920	102607570	A/G	0.65	0.62	0.389
rs3771167	79938	102607588	C/T			
rs3771166	79972	102607622	C/T	0.53	0.53	0.820
rs1974675	80125	102607775	C/T	0.55	0.56	0.842
rs1465321	80368	102608018	A/G	0.29	0.30	0.781
rs2041740	83484	102611134	C/T	0.28	0.30	0.658
rs3771164	85536	102613186	A/T	0.73	0.74	0.905
rs2270298	85829	102613479	C/T	0.19	0.18	0.654
rs2270297	86425	102614075	A/G	0.57	0.53	0.249
rs2041739	88083	102615733	A/G	0.42	0.41	0.892
rs2080289	88770	102616420	C/T	0.61	0.60	0.840
rs3821203	90622	102618272	A/G	0.62	0.63	0.927
rs3771162	90924	102618574	A/T	0.26	0.25	0.621
rs3213733	91634	102619284	G/T	0.75	0.74	0.728
rs3213732	92029	102619679	C/T	0.39	0.45	0.176
rs1035130	95152	102622802	A/G	0.62	0.63	0.792
rs3752659	95348	102622998	C/T	0.79	0.80	0.826
rs3755274	96145	102623795	C/T	0.27	0.29	0.618
rs2241117	96793	102624443	A/G	0.70	0.67	0.480
rs2241116	97015	102624665	G/T	0.15	0.15	0.849
rs881890	97064	102624714	C/T			
rs3771161	97711	102625361	G/T	0.68	0.70	0.681
rs3771160	97855	102625505	A/C			
rs3771159	98708	102626358	A/G	0.37	0.37	0.970

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs1420104	not mapped	not mapped	C/T			
rs2041738	not mapped	not mapped	A/C			

[0233] Allelotyping results were considered particularly significant with a calculated p-value of less than or equal to 0.05 for allelotype results. These values are indicated in bold. The allelotyping p-values were plotted in Figure 1 for the discovery cohort. The position of each SNP on the chromosome is presented on the x-axis. The y-axis gives the negative logarithm (base 10) of the p-value comparing the estimated allele in the case group to that of the control group. The minor allele frequency of the control group for each SNP designated by an X or other symbol on the graphs in Figure 1 can be determined by consulting Tables 13. For example, the left-most X on the left graph is at position 102527857. By proceeding down the Table from top to bottom and across the graphs from left to right the allele frequency associated with each symbol shown can be determined.

[0234] To aid the interpretation, multiple lines have been added to the graph. The broken horizontal lines are drawn at two common significance levels, 0.05 and 0.01. The vertical broken lines are drawn every 20kb to assist in the interpretation of distances between SNPs. Two other lines are drawn to expose linear trends in the association of SNPs to the disease. The light gray line (or generally bottom-most curve) is a nonlinear smoother through the data points on the graph using a local polynomial regression method (W.S. Cleveland, E. Grosse and W.M. Shyu (1992) Local regression models. Chapter 8 of Statistical Models in S eds J.M. Chambers and T.J. Hastie, Wadsworth & Brooks/Cole.). The black line provides a local test for excess statistical significance to identify regions of association. This was created by use of a 10kb sliding window with 1kb step sizes. Within each window, a chi-square goodness of fit test was applied to compare the proportion of SNPs that were significant at a test wise level of 0.01, to the proportion that would be expected by chance alone (0.05 for the methods used here). Resulting p-values that were less than 10^{-8} were truncated at that value.

[0235] Finally, the exons and introns of the genes in the covered region are plotted below each graph at the appropriate chromosomal positions. The gene boundary is indicated by the broken horizontal line. The exon positions are shown as thick, unbroken bars. An arrow is place at the 3' end of each gene to show the direction of transcription.

Example 5

Gene expression profiling in IL-1 beta and PMA stimulated SW1353 cells

[0236] The human chondrosarcoma cell line, SW1353, (ATCC HTB-94) was grown in L-15 media containing 10% FCS. Culture conditions were at 37 degrees with 0% CO2 with media changes every 2-3

days. SW1353 cells were grown to 80-90% confluence in 10 cm dishes and then stimulated with either 10ng/ml IL-1 beta (human recombinant, Research Diagnostics) or with 200nm PMA (Sigma). IL-1 beta stimulation was for 3 and 24 hours and PMA stimulation was for 3 and 24 hours. Control cells were grown and extracted in parallel with treated cells. As shown in Figure 6, IL1RL1 was seen to be upregulated by IL1-beta and by phorbol esters in a human chondrocyte cell line model (SW1353 monolayer cell line).

[0237] The expression profiling in IL-1 beta and PMA stimulated SW1353 cells grown in 3-D alginate cultures W1353 cells were cultured as above and then resuspended in 1.2% alginate beads at a density of 4 millions cells/ml according to the manufacturer (Cambrex). Cells were grown for 2 weeks and an alginate bead was removed from culture and tested for the presence of proteoglycans by Alcian Blue staining (Sigma). Positive staining indicated that the chondrocytes were expressing ECM proteins. Alginate cultures were then stimulated with IL-1 beta for 24 hours or with PMA for 3 hours. Control cells were grown and extracted in parallel with treated cells. As shown in Figure 7, IL1RL1 was seen to be upregulated by IL1-beta and by phorbol esters in a human chondrocyte cell line model (SW1353 3-D alginate cell line).

RNA extraction and cDNA synthesis

[0238] Cells from control chondrocytes and stimulated chondrocytes were isolated at the appropriate time period. mRNA was isolated from total cell lysates using poly dT beads according to the manufacturer (Dyna). Isolated mRNA was used to generate cDNA using SuperScript II reverse transcriptase according to the manufacturer (Invitrogen).

Expression profiling using semi-quantitative PCR

[0239] cDNA levels were normalized using the housekeeping gene, GAPDH. Specific primers corresponding to MMP8 and MMP13 were used in semi-quantitative PCR as positive indicators of induction of an osteoarthritic phenotype. All specific primers used, including MMP8, MMP13, BVES, CHDC1 and IL1RL1 (transmembrane form, soluble form, soluble isoform 1 and soluble isoform 2) for semi-quantitative PCR and are listed in Table 16.

TABLE 16: Primer Sequences for Expression Profiling

Gene	Forward primer	Reverse primer
GAPDH	ATCATCTCTGCCCCCTCTG	GAGGATTGCTGATGATCTTC
MMP8	CAATACTGGGCTCTGAGTGG	GGAAAGGCACCTGATATGC
MMP13	ATATCTGAACTGGGTCTTCC	GACAGCATCTACTTTATCACC
BVES	AACAGTATAGCCAGCTCC	ATCATCATCTTCTGCTCC
CHDC1	CCAAAGATCAGGACATGGATA	TGCTGTTTGTGGTAGGAGAG
IL1RL1 (TM)	CCACTCTGCTCTGGAGAGAC	GCCTGCTCTTTCGTATGTTG
IL1RL1 (Sol)	TCCGTCACTGACTCCAAGTT	TTGCTGCTGTGGAATACATG

Gene	Forward primer	Reverse primer
IL1RL1 (ST2_3)	AGGCTTTTCTCTGTTTCC	GTTGAATTCTTGGTTCACC
IL1RL1 (ST2_2)	TAATGTGATGACTGAGGACG	TGCAGAAACTCTGACACC

[0240] In a human chondrocyte cell line model, IL1RL1 was seen to be upregulated by IL1-beta and by phorbol esters. IL1RL1 has an unknown function, but it may possibly mediated inflammatory responses that can contribute to the development of OA. IL1RL1 is druggable by antibodies or by protein agents.

Example 6

In Vitro Production of Target Polypeptides

[0241] cDNA is cloned into a pIVEX 2.3-MCS vector (Roche Biochem) using a directional cloning method. A cDNA insert is prepared using PCR with forward and reverse primers having 5' restriction site tags (in frame) and 5-6 additional nucleotides in addition to 3' gene-specific portions, the latter of which is typically about twenty to about twenty-five base pairs in length. A Sal I restriction site is introduced by the forward primer and a Sma I restriction site is introduced by the reverse primer. The ends of PCR products are cut with the corresponding restriction enzymes (*i.e.*, Sal I and Sma I) and the products are gel-purified. The pIVEX 2.3-MCS vector is linearized using the same restriction enzymes, and the fragment with the correct sized fragment is isolated by gel-purification. Purified PCR product is ligated into the linearized pIVEX 2.3-MCS vector and *E. coli* cells transformed for plasmid amplification. The newly constructed expression vector is verified by restriction mapping and used for protein production.

[0242] *E. coli* lysate is reconstituted with 0.25 ml of Reconstitution Buffer, the Reaction Mix is reconstituted with 0.8 ml of Reconstitution Buffer; the Feeding Mix is reconstituted with 10.5 ml of Reconstitution Buffer; and the Energy Mix is reconstituted with 0.6 ml of Reconstitution Buffer. 0.5 ml of the Energy Mix was added to the Feeding Mix to obtain the Feeding Solution. 0.75 ml of Reaction Mix, 50 μ l of Energy Mix, and 10 μ g of the template DNA is added to the *E. coli* lysate.

[0243] Using the reaction device (Roche Biochem), 1 ml of the Reaction Solution is loaded into the reaction compartment. The reaction device is turned upside-down and 10 ml of the Feeding Solution is loaded into the feeding compartment. All lids are closed and the reaction device is loaded into the RTS500 instrument. The instrument is run at 30°C for 24 hours with a stir bar speed of 150 rpm. The pIVEX 2.3 MCS vector includes a nucleotide sequence that encodes six consecutive histidine amino acids on the C-terminal end of the target polypeptide for the purpose of protein purification. Target polypeptide is purified by contacting the contents of reaction device with resin modified with Ni²⁺ ions. Target polypeptide is eluted from the resin with a solution containing free Ni²⁺ ions.

Example 7

Cellular Production of Target Polypeptides

[0244] Nucleic acids are cloned into DNA plasmids having phage recombination sites and target polypeptides are expressed therefrom in a variety of host cells. Alpha phage genomic DNA contains short sequences known as attP sites, and *E. coli* genomic DNA contains unique, short sequences known as attB sites. These regions share homology, allowing for integration of phage DNA into *E. coli* via directional, site-specific recombination using the phage protein Int and the *E. coli* protein IHF. Integration produces two new att sites, L and R, which flank the inserted prophage DNA. Phage excision from *E. coli* genomic DNA can also be accomplished using these two proteins with the addition of a second phage protein, Xis. DNA vectors have been produced where the integration/excision process is modified to allow for the directional integration or excision of a target DNA fragment into a backbone vector in a rapid *in vitro* reaction (Gateway™ Technology (Invitrogen, Inc.)).

[0245] A first step is to transfer the nucleic acid insert into a shuttle vector that contains attL sites surrounding the negative selection gene, ccdB (*e.g.* pENTER vector, Invitrogen, Inc.). This transfer process is accomplished by digesting the nucleic acid from a DNA vector used for sequencing, and to ligate it into the multicloning site of the shuttle vector, which will place it between the two attL sites while removing the negative selection gene ccdB. A second method is to amplify the nucleic acid by the polymerase chain reaction (PCR) with primers containing attB sites. The amplified fragment then is integrated into the shuttle vector using Int and IHF. A third method is to utilize a topoisomerase-mediated process, in which the nucleic acid is amplified via PCR using gene-specific primers with the 5' upstream primer containing an additional CACC sequence (*e.g.*, TOPO® expression kit (Invitrogen, Inc.)). In conjunction with Topoisomerase I, the PCR amplified fragment can be cloned into the shuttle vector via the attL sites in the correct orientation.

[0246] Once the nucleic acid is transferred into the shuttle vector, it can be cloned into an expression vector having attR sites. Several vectors containing attR sites for expression of target polypeptide as a native polypeptide, N-fusion polypeptide, and C-fusion polypeptides are commercially available (*e.g.*, pDEST (Invitrogen, Inc.)), and any vector can be converted into an expression vector for receiving a nucleic acid from the shuttle vector by introducing an insert having an attR site flanked by an antibiotic resistant gene for selection using the standard methods described above. Transfer of the nucleic acid from the shuttle vector is accomplished by directional recombination using Int, IHF, and Xis (LR clonase). Then the desired sequence can be transferred to an expression vector by carrying out a one hour incubation at room temperature with Int, IHF, and Xis, a ten minute incubation at 37°C with proteinase K, transforming bacteria and allowing expression for one hour, and then plating on selective media. Generally, 90% cloning efficiency is achieved by this method. Examples of expression vectors

are pDEST 14 bacterial expression vector with att7 promoter, pDEST 15 bacterial expression vector with a T7 promoter and a N-terminal GST tag, pDEST 17 bacterial vector with a T7 promoter and a N-terminal polyhistidine affinity tag, and pDEST 12.2 mammalian expression vector with a CMV promoter and neo resistance gene. These expression vectors or others like them are transformed or transfected into cells for expression of the target polypeptide or polypeptide variants. These expression vectors are often transfected, for example, into murine-transformed adipocyte cell line 3T3-L1, (ATCC), human embryonic kidney cell line 293, and rat cardiomyocyte cell line H9C2.

[0247] Modifications may be made to the foregoing without departing from the basic aspects of the invention. Although the invention has been described in substantial detail with reference to one or more specific embodiments, those of skill in the art will recognize that changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the invention, as set forth in the claims which follow. All publications or patent documents cited in this specification are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference.

[0248] Citation of the above publications or documents is not intended as an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents. U.S. patents and other publications referenced herein are hereby incorporated by reference.

Nucleotide and Amino Acid Sequence Embodiments

[0249] Table A includes information pertaining to the incident polymorphic variant associated with osteoarthritis identified herein. Public information pertaining to the polymorphism and the genomic sequence that includes the polymorphism are indicated. The genomic sequences identified in Table A may be accessed at the http address www.ncbi.nih.gov/entrez/query.fcgi, for example, by using the publicly available SNP reference number (*e.g.*, rs1041973). The chromosome position refers to the position of the SNP within NCBI's Genome Build 34, which may be accessed at the following http address: www.ncbi.nlm.nih.gov/mapview/map_search.cgi?chr=hum_chr.inf&query=. The "Contig Position" provided in Table A corresponds to a nucleotide position set forth in the contig sequence (see "Contig Accession No."), and designates the polymorphic site corresponding to the SNP reference number. The sequence containing the polymorphisms also may be referenced by the "Nucleotide Accession No." set forth in Table A. The "Sequence Identification" corresponds to cDNA sequence that encodes associated target polypeptides (*e.g.*, IL1RL1) of the invention. The position of the SNP within the cDNA sequence is provided in the "Sequence Position" column of Table A. If the SNP falls within an exon, the corresponding amino acid position (and amino acid change, if applicable) is provided as

well. Also, the allelic variation at the polymorphic site and the allelic variant identified as associated with osteoarthritis is specified in Table A. All nucleotide and polypeptide sequences referenced and accessed by the parameters set forth in Table A are incorporated herein by reference.

TABLE A

RS_ID	Chromo-some	Chrom Position	Contig Accession No. [1]	Contig Position	Nucleotide Accession No. [2]	Sequence Position	Amino Acid Position	Locus	Locus ID	A [3]	Allelic Variability	OA Assoc. Allele
1041973	2	102576868	Hs2_22327_34:13	5021492	NM_003856	coding-nonsynon	E78A	IL1RL1	9173	R	[A/C]	C

[1] Contig Accession Number which can be found in the NCBI Database:
[http address: www.ncbi.nlm.nih.gov/entrez/query.fcgi](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi)

[2] Sequence Identification or Nucleotide Accession Number which can be found in the NCBI Database:
[http address: www.ncbi.nlm.nih.gov/entrez/query.fcgi](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi)

[3] "A" column is the sequence orientation ("F" is forward, "R" is reverse).

[0250] The following is a genomic nucleotide sequence for an *IL1RL1* region. The following nucleotide representations are used throughout: "A" or "a" is adenosine, adenine, or adenylic acid; "C" or "c" is cytidine, cytosine, or cytidylic acid; "G" or "g" is guanosine, guanine, or guanylic acid; "T" or "t" is thymidine, thymine, or thymidylic acid; and "I" or "i" is inosine, hypoxanthine, or inosinic acid. Exons are indicated in italicized lower case type, introns are depicted in normal text lower case type, and polymorphic sites are depicted in bold upper case type. SNPs are designated by the following convention: "R" represents A or G, "M" represents A or C; "W" represents A or T; "Y" represents C or T; "S" represents C or G; "K" represents G or T; "V" represents A, C or G; "H" represents A, C, or T; "D" represents A, G, or T; "B" represents C, G, or T; and "N" represents A, G, C, or T.

IL1RL1 Genomic Sequence (SEQ ID NO: 1)

>2:102527651-102626600

```

1      tgcaggattt gtatgtaagt atccaacaga caacacctgg ggtgatcctg tgaatgtaga
61      ggaagacgtg atcttaaatg gaccagggaa gtaagacctt aggatgtacc agccagctga
121     gtggcaggta atattgatct tcatgtttca ccccatgttc ggtcacttgt gacagatttc
181     ttcagttcaa ttctctggct agttaaYttg gtctgggagt cacaccagaa aatgtttctg
241     aaaataggta cctattgtga aaagtataat cctctttgct attgtgagta gtgctgcaat
301     aaacatacat gtgcatgtgt ctttatagca gcatgattta tattcccttg ggtatataacc
361     cagtaatggg atggctgggt caaatgatat ttctggttct agatccctga ggggagcggg
421     gagggatagc attaggagat atacctaagt taaatgacga gttactgggt gcagcacacc
481     aacgtggcac atgtatacat atgtaacaaa cctccacgtt atgcacatgt accctagaac
541     ttaaaagtata ataaaaaata tatataaagt ataatacatca aattgttaaa atcatgattc
601     tcatgaagta gattgtgtct gttgaagttt aattaatgaa ggaaacaaca ggatgtcagg
661     actgaatcca taaggatctg agaaactggg atttcataa gatgttaaga taatattgat
721     aactgggata caaaactgct taatgtccta caatgtaata aaacaatttc tgttgtgttt
781     tgcattgagat agaaacaaaa atacctccca ttggtcagtt ttctacaaga taatctttaa

```


841	ctttacaggg	ttgtaaaata	gctatgcctg	aattgttagt	taaaacccca	tttttttttt
901	tagagaaaac	aatgatcctt	agactcactt	actagaaaata	tggttctagt	tttttataaa
961	aataaaaata	aataaataat	tttattataa	aataaataat	atttttataa	taaaaataaa
1021	aataaaaata	aaaatatatta	ttttaaatat	ttttttcaag	catcagtata	ccttattctt
1081	gttcaacttg	gggaatggcc	ttattcaaat	tggaatcct	cagctcatct	ttgtctttgg
1141	cattccagag	aatgaatgtg	tttgggaaat	tggtgcagct	gagcagtgt	tacagaaagg
1201	gacaggagac	cactgaaatg	gttcagggtta	tagttagata	gttcctgcc	ctgggttagat
1261	caggagagtt	agatgggttat	agtttagatag	ttcttttatgc	tggcagtggg	aaacaagaga
1321	agaggacata	tgagggagat	gctcatgtta	ttgggaacaa	tatttggtct	ctggtagaat
1381	gttaggggcg	agggagaaga	ttctaagtgt	ttgagttcgg	gagccgctgc	gccattaata
1441	aaaccagaaa	ccttctacag	tgctccaggt	gggagccatt	agcatcaaag	gcgattctaa
1501	aatcagtcct	gaaagctatt	ctatcccttg	ttctgcatgc	agaacagctc	ctgagggcct
1561	gttgagggcc	cagggaact	ttggcccaag	gccaaggaag	gactgggtgt	cctctttggg
1621	ttagctctgc	tcacagacaa	ctgcccagaa	gggtccaggt	ccaagtcact	gtgcaagctg
1681	acacgtgtga	gacataggaa	gctgttggga	ctacagaacc	cagggactcc	aaacctgtt
1741	taagtaccac	acctgagggg	aagaagaccc	tgcttcccaa	ttagtcagct	gggtagaagg
1801	ctgaggattt	ttgaaaagag	gtagttgggt	tagcctcagc	tttctttaga	ataatattgt
1861	ggtttgaaag	tggtcaacct	cctagtgtca	tcatttcctt	ttgtccctga	cagaactgtc
1921	ttcacgctgg	aaataaaaagt	atgggacagg	cttgaagcag	agttgtgaag	tagaagtttg
1981	ctaggaatcc	attttttatt	gaaagcccca	ggcaactctg	attaattttg	tctgggagtc
2041	atacatggag	aaatactgtt	ctaggagctc	attcagctaa	cacctctctc	acctagaggt
2101	catgcgggga	aagaaatgtg	tattgcatta	taattcatag	tagactgtga	ataactaata
2161	ggaaaaagatt	cctttcagct	tctcctgtct	agttaaagtt	cagcagggaac	acacctttag
2221	cttaaaaggaa	tgcattttag	tggtgatggg	gggtggtggt	gtggtgatgg	tggtggtggt
2281	ggtggtggtg	gtgtgtcttc	ctaggtcctc	tcaaatcaca	tcacatgggt	gagggataaa
2341	aagaggcagg	taaaaaatag	catttgttct	acaattgatg	aatgactaaa	tgctctcttg
2401	aacataaaga	atttatattg	gtaaaagctt	ctctgctatg	tgcattagta	aaaacaacaa
2461	catcgtgccg	ggcgcggtgg	ctcacgcttg	taattccagc	gctttgggag	gccaagtcgg
2521	gtggatcaca	aggtcaggag	atcgagacca	tcctggctaa	cacggtgaaa	tcccgctctt
2581	actaaaaata	caaaaaatta	gccagcgtgc	tggtcaggtg	ctgtagtccc	agctactcgg
2641	gaggtctgag	caggagaatg	gtgtaagtga	accggggagg	cggtgagcct	agtgagccga
2701	gatcaggcca	ctgcaatcca	gcctggggga	cagagcaaga	ctctgtctca	aaaaaaaaaa
2761	tcgtttgctg	atttagaact	cttcttaag	agcctccata	tgtttaaaaga	gccaatgcct
2821	atgactgtat	gactataaatt	ttataaaagc	ctttccctac	agtatcttac	taaatccctt
2881	cagcaatcct	ggaagtacca	tcattatctt	tattttgcat	attcaagttc	tgaaagcctg
2941	gtttgctcca	gtaagttagta	gagctaggac	caaaacccaa	gttttggttg	ggttttcagc
3001	cctgaatcct	tcagccctga	accttttcat	agctgcctct	gacttcacag	ctcactgcat
3061	aaagcctctt	tcagaccat	cctctgtcag	catcgtctag	tctagcctgt	caggtagttt
3121	ggcctccaca	ggagatcccta	ttctcaatgt	ttgtaaaatat	ttagctaaat	ctgtagcaga
3181	catctggttt	cataatgaga	aagagcattt	ttgttttcat	tagggaaaaa	gagcatgact
3241	gggcgcagta	actgcagttt	tcacgtgtga	gaaaaagaga	gtgagacttg	aacttgaaaa
3301	agtgaagcca	agcagtgtag	ttggcaggtg	gaggggtggg	aggagggaga	ataaagacaa
3361	gtcaggaggga	gagagaggaa	aatgatgcac	agagaaaagag	ggaagaggca	aagagaaaag
3421	aagggagcct	ggacagcaga	gggtgtctct	tcaggaaaca	gagttgaagt	gaaatagtgt
3481	aatccccagg	tggtcaggtac	aacattttct	agcacaatga	ctctgaacaa	cttaattctt
3541	tcctaggggga	agtagttaca	cggaaagtgt	aatgtgtgct	gcacattttg	agttgtgata
3601	ccatcagaaa	gaggtacttg	ctgtggaaag	aacttctcaa	cccctccatg	taatgacctt
3661	tggaagtgc	attatcaaag	cagagtcctg	cagcctgaaa	gtaaacagca	tctacttaga
3721	aatacagtga	catgtaaact	ttccccaaat	caacagtga	accagttagc	ataactttga
3781	tgaaacaaag	gggcattgcc	gagctgtcag	gacacaacag	agcacaacag	aacagcccca
3841	ggtaaatatt	gataaattag	gttgatctgt	gtattcttag	tcatgggaag	ctggggcaga
3901	taacgaaacc	ttgtatgtgt	cctttatagc	tctgtctgat	gagtttgggc	gacggagctt
3961	tgctctgtcg	cccaggctgg	agtgcaatgg	cgtgatctca	gctcactgca	acctctgcct
4021	ccctgattca	agtgattctc	ctgcctcagc	ctcctgagta	gctgggatta	caggcacgtg
4081	ccgccaagcc	aggctaattt	ttgtattttt	agtagagaca	gggtttcacc	atgttgatca
4141	ggctggtctc	gaactcctaa	actcatgac	cgcccacctc	agcctcctga	agtgctggga
4201	ttacaagcct	gagccaccgt	gcccagcctt	gttttttttt	aagtgatttt	tgagggcagt
4261	tttatgggca	gaaaagactc	ttcgtgaatt	tattttgatt	ttaaaattac	tattcaattt
4321	ttcaaagtta	aaaatgtaaa	aaatctagtt	tattataaat	tgaagaccag	cttaaaaaat
4381	atataatacc	atttatatgt	ctagcacatt	ttaaacaaact	tcaacactag	gttactccac
4441	ttacaaattt	ggcaaaactaa	atatttttaag	gtatttttaa	ccgcattttat	acatttactg
4501	tatttgattt	ttcttcttaa	gaacttttggc	taaaaccttc	ccaagtaatg	aattaattct
4561	tataaattta	agttctctta	gaatttttga	cgctacatat	aagcttaaat	attgggataa
4621	aacttagtaa	ggattttcact	taaaatcgta	aatctaaaca	atttccaatt	ataccttttt

```

4681 aaaaaagagt tacatgactt attctaattgg gtcaatatatt taggcacac aaatacataa
4741 ttgcaaatat atagattcct taaattatata catggctcttg attcttatta catagatgtg
4801 tacataacct tctaccagg tctaaataacc actgaattca aaatgagctt tgcattctaa
4861 gtacttcgaa attcttaattg ggtattaaaa agtgaccag ttgcttatgg ataaacctca
4921 taatttgccct tgatacttgg tcacaaatta aaggctattc tactgacaaa ttacttgtat
4981 acaatctaca aaacaaatag catgcaattc tcattacagc acacgtgttc agactttaac
5041 aaagctgttt gaagtctaca tcattctctg agttagagaa gccccaattg ccacatacac
5101 atacttagta ctgtcatata gagtcacata tctactggat tctacctgga tcttaggatac
5161 aagatgcttg tactcagaca aacaaattag gaaagtagcc tcttttgag agtgggtctag
5221 ggggtgttac agccaaaaaa tcattcacgg ttttatgggt aagaagtgag atgatctgta
5281 atgaaacctc acagagattc tgttaaataa caagtgccca aaagctactt ggaaaaaggag
5341 tagactgaag agaaaaatgag agaatacaaaa atagttttta tttcctgtta gaatcatctc
5401 ctttacttta ctcttgcatg tgtaactgtg gaggagattg taacatttcc cttagctaac
5461 tgtacttgtt actcttgatc aacatccctt agtaactgtg tatatgtgat gcttcatgca
5521 ttagtcagag ttgagaacaa aaacagagta gctcaacaa aacatagggt tatctgtccc
5581 tcatgtaaca acacatgggt agccagggtc tctagggatg gtagatggat ctgcttcag
5641 aagtcactca gaatcccaa ttcctcctac ctgtctgctc tgccctgtgt ggtcctcatc
5701 tgtctcaccg ctgaagccac ctgtcagttc acctagaaga gaatatgtac tgtttctgcc
5761 aaatctgtgc tatagatact agatgctttt aatggagagg ttagccaaga aacatgacat
5821 ttctcttata ggtaataaaa tacttctctc taaagaaata cttagtttaa aattttattc
5881 tgctatagtt ttagcagtag gataaaagct tagtttgag aagcggaaat tatcctatat
5941 ttaggcaaaag tgagctatct gtgtgttatg attagagaga ataccaagaa gtgatttctc
6001 tctttaaatt aacttctcYa aatttccacc attaactacc cattcttcaa ctcttccaat
6061 ttttcttatt cctcccatgg agggagtgca tgtatttaat tactaacttt actagtatta
6121 tataatctat gctccaaaat gggttagtcta caattagtag agggataagt ctttaggggt
6181 ggaaagaaaa aacagttatt aaagatctac tattgtctga tgctcatact actcttctta
6241 cttattatgt tattttatacc acctaacagt ttgataatat taccatccc cccgtctttt
6301 tttttaagag ataaggcata tatgacttat atagagttta ggggattttc ctcaagatta
6361 gacagttaga agtctcttgg gtgggagagc agttctaggg gaaaaggaaa gatMagaaag
6421 acaagtcaac tactttgagt aaagacctct ggctgagcag gtcatttgtt attcccagaa
6481 tttgtcacca actagtttgt tgggttttgg cataccctt cacatcacct caatgtcacc
6541 tttggtaaag tgaaagaatt gggtgttagat attctttaa ttatctttta ttcaggcttt
6601 ctacagccca attctctcaa ttgttgactt ttagtagaa ttttgggcaa acactagctg
6661 atacaatcca tttaaccaaga tgtttatctg atgacatttt catcaagttt cttaaagatgc
6721 catattgtct ttctggcagg cttttggaaa gtgttcaaga tctcctgttt tattttcaca
6781 gttggccctt gagcctcaag tgtaagcaga gctgggctga gaggtctagg tctcctggc
6841 tgatgtcact aggtgaggg gccttgggga agaaaacaaa tttctcccag attcaacctt
6901 ccaaccaact caggttctg gaacagttag taactccttt actcagaagc tgaaccttaa
6961 aagtcttttc tgattcttac caacttggca cataagaaat acagtcattt cctcaaatat
7021 atttttatta tgagggtact gaacattgta tttattgggtc atttgcatth tttgtaaatt
7081 gtagattttt aaaaacctct ttgtctgggt gcggtggctc acacctgtaa tcccagcact
7141 ttgggaggcc gaggaagggt gatcatctga ggtcaggagt ttgagaccag cctgaccaac
7201 atgggtgaaac cccatctcta taaaaatac aaaaattagc tgggcttggg ggcgtgcgcc
7261 tgtaatccca gttactccgg aggtctgaggc aggagaatag cttgaaacca agaggtggag
7321 gttgcagtga gccaaagatcg Ygccactgca ctagcctggg caacaagagg gaaactccat
7381 ctcaaaaaac aaaaacaaac aaacaaacaa aaacattttt gtattaaact gtaaagtctc
7441 ctgatacatt aagaatatta aagacaggga tatagttagg tttttttgtt tagttccat
7501 atgcctttta atttgtttta ggaatagatc atttgtttag actataggta aggaatagtt
7561 atatcttttg ttccagaaag ttccagattt tgaggggaata ttactattcc taaggtttta
7621 ttgacatata aattttaaaa atattatgta atgagagcta tataatatata ttcttttttt
7681 gtgcattttt tcatgggtac taggttaagt gtctgtttct atgaacatac aacttactta
7741 acatatgact tggaaacaga acatgcatag taaatgtttc tcaagtaaat aagtaaaagt
7801 atatagaaaa caaatgtgct gtttcatgtt tgtcatagga atcatcttag cactaaatgg
7861 ataattagga tccaggttca tcttgggct tggcacaat gagcttgga aatctgaaat
7921 atggatgggt gataataggt aattaggttt aaattatacc aggaaactga agaacttca
7981 gaaaatgggt acagataatt acagaagggt gcattacaga ggaataattt ctcacagtga
8041 gagacaattg gcctcacatg ccttactgta ggcatacatt gtgtcataat ttccttttat
8101 tgcaccttca acattttgaa gggaaattaat tgtctgaatt aggcctagatg tcaatttttt
8161 cttggaatta gaagaaagat tgagtaaccc cttatgttta tctggaacat gtctttctgt
8221 gcatttaaaa atctcagagc ccttcagaac cttgcccgtg acccgtcatt gggaatatct
8281 taaaaatgtg tgtgtgtggg tgggtgtgtg tgtgtgaata taggaatgag ggaacactgt
8341 cgtagacaga tatatctgaa gcttactttt tggtttaggg catttggctc tgcatacct
8401 ttttaagtctt atgctatcct tgacttttga ctcttagatt tttgtatggt tttgtatggt
8461 ctaagtctct cctttgcagt attagaggtc tattttccca gactaggggac tggagtgttt

```

8521	aatcatcact	gtcatgtaga	cctaatatag	aaatacaaat	gcaataagaa	aaatggttag
8581	aaattaaagt	cagaaacata	tttgttgtga	tacatgttca	aaaataaatat	atttcattgc
8641	aggaaatagc	aaatccagag	aaataaaaag	aaagaaaaaa	aataatctgc	atttctacgc
8701	atgcagctaa	ccattgtctga	gatttttgag	tccttgtttc	ctaggcacgt	tttccatagt
8761	ctgtgtgcac	acatgtatgg	gatgttgcac	atgtgtatgt	gtgcatgtgt	ttacacatgt
8821	atttgcaggt	atgtgttgat	tattatacat	tgagtcataa	tgtatattac	atttaaaatt
8881	tcctgttttt	acggctttat	taaggatata	ttgagatatg	aaaaattgca	tacacttaaa
8941	ttgtacagtc	taagttttgt	catatgtata	cacaccagtg	aaacccttac	cacaatcaag
9001	ataatgaaca	tacccatccc	ccgtaaagct	tctacacccc	tttcgaagtc	catccttcaa
9061	cttctcctac	cgaatccaca	ggcatccact	gacctgattt	ctgttactat	aagtttggtc
9121	acatttttcta	gaaattgata	taaatggaat	aatacagcat	gtgcttgttt	ctctctggct
9181	tcttctattc	tgcgtaatta	ttgtgaaagt	catccatatt	attgcattta	tcagtacatt
9241	catactattg	catttatcaa	tatgtcattc	ttgttgattg	tttatcatat	tcccctatta
9301	tcttcttaac	atctatagaa	acttagtggt	gtcaactctc	tttttcttga	tatttagtaat
9361	ttgtgtcttc	tttctttttt	cctcagtcag	tgtgactaga	gagttatcaa	ctttattagt
9421	cttctcaaca	aaccagcttt	tggcatcatt	gatttttctt	tattgttttt	ctgttccatc
9481	tcactgtttt	ctgcattgat	ttgtattatt	tcattttctt	ctgttttctg	tgtcttcttt
9541	gctcttcttt	ttctagtttt	ttaaagtggt	aaccaatatt	gatttatgac	ttttattatt
9601	ttctaagtga	tgcccttagt	gttgtaaaatt	tcctctttta	gtggcatatc	ccaaattttg
9661	atatgtagtg	tttttggttc	catttagttc	acaatacttt	ctaactgccc	ttttgatttt
9721	ttgtttgcac	catgggttat	ttaaaagtgt	attatttagt	ttttgcacat	ttacaaagtt
9781	tctatatatt	tcttttattg	attttgtgat	ttaatccac	tgttgtcaaa	taacacactt
9841	tgtatgcctt	gtccatttta	acttatttag	acttggtttt	gggactggaa	tatgctctct
9901	catggtaaat	gatccttgta	tgcttaagaa	gagtgcctat	tccagtgtct	tcagggtggag
9961	agttctataa	ataacaatta	ggctctactg	cttaacaatg	gttttcaaat	tttctatata
10021	tttacagatt	tttctgtttc	ttctatcaat	tactgaaaga	agaatattga	catctctgac
10081	tgtaactcaa	gatttgtcta	tttctccttt	catttttatc	agttttttcc	tcattgtattt
10141	tgaagctcaa	tatttagaag	cataaacagt	attgttatat	tcttcagata	aattgacccc
10201	tttatcatta	tggaataact	ccctttatct	ctggttatat	ataatatatg	gaataactct
10261	ctttattcct	ggttatacat	aatatatgga	ataactccct	ttattcctgg	ttatatataa
10321	tatatagaat	aactctcttt	attcctgggt	atgtataatt	ttagagcaat	atataatatg
10381	catatttttt	gtctaacttt	attatagcca	ctccagccac	gttttgattg	gcattaatat
10441	ggaatattct	tttcttctct	tttgctttga	aacttggtgt	gtctttgtat	ttaaagttag
10501	attcttgttg	gcaaaatgtt	gttgggtttt	ccttttttaa	tccaatctga	gaatctctag
10561	cttttagttg	gggtgtttgg	agatcattta	tggtaatgtg	attgatagtt	tgggcttaaa
10621	attcttctct	tgctatttgt	tttctatttg	tcccatctgt	tctttgttcc	tcattttatcc
10681	tttttgtgtc	ttatttttga	ttacttgttt	ttttttataa	ttccaaattt	tctccattgt
10741	aagatcggtc	tctatagctc	tttgttgtga	tattgtagtg	gtttctctag	ggttatctgg
10801	agttagtata	catcttttaa	taacacagtc	caccttcaag	tgatatttga	ccaattcact
10861	gataatttaa	gagctttaca	acagtgaact	tccattttct	ttctctgggt	tttgtgtgtg
10921	tgctgtcata	catgttgctt	ctacacccct	attataaaac	ccacattata	ttgtcattac
10981	tttYgcttcg	aacaatcaat	tatcttttaa	ataattttaa	caataagaaa	taaaagtctt
11041	tttatttaac	ccatagatgc	cattttgggt	gctctgcac	ccttctgtgt	gatcagatct
11101	ctgtctggta	tcagttcttt	ctacttggag	gacgttctct	tcacatgtct	tgtagtactt
11161	gtctgttact	gacaaattgc	ttcagctgtt	gtatgcctga	aaaagttttt	atttctgtct
11221	cacttttgaa	caatatTTTT	attaagtaaa	aaatttctaag	gtgacttttt	ctttcagtea
11281	tttaaagatt	ttattctgct	tgcatgtttt	ctgatgagaa	atctgatgtc	accctctccc
11341	tagttcctct	atagtaacat	gggtttttct	tttctcactt	ttaaagattt	ttctttatca
11401	ctatttttag	tgtttgagtt	tctgggtact	tcagggtttt	atacttttca	tcaaaattgc
11461	aatatttttg	cgttatttct	tcacataact	ttttttctgt	ccttttgttc	actcctttcc
11521	tcctggaact	tcaattatac	ttacattaga	tgaactgaaa	tttccccaca	attcacagat
11581	gctgtatttt	tttcagatct	gttttctttc	tgtattttat	tttgcgtagt	ttctattcca
11641	tacaatatat	ttttcatctg	aaatgtagct	tttatctgta	gatgttttat	ttagggtcttt
11701	ttaaaatctg	ccatatctct	gcttaacaca	atattttcata	taggtttttt	tttcacatat
11761	ggaattttga	tataatagct	gttttcatgt	ccttttctac	ttattctatt	tatctatgtt
11821	aattctttgc	tagttttgat	tgatttgattc	ttctctttat	taagggtagt	attttctgct
11881	cctttttagt	cttgaaaatt	ttttattgta	tgccagacaa	tgttaatttt	aacatatatga
11941	tgcttgaata	tttttctatt	tctataaata	tttgagctgt	gctctgaatt	actgttatgt
12001	tgccctgaaa	caagtttgac	atttttgggt	cttcccttta	agtttttttt	atgtgttaacc
12061	agagtgtacat	ttagcctgtg	gttaattttat	actactattg	agacaaaact	catgagttat
12121	gtcatttttc	attttgaaata	gtgggacag	gtactatttc	tgaccctgta	agagttgtgg
12181	taattgttcc	ctctgatcgt	tttgggtggt	tctttctttg	accacagatc	acttcctcag
12241	aagcatgaac	tcgtcagtac	tgagctgagt	aactgaagag	ggcgctgcag	atatctctgt
12301	agtgatctcc	tcagtactct	gtgaactcaa	gtcaccttag	cctttccaga	Stcccagctc

12361	tgattcctca	tctcggagag	accactggac	ttcatctctc	ttcctcttct	ctttgccaga
12421	gttcagaaac	tctccaggca	gtaaccaggg	caattgccag	cctctttttt	tgcttcccat
12481	ctctcaaggt	tcaccgtcgt	ccactgcctg	atgcttatat	cttgaaagct	gttgattcat
12541	acgttttggt	cagtgtttag	ttattttaagt	caggagggtg	aatcttattc	ctattactct
12601	atcttggtcg	gaagtagaaa	tcacaaaact	tgctctctaa	caaagtatat	cacaaacatt
12661	ttctattttat	ttaaatatta	ttagtctaca	tcatttttga	tgactacaaa	gtatttttatt
12721	atttaaaaat	accatatatt	aattaatact	ttattttttt	tatttcgttt	tttcctgcta
12781	ttgttacaat	gttggtgaatg	agcagataaa	tatttttgaa	tatccatgat	tatctcaact
12841	gtattagtag	aagagaaatt	gctgagttaa	gggggtattt	gatgcagatt	tccaaattat
12901	cgtctaaaaa	gggtgcaccg	atztatatac	ttattatctc	tccaaatata	tggttattat
12961	tattataaatt	tttttaaacc	tccaagcttc	ataagtaaaa	atggcacatt	tattgggttt
13021	aattagcatt	tttattttct	ttgatgtata	atattttta	tagttttatt	aaaatctctg
13081	tccttccttt	ttgaatttag	tttatatctt	ttgcataatt	taaagttag	attgttgtct
13141	tttctgttat	taattttata	aatattttgt	ttgagtgtgt	gagtgcattg	gcattgcatt
13201	gtatgcgtat	gtgtgtgttt	gtaacatttt	catcagtttt	ttgcttgccc	tctattttat
13261	gtattttcag	atgtgattag	atztattttg	tctttgacat	tatgattttc	gtctctatca
13321	ttgagtttag	aaggYcaata	ttattcctac	ctcattacca	aagaaatact	taattctatc
13381	tgcttacaga	tttaactttt	ttctttttcc	ttttaaatct	ctaatacatt	tggaatttaa
13441	ttttcttact	gattaaactt	tacttgtata	tgtttatatt	ttataatgat	aatattaaac
13501	catttgtaat	gcttaaatta	aatattaaat	ggtcataaca	ccattttatt	aaagcctatt
13561	ctttcctttc	ggtttgatat	actgactttt	tcattcatgt	gataatcttg	tgatatattc
13621	ctgttaagt	tccatttggt	tctacatttt	ttatcctgtt	cttataagtt	gtctgtctcc
13681	tctgttggtc	ttcttatttt	attttaattt	ctgaaacttt	attggacaat	agtaactcca
13741	gaagagaata	tctgtaggac	aacagtaggc	tcaaggagaa	atcatctgtt	ctcctaactc
13801	tttactattt	ttcgtatttt	cctgactgat	cttcagtatt	tctggaaaat	tgacaagcaa
13861	tgacagattt	ggataatagt	gcaggcttca	ctttcattgt	gcttggttcc	aaatcccagc
13921	ttcttagctg	actggcaatg	tgaccagca	aatttatttt	ctttggcatg	gctcagtttt
13981	cttatctgta	aagtaagggt	aatagtagtc	cctatattat	aagtttatta	tgatgttgt
14041	gtgggtggaa	cccggtgtgt	gcacacaccg	gcacttagtg	agaagttagc	tttgccattt
14101	tcctttattc	ttcactttaa	ttttagaatt	attttgtcaa	cttcaaaaaa	gttcattatg
14161	aatcttatta	ctgagtcctc	tctagaagca	tgacatgact	cttcattcac	ttgttttctt
14221	ttgcgtctct	cgggaagttt	tgcattttct	gttgtgtata	tataatattt	gtacattata
14281	tctaactatc	tatctatcta	tctatctatc	tatctatcta	tagatatata	tataactttg
14341	cacaattata	tccacataca	ctctaagaaa	taaggccagc	agaaaaatag	tggttatgtt
14401	agactataat	tatctctgag	tatttaggtta	tgagaatttt	ttcatttgta	gtattctata
14461	cattttaaaa	cttattaact	gagcattact	gatataaatc	aataattttt	aagtgacttt
14521	tggtccctac	tacgctgggt	ctgtgtgctt	cagactgaag	ggcagtgctt	gttagacttt
14581	atgtgctaca	tgttacacaa	gtactttggg	aaataagctg	ttgtttttaa	aaatgtgtca
14641	tcaattttcta	gagaactgga	cataactttg	aagcaaaaac	attttaagt	gatgactaaa
14701	atccttctcg	aaaacgcacg	cctgtggtcc	ctgtgaaatc	accttttctc	cccctttcct
14761	aatctccttt	ccctcctaaa	tctaaatttt	cttgtaatgc	ttcaaaatat	ctggacttga
14821	tctcagaaga	tattctgtca	tgcatattga	caggactggg	tactttcagc	aaaacaaagg
14881	acattcttta	atttttacca	gccccagata	gaagtgtcta	gagttctaga	tttaggaga
14941	aatacagcca	tgaaggaaaa	tggtgacatt	tatttcaacg	tttcaacagg	aggaaagaat
15001	gagaacacaa	tgtacagatc	agcctttcct	ctcatgttct	tacaatggga	gaaggagaga
15061	gggtatttga	gacaccaaa	catgaaagcc	atgacacagg	gaaaatactg	agaacataac
15121	ctacagatca	gattttcctt	ttatgctctt	accatgtcat	aaggcaaa	gcttggttga
15181	gattttcagg	cacaagagcc	actacagcag	gaaggcgtcg	catcatcgga	acatttctga
15241	tcaaagagaa	gactgtctgc	acaaagcacg	gactgcagcc	aagggttctt	tcacccactg
15301	ttctcacaaa	tgcttgccct	tgctatcaca	actgctattg	ccagctggac	gctgagtgtc
15361	ccctcagggt	tcatagagat	ctgtctccct	gaggtctctt	aggtgctgct	gctgaccagt
15421	agtaacttgg	tgaagaccct	cgatttgtgag	gacatttgtg	tgaaatgttg	ctttcttgac
15481	aaaacaaatg	tgtttccttc	tgatccatga	acaaagatct	gttgaataaa	tattatgagc
15541	gtgtagaagg	gagagacttt	atctgatcag	actagggaaa	gggtgctttt	aatatctgtg
15601	gaacaatctg	taagatcgga	cgtttcctct	gataacagaa	actccagagt	tacaagagaa
15661	atggcttctt	gacatcacag	acactaaaag	gccttctgag	taggagtagc	agtgaattt
15721	ttgactacta	tgtaaaggaa	atacagtacc	aaaaaaaaaa	aaaacccatg	gagatcaagt
15781	catttcttac	tagcaagtac	ccctgacttc	tacgtatttg	ttgttagatc	cacaaagaa
15841	atagtataac	ttcattttct	atcaactatt	agggatctat	agtgccataa	caaagtactc
15901	taaaatttat	cagcttaaac	agtaaacctt	tattatctca	catgggtcct	gaggtcagg
15961	aatctgacag	tgacctagct	tggtgattct	gcctcggggg	tgctcatgaa	gttgtgtgca
16021	agctgttgag	tacacttttt	catctcggaa	gacttgactg	caactgaggg	acttgctgct
16081	agggtcactc	atgtggctgt	tggcaggagg	cttcaggacc	tgtctgtgtg	gagcactctc
16141	tggggctgcc	ctcgagatgg	cttctctcag	agggggtgat	tcaagagaca	gagtcacaga

16201	caagtacagg	atgccttaca	taacctaatc	ttggaaatgg	cacgtgatca	cttattccat
16261	attatattga	tgacatagac	ctgacctggg	acagtgaggg	aaaagactac	acaaggatat
16321	aaacaccagg	atgcagagat	cagggggcca	tcttgagggc	tgcccgccac	agctattaaa
16381	ggtaatttgt	tgacaactca	caattttctag	ctaccaggtt	gctcattctt	ttgcttaaac
16441	tattcaaggc	tggtggggga	catgtgaatc	ctgttaaaat	gtggaaagat	ctaaatgtgt
16501	tttatagaaa	aaattgagta	aacttttttt	gcttaataag	caaaagaatg	atgaggaagg
16561	aaggggcaat	tgtgtgtgtg	tgtNagagag	agagagagag	agagaatata	aaaatcta
16621	tttttacc	aatatttttt	tttcttccgg	gtgaacatgt	ggctttaaca	taacttctat
16681	tccacaaact	caaaatcaag	cacctctgtt	aactcttaac	taaacataga	ctttttStga
16741	actttggaat	aggagtaagg	gggaagagt	aaacacacta	gctttcatgc	ctgtttta
16801	ttctaatttc	ttaaagagt	gacaagaaag	agaatgaatt	cagcaaagtc	tttgatccct
16861	acagttcata	ttcagacaaa	taggagccaa	ttattaaggc	taactgcctc	agtaaaata
16921	aaaacagcca	atttaacttc	tgaacacagg	aagggttttt	accattatg	gaatcatgaa
16981	agatctgaat	gcacatgata	tggtgtaacc	ataaaataag	gttgagtttt	tgcttctctg
17041	taaatctcat	gagaacaagc	attctgagt	aggggtgcgg	taaagacaca	cagggctagt
17101	cttaaaagaa	ggtaaaagtt	ctggctatgt	attaggcttg	attagaat	tctgggttaa
17161	acgaattctc	cttcagtttt	gtttctttca	tagatgctgg	aattcctata	aaagccattc
17221	agacatttat	atttatgact	tttctacttt	ttaaaaaact	atactcctcg	agagaataaa
17281	ggagtagggt	ttactagaca	ccatatttaa	tggtttaaag	caaccaagta	agaagagggg
17341	atgttctaga	agtgaaggaa	aggggattca	tgacagacatg	aaagtgaagc	aaaggtaaat
17401	gtgacagaga	aaaatgaatt	tgccatctct	ttctttcttt	ctctctctct	tccttctctc
17461	cttcttctct	tcctctctct	ctctctctct	ccctctctct	ctctctctct	ctctctctct
17521	cttcttctct	cttcttctct	cttcttctct	cttcttctct	cttcttctct	cttcttctct
17581	ctctcttctt	ttctctctct	ttctctctct	ttcttcttct	agccacagtt	tcgctgttgt
17641	cgccagggtc	ggagtgcatt	ggcaggatct	tggtcactgt	cgacctctgc	ctcccagggt
17701	caagtgatct	ttctgcctca	gtctcctgag	tagctgggat	aacaggcatc	tgccaccacg
17761	ccgggtcat	ttttgtattt	ttagttaaag	cgggatttca	ccatcttggt	caggctgggt
17821	ttgaactcct	gacctcagg	tatccacca	cctcggcctc	ccaaagtgtc	ggcattgagc
17881	gcatgagcca	ccatgcctgg	actatctgct	ttctttctaa	aagagataaa	gctttctagc
17941	tgccatgtac	cttggtgaat	ttgggctgag	gccattcagc	gacaagcact	ggaaagaatt
18001	gaagtgtctc	caagtacctc	tgcaaggga	gaggggtgat	gagcagggga	gaggagagga
18061	ggaagaggac	ctggtggatg	gtaggaggcc	atcaggctct	ccatgtgatg	tgcaaatctt
18121	tagctaggta	caccgtat	tagaaatgtt	tggtgtaaat	ggatttcttt	tgcaaatctg
18181	agaggggact	gagttttggg	ctgatgctga	gtggaacaga	gatgggactc	ctggagcttg
18241	agacacagga	tcttgagaa	aatgagcccc	agaaatcagc	agatgtcatg	aggggactct
18301	gggttatcat	aaagtgtgga	attgggtatc	gatctgaact	tgtttcttca	aagtgcagg
18361	aagaccagct	aatctcttgg	ttttgccaat	ttagggcaat	tttcaacatt	acgaaaattc
18421	atttagtttg	gggtgcagac	tcagatgtcc	tctccatgtg	gacacaaccc	tacatgtgca
18481	cacacaaaca	agcacttgag	cacacatgtg	tggtgcacaa	ccccactttt	ctgcttttcc
18541	aggagcaccg	tatgttat	cagacaaata	agtttgccca	actttgatct	ttccattcag
18601	gtcactgatt	gctgaattgc	cacagatgtt	gttctgcctc	ccttaggttc	tagggcattt
18661	tcattaagga	gagttacctc	caagaggggt	catggcaggc	gagcaaacca	tacttggggg
18721	gcaccattaa	agacctccac	ccctggggag	cgatccctac	agcgggagag	gacttggccc
18781	cttacaagtt	tgccatgtct	ctccctgaca	gggtgggtaca	gcagcaggag	tctgaattcc
18841	acattttgca	gagccctggc	atagacggat	cattcaagag	aaacttcctt	aagctgcccc
18901	cggctgtctca	ggctcctcat	tctgcattca	gatgtggcct	tctttattac	taactcagga
18961	ggaccttgat	ggatgttagt	ctccctggat	ttgaaaacta	tttatgggag	cactgaaaat
19021	ggcattattc	gttttgatgg	caatcaagta	cataaatgcc	aatgatagag	actgaaggat
19081	aagtccaca	gcggatgtgg	ttcaagtttc	taaatactgc	tgccatgatt	ctcatgtgat
19141	gtgaaggata	ttaagagatc	tagaactagg	atagaactgt	agctcaacca	tgctagaaaa
19201	aaattttttt	aagttccact	ctatttaaaa	atatttgtgt	agagacaaaa	tctcactgtg
19261	ttgcccaggc	tggtctcaaa	ctcctggcct	caagtgatcc	tcttgctttg	gcttcccaaa
19321	gtgccagaag	ccactgtgcc	aggccaaaaa	gttatactcc	tgagtaaaag	ctactttata
19381	gtctcttgat	aacctaccat	aatttaaaga	atattctgat	tgctgtaaat	ttctgtataa
19441	tttaaatctt	aaggccgggg	gcagtggctc	atgcctgtaa	tcttggcatt	ttggggagcc
19501	aaggagggag	gatcttctga	ggtcaggagt	tcgagaccag	cctgacccaa	atggagaaac
19561	tccatctcta	ctaaaaat	aaaattagct	ggatgtgggt	gcaggtgcct	gtaatcccag
19621	ctactaagga	ggctgagcca	ggagaactac	tgaaacccgg	gaggtggagg	ttgtggtgag
19681	ctgagattgt	gccattgcac	tccagcctgg	gcaacaagag	tgaaactcca	tctcaaaaaa
19741	aaaaccaaaa	aatctttaat	ttgcagattt	gtaaaatcct	acatccctgt	ccccactctc
19801	cttttcccat	gatctttagt	ttagttcctc	aaggctcagga	atgagtctca	tcttctcttg
19861	cacctctcac	agtgccctgac	acaatatagg	ggacattgat	aagtattgtt	ttgtgtatta
19921	cttaggcata	tttctgtgg	tctcttagca	gtggagaata	aatgattgat	gatcttatga
19981	agtcatagtc	cacctaaaga	ctgcgtagta	cgcaaatgag	tctaccatta	tctcctcgat

20041	gtagatttttc	atctttttatg	tatggtgact	ctaggtaagg	agaagagggtg	atctagctca
20101	cttgggtggga	cgagcgtctt	gacacaaaatc	cacaaaaaaa	ggagagtaca	cacagctggt
20161	cattttgtctg	tgtgttgagg	tgggggtggg	ggagggtgagg	ttgtattcac	acagagaaga
20221	catcttagct	ctgcacccaa	acaaaaacga	gcgtcagtga	tgttaaagat	tgaaggctcag
20281	gtgctaccca	ggttttgtta	gtctcttgac	ataaacatgg	tgtctagata	tggtagatat
20341	tatgaatcat	tccatctttt	caaatacatt	ttgaagggtt	tttttgtttg	tttgtttgtt
20401	tttgagacag	agtttcgctg	tgtcaccaag	gctggagcac	cgtgggtgcag	tcttgggtca
20461	ctgcaacctt	tgactcccg	gttcaagcaa	ttctcgtgcc	tcagcctcct	gagtagcttg
20521	gatttagaggt	gtgcaccatc	acacgcagca	aattttttgta	tttttagtaga	gacgggggtt
20581	caccatgttg	gccaggatgt	tgggattaca	ggcgtgagct	accatgccct	gccagaaggt
20641	ttgtttttat	tttaaacaca	attgtgctgg	gtgtgatagg	atgggtatat	gatagagcag
20701	aaaatcacta	gtatttcac	aatatggata	gcacccctca	taggttactg	atttaatat
20761	gacaacaata	cccttcacac	gagagagagg	ttagagaatt	tgcccaaagt	caagcagctg
20821	ggaagaggaa	aactaggctg	tgctctccct	aaatctcatg	ctctattata	ttaggggaaga
20881	ctctggcaga	tggcacatcc	tgattatttg	aaagtcacca	atatttttag	aaattgcata
20941	gataattaag	gttagtttat	ccagaattct	aataattgca	gcacatgtcc	ataaatctct
21001	attacaacca	cctgagatag	gccatctcgg	gcattgtgga	aaagcccagg	tatagacact
21061	ttggatcctg	gatttccctt	gtactggctg	ctaccttggg	taaggtaatt	ctcctctctg
21121	aagctcctgt	cagcttctga	ggattgctg	ggatagcaca	taccaaatta	ctgcacacag
21181	agcctggtgt	acacttaagc	acacgagatg	tgtcaaagtt	ttcaaaaaaca	ttgccaacga
21241	ggcatcagtt	acaaaacttg	ctgcagagt	agctgatatt	gtgccactgc	actccagcct
21301	gggtgacaca	gtgaggcttt	gcctcaaaaa	aaaaaaaaaa	aaaaaaagaa	agaaacacca
21361	aataagcaac	ttgctgcaga	aatgggtact	cttgttctag	aaatgtgact	ataggggaagt
21421	tacaactacc	aactcgcgtt	aagggaatg	agtgcactgc	cacctacatg	gtgttaggga
21481	ggttttgctg	agaaagtcac	tcatgaagaa	ggcaaaatat	agttaagaca	aaatgtaact
21541	atctatagag	ataaggtaaa	aattggaaat	agaacttcat	taaagatcct	tcaaataggg
21601	agaatgtgg	gaaaactgca	gttaacattt	gttaacagt	tgatcatcgg	gttcagctta
21661	tcagtaacct	ggttcctgtc	tcttaactga	taaagaaaat	gggagggttt	taaagagagg
21721	ctggctggtg	tatttagtaa	agctataaa	ctgtaagaga	aattggcttt	ctgagttgtg
21781	aaactgtggg	cagaaagtgt	aggaagaaag	aactcaagta	caacccaatg	agggtaagt
21841	gctttgggg	atttttcaaa	aatactttta	tctcaaagg	aacaaaat	tcacatacga
21901	atthaggtca	ttataacaat	aatattcatt	gttatattat	tataacatta	tatgttataa
21961	taatatataa	tatatataat	atataattgt	tataacatta	taacaattat	atattatata
22021	taatacaatt	atataatata	tattatataa	ttgtaatata	taataataat	atataatata
22081	tattatataa	tataatata	aatatatcat	atatgttata	tattttatta	tataatata
22141	attatatata	atattatata	taatatatat	tatatataat	attatatata	atatatatta
22201	tatatataat	atttatatat	attatatata	atatatatta	tatatataat	attatatata
22261	taatatatat	aacattattg	ttataattgt	ataacattat	tatatattaa	atataatata
22321	tataatatta	tatttatatt	gaggaaaaca	ttcactcaat	gacagaggga	agacttagct
22381	ttccaaacaa	tcttctgtta	aaagaaaaac	tttagctgaa	ttaaatttaa	aggagttaa
22441	ttgtgttttg	gtgccttatg	caaatgaagg	gcctataata	taatatataa	tgtaatatat
22501	ataacattat	aacaataata	atcattgtta	tcaattttgc	ttgtgagaaa	agtagtatta
22561	ccaatgggaa	atcatgtgta	cagattgatg	aaatcccttg	aaatcctgtt	tgtgtaatat
22621	gggacttttg	tccaaagctg	tggaaaagac	ctgggtgagg	gtaagaaagg	atgggagctt
22681	tatagtatac	acacagagt	ctcatattct	ggagttattc	tttctgaaat	ccacaaaatc
22741	cagcagtgtg	atctactcag	atggagatga	aggaaaaaaa	caaaaacaaat	gaagcaagaa
22801	gctgctggcc	aaaaggggtg	aggaagcagg	gtcataccca	tctgcaagaa	gaaaatagag
22861	aacggacatg	agaggggtg	atatgaggat	atgagaaggc	cctcttgagt	gagggccatt
22921	gtttctggag	gggtggggag	tgaatgactg	atgtaagtgc	aagtttgttg	cgggtgctctg
22981	ctttgatcct	ctgcttgggtg	gctccattct	tcttctctct	gaaggctact	tcaacagagg
23041	gtgcagaggt	aaacatagca	gaactggccc	ccaaagcttt	atccactgaa	tgtcagtttt
23101	tcctttaatt	tcttccaggc	ataaggaaat	cggaggcatg	tttctgtctg	gctataacag
23161	ttctcctact	agatcctgag	gccaaactat	tcacatgcca	ttgttctctg	ataccattgt
23221	ggacataatc	atctaatttt	ggctatttcca	tgcagaggtt	tggagacaga	aagctctgga
23281	ctaattgcaga	tctgcattta	atccctgctc	ttacacttac	ttgttgcatg	accttaagca
23341	actcatctat	gtcttttaaat	cttgagtttc	ttgcttacaa	agaggtgacc	agcatattag
23401	taataaatatc	atgttttagag	gggtggtttc	gaaggttaaa	tgggtgtaag	tgttttagtgc
23461	attactcagc	cagcagtcac	cacttaatga	tgtcagacct	catcattgtc	cttatttttt
23521	ttgttccaca	ctctgggaac	ttttatctct	gcgccttgta	gatatgctgc	tgtgactgct
23581	gacttgaatg	ttacgggatc	cccagcagga	tctgggatcc	tctctgttct	tgaatgcgtt
23641	gttttaggtga	ggagattgat	tccaagttac	ttttctactt	gggtgctct	gtgtttggag
23701	atgtggccgc	atagctcaag	tgtatctggg	gtgtcttcag	ttttcggata	cctgtttttc
23761	ctctaggaga	attcttctct	tatgtccttt	aaaatatttg	tcctataatc	acaaggggtt
23821	atattttctct	gcccactcct	ccatacttcc	tggttttctg	ggagtgcaga	ggcagacaac

23881	tgcaaggggag	agccccRcaa	ggattttgggt	gatgactttg	agccaggctg	acatccatgt
23941	ccaagggcaa	atgcagtcg	gttgggagga	tacaatgcag	gagtcttaca	acagtggcga
24001	tgccaacatt	gtgggagcat	gcatgtgtgt	gtgcacgagt	gtgtgtgtgt	gcgtgcRctt
24061	gcatgcgcgt	gcatgtgcag	tagggctcta	ctacaggttg	gtggaaaaga	tccctctggt
24121	tctagaacaa	aaatctaaca	gcaaccaaga	gtccagttcc	aagaaaagaga	aaggaaaggg
24181	ctagttaggc	agggcgctcg	gattctgaat	aggggctgag	gccttggctc	agacacagag
24241	gagaatggag	aaatgggggtg	atgacagaga	catctttaaa	atatttgtgg	gccaagggta
24301	ggatggcttc	aacttgtctg	ggatgtattt	gtccttagca	cgcttggaa	aacatagcag
24361	cagcagcagc	agtcgacact	tactaagact	gctatgtgcc	agaccctgag	acaagcactt
24421	tccacacacc	acatcctgcc	attccttatga	tgatagtgc	gtgaagttag	gatgaaacca
24481	agtcttggct	gactccaatc	ttgtacttcc	aaccaatgct	tgtgagggcc	ccaggccccc
24541	tacagcaaga	ctaaacatgg	acatatgtgt	ggctgggctg	agtctgtggg	attggctctg
24601	gagttgggtg	tgtctgagcc	ctgggtagaa	agggatgcta	tcctaataga	aaaacacaga
24661	ataaagatag	tgtccaccaa	gatgtaactg	agattttaaag	aagacttgat	aacttatcag
24721	ttgggtgggt	agtcttgaat	ttcaacaact	gcagatccta	tctaagacca	cttttgtctt
24781	gtgacaactt	agttaaacat	gacttttagtg	tggatatcag	tggccaat	tgagcccat
24841	ctatgatagg	aacaaaggct	tccctgtcat	aggtgagtga	caactatctg	gtctgggtgg
24901	acaggggtaa	aagaatttac	taagacagtt	gtagataaag	aaaggcagat	ttattagaga
24961	aagtatgaaa	atacattaca	aggttgcaat	gggcagcaca	gccagagagg	agctgactgc
25021	aaagaaacaa	aggcttgctg	gatatttata	ggatagttcc	tgggctccag	ggggctatat
25081	gcagtactga	taatgccaag	gttgtagtga	gctaacttgc	aggtgtctgg	tgatagttgg
25141	gtgcYggaag	attctgagtt	atttgcctag	aagagctgtg	tgctctgggc	catgaagaaa
25201	ggcaaacctta	cagtttatct	gctttctgtc	tttgccttcc	cttgggtactg	ctagctctgac
25261	ttttttttcc	ctaattagga	ttccgcacat	cctatgcctK	tctctcagga	gccttgacgt
25321	caaagtgtga	tggagtgtct	gagggccgag	tcattgagta	atggggcctc	tgccctctca
25381	gccccactgc	cacccaactg	aggcttcctg	gatgagggtg	tatgccgtgg	ggaaaaggag
25441	tgggatgatg	tggatcccc	tggggttgc	gggtcatctc	ccaaatcccc	actctccctg
25501	tctaccacaga	ggaccagtca	gcatttctct	aattcctctt	cactctgggg	cattatgatc
25561	agaaaatatc	atgtaccttt	tgttgcaatc	ttggctgaaa	gaacctcaca	ctatacttga
25621	atgtctttga	tttaccatct	gagcagagat	ctcaaactat	aaagaaaatc	agagtctctt
25681	gatgcccatg	ttcaggacaa	gttttcttgg	atttcatgac	tcttttaggaa	cagtgcagctt
25741	atgggtaaa	accgagactt	tagtgaggaa	ttccctcatc	atttttctct	tcttgagcaa
25801	aaccttgtct	gatttggggt	tgtaatgtgc	aaaattat	tcttttcatt	tcaccttttt
25861	ttcttaagta	gtggtttctg	gaaatctgag	ctgctttgtg	caccttgact	agtctgtgcc
25921	agatcacgaa	cgtacacacc	aactctcaag	acaccagaaa	aatcacctt	tagaggaatt
25981	atctagaaaa	ctagccccta	tgcaaaagtg	ataacctttt	caaaatataa	tctacattaa
26041	gacttttgaa	actaacacat	tccctcaatca	tagcaaccaa	atgaattact	taaagtgggt
26101	ttggttctctg	ctttcattaa	gggagtattt	tcaggaaaatt	agagggtctaa	tgtaaacatg
26161	gatccttttag	gtttttccat	tttctttgtc	ttcaggctgt	ttgctgccac	tttcatcctc
26221	cccttatctc	agtctgccag	tgatggtttg	tgctctgggt	cKctgggtca	gatccaggac
26281	taattcactc	acctctgatt	tctagtcca	cMcttatgac	gaaagcattc	ttaaatctga
26341	tattcacata	aaaaaggatt	tgattgtctt	tggcatgtct	ctgcagttag	ttaatcatgt
26401	cttgagcaca	gaaaaatggg	aagaaaatgg	aaataagatt	tctttgatag	gagggtcctc
26461	gctaagactt	gtctgtccct	gagctgagat	atgctaattt	accttaaatc	tttccataaa
26521	ccacattctg	aattccagtt	tataaatctt	tatcttattt	ccgaacctc	atctcatact
26581	ttttatgtRa	tctgggtggc	atagatatct	tcttgggtgaa	cctgaggaaa	tctagaatga
26641	caaaggatct	aaaataagta	acacagttgc	tcaagttcct	gggcccctatg	gtagaatttc
26701	cttcttcaga	gaaggggaga	acaaggtaga	taaagaaagg	agcatttcat	cttgagcag
26761	cttggaagat	agctgggagt	ttaattttta	taaaaaagaa	agcaatcaaa	ccatccaata
26821	cagcccattt	tcaacccaaa	gtatttcaga	attacctgga	gatttatcta	aaattatgta
26881	aaaattacct	agaattacct	aaaaaaattg	tacaatttca	tttcccttct	gttacatgat
26941	atggataccc	agctactatt	tattagtagt	agatacagac	tatttaagag	acaaaaat
27001	atattccaaa	aagtgtgacc	cttagaaacc	aaaattccaa	agaagagttc	ttgtaatggg
27061	caaggctggc	tctgattgag	tgtcaaaact	cctgtacaat	gatggatcaa	cttagaaatt
27121	tgatagattc	aaagcattct	gaaattgtac	aactcgctca	gcacttgtat	tatttacatg
27181	tcttctgtta	ttttccattg	aatgatgttt	tcatgtatac	tcagctgctt	ataagggcaa
27241	tattttaaaa	tcagagcaat	ttctttaaaa	ttaaaaatgtt	tcagcccagc	atgggtggctc
27301	aYgcctgtaa	ttccagcact	ttggggagcc	gaggcaggtg	gatcatgagg	tcaggagWtc
27361	gagaccatcc	tggctaacac	gggtgaaacc	catctctagt	aaaaatacaa	aaaattaaact
27421	gggcgtgggtg	gtgggcgcct	gtagtcccag	Stactcgga	ggctgaggca	ggagaatggc
27481	gtgaaccag	gaggtggagc	ttgcagtaag	cccagatggc	gccaccgcac	tccagcctgg
27541	gtgacagagc	cRgactctgt	ctcaaaaaaa	aaagtttcag	caaaaactt	tttaaaatgc
27601	actgtaatta	ccctaacaat	attacactgt	tacagatagt	ttagaataaa	taaaaaatgt
27661	aattcataaa	ctcactcctt	taatacaaca	aacctgatta	atgttctgtg	ttccttatta

27721	gacttttctcc	catgtatagc	tttacaaaagt	ggtagttgat	gagtaagtag	aattttgtgat
27781	attttttttca	cgtgagaaca	aactcaatat	gtcaattact	tcatagattt	ttaattttata
27841	aaaatttttct	catatctctt	ataaaaaataa	aaaaagattt	gatttcagta	aacacacatt
27901	tggagagaaa	gttgatcctc	atataaactc	aaccatagac	cattcagtg	gttgcaagtt
27961	ataaatgccca	tggaggaaaa	aaatcaagca	gagttaggaa	gattgggagc	acaggggttag
28021	ttgggtcaaag	gggtgggagag	gatagacctc	attaagaaa	tggcgagacct	cattgagaaa
28081	gtgagggagt	gagtcacaca	gacacctgga	ggaagaaaa	gcaagagagg	gtaaacagtt
28141	gctgcaacac	cctgaggtgg	gagcaggctc	gggaggccaa	gcaacaggaa	ggacaaaagt
28201	gcacgtgttg	tgtagttaag	attgggggtg	tagcaggatg	taaatcagag	aggtagaggg
28261	tgacagaccc	ccagggggtc	ttcttgttca	ttgcaagcaa	tttggctttt	gttgggtaaa
28321	gcagagggtt	gaagagagga	gtaatttgaa	aggatcactc	tagcttctgc	tttgaaaatc
28381	aattataggg	gacaagggaa	ggatcagtgc	aaagactagt	gcaataattc	aggcaagaga
28441	tgggtgggtgg	ttggatcagc	aaagatggcc	atgagaagtg	gtcacatggc	tgaattctgg
28501	ctgtatttgg	aaagtaggtt	cactgggact	tattgggtgg	ttgagattga	tgtgctggag
28561	aaagagaggt	ataaggatac	ctccaaggat	tttgatatgt	gcagctgaaa	aaagatgaag
28621	ttgccatcaa	ccaagatgag	aatgatgggt	ggaagagcag	attttggggag	aagaacaggg
28681	attcattctt	gacaggttat	ttttgtgatg	tctggaatat	agacaagtga	aggcattgag
28741	tcagcagggtg	gacatgagaa	cctgaagtcc	aggggaaaa	tgtggacggc	aggtgtaact
28801	gcaagagtgt	aatcagtata	gagatgggtg	ttcaaaccag	tttaactggat	gacatcatgt
28861	ggggagttag	tgtggacaga	gaagaaaagt	gcttcaagga	ctgaaacttg	agtggttgga
28921	gagaagagga	gatgtgaagc	agtagcctgt	gggtcctgaa	gaaagatggt	ggagaaattg
28981	ttccactttg	acagaggctg	cttatagctc	aaggtaaggg	gaagacgcag	gactgaggat
29041	tcctaagcaa	catggtggta	attgacgata	ttgataacag	cataaagaca	tcataattta
29101	aactaattat	taacaaaatt	gaaatttaaa	gaaacaagta	atgcaatggt	tccaaagtgg
29161	attcaaattc	cataatatta	ttgcaaaaaca	aacaaaccaa	acaaacaagg	aaaacaaaga
29221	aagaagggat	tctaacataa	aagaatttaa	aaataagtaa	atcagctcgg	aaaactcagc
29281	aggcttatat	ttcttgggtg	ttagaaatat	ctgcttatta	aaaggtttca	aaggctcttt
29341	gggaatagaa	cttattgcaa	ttgttttggc	tgtacatttc	ttacactttt	tttttttaact
29401	gaggagtcaa	ttaaaatata	ctgaagtgc	tgtccataga	acacattttg	aaaacacaaa
29461	tgctatataa	tcacaaatat	atctccctcc	cctttgtctag	tgattgtttac	caaactgcct
29521	ctgctagcta	ggattcaact	ctttctctta	acaactatgc	tttgatggaa	caattttttt
29581	agatacaaat	attgtcaatg	agaacaatta	ttatacagtg	cagtcacaga	agagaaacag
29641	aaaagaaagg	gaggtgcaac	aaaatgaagg	taaatattag	ccttcacact	taaatcactt
29701	tgatgagggg	ataaaatgta	catgtagggtg	tggatttatg	ggctgtgttt	ttcaaacaat
29761	taccaaatat	ttattaacca	ccaactcagt	gtaagctagt	acactaggtg	cctatagtga
29821	tccagcaggc	tataaggcag	gatttctgct	cttatagaat	tttggggcat	attctcagta
29881	tcttttgtat	ctctcgccct	cttttctttt	ttttgtgaca	caagatgtca	ttctgtcatc
29941	caggctgtag	tgcagtgaac	cttgactggc	tcattgacgc	ccttgacctcc	caggctcaag
30001	cgatcctctt	gcctcagcct	cccaagaagc	tgggaccatg	ggcatgtgcc	atcatggcag
30061	actaattttt	aaattttttg	tagagatggg	gacttactat	gttgcccagg	ctagtgttga
30121	actcctgggc	tccagcagtc	ctcccacctc	agcctcccaa	agtgtctggg	ttactgggtg
30181	gaaccatcac	tcccagccct	ttcttttgc	ttgttatttt	aaaaactttt	ctttattctc
30241	tttctgttac	cttttaataa	actataagaa	gtctttcaaa	acaaaaatgt	cttaagtcca
30301	gtgggttagg	ttttgtcctg	cattattttt	ttttacccca	tgggtggggaa	aaaagcaaaa
30361	aactgttttg	tgcctataca	atgccttatc	gcacagcttt	ggtttgtgtt	tactccagtg
30421	tcgtctttta	gggtgtgagg	tcagtgcagc	tggcctgggt	cagaactcag	ggctacttca
30481	tgccagatgc	tcaccacctc	tgcagtgttg	tatgcagaga	tccaaattca	tccttcaggg
30541	aaggatgaac	acttattctc	tgggatgttt	tacagtgaag	atcagaagtt	gctctattgt
30601	gcctcatggt	cctagctact	tccactcttt	tgaagatctt	acctgggtct	atgggtttta
30661	tttcatctat	acagtgcac	atcccaaatt	tgtatctcta	gcccataatg	tctctgaaat
30721	ttcagaagca	Ratattcatc	ctactgatgg	gttcacatct	ccagttttat	gtctaattgag
30781	gtgtcaagct	gaatatggcc	aaaactagt	taactctact	ctaaaacctc	taccacctgc
30841	cttttcttaa	ttcagtaact	agcaacccta	tttgaccagt	tactcagggc	cccaaaccct
30901	tcttgactgc	tctcatatcc	tgtccatcaa	gaagtcttac	tagttctacc	ctcaaaatct
30961	atctgcatcc	caatcatgtc	tcaccacctg	cacttccccg	ccttgggtcat	agccaccgct
31021	tctgtctcac	ctggatacct	catcccttgc	cattctttaag	agtgttttca	cattcagagt
31081	gttttaatacc	tacgtcaagt	ttgaggtcat	gtcactcctt	agcttgaaac	actccagtg
31141	tcttcatcac	acttaataaa	agccaagggtg	ctcagggtga	ctcactcgca	atctagtctc
31201	taccctctct	caaccagctc	tcactgctct	ggagttctct	atgccctgtt	ggccatgtgg
31261	cttccctact	ggccctcgga	cacaccaggc	ttgcctccat	ggctggactt	tcagtgtgcc
31321	tgccctttcg	acctgggctg	tttattaaat	gtctccttcc	tagttggcct	tcccaggaca
31381	cttggcctga	aaattgctct	ctcctgctgt	atttttctcc	tttaagtggat	cacactctaa
31441	gatcttttgg	aacttttttt	tattctttta	tgttaacttt	tgtcctctgt	taggacatga
31501	attccacaag	ggcaggagat	ttttgtttcc	ctttgtctgt	tgtgggtgcat	tgctgtatcc

31561	ccagcatctg	aaacagtgat	tggcatgaaa	gaataaccct	cactgggtgt	ctgggttcag
31621	tattttgctt	ttctaagctc	agttgatgca	gaacaactgg	ttttctgggt	tcagtatttg
31681	cttttctaag	cccagttgat	gcagtggttg	tatgtgcggc	catgttagat	gttagaacac
31741	tgacatccct	accactgatg	agtcaatagc	cactgcccc	gacctcctg	atattttatg
31801	gtccgagtaa	ttactagatg	catctacatt	taaggctgca	aacatgaatt	tactggagga
31861	agcacagtg	tggtggatga	cccaatctct	ctctcaaaact	tacaaaaatc	accaaggaat
31921	cataaatcca	ccccctcttg	catcttccaa	gcaaaggaaa	ttgtagaaaa	cacaagtgaa
31981	actgtttcac	agagatatca	gcaatacata	gcaaatttga	gatgatggag	attaagagga
32041	aaattaaatc	attcttaagt	ggcgaaggta	aaaacattat	tggtYgggtc	gctatagtta
32101	catttaaaac	agtcgaagt	caaacaactc	tagtctgaYt	agtcttgtca	ttgatatgtg
32161	ctgtcttaga	attctccaga	gagacagagc	taataggaga	ttatctatct	atgtatctat
32221	gtatctacct	aatctatcta	tactctctct	atctatttta	aggaactgac	tcagtatgat
32281	gtggggcctg	gcagtcctaa	agctacaaag	caggctggca	gactggaaat	tcagataaga
32341	gttgggtgtg	tagtcttgac	tctgaattcc	ataaggcagc	cagtcggaat	ttcaggcggg
32401	gtttctgtgt	tgcaagtctg	aggcagaatt	ccttcttctt	tgggaaacct	cagtctttgc
32461	tcttcaggcc	ttctgctgct	cacattccac	agtgtgtgtc	ttctggccat	ccttcctgct
32521	tttgtgttgc	ctgtcccat	gcccttaatc	ttatatggaa	aaatggaaat	aaattcagag
32581	cggaaactta	tctaaaagtt	ttgagggaaa	aatgatcgaa	accagaatta	ttcacaggac
32641	aacttgttct	atgaataatt	tttgaaaagg	aaccatttcc	tctacagctg	gcttattatg
32701	aggagcttga	tgataaaata	ttggcaaggc	ctccagtggg	catttatcgt	gttgtgacag
32761	atcccagaaa	tgaatctggg	tctcccgact	tcaatacagt	tctcttctta	ttacataatg
32821	agagaatatg	atcttctact	cttttctttt	actttacttg	ttgagaaaca	actaatattc
32881	aattaaaage	atcaatctta	catattcagt	tgaatgagat	tcagcaatca	tatccccat
32941	gtatcatcat	ccatataacc	atcccacagc	cacagaaagc	atcttctctt	cccagagagt
33001	tgccctcaca	cctttccaat	caaatttcca	catactctct	agtttccagc	atgatagatt
33061	ataatttgcc	tattgttggg	cttcctatag	gtatgatatg	taatatgtag	tcttctgtgt
33121	ttagtcttct	ttgcttagca	taatttttgc	ggagcaaggc	tttattattt	ttttgtttgg
33181	aaaYgaactc	agagtacat	aacatgtatg	ttttgacagt	catcctatgg	ttatatcagt
33241	atcttcttcc	ttttcattgc	tgagtgtttt	acattaaaaa	aaggatccat	tctcctgttg
33301	atagacattt	ggattatgtt	taatttttgg	tattatgagt	atggcattta	tgaacattct
33361	tttacaagtg	ttttgtggat	atgtttgtta	attctcttgg	gtaagggggg	agttattgag
33421	ccatacagta	gatgttcttt	aactttttgt	taggttttat	atataatata	atataatata
33481	atagtgtgtg	tgtgtgtgtg	tgtgtatata	tatatgggtg	atataattta	tatacactaa
33541	aatacacaca	tttttaagtg	taaagttcaa	taagttttga	tacatgtata	ctccattggc
33601	tttgttttgt	attgctataa	aataatacct	gaggctgggt	aatttattaa	gaaaaagttt
33661	atttggctca	tgattttaat	ggctgcaaag	ttcaagactg	ggcaactgca	tctggtgagg
33721	gcctcaggct	gcttccaatc	ctggtggaag	gttaagggga	gggtggctgt	gcagagatca
33781	cattggagag	aagaagcaag	gggtggggga	gtgctaagtt	ctttttaaca	gccagctccc
33841	atgggaagta	atagagtga	aactcaccac	caagggaggg	gattgaagga	gggaattaat
33901	ctattcatga	gggatccacc	cccatgaccc	aaatgtctcc	ccttaagccc	caccttcaat
33961	attggggatc	aaatttcaac	atgaggtgag	gagggtagaa	atatccatgc	ataccacctc
34021	tgaaaccatc	atctcaattg	acatatccca	caaactcttc	tcatactcct	ttataagtaa
34081	ttgctaccct	tcatcttcca	ttctaggtag	ccactcactg	gccttgcagt	ttgggaacat
34141	tataataatg	ggacgatata	atatgcattc	ttttaaaact	ggcttctttc	attcagtagt
34201	tttctaagat	tcatcagtag	ttcttttttt	tttttttgc	gagtgtgtgt	ccattgtatg
34261	aatatagaat	agtttagcca	tatatgtgct	gacggtcatt	ggctctgttt	ccagtatttg
34321	gctatatgaa	ttgaactgg	atgaacattt	gtgtacaagt	ctttttgtgt	gcataagttt
34381	ttatttctct	taggtaaaac	cccaggaaga	gaatttctgg	agtgtaacac	aagcacataa
34441	tcagaaactg	ccaaactatg	ttcactgtat	catgttacac	tccatcaatg	atgcatgaga
34501	gttctagggt	tgccacatcc	ttgccaaaat	ttggtattgt	cagtcttttt	tattagctat
34561	gaaatagaat	ctcgatatgt	tggagccaag	atggccaaat	aggaacagct	acagtctaca
34621	gctcccagcg	tgagcgacac	agaagacagg	tgatttctgc	atttccaact	gaggtactgg
34681	gttcatctca	ctggggcgtg	tcggatagtg	gggtgcaggac	agtgggtgca	gagcactgag
34741	cgtgagccaa	agcagggcga	ggcatcgctt	cacccaggaa	gtgcaagggg	tcagggaatt
34801	ccctttccta	gtcaaagaaa	ggggtgacag	atggcacctg	gaaaatcggg	tcactcccac
34861	cctaatactg	tgtttttcca	atgggtcttag	caaatggcac	accaggagat	tatatcctgc
34921	acctggcttg	gagggctcta	cacccgtgga	gcctcgctcg	ttgctagcag	agcagtctga
34981	gatcaaaactg	caagtgtgca	gcgagggctg	gggaggcgtg	cccaccattg	ctgaggcttg
35041	agtgggtaaa	caaagcagcc	gggaagctcg	aactgggtag	agccccactg	agctcaagga
35101	ggcctgcctg	cctctgtaga	ctgcacctct	gggggcaggg	catagctaaa	caaaaggcag
35161	cagaaacctc	tgcaagacta	aatgaacctg	tctgacagct	ttgaagagag	tagtgggtct
35221	cccagcacgc	agctggagat	ctgagaacctg	acagactgcc	tcctcaagta	ggctccctgac
35281	ccccaggtag	cctaactggg	aggcaccctc	cagtaggggg	cagtctgaca	cctcacacag
35341	ctgggtactc	ctctgagaca	aaacttccag	aggaacgata	aggcagcaac	atttgctgtt

35401	caccaatatc	cgctgttctg	cagcctctgc	tgctgatacc	caggcaaaca	gggtctggag
35461	tggaaactcca	gcaaactcca	acagatctgc	agctgagggg	cctgacagtt	agaaggaaaa
35521	ctaacaaaca	gaaacgacat	ccacaccaaa	accccatctg	tatgtcatca	tcatacaaga
35581	ccaaaggtag	ataaaaccac	aaagatgggg	aaaaaacaga	gcagaaaaac	tggaaactct
35641	aaaaatcaga	gcacccctcc	tcctccagag	gaacacagct	cctcaccagc	aatggaacaa
35701	agctggatgg	agaatgactt	tgacgagttg	agagaagaag	gcttcagatg	atcaaaactac
35761	accgagctaa	aggaggaagt	tcgaacccat	ggcaaagaag	ttaaaaacct	tgaaaaaaaa
35821	ttagatgaat	ggctaactag	aataaccaat	gcagagaagt	ccttaaagga	cctgatggag
35881	ctgaaaacca	tggcagcaga	actacgtgat	gaatgcgcaa	gcctcagtag	ccgatttgat
35941	caactggaag	aaaggggtatc	agtgacggaa	gatcaaata	atgaaacgaa	gtgagaagag
36001	aagtttagag	aaagtagaat	aaaaggaaac	gaacaaagtc	tccaagaaat	atgggactat
36061	gtgaaaagac	caaatctaca	tctgattggg	atacctgaaa	gtgacaggta	gaatggaacc
36121	aagttggaaa	acactctgca	gggtattatc	caggagaact	tcccaatct	agcaaggcag
36181	gccaacattc	aaattcagga	aatacagaga	acaccacaaa	gatactcctt	gagaagagca
36241	actccaagac	acataattgt	cagattcacc	aaagttgaaa	tgaaggcaaa	aatgttaagg
36301	gcagccagag	agaaagggtcg	ggttaccac	aaggggaagc	ccatcagact	aaaagctgat
36361	ctcttggcag	aaactctaca	agccagaaga	gagtgggggc	caatattcaa	cattcttaaa
36421	gaaaagaatt	ttcaaccag	aatttcata	ctagccaaac	taagcttcat	aagtgaagga
36481	gaaataaaat	actttacaga	caagcaatat	ctgagagatt	ttgtcaccac	caggcctgcc
36541	ctacaagagc	tcctgaagga	agcactaaac	atggaaagga	acaaccggta	ccagccactg
36601	caaaaacatg	ccaaattgta	aagaccatca	aggctaggaa	gaaaatgcat	caactaacga
36661	gcaaaataaa	tagcaaacat	cataatgata	ggatcaaatt	cacacataac	aatattaaac
36721	ttaaatgtaa	atgggctaa	tgctccaatt	aaaagacaca	gactggcaca	ttggataaag
36781	agtcaagacc	catcagtgtg	ttatatctag	gaaacccatc	tcacatgccg	ggacacacat
36841	agactcaaaa	taaagggatg	gcggaagatc	taccaagcaa	atggaaaaca	aaaaaaaggc
36901	aggggttgca	atcctagtct	ctgataaaac	agactttaaa	ccaacaaaga	tcaaaagaga
36961	cacagaaggc	cattaataaa	tggtaaaggg	atcaattcaa	caagaagagc	taactatcct
37021	aaatatatat	gcaccaata	caggagacc	cagattcata	aagcaagtc	ttagagatct
37081	acaaagagac	ttagactccc	acacaataat	aatgggagac	tttaacaccc	cactggaaac
37141	attagacaga	tcaacgagac	agaaagttaa	caaggatata	caggagttga	actcagctct
37201	gcaccaagca	gacctaata	acatctacag	aactctccac	ccaaaatcaa	cagaatatac
37261	atttttttca	gcaccacacc	acacctatc	caaaattgac	cacatagttg	gaaataaagc
37321	actctctcag	aaatgtaaaa	gaacagaaat	tataacaaac	tctctcttag	accacagtgc
37381	aatcaaaact	gaactcagga	ttaagaaact	tactcaaaac	cgctcaacta	catggaaact
37441	gaacaacctg	ctcctgaatg	actactgggt	acataacgaa	atgaaggcag	aaataaagat
37501	gttctttgaa	accaacgaga	acaaagacac	aacataccag	aatctctggg	acatatttaa
37561	agcagtgtgt	acaggggaat	ttatagcact	aaaagccac	aagagaaagc	aggaaagatc
37621	taaaatttga	acactaacat	cacaattaaa	agaactagag	aagcaagagc	aaacgatctt
37681	aaaagttagc	agaaggcaag	aaataactaa	gatcagagca	gaactggagg	aaatagagac
37741	acaaaaaac	cttcaaaaa	tcaatgaata	caggagctgg	ttttttgaaa	agatcaacaa
37801	aattgataga	ccgctagcaa	gactaataaa	gaagaaaagg	gagaagaatc	aaatagacgc
37861	ataaaaaaat	gacaaaggcg	atatcaccac	cgatcccaca	gaaatacaaa	ctaccatcag
37921	agaatactat	aaacacctct	atgcaaataa	actagaaaat	ctacaagaaa	tggataaatt
37981	cctgttcaca	tacactctcc	caagactaaa	ccaggaagaa	cttgaatctc	tgaatagacc
38041	aataacaggc	tctgaaattg	aggcaataat	taatagctta	ccaacaaaa	aaagtccagg
38101	accagatgga	ttcacagccg	aattctacca	gaggtacaag	gaggagctgt	taccatctct
38161	tctgaaacta	ttccaatcaa	tagaaaaaga	gggaatcctc	cctaacgcac	tttatgaggc
38221	cagcatcatc	ctgataccaa	agcctggcag	agacacaaca	aaaaaagaga	attttagacc
38281	aatatccctg	atgaacattg	atgcaaaaat	cctcaataaa	atactggcaa	accaaatacca
38341	gcagcacatc	aaaaagctta	tccaccatga	tcaagtgggc	ttcatctctg	ggatgcaagg
38401	ctggttcaac	atacacaat	cgataaacat	aatccagcat	ataaacagaa	ccaatgacaa
38461	aaaccacatg	attatctcaa	tagatgcaga	aaaggccttt	gacaaaattc	aacaaccctt
38521	catgctaaaa	actctcaata	aattaggtat	tgatgggacg	tatctcaaaa	taataagagc
38581	tatctatgac	aaacccacag	ccaatatcat	actgaatggg	caaaaactgg	aagcatcccc
38641	tttgaaaact	ggcatgagac	agggatgccc	tctctcacca	ctcctattca	acatactgtt
38701	ggaagtctctg	gccagggcaa	tcaggcagga	gaaggaaata	aaggggtattc	aattaggaaa
38761	agaggaagtc	aaattgtccc	tgtttgcaga	tgacatgatt	gtatatctag	aaaaccccat
38821	catctcctta	agctgatagg	caacttctagc	aaagtctcag	gataaaaaat	caactgtgcaa
38881	aaatcgcaag	cattcttata	caccaataac	agacaaacag	ccaaatcatg	agtgaaactcc
38941	cattcacaaat	tgcttcaaga	gaatgaaata	cctaggaatc	caacttacia	gggatgtgaa
39001	ggacctcttc	aaggagaact	gcaaaccact	gctcaatgaa	ataaaggagg	atacaaacaa
39061	atggaagaac	attccatgct	cataggtagg	aagactcaat	atcatgaaaa	tggccatact
39121	gcccaggtta	atttatagat	tcaatgccat	ccccatcaag	ctaccaatga	ctttcttcac
39181	agaatttgaa	aaaactactt	taaagttcac	acagaaccaa	aaaagagccc	acattgcca

39241	gtcaatccta	agtcaaaaaga	acaaagctgg	aggcatcacg	ctacctgact	tcaaactata
39301	ctacaaggct	acagtaacca	aaacagcatg	gtacttgtac	caaaacagag	atatagatca
39361	atgggaacaga	acagagccct	cagaaataat	gctgcatgtc	tacaagtatc	tgatctttga
39421	caaacctgac	aaaaacaaga	aatggggaaa	ggattcccta	tttaacaaag	ggtgctggga
39481	tatctggcta	gccatatgta	gaaagctgaa	actggatccc	ttccttacac	cttatacaaa
39541	aattaattca	agatggatta	aagactgaaa	tttttagacct	aaaaccataa	aaaccctaga
39601	agaaaaccta	ggcaatacca	ttcaggacat	aggcatgggc	aaggacttca	tgtctaaaaac
39661	acccaaaagca	atggcaacaa	aagacaaagt	tgacaaatgg	gatctaatta	aactaaagag
39721	ctttctgcaca	gtgaaagaaa	ctaccatcag	agtgaacagg	caacttacag	aatggggagaa
39781	aattttttgca	atctacttat	ctgacaaaagg	ctaatatcca	gaatctacaa	ttaaactcaaa
39841	caaattttaca	agaaaaaaac	aaacaacccc	atcaaaaaagt	gggcaaaagga	tatgaacaga
39901	cactttctcaa	aataagacat	ttatgcagcc	aaaagacacg	tgaaaaattg	ctcatcatca
39961	ctggccatca	gagaaatgca	aatcaaaaacc	acaatgagat	accatctcac	accgattaga
40021	atgggtgatta	ttaaaaagcc	aggaaaacaac	agggtgctgga	gaggatgtgg	agaaatagga
40081	acactttttac	accgtttggtg	ggactgtaaa	ctagttcaac	catttgtggaa	gtcagtggtg
40141	cgattcctca	gggatctaga	actagaatta	ccatttgact	cagccatccc	attactgggt
40201	atatacccaa	aggattataa	atcatgctgc	tataaagaca	catgcatata	tatgtttata
40261	gcggcactat	tcacaatagc	aaagacttgg	aaccaagcca	aatgtccaac	aatgatagac
40321	tggattaaga	aaatgtggta	catgtacacc	atggaatact	atgcagccat	aaaaagatga
40381	tgagttcatg	tcctttgtag	ggacatggat	gaaactggaa	accatcattc	tcagcaaact
40441	atcgcaagga	caaaaaaccg	aacaccacat	gttctcactc	atagatggga	attggacaat
40501	gagaacacat	ggacacagga	aggggaacat	cacacaccac	ggcctgttgt	gggggtgggg
40561	gaggggggag	gcatagcatt	aggagatata	cctaactcta	aatgacaagt	taatgggtgc
40621	aatacacaaa	catggcacat	gtatacatat	gtaaaaaacc	tgcaogttgt	gcacatgtac
40681	cctaaaactt	aaagtataat	aaaaagaaga	agtagaatct	catttgtgatt	ttaatgttt
40741	acattttatct	aataactagt	aactttgtgc	actttgtcct	gtgcttattg	aacattgata
40801	tattttcttt	tgtgaaatat	cagtacaagt	cttttctctca	ttttaaaaat	tgggctattt
40861	tatctttttc	atatagaactt	gtaagagtta	tttatgaagt	atagatacaa	gtctttcattc
40921	tgatatgcaa	attatgagta	ttttgtctgg	actgtggctt	agtctattca	aatttctaag
40981	atgtctttga	agaagaaaag	tttctaattt	taataaagtc	ccagctatga	tttatttttc
41041	tttcatgatt	agtgattttt	gtatccattt	aaaaaatatg	ttcctacttc	aggtttaaga
41101	tgttctgtta	tgtaatacaa	tccattttta	tttccattttt	ctgtataata	tgaggtagag
41161	cttttttcaca	tagagagtca	atttttctat	cattatgtgt	cgaaggcagt	gtttttcaca
41221	ataaacttat	gttggcactt	taatcaaaca	tcaatttact	atataattttt	gagtctactt
41281	ctggactctc	tcttctttga	tcaacatgtc	tgtctttatg	cccataccac	actgttttca
41341	ctatggtagc	ttttatatta	agtcttaagg	tcaggttgtg	taagttctct	gactttgttc
41401	tttttcttta	accatgtctt	gggtattccc	aggactttaa	tttgccatgc	agacttttaga
41461	tttccataga	agcttttagaa	gcagattctg	ctgctgggag	aataagttac	actgacctca
41521	ggacaaaaga	tgtacatgaa	ctaaataaag	gacgacaaat	gcagaccaca	gcaataaagt
41581	ctgtggaatt	agtatgtgag	aaattacaca	atgggtctaaa	atattagtct	tgaagggatc
41641	ttaatgatga	tttagtcatt	tcacatgtgc	aaactgttaa	gactgctggc	tgtttttcac
41701	atggccacca	gcccatttct	ttttctctgag	tgtctgcagt	ccacagagct	tcttctggct
41761	ctctatgtctc	catctgttct	cgccccagga	gttcccatgg	gacctcccaa	gggtgactca
41821	ggtctcatct	tccgataaga	taaaagaagt	aagacagata	ttcggggtag	agatgtgaaga
41881	gcatggtgaa	agacagactg	ctcctgttta	gatccatata	taaaagcttt	attttttgaa
41941	tcccaaattc	catcccttgg	tcactctgtac	tggttcattc	aataaatatt	tctgagggctg
42001	ggcatgggtga	ctcaagcctg	taatcccagc	actttgggag	gtcaaggttg	gtggatctct
42061	tgagcccaga	tgtttgagac	cagctttggc	aatatgggtga	aaccccatct	ctacgaaaaa
42121	tacaaaaatt	agctgggcat	gggtgatgtgt	gcatgtagtc	ccagctattc	tggaggctga
42181	ggtgggagga	tcacctgagc	ctgggaggtg	gagactgcag	tgagccatga	tcacaccact
42241	gcactccatc	ctgggtgaaa	gagtgtgagc	ttgcctcaga	aataataata	ataatgataa
42301	taagtaaaaca	tttctgagca	cctacttggg	gctcttccag	gcacatgagc	tatatcaata
42361	gacaaaactc	acaaaaataa	tMttgccttc	tggagggtcat	attccaatgg	ataaaaacaga
42421	aaataataaa	catgatgcat	aagtagaatg	ttagaagtga	tgaatgcctt	agaaaaagat
42481	tggagcaggt	taaggagatg	gggattggga	gaggagacat	tgcaattcaa	aattgattgg
42541	tcagggaactc	aaacaaatac	ttggacacYg	atagcagcat	tattcaaaat	agtcfaatagc
42601	tagaagcaac	ccagatgccc	attaagggat	gaatggataa	acaaagtgtg	gtaggcacac
42661	acagtgggaat	attattcagt	cattagaaac	aataaaagtac	agacccatgc	tacaatatga
42721	acaaaaacttg	gaaagattat	gctaagttaa	ataaggcagt	cacaaagggc	acttattgtg
42781	tgactccatt	tataggaat	attcagaata	gataaaccga	tagaatcaga	aagcagattg
42841	gtgggtggcta	tgggtttgtg	gtggaagagg	aagaatgggg	acttcatggt	aatgggtatg
42901	gggtttatact	cggggatggg	gaaaattggtt	tgaaactaga	tagagttagt	gggtgtacca
42961	cattgtgaat	gtaccaaagt	tcactaaatt	gtgcacttcg	aaatagttaa	ttttatgtta
43021	tgtaaaatttc	agcgcaattt	ttaaaaatca	gaagcaaaaa	aagaacagaa	aattgagtag

43081	ttaggctaag	tctcacagag	aatgtacagt	ttgagtgtc	acttggagga	ggtaagttag
43141	ctcttggagg	aggtgggtaa	caggaagaag	ctgtccaggc	agaaggaaca	atgtctgcct
43201	agtgccttca	aggaacagca	atgaggatac	gggggttgag	gggaggggtc	agagaggtga
43261	ttggtggtgt	tccatcgtgt	ggtacctccc	agcttctgta	aagacgttgg	cttttctctc
43321	gggtgaggtg	gaagactttg	gaggccccct	tgatttgacc	taggttctaa	cagaatctcc
43381	agagtgtctg	ttttaggaat	atacttaaga	gggtacaagt	ggaagcaggg	atagcaattt
43441	agaagcagtt	attaaaaatcc	aagttagaga	ccatggtggc	ttggacaagg	atggtggcat
43501	tgagaatgga	gagatgcaat	tgcaggtagg	atgtcccttg	aagatgaaac	cataagttgt
43561	cctgatggat	tgcatgttca	atatgtgagg	aagagaagag	tcaataataa	atggagtctt
43621	ggtctgagcc	aacattcagc	atggagtgtg	catcattaca	attagaagac	aatgggagat
43681	gctgaatttt	ctttggggca	agggaggcaa	ggaggctgga	ggagatcaga	agttctgttc
43741	tggagacatg	aagcttttgt	gaattccact	tgttccttga	atatatgatg	gtttcttctc
43801	tttttgtttg	tttgtttttt	taaattttag	attctaaggt	acatgtactt	gtttgttaca
43861	aaggtatatt	gcattactgg	tggggactgg	tcttacccaa	attgtgaata	ttgtaccag
43921	taggtaattt	ttcatctc	acccctacc	ctccctactt	ttggagtccc	cagtgtctat
43981	tatttccatc	tttatgtcca	tgagtacca	tgggttagct	cccacatatg	agtaagaaca
44041	tgtggtattt	ggttttctgt	ttcttaactg	gttcacttaa	gataatggtc	tccagctcca
44101	tccatgtagc	aaaggacata	atctcattct	ttttatggct	gaatagtaat	ccgtggtgca
44161	taggtacaac	attttcttta	tctagtcaac	cgttgatgga	cacttgagtt	ggttccatga
44221	ctttcctatt	gtgaaccgtg	ctgcagtga	catactagta	gaggtggaga	ggtgtctttt
44281	ttatacacta	atttcttttc	cttagaaaag	tagtgagatt	tctgggttga	atggtagttt
44341	tacttttggg	tcattgagaa	atcttcatac	tgttttctct	agagattgaa	ctaattgaca
44401	ttcccagcaa	aatgtataaa	gcattccctt	ttctccatat	ccatgccaac	atctgtgtgt
44461	ttttgagttt	ttgataatag	ccattcagac	gggtcttctg	gtttttggag	gggaggattg
44521	ggtgaagcaa	gaaggagttt	ggagggaagg	agtggaggct	tgagtgggcc	tagagtttgg
44581	agtatgggca	agaaggatcc	cagagacaag	cactttgccc	acagctacac	agctaattgga
44641	gctggggggc	ccagcatatt	ctccagaggc	ccaggctagg	ccgtctaggg	gcattgctgt
44701	tctgccccct	ccactgcagg	tcctgaaaac	attttcatca	ataaaaaaaa	ataaaaaaac
44761	agaataaaaa	tgatacccag	atgtcctcta	gtgaaatgag	gggaaaaaaa	acatccatcc
44821	ccRgcttatt	gtgagagtca	ctgaatgaga	gcctgactca	ctgaaattca	tataagatta
44881	atgtaaccaa	gttccctgtc	ttttgacact	ggtttacagt	aagagcaggc	cacacatggc
44941	cagctctgga	gtgtgttagg	acattttacat	tttacatttc	agtgtgatat	ctgctaagtc
45001	aaatgaagaa	gtcttgaag	ataccctcta	agttcggaag	tatttgagtg	tcacattcca
45061	tatgccagca	gttagttgtt	gccctcaaaa	cataagggtt	tgtttgttct	tttgtttttt
45121	gtttttttta	tggttatgta	agtgaagtag	attataaata	ggcacatata	ggatttcaaa
45181	actgtaacaa	aattaaagaa	aagctggttc	aatgagStta	gatttctatga	gattaatctg
45241	aaaaggggaga	gtagttatga	gaagtcttaa	aaaagtgggt	gtttgccaga	gaaacaagcg
45301	gacctgggaa	gatttctgat	taagttggca	gaaatttatg	ggtgcttaaa	atgccttgct
45361	ttattcatgt	attagaagcc	cttgcccttt	tgcagtttgt	cttaagttgc	tataaaactac
45421	tctctgttat	gttgaatgg	gcctgaatag	tgagaagcca	aaataattta	gttcttttca
45481	aagaagaaat	tatagactag	cttattttta	taaccagtc	caaattataa	aaagaaaagc
45541	tttaccascc	taatctctgg	tatagagaat	gttctctttt	tttagttgac	attgggggga
45601	Raaaagcttg	actttgaagt	tcagcaagtc	tggtttcaac	cccagccaca	actgggtgaa
45661	ctttgtcaaa	ttacttaaac	agtcttatcc	ttgggttttt	atttgtaact	ataaaaattg
45721	aStgatgtta	atgataagta	ccacagagta	ttgtactttg	aatgaaaggt	cttaattgtc
45781	aatgaacaa	ctgaattatt	ttataggaag	agttcaactt	taataaatac	tcttcagaaa
45841	tttcatcatt	atgatgttaa	aattgatgga	agctttattt	tttaaaactga	gaaactaatg
45901	cttacgtggc	ctagttttaag	aatgaatgct	ccaacttaat	acatgtttta	aaaagatggt
45961	ttgggaYacc	aaatgtaaaa	gaattccgag	tttgtgttat	tttattgaac	aaacctattc
46021	agcacttggg	gaatcgcagg	cagcattgca	gactcgctgg	ctcctggctg	tgatctcaca
46081	cccaaactgc	aataatatcc	tgataaaaac	gacttccaca	agtaggtcaa	gaataataat
46141	gtgcagacct	aattcctcta	atttacggcg	aacatctcat	ggtcaatctc	cccgcggtca
46201	aaggactgtg	tatctcttcc	tctcagagcc	actccacagg	ctgaaaggct	gactaaaccc
46261	ctgacagata	agagattcaa	gagtagtccc	agcccccatg	gggagcaaa	acgctggctc
46321	aaaaaacgta	ctgataaact	tcccttttgc	agctactcct	ttctgaacct	tcacaagca
46381	gtggcagttg	gatttctgtga	ttagtctagt	cttcagagcc	agccttcttg	agttcaaatt
46441	ctgacttcac	cccttaattgt	gaagtgcata	gggcaagttg	cttaactctc	ctgtgcctca
46501	gtgtccttgt	ctgtaaaaatg	ggcactataa	taatagcgcc	tgccacattg	ggtgagtggt
46561	agaatgaagg	aattaataca	tgtaaatcac	ttagactgtg	tctggcatag	aggacattct
46621	aaagaaaagt	tagctattat	catttatatta	ttatatgggt	ctggaattag	ttcctgaatc
46681	cttctgagat	gtgatgactt	ataaacgtag	gttgagttta	ctcatgatag	ggtcatcgca
46741	actatgcata	gctaaaaatca	aattttgtct	ttcaagtttg	ttttacctgg	agccctagag
46801	ttcaggggta	tggttttctt	tgtcactccc	cttgagggaa	gcttcttagt	cacactctcc
46861	ttctctttct	ctgcactcta	tgcactctag	aaaagctcct	tttttttttt	cttcatccag

```

46921 gcagagagggc ctactggggac ttaaatccaa ggagctgaaa tctgtttttgg gatgggggtgg
46981 agtcacatttc tggaacctag acagagaatt tctaagttcc agaaagtgc gcttacttgc
47041 catttcctct cccccacctt tgcttttgaa actcctggca ccaatgctgc caaggctggc
47101 ggagcttttcc tgagtgggtg ctgccaaatg aggagtcaag gaatatctgg aaaggcagcc
47161 tccaggtccc cgatgtcaag accatttaga actgaaagtg tcccaatcgc ggggtacagg
47221 caataagcat tagttattaa tcagcctgag aagttgattc taaaatagga ggaaatgatt
47281 caattatttc ctctcaaggg attactcaat gttgttttta tgtttaaata tttatttgtc
47341 aacatcaaga attcttagta catgatKcac cagcattttt gaacaagtca tagatttggc
47401 cacaaatcaa atttcaggat gggaggagtg tctccctttt aaaatagaag agagtggatg
47461 gtctatgagg agggacctac aaagactgga aactattctt agctccgtca ctgactccaa
47521 gttcatcccc tctgtctttc agtttggtga agcatcaatt acttatctaa aatttgtaat
47581 aagaaaagtc ttcataattc atgattgtgt ttatctttat gttagtaaat ttctatgttg
47641 gKctctattct tccccttata ttttaagaaa agaagtaaga aagtaaatga ttatttttct
47701 gaaagaaaaa attaatgtat ttattattat tcatagacct tcaactactc ttagaaagcc
47761 tttggtgact cctgggaaca agctgagtca ggaacaaaag tttgagggtt tggggttgag
47821 aataggacaa ttacttggct aatgcttttag tctagtctcg attttgctac tcttagttg
47881 ctttgtgatg actacttgca catgtgtctg tttgtgagtt atttttgtga gcatgtgct
47941 accagcctgt gtggatgtct gtggtttcac atgatacatt ttattttcta aagttctctg
48001 aatttttatgg ttttttttcc aaaaatagaa actcatattc tttccttctt aatttagttt
48061 ctttcaggac attctcatga gactgggtga atataactgc gaagtagcat gataactgtg
48121 aaataRcatg atcattgtga aagctatatg acccaaaact tccataggaa taagtgcatt
48181 gcttgcatat ctgaaacctg ctgttacatc tctttgcact taataaatat gtgttgactg
48241 attcatcttc ctgggtgggt ctgagaaagt aaaaatcatg gctgataaaa attctgttta
48301 tgggttttgtc taacttattt ttcagttgag atataggcta ctcttcccaa ctcagttctg
48361 aagagtatca ccaactgcct catgtgtggt gaccttctact gtcgtatgcc agtgactcat
48421 ctggagtaat ctcaacaacg agttaccaat acttgctctt gattgataaa cagaatgggg
48481 ttttggaatc tagcaattct cacaattctc atgtattcca cagcagcaaa gtttagtaag
48541 tattgccttc taagtataat ttaaattttt ataaattaaa taatttcaag aacatttacc
48601 ttgttttaag cagtttgctt ccagttgttc cagttgaatt gtaaaactgaa aaatatattg
48661 cttttgtaca atcatttttc attacaaatc tatcagaaga aattctttgt aatgaatata
48721 tcatcagttt ggctttgcat attcaaatgc agcagaattt aatgtgggtg ctgcacatgg
48781 gaagtgttgt ggatgtttat tgactgacac acagtttgtt tagatagata aggctgcttt
48841 tccattggat aactgtgggt gatttagctc caaattaatt cattaacatt tctaagaga
48901 tcttaacagt tacttattct tcccaagggt atcacagtat atgaccggct tctaaattta
48961 atcctagaag aaaatattga gagtataaga attatgatct tttcatttga tcatttcagg
49021 attgtcttta tatcttttat ttgcaggtaa acaatcatgg ggcttggaaa atgaggcttt
49081 aattgtaaga tgtcctagac aaggaaaaacc tagttacacc gtggattggg attactcaca
49141 aacaaacaaa agtattccca ctcaggaaag aaatcgtgtg tttgctcag gccacttct
49201 gaagtttcta ccagctgMag ttgctgattc tggattttat acctgtattg tcagaaggta
49261 ttatgcagaa ggcNccatc ttctttcacc ctgctcccct tcttctcagtg gttgattgcc
49321 tgagctgccc ttgctttcat tccctcccta gtcccttctg gaacagttaa atttataaaa
49381 tgatttgaat aaaagtgtat tggataaact tctaggaata ctatcagggt gaKgtctagc
49441 tcatcttgag ctatttggat ttacagttgc agggattgat ttgtagctga cttagagaaa
49501 aacctagctt tccatgtgac caagataact gagagcaatt gcttactttt ggcgtggaat
49561 aagaacaaac tagcacagaa aatagtaatc tggatgtttt ccatctcagK gggcctctag
49621 taggtgaaaa ggggcttcta accttcaagt taagccacag aaggctgatg agatttgttg
49681 cctaaaaaatt aattactttt gttcacaaat tgttaaattg tttgattttg tggctgtatt
49741 tggcacacac aaaatgtcaa atgaattaaa tcaaaaagca ggatgtatta gttaaagggc
49801 taggtctgag actagacaag tgtcaaattc atgctctgcc actagttaac tgtgcgatgc
49861 cagcaagtta cttctctgcc cttcagtttc cttctctgta aaatgcatat aatgtaataa
49921 tatatttcat ctcaaagcat tattgtgaaa ataaactaag gtaatgtgtg aaaagtgtc
49981 atcatcatca ctggtacaga gtaaaactct aataaaatag aattatcttt attacactgg
50041 gattacagca ttacagcaga ttagtgttat tgtagtgtat tgaagaagtc attgttaggg
50101 ctactatggg ggctatgttt ttagctcaag tgtaacaaaa aagtatttaa actctagatt
50161 ttaatgttta tttttaaata ataaaataac cattatgtat attgatgggt ttaaagaaga
50221 aaagcaatat taagtaaaagg ctgaatttag attaagttat ttcacaatgc taagtgactc
50281 ttttaattgt ctgacttatt ttaacagtc cactttcaat aggactggat atgcgaatgt
50341 caccatatat aaaaaacaat cagattgcaa tgttccagat tatttgatgt attcaacagt
50401 atctggatca gaaaaaaatt ccaaaattta ttgtcctacc attgacctct acaactggac
50461 agcacctctt gagtggttta aggtagaaga aaatttggaa ggaaatagat gaaaattaca
50521 caattaaaaa agacacaagt ggccggggc acgtggctcat gcctgtaatc ctgactctt
50581 gggaggccaa ggcaggcaga tcaattgagg ccaggagtgt gagaccagcc tggccaacat
50641 gaggaacccc catctctact aaaaatataa aaatcagctg ggtgtggtgg cacacacctg
50701 taatcccagc agcttggggag gctgaggtat gaaaatcact tgaacctaga aggcagaggt

```

50761	tacagcgagc	ccagattgca	ccactcactc	cagcctaggc	aacaaacatt	ctgtcaacag
50821	ataaataaat	aaaagtgaag	aattactgag	aaggaaatgg	aattttcttat	ttcagaattg
50881	tcaggctctt	caaggatcaa	ggtacagggc	gcacaagtca	tttttgggtca	ttgataatgt
50941	gatgacttag	gacgcagggtg	attacacctg	taaatttata	cacaatgaaa	atggagccaa
51001	ttatagtgtg	acggcgacca	ggtccttcac	ggtcaagggg	aagctactga	cattaatgag
51061	atagaatact	acgtgaaaga	agtcgaagtg	ggaacagcgg	tgcccttctg	gttgggtttc
51121	ttgactttct	ccctctccc	tttacttctt	cctgctccat	cttatcttat	acattctgaa
51181	ctatgacgca	aagaggtttt	ctgaacacac	tatcaagatt	taagaaattt	cagggggaaa
51241	ttacattact	aattcaaagc	cacatctggt	ctttattctt	tYtttgtag	ttaaatttcc
51301	aaagataaag	caatctgaat	gctaacttaa	cttacttttt	ttgaatggca	atacaactat
51361	ttggagagca	aaaccagctt	tttttttttt	tttctagttt	ggtgtcagag	tttctgcaaa
51421	ttaaaaaaga	gcttaactct	tagtaatact	cattggattc	aaagtYtaat	gagaggcttt
51481	gtgatggat	actatgggtg	acataaatgt	tgctgagtg	tttttaactc	ttgtttgcaa
51541	tactttcaac	atcatcaatg	gccttgagta	agtcacttca	ttctaataat	gtgttttcca
51601	agttatttta	aatttttata	aagcttattt	aagggaaaga	tttcacaatc	atagcttatc
51661	aatctcaaaa	ggattggggg	ctccttagca	caagtcgata	tacagacgta	gatgtaatag
51721	cccctttacg	tatgacagtt	ttttcagggc	aaagcaatat	tgagagacaa	tttttggagt
51781	ttttcaatac	tccaccgctg	taaaataagc	atcaccagac	cacatttcta	tcagtgcctc
51841	tttctgttta	atatcaacc	ttacagtgtg	ccttaatcac	actgtcatta	aataaatgag
51901	catgaaggga	tgaggagattg	cagcagtgct	ccataagcac	tgcccgctct	tcagccttag
51961	tggtcacagg	agtcagaatt	ccgtacgggg	aagatttcac	tgaggatggg	ccaccctagt
52021	ggagaactgc	gagcaaatct	gtggactcat	ccattttatta	ttttcatggg	tcttttgaaa
52081	tcttctctgt	agtcttatct	ttattctgta	gaagagtagt	tttctaacaa	ctactaggtc
52141	atgtaattag	ttttatgggt	tggattctgca	tttgtttaag	tgatatcaga	gaataatgat
52201	attaaagagc	atcataggta	ataaaaagaa	gttttattta	agtgcctttc	tgtttcgtgt
52261	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgttt	gtcattatgg	gttattgtca
52321	gaagaacttg	aaaaacattg	ctatgaaata	gaatagaaac	atgaaaatac	aagctttata
52381	ttgactagca	ttcaatgctc	tctaataatt	tatatattct	tttgtcttta	agatgagcaa
52441	ggcttttctc	tgtttccagt	aatcggagcc	cctgcacaaa	atgaaaataa	ggaagtggaa
52501	attggtaaga	aaatttatca	gaatgctgta	aatattgcct	ggaaaaatcc	ttccatatga
52561	cccctgttct	gaattccctt	agcaggggtc	aggcaattag	cataaggaac	cttgaggagt
52621	aagtgaagg	acatccctga	aagcacctgc	cccaagcatt	tgctaataat	gggaacaggg
52681	acacagcaat	tgcatgtttt	acatttggtt	attgtacttt	gtaattcatg	atgctttcat
52741	gtatgcatct	aatttcatct	tcactcttat	cccagagctt	gggatggaga	cctgaggggt
52801	gttcattctg	ggcaatggta	gccagatccg	gtaaaacatg	tttatcttca	aagtagctta
52861	tgagagagatg	aagagagtct	tgtagaaaaga	tgtggaagag	ggcagttgga	aagaaactct
52921	aatttctagt	agagggcaat	ccttttacta	gaaatccttt	gtaatgtggg	gttggtgaag
52981	cgagaatcat	tggccttggt	agtttcccat	gcagatgaga	atatagtggg	agctgagctt
53041	caaaaccagc	tggtgaaatg	aaggtaaatg	aagcagggag	gaggcaagag	aggacataga
53101	aagaggaagg	tgctagagat	gagggagggg	ggtcctgggtg	gggtgcatac	taagtgttca
53161	gtaaggtttt	ttttttacat	taaatgggat	aaaatgccag	tcgcagaagt	taattttatt
53221	ggtgaatgtc	cttactcccc	tctaggaaaa	aacgcaaac	taacttgctc	tgcttgtttt
53281	ggaaaaggca	ctcagttctt	ggctgccgct	ctgtggcagc	ttaatggaac	aaaaattaca
53341	gactttgggtg	aaccaagaat	tcaacaagag	gaagggcaaa	atcaaaggta	tttttatatt
53401	gaagagaacc	atcctcttcc	ccttgacat	ggtttgcacc	tgcaaagtag	gcattaaaag
53461	taacagggtg	ctttcttagt	ttcagcaatg	ggctggcttg	tctagacatg	gttttaagaa
53521	tagctgacgt	gaaggaagag	gatttattgc	tgcatgacga	ctgtctggcc	ctgaatttgc
53581	atggcttgag	aaggcacacc	gtaagactaa	gtaggaaaaa	tccaagtaag	gagtgtttct
53641	gagactttga	tcacctgaac	ttctctagc	aagtgtaaag	agaatggagt	gtggttccaa
53701	gagatccatc	aagacaatgg	gaatggcctg	tgccataaaa	tgtgcttctc	ttcttcRgga
53761	tggtgtttgc	tgtctgatct	ttgtagactg	ttcctggttg	ctgggagctt	ctctgctgct
53821	taaatgtgtc	gtcctcccc	actcctcctt	atcgttggtt	tgtctagaac	actcagctgc
53881	ttctttgggtc	atccttggtt	tctaacttta	tgaactcctt	ctgtgtcact	gtatgtgaaa
53941	ggaaatgcac	caacaaccgW	aaactgaacg	tgttcttttg	tgctctttta	taacttgcat
54001	tacatgttgt	aagcatggtc	cgttctatac	Stttttcttg	tcataatgaa	cactcatttt
54061	gttagcgagg	gtggtaaaat	gaacaaaaag	gggaagtatc	aaactactgc	catttcagtg
54121	agaaaaatcct	aggtgctact	ttataataag	acatttggtta	ggccattctt	gcattgtatat
54181	aaagaaatac	ctgagactgg	gtgatttata	tgaaaagagg	tttaattggc	tcacagttct
54241	gcaggctgta	tggaagcat	ggcgccactc	gcttctgggg	acacctcagg	agctttactc
54301	atggcagaag	gcaaagcaaa	ggcaggcact	tcacacagta	aaagcaggag	cgagagagag
54361	gtgccacact	gaaacagcca	gatctcatga	gaagtcactc	actattgcaa	ggacagcatc
54421	aaagagatgg	tgctaaacca	ttcatgatga	actcaccctc	atgatccaat	cacctccac
54481	caggctccac	ctcgaatact	ggggattacc	attcagcatg	agatttgggc	aggaacacag
54541	acccaaacca	taccacacac	attatcattg	ttaRactttg	taaagtattt	aaggtagcatg

54601.	gaacacacgg	gaagtctggg	agctcagccc	atttctttat	tgcattctgtt	attcaccatg
54661	taattcaggt	accacgtatt	ccaggagacc	tttcttgcc	ctcagtttgc	agtatacaca
54721	ctttccaagt	actctttag	catcctgttt	gtatcatagc	actgggcaca	ttgccttacc
54781	taaatctgtt	tgacagtctg	ctcaacacga	ctgcaagctc	catgagggca	gggacatcat
54841	ctcttccatc	tttgggtcct	tagtgcaata	cctggcagct	agccagtgc	cagctaata
54901	tttgttgact	gaataaatga	atgcacaacc	aaattattga	taccaaagt	tttttttgtg
54961	tacatttcta	cttctctagc	tataagtctt	aattatacaa	caaaatacta	tttttatatt
55021	tatgtttggg	aaattcaata	actttcccca	tcatttggaa	agtc aaattg	ttttattgctt
55081	ccctacagtt	ttttctgaat	ctagcaggat	tttaattgata	tcattataat	ttgacacaat
55141	aaaaggacaa	catgaaactg	atgaatcttt	attgggttaa	tttcagacac	tatataatct
55201	tttaaaaatg	taacattctt	ttttatata	aaataattgg	tggcatcaca	aatagccaaa
55261	gcagggtgga	gagagtgatc	cttcctgggt	gcaggcaaga	aggggatatg	ttttctacag
55321	agttttcaaa	acagtataaa	agctgtctac	aagtcattgt	gctttttatc	atcactatgc
55381	ccagacaatg	tgaaacatca	gagatgaagt	gctcttccca	cagagggtga	ctgatccttc
55441	tccccactcc	cttgggtgtg	ctctgaatgc	aatgttgtct	tggaaaacag	ctttccaage
55501	atttcactcc	tgagcacttg	ccagtttctt	cacttgttct	tcacatatcc	aggcaaagac
55561	atcctgtttg	ctatatgaag	cattgtatcc	cgtataaaag	gaaggaaaga	gagaaatata
55621	tttttacact	catcactcct	caggggctgt	acaatcatgt	agaaattgtt	taatgtgcYt
55681	gtcaaatagc	caaagagtgt	taaacctga	gttccccccc	atgtgtgtgg	tatggttagg
55741	attcatccag	atacacagag	agaggcacia	caggaggaga	aaggatagg	gtgtggggac
55801	agcgggcccc	caatatgggtg	taatcgtggc	aggtctctgc	ctgaagtgtc	atgtgggggt
55861	tttctgtttt	taattttgac	tttaacccct	gattttgaag	tttttcataa	aataaacaga
55921	atcataactc	atgtagatgg	ctataagtcg	cgtagtgttc	tgtgggtctc	tgggtctctgc
55981	cagtataag	tgtggcacc	caggaaaggt	gtggacccca	tcaagggtgt	atgtgagggc
56041	catgcttggg	gtgtgtgtgg	gcccagtaga	ccctgcagcc	atccatccag	cctgcccacY
56101	cacactgccc	ttgtgtactc	ctgctttgtc	acgttatcat	tgatcaatgt	ccctgggttac
56161	ctatgtgttt	gaattatctt	cRtgttacag	gtgttttaag	attttgcctc	ttctagctta
56221	tttgtatttc	acctgttttt	cttttaatca	acatggttac	actctgtttc	agcaactgta
56281	taaattaaac	acaaattatt	actactgcta	ttgagttgtc	atgatgaatt	cttttttatt
56341	tctgaaatta	tagcatttct	tgaatttaag	agaacaaaaa	cttgaaaggc	ctatgtctcc
56401	atlttattaa	ctattactaa	atacatattt	gatgctcata	ataataatac	acattttatc
56461	attatttctt	atgtacaagg	actcatctgc	ttatttttaca	tttaactttc	tcattttatt
56521	tctcaatact	tcaaaagtaa	agacaaagaa	agttgaataa	cttgcgaaat	actacagtta
56581	tggagcaagg	attcaaacac	agccagcatt	ttcctagcta	tatgtgtata	cagaaagtaa
56641	tgttttgtca	tcacatacct	gaattactta	tactttttata	aaataattca	cacttacgaa
56701	gacttctctt	gatgtcttgg	atcaacttct	ttcctctact	tggaaagcgt	cagccaatgg
56761	catgggttct	tcccagcaat	ccccacagga	agtacacatt	cctctgtgca	tccagctggg
56821	gatttttagag	agagagtgc	ctggaaagga	atcctgttga	aatgatttac	ttacggaggt
56881	ttcattattt	aacctgatga	cagtaagctc	tttgtcaatt	ttcacttttt	ccccccaatt
56941	ttgtgtcaca	tcaccttgat	aattcttgat	tccatactgc	tggtcattga	gagaactgat
57001	aaactattag	aggttgtgga	ggaattcgtg	aatatgggcc	agtgattttt	ctaccttaaa
57061	actgggagcc	catgcattga	gacttaagac	ggaaaagaac	cgtatcagca	aatctcattt
57121	gagattcttc	tcacattcat	cagtgcatat	gcatgttgca	tctacatttt	gtgaagcaag
57181	gagtactagg	aaaaatttct	gggttgtgtg	agtaattgtc	accatgagag	aagtatgggc
57241	tatgagtagg	acctagaact	tagtaatttg	acttttgaat	tctttatcaa	agacgcttta
57301	gccacttagg	tgactcttgc	ttcttctcct	acctcccaca	ctgctaagcc	cttagaggca
57361	acaagtgtct	cagaccggtt	gatgccttct	ccttaatgcc	ctgacagcac	cttgtccgtt
57421	cctttctcat	tattgcatga	gttacaaccc	tctgcattct	gcaacccaag	taccacactc
57481	cattcttctc	tgagtgccta	tagtttcttt	ccacagaaac	aaactttctg	ctaccatcag
57541	attaatctct	tgggaaaacc	actcaagtct	ccagtgtctc	tgtgaccttc	agaataaggc
57601	aatctgcctt	agttgggggt	tcaagtctgg	acagaacctg	gcctgacca	aactttctaa
57661	tcatactctt	caccaattcc	ccaaactggg	ttattccatt	tcctcagaaa	acacacttcc
57721	tctctgcact	taggetttag	gtattctctc	tgcccagggt	ggcattttct	tttttgcatc
57781	tccttgatc	ctactcatct	ttcagaggcc	tcctctctct	ccaggaaagg	tccttttccc
57841	agtcctgcat	ggagcaagct	ctccttctaa	actcctctgc	cagcaaaaat	catgcttttg
57901	cctcccatct	tagttaagtt	gacaagtgtc	tctctgcctc	ttttgccttt	gagaatgccc
57961	tataatgtct	agcctgatgt	gttgttagagg	ctcaataaat	gtgactgtcc	tggacttaa
58021	agcagccatg	aaaattccca	gtgggtatat	cttatgtgaa	attcttgtac	tcccagggga
58081	agccaacatc	catgtatcag	tttattatat	cttggttcag	tagtaataat	aatctttttc
58141	tttcttttga	atagttgatc	atcatagcat	ctactgcata	attgcagtat	gtagtgtatt
58201	tttaatgcta	atcaatgtcc	tggttatcat	cctaaaaaat	ttctggattg	aggccactct
58261	gctctggaga	gacatagcta	aaccttacaa	gactaggaat	ggtaagtggc	aaataccaag
58321	ttttctccc	aaagaaaaag	tcccataata	actgttggtt	acctgtctat	taatctttca
58381	gtagctaggc	tgctaagccc	agattccatt	ttgcttgcta	atctgttatc	agtgaagtgt

58441	gttttttggat	tttctttaaag	gccatttttcc	atcctgctat	gtaaatcctc	acggctcctga
58501	gatccatctc	aacagctcac	ttttcttccc	cgataggatt	gctattccta	ctgagttccc
58561	aataacagaa	tctgccccaa	gccagaaaag	gtgtaaattt	cataatgtat	cggtaagaca
58621	ttatgaagtt	aaacacagta	gcaaaattgt	tctgttttc	cagatgtgag	caggttagaa
58681	aggtccatcg	gaatgcatgt	gtgttctacc	tgaaaccctg	atctgtaaag	tctaaccag
58741	gcacacaagc	atgtgcatga	aaggagtcag	ttctgcctgc	tagatgcaaa	cttcatgctt
58801	acatttggag	gcagatacat	gttgcatttt	tcaaacagtt	gactgaagta	ggagctcatt
58861	gtttgatctg	tggaaaattc	agatccctta	aaaaattcta	tgcccttgct	actattagct
58921	ttaaattttt	tacttcccc	aggggagtat	ggggaaacca	aagatgaaac	caaagtctat
58981	tcagcacaga	aggccccctt	agtcatagat	tattaatcaa	aattgatgag	atggacaggt
59041	tcttgtccac	ttttttgtta	tttagtctgt	gacagtaaaa	aggagaaaca	ctttgggatg
59101	aagactgtta	tttcttgata	gtgttttgtg	gcagtggttt	gacgtcaaca	tctcttgagt
59161	ctagaatatt	ttggaggatg	acatacattc	accaacagcc	ataaaacttg	gagaggaatg
59221	tcttcaaaga	gtccagttag	aattttttaga	atcaagtaag	aagttgtact	tcttgttttc
59281	attttcagat	ggaaagctct	atgatgctta	tggtgtctac	ccacggaact	acaaatccag
59341	tacagatggg	gccagtctgt	tagagcactt	tgttcaccag	attctgcctg	atgttcttga
59401	aaataaatgt	ggctatacct	tatgcattta	tgggagagat	atgctacctg	gagaaggtaa
59461	agctattgac	atacattagg	gacagaaatt	catgcttatt	aaaggctgtg	aactagggtg
59521	ccttatccct	gcattggata	atgaattgca	tttactacca	caggccttaa	gaccagaact
59581	ttaaatattt	atccagaagc	agacacttat	ccttcaatcg	ccccctctcc	atcattgtcc
59641	tgggtgatgag	atcttcacag	taatgttgg	gggtgtgaatt	cagagttaga	agtcctttgc
59701	ttcaaggact	tagcaaaacca	tcctccctac	tttattccct	tgggtcccca	ccaggataac
59761	tctgccactt	cttaattctg	tccataagat	ttgaaaagag	acttaaaaat	tgaatgattt
59821	tgttctggta	gccataggca	ctagctgaaa	taccttaaaa	gtactcagag	agtcttcatg
59881	acttctctta	tggtgtgtaa	acatttgcaa	attttatatt	tcaccagaac	aaaaagaact
59941	atagcttctg	ttccttaata	ttcctaccca	attttatata	cttttgacag	ttttatcaca
60001	actcctgtgt	ttgcagtagt	tatttttccc	ttcccttcat	acatttatgt	ccagtacctg
60061	tggacctctc	ttgtgaactc	tcttctaatt	tctcacagac	caggaagggt	ttggaatata
60121	actggggctc	agctatcaag	ggcctaagca	taataaagta	aatgttcagt	tttacatttt
60181	aaactcattt	tactaagaag	aggaattcac	atgcctatag	atgtaaagg	atgaacaaca
60241	ggtgactttg	gtttaccctg	gaatatctgg	gaatgcta	agcctcaata	acggctcaag
60301	agacttgtga	aagatacaat	ttaggagaat	ctaattgcatt	tcttctctca	aggctctctt
60361	cttcccccat	tttcccactg	gccacccatg	caggtagaag	taatgagtaa	tgctctcaaa
60421	cactcttttc	atattacaaa	tgtactcaag	aacctgcagg	gactcctggt	gtttgtgagc
60481	tcaacaatgt	gccacatctg	gccacaagct	cttcacctct	tctttttcag	tcYatccacc
60541	taagttctag	ttacacttct	cctcagccaa	accagatgc	tagctctctc	acactcaagc
60601	ttgtgtgccc	ttcaatgtgt	gacaacatac	taatctggaa	tggttttcta	cttccYctcg
60661	tcaatgtcatg	tcctctgacc	tttccctaac	caaaataaat	gaaacccaac	aacaccaaac
60721	ttcactcttc	acttaggaaa	gttcatgact	gactaaggta	ctgtctatag	tctcatgcaa
60781	cttaccttgc	atttgcccga	tcaaaatcct	ctctgcacca	ccattccatc	cagtggccct
60841	gggtggctga	tcatcatgga	atccattgca	cccttgctct	ctgtctcagg	ctgggttttg
60901	ccaatgggag	gcactggcag	gaggctcagag	gggtggtcatg	tacctgcctc	tcacgtggg
60961	gcttctggag	cagctgtgct	tctccttctg	ggagcacctc	ttctcagctg	gctctgctca
61021	tgcatctgca	atccctcaga	caccctgtctg	tgagaatatc	ttggattggt	ttattcacgg
61081	ttgtgctttc	tcctgttgca	gtgaggactg	ggtatttcat	gttctttctg	agtcaccca
61141	gagctaattg	gaatcaccat	ggtgtctacg	ctgtataaat	gccaaatggg	aaaggggatc
61201	tattgtccct	tgagattttt	ctagtittgga	tcaaatcagt	ttctacaaca	gagattaatg
61261	ggggtgaagt	aaagttagga	cttacttttc	tagagacttt	ggacaatttt	gaggggcata
61321	gcttctctgag	tttgtgattt	ttaatatgtg	agttaaaatt	ttaagccatt	gaaaaacata
61381	taagcaaata	ttctaagaag	ataatatgta	ttctaagaag	aatgaaccag	aattctaagt
61441	ctctaattgca	acaatagact	aaatatcttt	acattcccat	ttacttggaa	ggactctggt
61501	ttagttaaga	ctaagctacc	tgggaaataa	aaagaggaca	ttggggctga	tattctcaca
61561	aatgaaagga	acacaaagaa	caaaacgggt	tctctatcca	cacatacttc	cacttctctg
61621	agtaagttag	ttgatgtcag	agaatctcac	accagattat	aacaataaga	cttttaaatg
61681	ttcaggatgt	ttatgtttaa	agcatttagac	tgataagaaa	tctgatctat	ttcttgtag
61741	actagatgta	gtcactgcag	tggaaaaccaa	catacgaaa	agcaggcggc	acattttcat
61801	cttgacccct	cagatcactc	acaataagga	gtttgcctac	gagcaggagg	ttgccctgca
61861	cgttgccctc	atccagaacg	acgccaaggt	gatacttatt	gagatggagg	ctctgagcga
61921	gctggacatg	ctgcaggctg	aggcgcttca	ggactccctc	cagcatctta	tgaagtaga
61981	ggggaccatc	aagtggagg	aggaccacat	tgccaataaa	aggtccctga	attctaaatt
62041	ctggaagcac	gtgaggtacc	aaatgcctgt	gccaaagcaa	attcccagaa	aggcctctag
62101	tttgactccc	ttggctgccc	agaagcaata	gtgcctgctg	tgatgtgcaa	aggcatctga
62161	gtttgaagct	ttcctgactt	ctcctagctg	gcttatgccc	ctgcactgaa	gtgtgaggag
62221	caggaatatt	aaagggatc	aggcctcagg	tttcatctgg	taactttcct	tccatttccc


```

62281   tgcttctggg   tggatgcaaa   atggccagaa   atttttctcc   tcaatcctcc   accatcctcc
62341   agccaccatt   ttcttccctt   ttcccttttg   cttgcctgtc   ttcactgtgg   tgtgggagt
62401   tttcactact   ctttttccct   ctctctctgt   cttgctttgt   ttctcctcat   tcttgtcaat
62461   aatctgaata   gcaaaactaat   cattcgagag   tagattttca   cgtcacttga   agaacattct
62521   gattccctca   ggcagaatgt   cagttgtaaa   tcttgttccc   aacatgccag   attttcttta
62581   ttttctatat   atatatataa   tattttatat   ataattattat   atataattat   ttatatataa
62641   ttttatatat   aaaatattat   atataattat   atatatataa   ttttctatat   aaaatgtgta
62701   tataattata   tataattata   taaaatataa   tatagaatat   ctaataatgt   ataatatata
62761   acatataaaa   ataattattat   ttaatatata   atattttata   tataattatt   ttatatataa
62821   tataatatat   attttatata   taattattaa   ttatataatt   aatatataat   atatatttta
62881   tacataatta   ttaattatat   ataattaata   tataatatat   cttatacata   attatcaatt
62941   atatatatt   aatatataat   atatatttta   tacataatta   ttaattatat   ataattaata
63001   tataatatat   cttatacata   atatatataa   atatatattat   tataatatat   attatatata
63061   atatttatata   taatatatat   tatatatata   aaattttat   ataattattat   atataattat
63121   atatatttta   tatacaatat   gatatatata   ataattttata   tattatatat   atttatatat
63181   aattattata   taaattatat   aaatataaat   tatatattta   tatataatta   ttatataaat
63241   cattatataa   ttattataat   tataatatat   aatataatat   aatattatat   ataatatata
63301   gtattctata   taaataatat   aacatatatt   ttatatagaa   tattatatat   aatataatat
63361   atattttata   tagaattata   tatataatat   aatatatatt   ttatatagaa   tattttatat
63421   atataattat   atatatatgt   atttgagaca   gagtctccta   tgaacatact   tgtggactta
63481   tgattttatt   ttgacactta   agagtggcca   tagggtaggt   gcatatttaa   ctttcagaga
63541   aacttataca   ttgtttcgca   aactaattgt   actactttac   atccccacca   gttgtgtatg
63601   agagctctgc   tgcctcattg   cctcaccaat   aattgggtgt   gccaagtttc   ttatatattt
63661   aacaattttc   acagggtgta   gatgaagatc   accatggtct   taacttgaag   ttccccgact
63721   catgatgatg   agcccttttc   atgttttcat   tggccattcg   tatatatatt   tttagtgaag
63781   caaaatattt   tgccttattt   aaattgtatt   tctttttata   ttgttgatgt   gtagggaatt
63841   tttatgtatt   gtggatgcaa   gttctttgcc   agatagatgt   aaagtgaaga   tatttccagg
63901   gttatctatt   cttttttaag   tgatgtcttt   gtttagtaga   catttttaat   tttggtgatg
63961   tccaattaat   caatgtgtcc   caaatggcta   ttttttttg   tgtcctagct   aagaattttt
64021   tttttttgoc   tgtccaagag   catgatttat   ttattttatt   ttgocctggt   caagggctct
64081   ctctgtattt   ttatgaaata   ttacggttc   tagcttttat   gtttaggtcc   atggtctatt
64141   gtgaattgat   acttgtatat   agaacaaggc   aaggacaaag   ttcttttttc   tgtctgtct
64201   tcttctgtag   aggtaccag   ctgttccagc   aatgtttggt   aaagactgtt   tttccccac
64261   tgaattgaca   tgggtgcttg   ttaaaaaaat   caattgacta   gatagtgtgt   gatctattag
64321   tctactttct   attttgtatg   ttgtatgtt   tctgtgaata   tcacattgcc   ataattacta
64381   ttgccttatt   ataaatcctc   aagtcagtat   aagtccttca   actttgttca   tctttgtcaa
64441   gattgcccag   acaggccggg   cagggtggct   acccctgtaa   tttcaacact   ttgggaggct
64501   gaaatgggtg   gatcacctga   ggtcgagagt   tcaaaaccag   cctgaccaac   acggagaaac
64561   cctgtctcta   ctaaaaatac   aaaagtagcc   aggcgtgata   gtgcattgct   gtaatccag
64621   ctactcgggc   ggctgaggca   ggagaatcgc   ttgaacccgg   gaggcggagg   ttgcagtga
64681   ccgagatcgc   gtcattgcac   tcactccagc   ctgggcaaga   agagcaaaac   tccgtctctg
64741   tccggacaa   cctagattat   ttgcattttc   atatgaattt   tagaaacagc   ttcttaattt
64801   ctttgaaaaa   ttttctggg   atttggattg   aattgtatta   aatatataga   ttctgtaata
64861   tatagagtct   aaaaatatac   agtgtggaga   atagatgtct   taagtcttcc   aatccgtaaa
64921   cgtgggtatat   ccctttatta   cttagatgtt   tcatctctgt   tagcaatatt   ttgtagtttt
64981   cacaggagat   atctcatata   ttatccaatg   aattttatact   ttgggtattt   gattttttaa
65041   tgctatggta   aatggcattt   ttaacaaact   tcacttttca   agtttccatc   tctaatatat
65101   agaattgcta   ttgattttta   tattccatga   tcttgataaa   cttaatatatt   ccagtagttt
65161   ttttttttgt   agatttcaaa   agttgggtcta   catataatta   tgctctctgt   taaaaccagt
65221   agtttttaatt   ctttcttctc   aatctttatg   ctttctaatt   ttatttttat   ttcttcaact
65281   gttgcaaagc   agttgtccca   ggtgggagcc   aaaatcctta   tctcattact   aatcttagga
65341   aaaagtataa   tgtttcacta   ttatgaggtc   acctgtaggt   ttcttataga   tgttctttat
65401   cagattaaga   aagatcattt   ctactctcgg   ttttctgatc   gttattaatt   cagaaagggg
65461   gttgaatttt   gccagatgct   tttatttgca   tttattgaga   taattacata   tttttattta
65521   ttatgtggtg   aattatctaa   attgggtaaa   aagaattaaa   atcattgtcc   aattgaacat
65581   tttgctgtgc   ggctatgggt   ttcccttttc   ctttgggtta   ataacagttc   tgccacaaaa
65641   taaaaatcta   gaaacacaca   ttcccttttg   gcctccttaa   aaaaaattaa   aacttcaaca
65701   attgcacccc   tctctattac   ttccctatag   tgaactccca   tccttctggg   aaagcaaaaa
65761   gcctggggcg   catttgtgta   cttgagacgc   ggagcccttc   tcaccttcgg   catcccccg
65821   ggacccctct   tccacctca   gccctccctc   cctcttcttc   tgaagagccg   ggcggccgct
65881   gcggccagcg   gtccctccct   ctggcatcct   ctgctgtgaa   ccgcggcctg   caggggtgct
65941   gcgagcgggc   cgggcgcgcc   cccctccggc   cccgcagggt   acccggtac   agcccggtt
66001   ttcccgggac   ccgcgcgcgc   cgctggggca   ggaagcgcca   gacgcctggg   gccacgcgcg
66061   tccgcgggaa   aagggcaagg   cgctgggttt   tccagcagca   acctttggac   cccgcgatcc

```

```

66121 agtagctccg gtaactccac gcggggcgtc tgggtggagg agccgggtcct ggagcacggc
66181 tgcgaggagc acccgagccg gagggtcccc agaccgggac ctccgagtca gggaggattc
66241 tacgccaggg agcgccccag actgagagcg ccccgagacc ctacactccc ggaccggag
66301 ctgcgccga ccgcgggcag tgcccacctg cagcctccac cggccggggg tagcagccag
66361 gagctgccag acgcctgaca ttcttcttct tgttccctact ttttttccct ctctctcttt
66421 tttttttttt ttgtagccct ctctgggtgc cttatctctt taatcacacc tctctttcac
66481 tttccacggg agtcaggagg cggagatcgc tgcttctcac ctactttctg aacttggcct
66541 ccgcagtcgc gacctggcgt gaaggagagg ctgccgcccc cgccccagcc tcggggacgc
66601 ctctctgaag gtaagggtgg gctccgctgc caccgcctac ccctccccac cccccagagg
66661 aagggaagac caccatccgg ggagggattc tcaaaacaag atcaattaag agagagagag
66721 agatagtgtg tgtgtgaata cgtgtgaata attgatgaga cagcatcctg tctttctctg
66781 aaagtaaatg tttagaaatt aagacatccc caattatttt ctggagaggg gagaacgact
66841 gaaataaatg ataacaatag ttgtcatttt ttaagtgtt actgtgtgcc tgacactgta
66901 gaaaattttt agatatctta ttttctacta atcctcctaa gggccacatg aaataggaac
66961 tattattatg ctttaataaa agggaggagg aattccgtca ttaccacaag agtatccagc
67021 tactaagtag tagatcccag atccacacct acagtttttc tgattccaga gcctttgtct
67081 tttttctgcc cagccttggg aagttaaaaat gccagcacc ttgcctcgca gttatcagac
67141 aaattaatga ggtgtcaatt gcagccagat acagagatcc aagattattg tatctatttc
67201 actgacttcc cttgcttcat tctcaagacc ctttgcaaat actgattttg tgtcatcac
67261 agtgctgcta ttgggagcac acctctcaac ctccgggccc tggtatgggt aggggggta
67321 aatttggggg attgggtttg tgcaggttct ggggacagtg ttttccctct ccttgcaaa
67381 atatacatcc aaaggctgag aactaaggct aaggcctagg aatgtggatt gaaaaggcag
67441 ggtctaaatc ccagcacttg ccaggctgag gtgggaggat catgaggcca ggaatcgag
67501 accatcctgg ctaacatggt gaaaccccgct ctctactaaa aatacagaaa attagccagg
67561 catggtggca tgcactgta atcccagcta ctccgggagg tgaggcagga gaatcccttg
67621 aacctgggag gcagagggtg cagtggagcag agattgtgcc actgcactcc agcctgggag
67681 acagagttag actctatctc aaaaaaaaaa agaaaaaaag agaaaaaggc ggttccctgc
67741 ctccagggac ctcaccagag agtgggagct agtccaggag tgatggaaac acctgacag
67801 tgatggagac gggcttggac ataggcatgt gccatttggg gctgttgcag ttggagagct
67861 tccttgagaa ggcaaatact gagccaagtt gaaaggactc tagggacctg gcactcggga
67921 taagtgggga ggggtggcca ggtagcacag gcataggcag atttgggggg aagcataagg
67981 ctaacaacag acacttgtgt gacaaggact atgaggtggc attgattttc ttggccttac
68041 agatgagaag ccagattcca cacaatttat tttgtttgtt agagtttaag cgtgtgtgtg
68101 tgtgtgtatg ttatgcccc aagatcatttt ctctcttttg catttggttg ttttatcatc
68161 tcacaggctg agtaaaacga ctatgcatgg aacactgtag aagaaaaatt atattaaaaa
68221 aaaactgggt ttatgatttt catccaggca ttttgtctca ggagttgctc gatttgtatg
68281 gttgctaagc agtgatttat attgaggcat ctacattgat tcatgtgtgt ccttgtgaat
68341 agctgtaatc tgaggctggc catttcactt cctcaaatct caggttcctc attagaaaga
68401 gctttgaaat ggctctttcc ctgtacatta tgtgtttctg tgaattactt tttagaaaag
68461 gtcagtttct cagggtggga cccataaaac agggcaactg ggcagagcca ggggttcagg
68521 tgactgtttg gacctctctg aagggtcttt tactgtgctg ccttgggaga cagagtgggtc
68581 agcttggaa ctagcttaag cctaggctac ccaatttttg aaggaaactt ttttttttca
68641 ttttagaata acctcatgcc tttgggtgat taggtaagtt tgtgactatt cgttatgtgt
68701 gtgtacacac acgtacgtac atatgtacat gcacaaatat ttaatatgtc tttagacacac
68761 caaatatatg catttaagat gtattaaatg tactttcctg agaatacaaa taagtgcctc
68821 acgtcggcgg ctctcttctc gactgtatgt tagagtcacc tgccggagttc tgaggactca
68881 agatgcccag tctgtcctcc agaccactgg gtggagcccc ggcacatta tttttttcca
68941 aacttgggtg agagctgggt gcctagactt cacattagtt gctaaaaacat actttccaag
69001 atatcatgcg ttaaaaagca tttcaaaagt agatttgtga gatgtgcca tggatcagat
69061 gatcacctag attcaaaatt atgtatattt tatggatgta attcattcaa taattcagca
69121 aataacaaa aaacaagcag acataaagtg aaaatatgac agttagtgat aagtgtctatg
69181 aatagaaaaa ctaaacatgg gagggtagag gaacattggg gtgtgtgagc atgtgtgtgt
69241 gtgtgcgtgt gtgtgcatgt gcatgtttgc atttgaaaaa gcatgctgtg ctgacttgc
69301 agtagagtgc tcaggaggga cctgtacatt ataagctagt gtcagcaaac cgtaggggaa
69361 atacaggatt atttaattaa caatagagaa gtaattagta ggtatttgag gaaagtaagt
69421 ttagttactc cctatcttca tgtcaatcaa gaaaattaat tgttgggtga tgaaaaaagt
69481 taaatataaa aacaaaacaa aacaatactg agccataaaa atgaagaac tatgtaagca
69541 tctatttgac caccaacagg aaaggtattt ctacacttaa aagcaatgaa aacatctcaa
69601 agcaaaaagaa tgatcggttt gactacatca atataaaaatt tgtcatatat tagcataaca
69661 aaagagagaa agtaaaacac aagtttagaca aacatctgag aactggacaa aagacataaa
69721 gagatgggtg ataaacatga aaataaaatg gctgataata agtgattaat atttgcctca
69781 tttatagcca aagaaatgca aattcagaaa acaatagat accatttttc cattttggct
69841 gtctaattac attttaaaag taaagctgct cagtgtgctt ctgggtgtgg tcgatatag
69901 ctgtcttgtg ctattgagtg agagaatatg aatattgcaa cacttctgga atgcagtttg

```

69961	tcagcatgca	tctgtcaggt	ttcaatgtag	tcttcaactc	aatcactgta	ctgccatcga
70021	gtaacatcca	ggaaataata	agaaatgtag	acaaataata	atagctaaca	tttaagcggg
70081	attaccattc	accagacact	tgcaatagta	actcatttaa	ctttcacatc	agttccagga
70141	gatggtatta	ttatccccct	ctatagataa	gaaaattgag	gcacagaaca	ggcaagtcag
70201	ttgcccacag	tcggttagct	ggttgaagg	agaatggaga	ttcaaatacca	cccaggctgc
70261	cacctgagcc	catcctgcaa	aaaaactgag	ccatcctggc	ttacctgtga	agatggctcat
70321	gtgattatct	cataatacat	ctggtaaagt	ataatatatc	cacatgaagt	aatatttaggt
70381	ggcaattaga	atgggttttaa	caaagagttt	tgtgacacag	gaaaaatgct	cattatgtaa
70441	tattaggtgg	aaatgcagga	tatgcaatct	tttaaacatc	ttttattttt	tgagaaggag
70501	tcttgctctg	tcacctaggc	tggagtgcag	tgatgagatc	tcggctcact	gcaagctccg
70561	cctcccggat	tcacaccatt	ctcctgcctc	atcctcctta	gtagctggga	ctacagggtgc
70621	ctgccaacgt	gcctggctaa	ttttttgtat	tttttagtaga	gacgggggtt	caccatgtta
70681	gtcaggatgg	tctcagtcct	ctgacctcat	gatccgcca	tctcggcctc	ccaaagtgct
70741	gggattacag	gcatgagcca	ctgtgcccgg	ccaaacatct	taattatgtg	acaacattta
70801	taaaaagtac	aagaaaacat	gttaaaatat	tatacatggt	gagattatct	tcttctttca
70861	gtcttcattt	tgtaaatctc	ctacattgag	tgtaaatgtc	tttggaaatc	agaaaaactt
70921	taaaaagaaa	gaaacttaag	agttacggaa	aagcaaaaat	attgatgtta	aacataacaa
70981	ttaaaaaccc	ttaaaattct	tacatgtgag	acattttaata	tttatattct	tctatgccta
71041	ttttattaat	acttgctaga	gtatctgtta	catttatcag	aatatctctt	tttctggaaa
71101	tgaattcatt	atttaataata	accttaattct	gttaaatcca	cacataaaac	ttaagtacat
71161	taaaaatttt	acatacacac	atccacattt	gcagaatggt	gtgcaaatac	cagctaattt
71221	ttgtatactg	agatcttaat	atgtttcata	ttgaaactca	gagttaactt	gtcagtttgc
71281	tgagctatct	cctgataact	ttgtctcttg	gtagatattg	aatatttttt	ttaaagtggt
71341	gctttttata	aggttacatc	agtcttaatc	agagtgcacat	aaaggaaata	acatttttta
71401	ttctatccaa	gataaaagaa	taggcagagt	taataataaa	atgtgtgtgg	aggtagtggg
71461	ggaggtttca	aaccatagac	ccagtctaatt	ttgattatgc	acagttggta	ctttccattc
71521	atacttgttt	ctttggcctt	tacattattg	attattatct	cttggaaatt	ccaccaataa
71581	tttgggtgatt	tttccataag	gatgtatgtg	aatgggttgg	cagcttagcc	attaagcttt
71641	atcctggatt	caggcattga	caactctgtt	tttaggatgg	aagatgagta	gttgttgggtg
71701	agaggggcat	tattctgagc	tgagaagctg	ccatgcactc	aggaagtctc	cataagcctt
71761	agatgggttta	atcactcaat	aattccagaa	acaggccttc	ttatcatctc	catttttggt
71821	atgaccaaat	aggctctaag	acttgctcaa	gttttgcaca	gcttgctcagg	actcaaactg
71881	gagtggcagc	ccaggtttgt	gtgtttctga	aaccagactc	tgccatcagg	ctgtgctccc
71941	tgcaactcagg	atggtaaaaca	agggatattg	tgttgtttat	gcagtattta	gactctgaat
72001	ggtctccact	gtgggggac	cttcctccac	tgggctcaaa	gttgtaatca	gaactccgaa
72061	tgctaggttg	cagttaggac	aaagttcaat	gcagatctta	gttccactgg	gacacagtca
72121	atgtaaagga	ggggtctgga	gtgtagagga	ctgtcacttc	atctctccat	ttccctaag
72181	taaactcata	tgggcagcca	cagacacaYg	cgaacacatg	catacacacc	tatgctcag
72241	tgacacatgt	tagtgagtgc	tggccatgtg	ctaggcatcg	tgctggattt	tagtgataca
72301	gtgaagagca	aaatagactt	agtgcctaga	attatgaaag	aattatgaaa	cctacgttct
72361	gaaggaggaa	gatggagttt	taaaaattca	accctaattg	aagatctcat	tacaattcag
72421	gaatggtttg	atgtgaaaac	acacacacac	actctgttac	atgggcagaa	ctgccatata
72481	tagctcagca	tgtcacagat	tgtttatcca	tagaatggta	atatttgtag	cagtataatt
72541	gttctgaact	ttggccttgg	aagcaggatt	tagtagacca	ggcctgaaat	tcttcagact
72601	ctgttgtatc	agagaaataa	attattaggg	atttcttcca	gaagaaaaac	ttcattgcoct
72661	tgaaatttta	ttaattttat	atggctgaaa	gttctgagaa	ttggttacta	tattaaggat
72721	tataaaaaatc	ttctaggttg	tttttttaaa	aatctgtgtg	ccagaagatt	tttaaacytt
72781	cataagatag	gcacactttt	gtttgaaagc	tttggctgaa	tctgttttat	tctgttttcc
72841	agagaagcca	tttgaagcag	aatccaaacc	atgaattgta	gagaattacc	cttgaccctt
72901	tgggtgctta	tatctgtaag	cactgcagg	aagtgattat	acatactctc	aaacatattt
72961	catgagtaat	tgaggaagaa	tgtcaaagt	ttttttttta	tgtgggtggct	actgaagatg
73021	ctgaatttat	tcagaaaaga	aaagattctg	cagtctgagt	tcatgtagt	agagcagagt
73081	gaaaaacttg	catcttgaaa	taaattacat	ttgtctgagg	tgaaaattta	ttcatgttta
73141	tttgaaactg	aggaggtggc	agccatcttt	attattgggt	tttaggaagt	ttgaaacaca
73201	ctttctcctt	cctgagaggg	aggcaaagat	tcatctcatt	atttaggtta	taatgagaaa
73261	agtaaacgac	aaatatatta	gacagcttaa	aaaaattaga	gtgagacaga	atatacaaaa
73321	aagagactgg	ctagaccaag	gagctcaagt	aggcttcata	gtagatgtca	aatgccaatt
73381	tttaatttatt	agcagtgatt	gcctagagtt	tttttttttt	atttgagaag	gattctgaga
73441	cttcattctt	tagcgttcca	tgattgaata	gcaaggcatt	ccttaggctt	tgggggagaa
73501	agtgggagca	caaatattaa	tttgccctga	tctattatct	aggagaggga	aacacatggg
73561	ctcattttccc	tacttttgata	attactgctg	aagagatagc	tgaattaaagc	ttttgggtact
73621	ttcaaaataac	acaggtccaa	tctcagggt	tatttactta	cgtgaatcca	tttattattg
73681	agatccctgc	aatggaaccc	taccagatg	ataaaagaat	gaggtagatc	ttcatttttt
73741	tatatgtaat	gatctgtcaa	acaagtgagt	ggaaaagcaa	ggtacaggaa	aatgtgtcat

73801	gagttccatg	tccgtgtggac	atacactaat	agccttactc	ctcattataa	tgagagcatg
73861	tttccaggcac	agaaacagcc	atgcagccag	ttgtgcaaag	ttgccaagct	cccagctgcc
73921	tgccctgaag	agcacttttc	atgaatgttt	cactctaggg	agacatgaca	atgttctaca
73981	tgtaggattc	actgaacctc	gttgagttta	aatgacaaaa	tgctatgatt	gtccaaactc
74041	aagacagttt	caaacacaga	ctttattcca	aagggcattg	gttggttggca	ctgctggggt
74101	cttatactgt	gtttatggaa	caataggagt	gcctattttg	gcacttggaa	ctccacaaac
74161	cttgaattcc	acttatttat	cccatcaagg	accattttcca	acaagcatta	tggttaatcaa
74221	caaagcctct	aatggtaaac	catgattaga	tatccaaagc	ttctagctgc	ctgaggaggg
74281	gggtgggtg	gaStttcaat	tatcaacctc	ccacctctgg	agagtgtgta	attcacatta
74341	agtttcttca	aatggtaata	cttccagaga	gcacatgtcc	atccaaacac	agtcatatgt
74401	gtttatagaa	gctttttaag	acaagcgaag	acctgaaaac	ctagaaataa	gccaatatcc
74461	aacagacatt	tgtttaataa	accaaatccc	caacatgcat	ccttttataa	aatggataaa
74521	ttgcgaaatg	gtaacacgat	tagatactac	attacaatga	gaaaagaaca	catcactgct
74581	acagcatgaa	tgcatttata	acaatcatgt	caaaataacc	cagacataaa	ggagcacata
74641	ttgtatagcc	tatgcatttt	attatattaa	ctctaaaaca	ggaaaataaa	tgaactgtta
74701	atgactcacc	agggttttgc	atgtcaattg	aagctgacac	ccacatatac	acatgtatca
74761	caccttctat	gttgaagtat	tagtataaaa	tagagattgt	attgcaacca	gaaaacatga
74821	agttgggtgct	ccttaactct	tgtgttttgt	ggtagattcg	acatccatgt	tttcaaagaa
74881	tgtgtattag	tccattctca	tgctgcta	aaaggcatac	ttgagactgg	gtaatttata
74941	aaggaaagag	actttattga	ttcacagttc	tgtatggctg	gggaggcctc	aggaagctta
75001	caatcatagt	ggaaggggaa	gaaaacatat	ccttcttcac	atgggtggcat	caaggagaa
75061	gctgagcaaa	aaggggaaaa	gccccctata	aaaacatcag	atcttatgag	aactcactca
75121	ctatcaggag	cacagcatga	gggtaatcac	ccccatgatt	aaattacctt	ccaccaggtc
75181	cctcctatga	cacatggggc	ttatgggaac	tacaattcaa	gatgatattg	gttgggggat
75241	agccaaatca	tatcattcca	cccctggcct	ctcccaaatac	tcatgtctct	acatttcaaa
75301	acacaatcat	gcccctctaa	cagtccccca	aagtcttcac	tcattccagc	attaactcta
75361	aaatccaagt	ccaaagtctc	atctgagaca	aggaaggctc	cttcctatga	gtcagtaaat
75421	tcaagagcaa	tttagttact	tccatgatac	aatgggagta	caggcattga	gtaaaatacac
75481	cccttccaaa	tgggagaaat	tgactaaaac	aaaggggcta	ctggccccat	gcaagttcta
75541	aatttaatag	ggcagtcatt	aaaccttaaa	gttccaaaat	agtctccttc	aactccatgt
75601	ctcatatcca	ggtcacgctg	ctgcaagagg	taggatccca	tggccttggg	cagctatgct
75661	cctgtgggct	tgcaagggtac	atctttcttc	ctggtttctt	tcatgggctg	gtgttgagtt
75721	tctgggcttt	ttcaagtgca	tggtgcaagc	tgtcagtgaa	tctatcatcc	tggggcctgg
75781	aggatgggtg	ctttcttctc	ttaaactccac	tagctgtact	ccagtgggga	ctctgtatgg
75841	gagcccaaac	accacatttc	ccttccacac	taccctagca	aagattctac	atgagggttc
75901	cacccttgca	gcaaactttt	gcctggacat	ccagcatttc	catacatcct	ctgaaacctc
75961	ggcgtagggt	cccaaacttc	aattcttgac	ttttgtgcac	ctgcagcctc	aacaccatgt
76021	ggaagctgcc	aaggtttggg	gcttgacacc	tctgaagcca	cagcctgacc	tgggtctctg
76081	gcctgtttta	gcaatggctg	gaggggttag	atgcagggca	ccaaatccct	aggctgcaca
76141	cagaaaggga	ccctgggccc	atcccaggaa	atcatttttt	cctcttaggc	ctctgggccc
76201	gtgatgggag	ggctctctcat	gaagatctct	gacataccct	agaggcattt	ttccccttgt
76261	cttggcaatt	aacatttgag	tccctatttc	ttatgcaaat	ttctgcaacc	agctttaatt
76321	ccatgcctcc	cattcccacg	aacatggatt	tttctctcct	accacattct	caagctgtga
76381	attttccaaa	ctcttatgct	ctgtcacctc	ttgaatgatt	tgctctttag	aaatttcttc
76441	ttccagataa	tctgtctctca	agttcaaagt	tccatagatc	tctaggacaa	gggcaaaatg
76501	caactaatct	ctttgctaaa	cataacaaga	ttcacttttg	ctccagctcc	ccaaaagtcc
76561	ctcatctcca	cttgagacca	cctcagcctg	gactttattg	tccataacat	tatcagcatt
76621	ttgggttaaa	ccattttaaca	agtccttagg	aagttccaaa	cttttccata	ttttcttata
76681	ttcttcaaac	tgttccaact	gttccaaact	gccccccaaa	ctgttccaac	ctctgctctg
76741	atgcagttcc	aaagtcactt	ccacattttg	tgtatcttta	cagtagcacc	ccacttctgg
76801	taccaattta	ctttattagt	ccattctcac	actgctaata	aaggcatacc	tgagaccagg
76861	taatatataa	aggagaaaga	tttaattggac	tcagttctgc	agggctgggg	aggcctcagg
76921	aaacttacaa	aagggggaaa	agccccctac	aaaaccatca	gatctcatga	gaactcactc
76981	actatcatga	gaacagcatg	aggggtgactg	cccccatgat	taaattcaag	atgagggttg
77041	gatggggaca	cagccaaacc	atatcagaat	acttctatca	catcacttcc	tctttatggt
77101	gtgggttaaca	attttgagtt	aaaaccagac	tgtgtctttg	agaaacaaaac	cctgactata
77161	gagaaggcat	tctgtccatg	tccataaggga	aatgtttcgt	tcagttttaa	tactctcatt
77221	ctcaaaatgt	ggtaaaaagt	cacccagag	tcactggagg	gtagattatg	agaaaagacc
77281	attaatgctg	aacttgaagt	accacaagt	ccgaaagagg	ggaacgagca	cctaYcctgg
77341	gtagatgatg	gtcagatata	tttccaaagc	cagagaatct	gggtcaattg	agaaaagagg
77401	aaagtgcacg	atatgcaaat	ttggattgat	attatattaa	tgaattcttg	attatccaca
77461	tggtgcacct	cagtaataat	aaatgtacac	acactgtaag	ttacataggc	acacttttaa
77521	ccatccccac	acttaccagg	gaatgttaga	taggcagggt	gaatgcaagg	tgagtggagt
77581	ttctgatggg	gcagaggaag	aacgccaaag	ttgctagatt	tcttggttttc	ttttctactg

77641	agactcctca	gcaggggtata	ttttgaggtta	ggatatggcag	caccgtgact	tctgtggctt
77701	tccctatgaa	gaagttgtaa	tgtgtaatat	tttcttctaa	gaggtgacac	aattatcagt
77761	cttctagcta	tggttgggta	agttctgata	ccttcctgtt	ggggagaaac	tgtcagaagt
77821	tgtgttttca	tctatgttct	gaaagtgcct	tatcctttct	agtgttgga	agattgacgc
77881	aaaaataaag	aaccacacag	aaattgacac	cgagatttct	caggactttc	ttgctaacct
77941	tgtctcttca	cctaattgcat	taggagacca	aaaaaagtta	ccttgtcatt	ttgggtttttg
78001	tttttattta	ttttacttta	ctaactcttYt	gaagaatctt	gtactttcacg	tccccacatt
78061	actgtgggtg	aaggggaacc	tttctatctg	aaacattgct	cgtgttcact	tgcacatgag
78121	attgaaacaa	ccaccaaaaag	ctgggtacaaa	agcagtggat	cacaggaaca	tgtggagctg
78181	aacccaagga	gttcctcgag	aattgctttg	catgattgtg	ttttggagtt	ttggccagtt
78241	gagttgaatg	acacaggatc	ttactttttc	caaatgaagt	gagtaacctt	ttctttttcaa
78301	aatgtatttc	acagccctct	tgtcctttgt	tcagcaactc	aaatatgcag	taatctgaaa
78361	ggtcagataa	tcaScacatc	cttttctttc	ctactcttcc	tatgacatga	aatacattct
78421	Wtgttatgga	acaRaataag	tttatctctc	tctgcttatt	ttcttagtga	ccttaatgaa
78481	aggagattac	tttgatagga	tttcttttta	ggggatcctt	accaatgaca	agtgcagatt
78541	gcatgaaagt	cagttttaaa	attcagctgc	tcctgttgtc	tacatgcccc	cagtcaaatg
78601	aaatcagcag	ctcggaacttc	acgataatat	taatgtgttg	cgaatggggc	agtgtcagct
78661	tcctgggtgg	catccctggg	ggggagcagg	gatgggggtg	atgcagaaac	accctagtcc
78721	agtctgcagg	ggctcactgg	gagccagggtg	gcagtgcctg	tggaggaaagt	gtgtgtctgg
78781	cagccaatcg	caaccacacg	ctggcggcag	tgagagaggg	caacacggaa	gggctttgca
78841	ttttactcat	gaggtggccc	tagattgtgc	cagaatactc	gaaattgggt	tgcataaact
78901	ccatgaaatg	agcacagcca	actgaaagca	tcacccacac	ttaccgaaca	tgtttctttt
78961	tagatgtacc	tacctacata	tgtaggtagt	tttatagaga	cctgagactg	acctgtcaaga
79021	aatagctcag	ggccagctga	aggtgatggt	gtgtagattt	catatgtagc	agattttctt
79081	tagaagcact	tctagagtga	gtcctgatca	ttatcaacca	tgtctgttag	agcagagtga
79141	gctaccactg	tgaaaccttg	gtagcacttc	tgtRgttttg	caccaaataca	ggtcattttt
79201	gtttgttttt	atacatagga	actcccaggc	atcagaaaaa	aattaaataa	ctctttttgat
79261	aaaaatcagt	acatctttag	atgacctttt	aagagtgata	attacagaaa	tgggtcacaa
79321	ctgggatttt	tcataacaag	ctaaggaaga	atgaatactc	acaaatgggg	taaaggaaaa
79381	agaacaacaa	acaccgNccc	ccccaccaca	aacttccaac	tcctgattga	atgaaggcac
79441	aatttaaagg	aataaagtat	tctggacagg	cctgagagag	cacgttgaga	ggaacagcca
79501	ggcatctatg	atcatcactt	ggagataaca	gaagcaaatg	gcattggcca	tctttctgat
79561	aYgggtgtga	gagaatacac	cctggccttag	gaagcaacaa	tgggaagcaag	agattgaggc
79621	aggatgtcag	agagaggtgt	ggagagacag	ggtagcagat	aggagatgct	aagaaaaatg
79681	aggtgtccca	gagtggtataY	tggagactga	tcactatgag	agtaaagtW	tgaggagaga
79741	agcagctttg	acaatggcct	tgaaaaataa	tgggatttcta	catggaagca	ggttgtttta
79801	gacaccagag	agcatagaag	atacacagat	attcaaatat	agcataatta	gtaagcagta
79861	tttactgtcag	atgtgtgtgt	atacacatat	gtgttctaac	ttaRgtgtgt	aaccttttgY
79921	agtttgatgt	gggatctRtc	agtgaacaga	ctttacacct	gaaaatttcc	cRttagaaca
79981	gtaattcttt	aatttttagg	agtacattgc	taataatcaa	atgccactga	ggactgataa
80041	tttaatcctg	cagtgaaaat	cacttttatcc	caccaaattt	taagaacgaa	atcaactaag
80101	aaggaaaggg	atacaaaaagg	gataRttttc	aatgatatag	atgaagaaat	gaaggttagag
80161	ggaaatgtac	acacagaaat	ctaataaacc	aatcctaggc	tgacaggcag	caagtctcagc
80221	ttggtgagca	gcctcagaag	tgggggctgg	tgtttatccc	ctgggtgtctg	tggacaaaaa
80281	tgagtgggtt	tcataaccag	gatgggctgg	gcctgcagca	ggaaagtgtg	gtcacagctt
80341	tgggtcagtt	ggcctcagtg	ttaaacctYag	ccttggagct	cctggatggc	aggtgcagtg
80401	tgttgttgat	tgtttcagtg	ttcccagagc	agtgtcctgc	acatggagtg	tcatcagttc
80461	tctagcattt	gttgagtgtt	aggaattgag	gattacagag	gtagagaaca	atgtagtctg
80521	aaaaaatggg	gatattcatg	tacctatttc	cttttaagca	acaagtcata	gagatccaga
80581	aatctctatc	tctccaattc	attgaggtca	aagttgggga	gacattacga	aaacacactt
80641	gagaagaagg	tgctgccaat	gggatccctga	atccattttca	agagccagggt	agctctatca
80701	tgtcccattg	ccatggaccc	actgcctata	actgtgacaa	cagcctgcca	cattctccag
80761	tcacggccaa	tcttttataa	attcagcccc	aagggtgaagg	ggccagattc	attggattgt
80821	gaaagtgtag	aattgtgcag	agcacttctg	gcctctgggg	ccaaatagat	gtgcattttgt
80881	atcctggccc	catctttag	caagtgtgtg	gcctgagtga	gttgttttaac	ctgtctgaga
80941	tttagcatte	tcatctgagc	ctaaggaaaa	tagtcatctc	ccttgcatgt	acatagtcta
81001	atacctggaa	ctcagtaagt	gttagtcttt	tcttcttctt	atcctattgt	agacctaaag
81061	gggaactgga	agagcctaag	gtgggcacaa	atgtgtcagg	catagaggat	aacttaaaaa
81121	cacgcattctg	ctgtattttag	caaataaatc	tatacatcac	aggtgcagtg	gaagcaaaaa
81181	tgaaatttga	aacattttct	ctttaaaaatc	ttcattttaa	aaatactgta	ttgttttcca
81241	attccagatc	accttttttt	gttgttgttg	ttgttgtttt	tttgagatgg	aatttcgctc
81301	ttgttaccca	ggctggagtg	caatggcgcg	atctccactc	actgcaacct	ccgcctcctg
81361	cctcagcttc	ccgagtagct	gggattaccg	taccagctca	atttttgtag	tttttagtaga
81421	gacggagttt	caccacattg	gccaggtctg	tctcaaaactc	ctgacctcag	gtgatccacc

81481	tgccttgggc	tcccaaagtg	ctgggattac	aggtgtgagc	cactgcacct	ggcctagtga
81541	tagtcctgat	cactaatctc	tgatcaggag	taacaacaac	tataaaatct	attcacactc
81601	actttttggc	agtaaggcat	ttaaagagct	aattcaatta	cactgagggc	agcaactcca
81661	gacttttggt	tattcaacag	taaaagaagg	ggattggaag	aagttgcctt	gagaaacaaa
81721	acctaataata	tatatacaca	catttagaaa	acaacatcag	gagtttatag	accttttgaa
81781	accaaagcca	ccctcccatc	ctggggccaa	actctctgaa	cttatccatc	agtgaagatc
81841	actgacattg	taaagatttg	cttttctgac	atccataata	tattgtctgc	agtaggatat
81901	gtgcgtgtgt	gcgtgtgcat	gtgtgtgtct	ctgtgtgtag	actgcttagg	ttttcattta
81961	ttacccctcg	ctcccatgac	agttttttaa	gttcttgctc	ttctgaatca	agcggaggca
82021	gagcaggggt	tgcacatcaa	tgaatcaatc	tctttaataa	aaataaagga	aaaatattgt
82081	aactgggttac	taaaagggaag	atgggtgata	tttgcaaagt	ttctgtagca	ttataaaata
82141	cctttacact	tttattccat	agaaattata	ctcagaaatg	gaaattaaat	gtcatcagaa
82201	gaaataaaca	cagctgtttc	actgaaagac	aagtaactag	taaaattgtg	gaagttaaaa
82261	aattttttca	gataacctgt	gaaaacaggt	actatcaaac	actggccaac	agcacatcat
82321	tgtataaggt	aatgctttta	taatatttta	actttaagac	ttgatggaaa	agataaaatt
82381	cccaaatgag	gggtgagag	ctaccattct	gggtctcata	caaataagct	gcctgatccc
82441	acatggctca	cttgccctgt	ttgagccaag	tatctcact	ggcttgttgt	caagagctga
82501	tacatagtat	taaaatatgt	tccacagtac	tttccctgga	tttgggtgtc	aataaattgat
82561	cacagtttct	tctccacac	tcttcttca	tttctctct	ctttcgataa	gttagttttt
82621	aggaatgcta	gtttaaggat	ttccattttc	tctgtgcaca	tgtacttaac	atgtaaaact
82681	caattgtata	tgtttttctg	aatatattag	ttcattttat	aaaattggaa	atggtaatgc
82741	ttttataata	ttttaacttt	aaaactgaaa	aatgaagaaa	gcaaaaatca	ctcataaatc
82801	catcacagac	tttttttttc	tgtgaagcat	ctgcttttta	aaagtgggat	attttatttt
82861	tttatgtttt	ttctcttaag	aattacgttg	tgactatccc	ttcacatctt	taaatgatct
82921	tctaacaatg	ggctttcagt	ttttatgtgc	ctggtttcat	ctaactaacc	cccttggttc
82981	gtctaactaa	tcccattggt	attggacatt	tgtgaattgc	ctatttttca	ctattattta
83041	aaggctaaaa	tgaataccat	ttccacaaat	ccttggggtg	ttatatgatt	tgtccttcaa
83101	ccaaatccct	aaatgtagaa	ttactgtatc	agaggctgtg	agcatgtttt	tatgtctttt
83161	tcctcacact	atcaaaactg	tctccaggga	gctctgccaa	ttttacccca	cacttgaaaa
83221	aagaatccca	attttttgtc	acctccacaa	cacagggaag	taatgggtcc	agaatgttta
83281	aaatttgata	tgaaaaattt	ctaaaactcc	tagtggtttt	ttcacttttc	ttagtaataa
83341	attaaacttt	tgatatattt	tattgcatct	tactgcaatc	aggcaatttt	gtgggttgcc
83401	tgtttatttt	tttctgtttt	cttcagttgg	tatacctttt	acctggtgaa	ttttaaagc
83461	tcttatacac	catggaatac	tatRcagcca	taaaaaagca	tgagttcatg	tctttttag
83521	ggacatggat	gaagctggaa	accatcattc	tcagaaaact	aacacaggaa	tagaaaacca
83581	aacactgcat	gttctcactc	ataagtggga	gggtgaacaat	gagaacacat	ggacacaggg
83641	aggggaacat	cacacaccgg	ggcctgttgt	gtgggtgggg	agggtagggg	atgtatagca
83701	ttagggagaa	tacctaatgt	agatgcacaa	ttgatgggtt	cagcaaacca	ccatggcacg
83761	tgtataccta	tgtaacaaac	ctgcacattc	tccacatata	ccccagaact	taaagtataa
83821	taaaaaaaaa	agctctttta	gaccacgcta	taggaattat	atatacacat	acatagcgtg
83881	tgtgagtgtg	gtgtgtgtat	gcataaaaaa	catacgcaat	cccatccaca	cacatacgca
83941	acacaaattg	tgtagttcag	gggtccccaa	tccccatgcc	actccccctc	actaacatta
84001	ccactccctg	tgagatccgc	agctgcatta	gactctcaca	ggagtaagaa	ccctattgtg
84061	aactgtgcat	gcgaggaatc	tatgttgcat	gctccttatg	agaatctaata	gcctgatgat
84121	ctgtcactgt	ctcccatcac	ccccagatag	gaccacctat	ttgcaggaaa	acaagctcag
84181	ggctccactg	attctacatt	atgggtgagt	gtataattat	ctcattatat	attacagtgt
84241	aataacaata	gaaataaagt	gcacaataaa	tgtaatgcgc	ctgaatcatc	cccaaaccaa
84301	ccattccccc	ctcaaccctc	gcccaccctg	gtccatggaa	aagttgtcat	tcattgaaatc
84361	agtctctgtg	tcaaaacggg	tggggacagc	tgatgtagtt	tatatggaat	aacaaatctg
84421	aataatatga	ctctgtcgtg	gaaactttta	agacctataa	gagagtgggtc	tgaacagaac
84481	ttgggaaatc	tgaagcgagt	gatgataata	tcttgaatat	ttttgtttgt	gccttatgct
84541	tgaacactgt	ttacttgtga	tttccaaaga	cagctcttat	ctgaaatgtt	ttctaaacac
84601	tcgaatcagt	cttgagttga	ctttattcta	tttcccatca	atgtacaaat	gtgttacagt
84661	atatgtaaat	tagtgaggct	tgggtgtgctg	agttttaaga	aattccgttc	gggtgcagtg
84721	gctcacacct	gtaatcccag	cacttttgta	ggctgagggtg	ggcggattat	taggtcaggt
84781	gatcgagacc	atgctggcta	atatgatgaa	accccgctctc	tactaaaaat	acaaaaaatt
84841	agctgggtgt	ggtggcacat	gcctgtatgc	ccaactgtctc	gggaggctga	ggaaggagaa
84901	tcacttgaac	ccgggaggca	gaggtgtcag	cgagccgaga	ctggggccact	gcactccagc
84961	ctagggggaga	gagcgatact	ccgtctcaaa	aaaaaaaaaa	tgaaattcca	aagtgcagct
85021	atttaaatta	tgagcatttg	tgcaccaagg	atatttagct	aaacaattga	ccacagggct
85081	aagtattcta	agcctgttga	ctgatcatga	cttcacccga	gagcaaggag	gctaattcag
85141	tagataattg	attggaaaagg	aaaatgaaga	gtctctgatc	ttttctatag	cttgaaaaaa
85201	ttagtttggc	tttataaaat	tttgacttat	acataaataa	tttactgacg	tgaggtacac
85261	atgtgggtgc	ttcacgggca	cattctatgc	acaatgggtc	tagccccagt	ggctgccagc

85321	tctgagggag	aagtctgtgg	gcagtaggtt	ctccttgctt	ggtggttgca	gaaacagtgt
85381	ccaatgggtca	aggatggcca	ttcagccccc	agacatccca	tgtgggtccct	gcattggctct
85441	gggacctatcc	tctgggtgtc	agatgtgctg	gattgaagaa	agtgggttta	ttacaattag
85501	tattaattcc	tgtgacatgt	atggaaatgt	gtgtgWgaga	gagagagatg	tttgagtgtg
85561	cctatggatt	tgaatattgc	tgatgcatct	ctaatacagct	cgctggcttc	tgatggaggg
85621	tgtcaaaggt	gtgggtgggtc	tgctagctac	tcattctctg	agtaattctc	cacccatccc
85681	actatccacc	ccttggtatgc	atagtcacga	atacacaaaa	ttggactgaa	catgtatgaa
85741	atagagttgt	gactcaagca	agggtttttg	aagtagtgtt	ctctctctct	ctctgtctct
85801	cgctgtttct	ctctctctgc	atgtgtgtRa	aagagagaga	tgaagaata	ttgatgaaag
85861	cagctacagt	gctcatattg	ccccatgctc	tacttcccag	catatattaa	taatgataat
85921	catgccaaaca	gcaatgggat	cgcatttaatt	tgtttcagta	aaagtagtac	caagtaactg
85981	ggacataattg	ccaggaattg	ctactttcca	ttcttttttc	ctttttctct	aaagatcttt
86041	aactcaaaaa	tttggtacac	tgtaatatca	atttggcttt	tacttaaaagt	attttaactt
86101	gttttattaa	aaacagaact	gtaaaaagct	actactggag	aacaataaaa	acccaacgat
86161	aaagaagaac	gccgagtttg	aagatcaggg	gtattactcc	tgcgtgcatt	tccttcatca
86221	taatggaaaa	ctatttaata	tcacccaaac	cttcaatata	acaatagtgg	aaggtaaggg
86281	aaatcttaga	attgggaaga	aacagacgta	ttttagtaaa	atggaatttt	ttcattcttc
86341	aaaactgtgt	aggaattgag	agtccactta	gttggggttg	tgaccacacc	actagtccaa
86401	atatgatggg	caaaatcttc	attcYgggtgc	tcctctactt	ggctaaataa	acctttcttt
86461	ttggcaggaa	atgaaaatct	gtatgaataa	acctcacatg	agtcagctct	ctcttatata
86521	tgaattttga	gtaaattgtg	gaatcttttg	ttgttgtaatt	tacattttca	ctttacaagt
86581	attagtgtaa	gatatctata	ctcaataaac	tgtacttagc	acaaggaggc	agggaaggca
86641	gttaagtatga	gatgaagtga	gcactgtact	attctcaagg	gatttgattc	taatacaggag
86701	aggcaataag	ctacataaag	gtgtatgaaa	cagcatcatc	tgtgaggctg	caagagtgcg
86761	gggggaggtt	ggaggaagga	cagatgcagg	aggctccatt	tgacctgggt	cttgaggggg
86821	gagcctcatg	aaacagtgc	ctgctggggg	aagggatctc	cactgggaga	gtgtaaggaa
86881	cactgatgtg	ctggtggggg	gggagggatg	atggacccag	gctgtgtgtg	atggaggaac
86941	agaatcctgg	gcatttaaat	gtatttaatt	aaacctcacc	cagtgaagat	attcatcata
87001	aggcacagcc	aatgattgat	catccagtcc	cttcttggga	actatcaagg	aaatgaccaa
87061	atcacacagc	agtgtagtcc	agattttta	atctgattgt	tgaagtcttt	tttttccatt
87121	gagtccaaat	atcccttctc	gtagcttcca	accactgatt	ttgatttgcc	ttcaagaatt
87181	tcacagatta	aatctggctc	cttcttaaaa	tgacagctcc	tttctgtgatt	tgaagacagg
87241	ttgcttatoc	agtcctggatt	tttttcccca	tcatectgag	aaactggaaa	ctgtaacact
87301	tgtgtgggtg	gcttgtttca	caaaatctgt	gggtccacat	ttgtacagc	ctttgtttta
87361	gcaacatctt	tcttcttcac	tacaaccata	tagctatata	caccacatg	ttgccacagt
87421	aacaaattat	cccaagttta	gtgtcttcgg	taaaatcaag	gttttgccag	aattgtcttt
87481	cttctggagg	ctgtagggga	aaatgcgttt	cttttatttt	tttatttttt	tttatatttt
87541	gagatggagt	ttgtctctgt	tgcttaggct	gcagtgcagt	ggcgagcct	tgggctcac
87601	tgcaagctcc	gcctcctggg	ttcacacccat	tctcctgcct	cagcctcccg	agtagctggg
87661	actacaggca	cccgccacca	ctcccggcta	atttttatat	tttttttagt	agagacgggg
87721	tttcaccgtg	ttagccagga	tggtctcgat	ctcctgacct	cgtgatcccc	ctgccttggg
87781	ctcccaaagt	actgggatta	caggcataag	ccactgcacc	aggctggaaa	atgtgtttct
87841	ttgcctttgc	tttctccagc	ttctagagac	cacttgcatt	tcttggcttg	tgcactttca
87901	tttcagagcc	aaacacattt	gcttccctca	cctcatctcc	tttttgactc	tgacctttct
87961	gtctccctct	gatgaggacc	ttgagacagc	attgtgcccc	cctagataat	ccaggggtgat
88021	ccccctatct	caagatcctt	aattttaatca	cacctagagg	ttcctttttg	catgtaacat
88081	atYgtattca	caggaactca	ggagtaggat	gtgggaaact	tcagggtcta	ttattctgcc
88141	tgccacagcc	cagaacctgg	gaaacccata	actgaatttt	aaactcaaaa	acttaaatct
88201	tgtgtataat	catctaccct	aaactctcca	actttacttt	cctacatcta	tttttaattct
88261	catataaatc	tctgttactt	tgatactttc	agaacctaca	ccctctttcc	cacctctttt
88321	gctttctgcc	catcagcagc	tctttctctc	cttctttgat	gaagctgtag	gaatatccat
88381	tattaaaagg	gtgcttggtt	tgggcccagg	atagtgccta	gtactggagt	tgaatcatgt
88441	catataatcc	tcacaacagc	ctgtgagac	tgtggccttg	ggtaggttaa	tttcttagt
88501	tcctctctgc	ctcagattcc	tcattcatgaa	atgggacagt	aatggttcat	ccctcgtagg
88561	gttggtctgac	aatgactgag	tgagtgtgtg	tacagctcta	ggatggctct	agggacagta
88621	agagtctctgc	tgtaatgacc	atctcccact	gctagggtcc	caaacctcac	ctgcagcaca
88681	agctattctt	ctcccataat	tgtccattct	atttttcttg	tcttcttgga	gaatgtcaac
88741	tgagtctctc	aggactccac	tcaaatgtcR	ctcctccttc	atgcccccat	ggcctcttgt
88801	ttgtatttct	gattgtctgtc	agaattgcaa	tacatgtgtg	tctctgtcaa	taacttgaaa
88861	ggtttctgga	aagggttgca	ctgacttctg	ttcctcatct	ttgcatcttg	gatacctaca
88921	attggcactt	ggcacataaa	gggtgctcatt	acatgcctgt	tgtgtgcatc	actgagacag
88981	aaacaactcc	ttttagtgcca	catacaacaa	gaagtctaga	cacttcacca	tcctggctat
89041	ttttcttttg	atttggcaaa	gtttgccacg	agtctacaga	aattagagct	tggagtggg
89101	gaagacagcc	aggaggtgtt	ctgacctgtg	ttgaggacag	agaggttctg	agctcgtgcc

89161	ttctccatgt	tgtgtcttta	ttacagtccc	cttgccctca	cagatggaga	tctctcagct
89221	gctacatagt	gactgctgta	gtgggtggaaa	gggtgtgatac	ctctccctccc	catcctaagg
89281	gtcatggcaa	tgttcccata	acaaaaagaca	gattaacaag	gggcaagcaa	gttttatgtg
89341	acatgggagc	cttcagaaat	gaagaccctg	gggccgggtg	tgggtggctca	tgctggtaat
89401	cctagcactt	tgggaggccg	aggcgagatg	atcacctgag	gccaggagtt	cgggacagggc
89461	ctggccaaca	tggcaaaacc	ccatctctac	taaaaacaga	aaaattagct	gggcttgggtg
89521	gtgggcacct	gtaatcccag	ctacttggga	gactgaggca	gggagaattg	cttgaaccca
89581	ggagatggag	gttgagtgta	gccgaggttg	tgccattgca	ctccagccca	ggtgacagag
89641	caagactcgg	tctcaaaaaa	aaaaaaaaaa	aaaaaaggaa	agaaatgaat	accctaagac
89701	tcagggaaac	ccgttttttt	ctttttaaat	gcttaggttc	tagaagcatg	gacagccatg
89761	tagaaatgtg	actggacaaa	agggtatgac	ctaattgctaa	tggactgagt	ggggaaaccc
89821	agcaagacct	gtccagattc	ttcttggcct	ctctgttata	tttcccttttc	ctgggtagag
89881	ggcagagggg	cttaagactt	actgtcagac	caaagaaggc	caaagaattt	atagccaact
89941	cctagacaga	aaggcaggag	aagggttagag	tcatgtctct	aggttctatg	gcttactttg
90001	gggaaaagga	ttctagtttt	tatgatctgc	ctttgggaag	agggagtctg	gtttctgtga
90061	cttgcttttg	ggagaatgga	ggcatgaagc	aggaggggtca	gagagatcct	gcttttttgag
90121	gctgctttga	ggccttccaa	tgtcgtttgag	tttaaagtac	tcagcctgcc	aaaacaccat
90181	acttttggac	tgttttttga	gcccaggagt	tccattgcct	tcagcttgtg	ctcgtgaatc
90241	acagtacact	gaattcctac	tgggcatctg	ccactttcct	gggtcttatgc	tctggctgat
90301	cgggtggcgt	ctcctcctac	tgctgacaac	ctctatgccca	ttttgactct	gatagcctcc
90361	taggttaggt	ggccatgtca	agggcagatg	ctaagatgtt	gtcttccctc	catgacctac
90421	atgggactgc	acccttcact	ttacaccagt	tgtgcaaact	cagggtctgat	ctggatttcc
90481	aatgatataa	tttgagtgtt	agtagacagc	atcctttgct	gaagatgtac	ttcacactgc
90541	cccttctcaa	gtctcccatg	taagtttctg	ggggaaaaaa	tggatccaga	gaaaggtagt
90601	cagtagcagt	tttcccccct	aYaccgaaat	tgcctcctgc	cctttgtctt	tgaatccaag
90661	ccggtgttgc	ttcttactgt	cagacctgag	agttagttct	ttccctggat	acatctcagc
90721	tcctcctgcc	tgtttgccaa	cattccaggc	ttgcccagag	actccaaatc	ccaggataac
90781	ccagacttga	ctctgaactc	cggagtcac	tgtgctgggt	tcattctcct	gttcttgtct
90841	acatatctgc	ccactgcatt	ctcaactgct	cactctggca	ctgcactttc	tgagagggtc
90901	cagggagggt	tgggagctgc	aggWgcactc	ctgagtctca	ctgtactcca	ctcaaccagg
90961	cattctgctt	gctgagcacc	tgcaagtccc	agaagggatg	ttctggacat	tgcttgggaa
91021	tgctccaaa	gcagtggggc	tactagcagc	gaacagtcct	ggteatgagg	aaagttaacca
91081	atgaggatat	cagggtctaac	aataacttga	ctatgcacca	gttcaaactc	atgacctcag
91141	ctgctcttag	ggtttgagct	tgccagctgc	cttaagcaag	agcctggttg	gtgatgactt
91201	acttccaaag	catcaccaga	tggggactga	gggggcagaa	tttatgtgca	gtacttccag
91261	tcgggggtcag	aagccactca	ggagcagaag	tagaacttgg	cctacaggca	tgaacttaac
91321	agcagggccca	gggccaaagg	gaggtttcctg	gggcacaata	ttgaagggag	actgctctca
91381	gcattcctgca	agggaaagg	gggcacatag	agtgaaggat	ttgcttttct	caacctgtct
91441	tggccctgca	acctgtaaat	ccatcactgg	ccagctgagg	aggacagatg	gagagaatcg
91501	agacagggca	gaaaggctct	tcccagtgat	tttgcatggg	ttgactcttg	cacgtttgat
91561	catctgagag	tcaggctgca	gtggatgggc	atcttctctc	gccttttagt	tgaattgagc
91621	agaagctgca	gatMttagtg	agagaaaacc	agatacaagg	tgctttcaac	atctgtgacc
91681	tttagttaa	gcaaatagga	ctcaagtga	cgtaaaccag	taactatttg	aatctttgtt
91741	acatgaaatg	agcatattat	catagatgct	tgtcataaag	aagctcaagg	caacactaat
91801	acatttgtct	tttcttttgt	cacttctaga	tcgcagtaat	atagttccgg	ttcttcttgg
91861	accaaagctt	aaccatgttg	cagtggaaat	aggatatatt	caatatacat	atattctgca
91921	tttataagta	ggggacataa	tagagccttc	caagcgtaaa	tatgattcat	tatttgatga
91981	cactggatac	acatttcata	tttactgaat	aacattacaa	aactaagaRa	agagtggcat
92041	tttttgaatg	ttgccacttt	taacctgact	taaaagtggc	aacattttta	agttcaagag
92101	acagtgggac	tgccctgtgg	ctgtagacta	agggttttgt	tgtgctgtgt	gtggcttgct
92161	tttaactctc	tctatggtca	tttctaaata	tgaaaattta	ggccggggcat	gggtgctcac
92221	gcctgtaatc	ccagcacttt	gggaggccga	ggcaggtgaa	tcacttgagg	tcaggagttt
92281	gagaccaacc	tgaccagcac	gggtgaaacc	catctctact	aaaaatacaa	aaatttagcca
92341	ggcatgggtg	catgcacctg	tagtcccagc	tactcaggag	actgaggcag	gagaatctct
92401	tgaaccagg	aggcaagggt	gtaatgagct	gaaatcacac	cactgcactc	cagcctgggc
92461	aacggagcaa	gactctatct	caaaaaataat	aataataata	acaataataa	atttaaaaaat
92521	tccgtgagag	cactctggag	agatgagtc	aactaatttt	gtgggtgtgaa	tgtttgatta
92581	attgattcac	tttgaatcaa	ttgactgaat	tgattgtata	tttggagttt	gtctagataa
92641	gtcttatgaa	tcaacatgtc	caatttagta	atttctttca	aaagagaaag	gaaagaaaga
92701	aagggaagaaa	ttcacatatg	ctaaatatgc	taagccagg	atcatgctag	gtcattgaaa
92761	tatatgtgtg	aattaaatcc	tccaagcaac	actgaggcat	gtattctcat	tttatgaatt
92821	aaataattga	agtgcaaaaa	gggtcaagtaa	cttgtctaaa	gttaaatcac	taaaaagtgg
92881	caagtctctg	tttggggact	ttgcttccaa	agtcgccacc	ttataaccac	agttgggggtc
92941	acagtgggtt	atatgaccac	atggggccag	tgcagctggg	tcctatgccca	tttgtacatg

93001	agggtttacct	gcttttatatt	tttattttatt	tctgtcttttg	tctttctttat	ttttttcttc
93061	tactcagtg	ggcttaacct	gtatcttttg	ttctagtttg	ttgacctgaa	gagttagata
93121	attaattttta	attatcctct	ggtagtatat	accttcaaac	tccaagtttc	cctgtaaaca
93181	ctacttttagc	tgttttctcat	atthttcatte	tattcagttt	aaaccattac	ttaaaatttc
93241	ccttatgatt	tctttttcca	acaaaaaaa	ttggtatttc	ttaattttcca	aatatttggt
93301	gaacttttcta	gttcttgtct	cttattcatg	tccagtttag	attcattata	gtccaagatt
93361	atacacagtg	tcattttcaac	cttttggaat	ttgtagtac	ttacttaagg	cccacagtat
93421	ggtatatctt	gctgaatggt	ccaagtgcac	ttgaaacaaa	ggatatattc	atagggtttt
93481	gtttttattat	tcttttaaatg	tctatttggt	taagttcatt	aatgggtgtg	ttcaaaaaat
93541	ttatatcctg	actaatcttt	tatctgcttg	ttccatgtgt	tgctgaaaga	gatgtgaata
93601	tctccagcta	ttatgggcaa	tgtgtctcta	tctccttttag	ttctgtcaat	ttttgtctta
93661	catagtttg	agctatctta	tatgcataca	cggatttatg	ctcgttgaat	taacactttt
93721	atcatatatga	aatatctctc	tttatctatc	ataacacttc	ctctctcaat	gtgtagctct
93781	gtcatatgaa	ataatcacac	aagttttctt	ttgcttgga	ttggcatatt	tgtctttttt
93841	taaacatccc	tttactacta	acattttttt	ttgttctata	cataagtgtc	tctcataaac
93901	tgcatgtatt	tgggtctttt	ttgaaatatg	gtcagtatgg	tgtttagtcc	atctgtatat
93961	ttaaaattac	tgttacagtt	gctatatcat	atatgcata	tatacaata	ttcaatttat
94021	tctttttaaa	ataaatata	ctttgttgaa	aatgaccata	ttccatcca	ctgttttctc
94081	ttttctctta	ttttctttca	aacagttaca	gtttttaatc	tgctaaattc	agcatctgta
94141	ggctcgtctc	tattagctgt	cttttctatt	gattatgggt	cacattttct	gtgtctttgt
94201	atgtctctta	actttttatt	gttgttgatc	tttatgtatc	aaacaattaa	agtgaatata
94261	gtttgtgtta	ttttttctta	caagtaggta	gcttgagagt	tgagtatctc	agttgactca
94321	gaattgagtt	ggggtggctg	ggatgtaggt	atgttctact	caatctgtct	tcatctctga
94381	tagctgggtga	gggagggggt	gctgcagtc	tgtgtttgat	gcaggcctct	tctctaata
94441	gacttgctct	cctgattacc	atgagactgc	aagtgatatc	atcacgcctt	tacatctttt
94501	tacgtctgtc	gagcgttag	cagtaattct	gcaagcctgt	gcagctgccg	agagcttcac
94561	tggattttct	tgtttctatg	agactctttc	tgtaatttac	aaaccaaaagc	aaattcttct
94621	atggaatgaa	atggccacct	atcttagctc	accctagaaa	ggatccttct	taagtacgtc
94681	tgtagttaa	aaattttctc	ttattttctc	tgtactttga	tgtctttaat	gtttgtctaa
94741	tttaattttt	ttgtgattta	tccatttggt	ttatctagaa	gtctcagtga	gagtattgtc
94801	ctgatgctac	gaaaagaaag	tacactgatc	actctaagtt	ttaatagttg	attaaaaaat
94861	aaatgtttta	aaagaagcca	aatcatgttt	tgatgatgac	ttgtaattgc	tacctatttc
94921	ttctgcttta	tatattttgt	tttatttaaa	gcaaggcata	tttattctct	ttctgggatg
94981	gagcaccacg	ttttgcttta	ggttaacata	catttgattat	attgttttga	aacttttaag
95041	aaacctgagt	ttcaaaaatc	agaacttttag	ttgccaactt	ttaccaggaa	aaaacgtaag
95101	gctcaactgc	tctgctttgc	tgaatgaaga	ggatgtaatt	tattggatgt	tYggggaaga
95161	aaatggatcg	gatcctaata	tacatgaaga	gaaagaaatg	agaattatgt	atgtatgtgt
95221	aatataatct	tcatgatata	taccatataa	caatcatata	tattatata	aacatcatat
95281	taaaaaact	gggtggctga	tgtgtatttt	gggtagttt	aaattataat	tataatggac
95341	atattttRta	attatagtgg	ccatacccta	gggtggacgca	ttatgcagaa	atgtattgcc
95401	aagatctaag	ctggaaaaga	aggtccatga	gaaggccatt	gagggtattt	agcatcacct
95461	tataaagtag	cacttggtca	gtcaggatcc	gatggggatg	gggattttac	ttagcttctt
95521	agaaaaaggc	agttgcctag	gccaagcttt	ttttttttt	gaaaaatttg	ttaaagtgtt
95581	tattttttcta	atggggccaaa	aaggctccaa	atggcatgca	tattgatagt	taaaaagcc
95641	tatatctctc	cattaaggaa	tgggtcaaact	tataaaaaga	atcagtctaa	acatatagtc
95701	acctaaagctt	ttctgaatga	ctttgggtca	tactgttaagt	atccattatt	atactgatac
95761	actactcagg	gtctagttag	tgtctagcct	aagttgtcta	ccacctttgc	tgacttgtt
95821	gagttttttc	ttctgctttt	tacacatttt	ttggtacctt	ctttgttacc	atgcttgcag
95881	ctctacattc	ttgtctgacac	ttgtctacaa	gctctttaca	ccacaaagtc	tggtctcttg
95941	ccggggagca	ggcatgtggt	tcatgccac	tacatgttga	attcatttga	aatttgtgga
96001	tctcctgcca	tcatatctca	tctcagcca	ctggcctcca	tttgagtttt	gtattttctc
96061	ctttggataa	tctctttcta	atttttagag	gggtagaaaa	ccacagtga	ttcttagaa
96121	atgcagctta	agctacaaaa	gcagRgaggt	ctttctttat	agttgggtgc	acacaccttt
96181	gatatcatct	gttttgtcct	ctcaatggcc	tctgtgttt	tacttctgga	tttcatgtgt
96241	tttagatgg	tgttattttc	ggatgggtga	cttaggaaaa	gaattacatt	ccaaaatgta
96301	cttgaggcag	ttggaggcta	cagtggggt	ctgtgtccc	ggctcctagat	atcctgtgtg
96361	ctaggaatgt	gggcacatgg	ggcccatgtc	tggctgtgtt	gactgggtga	gctatcagag
96421	cctgtcatgt	gtgggggaag	tggatgtcat	aagtgtttac	ctggcatcaa	ccacaggaca
96481	acttgaatcc	tttaagggaag	agaaaaagaa	cgtgctgcca	gtggctttct	caagtcattt
96541	tctgacactc	atggaacaac	ttactggca	cttctcatgt	gcctcggggt	gcttgagaac
96601	agtgttatgt	tttttaatgc	tgaacacatt	aaaccagttt	gttggtattc	atggacaaat
96661	gtaatacga	tctgcatcta	tgtcaataca	cttacagcct	tgtcataatt	agtgggaacc
96721	actctgtgga	aagaaccca	agttgttagg	aagagagaag	tagagaaaa	taattgagag
96781	agaatatttt	ctYatat	caacttagca	tcatgatctt	ccagccattt	aaacttcagg

```

96841 taattgacag caccattccc aaatggcctc aggagggctg tttctgtcag ttctgatgct
96901 ccacggagga ggggacgttt attgtagtc atgctttaag agtactggcc agaaagggaa
96961 gaaataatgc aggcaacatc acagctgcct tcaagcattt taaacatgtg aattMccctc
97021 tcaagggtaa cgaacagagc ctactgtctaa attattttgc cctYttacag gactccagaa
97081 ggcaaatggc atgcttcaaa agtattgaga attgaaaata ttggtgaaag caatctaaat
97141 gttttatata attgactgtt ggccagcacg ggaggcacag acaccaaag cttcatcttg
97201 gtgagaaaag gtgagaaaaga tttatttttg gaagttttga aacttagctc attgctactg
97261 agagacattt caaagatggc cactttctca ttttccacac cagaacccag ctccctgagag
97321 gggaaatcag tcacctcatg tcacaggcat tcagtggggc ccctctgtct catgatgcca
97381 agcagagaaat gaaaacagaa ctcatccacc tgctctcaca gtcataattcc atcccatgtg
97441 gaaatcgggg ggccctgaggc ttggagatac agatgctgag agtgaggctc atggggaggc
97501 catcaggaca acccctgcac ccagcactgc acccagagca gccagagggg agtttgcaga
97561 tctgcgtggg gtgaggccag tgcaaacttg gtgtgactgc tgctccagcc tgccctcagca
97621 ggggtaccagg ctcagggtcc ttgtgtgtgc tcattcattc attgectcct gaacttggca
97681 agcaggcccat tgatagccct gatctgtggg Mtcttaaagt ttttcagtgc tcacctgatg
97741 gagggcccca gggctgccat ccctttctc caccaaagta gcacagccca gggccttcag
97801 ccagtagctt gctcagaaat ggctgtgact ggagccagaa agctgtgatt tccaKttgtc
97861 actactcatt cactgttcat tcccaggctc caccatcaac tccctggata tgtagagaaa
97921 ggtcaagatc tgcaagagag agagaaaagg agagagacag agactaacac acccagagac
97981 agatggagac ggagagagac agacacagag agaggagaaa gagagataca tgagatggag
98041 ggacagagac aaacagacaa ctctagagag atgaagacag aaagagaaag agaaagagag
98101 acagagacac agagagacag agaaatgaga gagacagggg gagacacaga gacagaggaa
98161 cacagaaaag gggagataga gaggcagaga catgaaggga tgcaaataca gagagatgag
98221 agtgaaacag acagagagac agagtaaggg agagatacac acagacacac acaaacatgc
98281 agagacagcc acacacacag actgggcctt ggctttgtga gaaacggaag gagtgggaca
98341 ggaagagcac aaaggctgga aacccctcc agctgggcta tcctgggtgcc caggggcagc
98401 tccccagca ccatgtttt agagccgcct ctctaccata tgcactcata acaacagctc
98461 acatcccata catgttaatt acatgacagg atctgggtga agttcctgcc atgatctcat
98521 ccagtcttaa cgacaagctt tatagagggt aagaaaacttg ccagggtca caggcagggt
98581 gaaggtattg aaactcagac ccgattaaat ctggaatctg tgttcttacc ttctgcaggg
98641 cttgtgcctt gtggtcttcc acccctgtgt gattgcctgt gctgtggtcc actcacttgt
98701 gagggagYgg ggctcaaatc tttgttggac catcacctgg ccaggcttcc ctggggcctg
98761 ctcaccaccg gatcacctct cctttcttag aacagggcag gactgtccta ttccctgcct
98821 agacgcttct ggccagtc aa ttctcctgct gctgctctca caaatgtagg tttagaaatt
98881 ggggctcaca acccaccatc acccctgtcc aatgtgtgct tgcgtgtttt tgcaaatgtg
98941 tgacacagtt

```

[0251] Three alternatively spliced transcript variants encoding distinct isoforms are depicted hereafter. cDNA sequences 1-3 show the human cDNA structure for transcript variants 1-3 of IL1RL1, respectively. cDNA sequence 1 encodes the longest isoform (1), which is depicted hereafter as amino acid sequence 1. cDNA Sequence 2 differs in the 5' and 3' UTR, compared to variant 1. The resulting isoform (2), depicted hereafter as amino acid sequence 2, has a distinct and shorter C-terminus, as compared to isoform 1. cDNA sequence 3 differs in the 5' and 3' UTR, and contains an additional internal segment, compared to variant 1. The resulting isoform (3), depicted hereafter as amino acid sequence 3, has a distinct and shorter C-terminus, as compared to isoform 1.

IL1RL1 cDNA Sequence 1 (SEQ ID NO: 2)

NM_016232 Homo sapiens interleukin 1 receptor-like 1 (IL1RL1), transcript variant 1, mRNA

```

1 aaagagaggc tggctgttgt atttagtaaa gctataaagc tgtaagagaa attggccttc
61 tgagttgtga aactgtgggc agaaagttga ggaagaaaga actcaagtac aacccaatga
121 ggttgagata taggctactc tcccactc agtcttgaag agtatcacca actgcctcat
181 gtgtgggtgac cttcactgtc gtagtgcagc gactcatctg gagtaatctc aacaacagag

```

```

241 taccaatact tgctcttgat tgataaacag aatgggggttt tggatcttag caattctcac
301 aattctcatg tattccacag cagcaaagtt tagtaaacaa tcatggggcc tggaaaatga
361 ggctttaatt gtaagatgtc ctagacaagg aaaacctagt tacaccgtgg attggtatta
421 ctcacaaaca aacaaaagta tcccactca ggaaagaaat cgtgtgtttg cctcaggcca
481 acttctgaag tttctaccag ctgcagttgc tgattctggt atttatacct gtattgtcag
541 aagtcccaca ttcaatagga ctggatatgc gaatgtcacc atatataaaa aacaatcaga
601 ttgcaatggt ccagattatt tgatgtattc aacagtatct ggatcagaaa aaaattccaa
661 aatttattgt cctaccattg acctctacaa ctggacagca cctcttgagt ggtttaagaa
721 ttgtcaggct cttcaaggat caaggtacag ggcgcacaag tcatttttgg tcattgataa
781 tgtgatgact gaggacgcag gtgattacac ctgtaaattt atacacaatg aaaatggagc
841 caattatagt gtgacggcga ccaggctcct cacggtcagg gatgagcaag gcttttctct
901 gtttccagta atcggagccc ctgcacaaaa tgaaataaag gaagtggaaa ttggaaaaaa
961 cgcaaaccta acttgctctg cttgttttgg aaaaggcact cagtctcttg cctccgtcct
1021 gttggcagctt aatggaacaa aaattacaga ctttgggtgaa ccaagaattc aacaagagga
1081 agggcaaaat caaagtttca gcaatgggct ggcttgctca gacatgggtt taagaatagc
1141 tgacgtgaag gaagaggatt tattgctgca gtacgactgt ctggccctga atttgcattg
1201 cttgagaagg cacaccgtaa gactaagtag gaaaaatcca attgatcatc atagcatcta
1261 ctgcataatt gcagtatgta gtgtattttt aatgctaatac aatgtcctgg ttatcatcct
1321 aaaaatgttc tggattgagg ccactctgct ctggagagac atagctaaac cttacaagac
1381 taggaatgat ggaaagctct atgatgctta tgttgtctac ccacggaact acaaatccag
1441 tacagatggg gccagtcgtg tagagcactt tgttcaccag attctgcttg atgttcttga
1501 aaataaatgt ggctatacct tatgcattta tgggagagat atgctacctg gagaagatgt
1561 agtcactgca gtggaaacca acatacgaag gagcaggcgg cacattttca tcttgacccc
1621 tcagatcact cacaataagg agtttgccta cgagcaggag gttgccttgc actgtgcctc
1681 catccagaac gacgccaagg tgatacttat tgagatggag gctctgagcg agctggacat
1741 gctgcaggct gaggcgcttc aggactccct ccagcatctt atgaaagtac aggggaccat
1801 caagtggagg gaggaccaca ttgccataaa aagggtccctg aattctaaat tctggaagca
1861 cgtgaggtag caaatgcctg tgccaagcaa aattcccaga aaggcctcta gtttgactcc
1921 cttggctgcc cagaagcaat agtgccctgct gtgatgtgca aaggcatctg agtttgaagc
1981 tttcctgact tctcctagct ggcttatgac cctgcactga agtgtgagga gcaggaatat
2041 taaagggatt caggcctc

```

IL1RL1 cDNA Sequence 2 (SEQ ID NO: 3)

NM_003856 Homo sapiens interleukin 1 receptor-like 1 (IL1RL1), transcript variant 2, mRNA

```

1 gaggagggac ctacaaagac tggaaactat tcttagctcc gtcactgact ccaagttcat
61 cccctctgtc ttccagtttg gttgagatat aggtactctt tcccaactca gtcttgaaga
121 gtatcaccaa ctgcctcatg tgtggtgacc ttcactgtcg tatgccagtg actcatctgg
181 agtaatctca acaacgagtt accaataact gctcttgatt gataaacaga atgggggtttt
241 ggatcttagc aattctcaca attctcatgt attccacagc agcaaagttt agtaaacaa
301 catggggcct ggaaaatgag gcttttaattg taagatgtcc tagacaagga aaacctagtt
361 acaccgtgga ttggtattac tcacaaacaa acaaaaagta tcccactcag gaaagaaatc
421 gtgtgtttgc ctcaggccaa cttctgaagt ttctaccagc tgcagttgct gattctggta
481 tttatacctg tattgtcaga agtcccacat tcaataggac tggatatgcg aatgtcacca
541 tatataaaaa acaatcagat tgcaatgttc cagattattt gatgtattca acagtatctg
601 gatcagaaaa aaattccaaa atttattgtc ctaccattga cctctacaac tggacagcac
661 ctcttgatgt gtttaagaat tgtcaggctc ttcaaggatc aaggtagagg ggcgcacaag
721 catttttggg cattgataat gtgatgactg aggacgcagg tgattacacc tgtaaattta
781 tacacaatga aaatggagcc aattatagtg tgacggcgac caggctcctt acgggtcaagg
841 atgagcaagg cttttctctg ttccagtaa tcggagcccc tgcacaaaat gaaataaagg
901 aagtggaaat tggaaaaaac ctaaaccctaa cttgctctgc ttgttttggg aaaggcactc
961 agttcttggc tgccgtcctg tggcagctta atggaacaaa aattacagac tttggtgaac
1021 caagaattca acaagaggaa gggcaaaatc aaagtctcag caatgggctg gcttgtctag
1081 acatggtttt aagaatagct gacgtgaagg aagaggattt attgtctcag tacgactgtc
1141 tggccctgaa tttgcatggc ttgagaaggc acaccgtaag actaagtagg aaaaatccaa
1201 tgaaggagtg tttctgagac tttgatcacc tgaactttct ctgacaagtg taagcgaat
1261 ggagtgtggt tccaagagat ccatcaagac aatgggaatg gcctgtgcca taaaatgtgc
1321 ttctcttctt cgggatgttg tttgtctgtc gatctttgta gactgttctt gtttgcctgg
1381 agcttctctg ctgcttaaat tgttcgtcct ccccaactcc ctctatcgtg tggttgtctt
1441 agaactca gctgcttctt tggtcactct tgttttctaa ctttatgaac tccctctgtg

```

```

1501 t c a c t g t a t g   t g a a a g g a a a   t g c a c c a a c a   a c c g t a a a c t   g a a c g t g t t c   t t t t g t g c t c
1561 t t t t a t a a c t   t g c a t t a c a t   g t t g t a a g c a   t g g t c c g t t c   t a t a c c t t t t   t c t g g t c a t a
1621 a t g a a c a c t c   a t t t t g t t a g   c g a g g g t g g t   a a a g t g a a c a   a a a a g g g g a a   g t a t c a a a c t
1681 a c t g c c a t t t   c a g t g a g a a a   a t c c t a g g t g   c t a c t t t t a t   a t a a g a c a t t   t g t t a g g c c a
1741 t t c t t g c a t t   g a t a t a a a g a   a a t a c c t g a g   a c t g g g t g a t   t t a t a t g a a a   a g a g g t t t a a
1801 t t g g c t c a c a   g t t c t g c a g g   c t g t a t g g g a   a g c a t g g c g g   c a t c t g c t t c   t g g g g a c a c c
1861 t c a g g a g c t t   t a c t c a t g g c   a g a a g g c a a a   g c a a a g g c a g   g c a c t t c a c a   c a g t a a a a g c
1921 a g g a g c g a g a   g a g a g g t g c c   a c a c t g a a a c   a g c c a g a t c t   c a t g a g a a g t   c a c t c a c t a t
1981 t g c a a g g a c a   g c a t c a a a g a   g a t g g t g c t a   a a c c a t t c a t   g a t g a a c t c a   c c c c c a t g a t
2041 c c a a t c a c c t   c c c a c c a g g c   t c c a c c t c g a   a t a c t g g g g a   t t a c c a t t c a   g c a t g a g a t t
2101 t g g g c a g g a a   c a c a g a c c c a   a a c c a t a c c a   c a c a c a t t a t   c a t t g t t a a a   c t t t g t a a a g
2161 t a t t t a a g g t   a c a t g g a a c a   c a c g g g a a g t   c t g g t a g c t c   a g c c c a t t t c   t t t a t t g c a t
2221 c t g t t a t t c a   c c a t g t a a t t   c a g g t a c c a c   g t a t t c c a g g   g a g c c t t t c t   t g g c c c t c a g
2281 t t t g c a g t a t   a c a c a c t t t c   c a a g t a c t c t   t g t a g c a t c c   t g t t t g t a t c   a t a g c a c t g g
2341 t t c a c a t t g c c   t t a c c t a a a t   c t g t t t g a c a   g t c t g c t c a a   c a c g a c t g c a   a g c t c c a t g a
2401 g g g c a g g g a c   a t c a t c t c t t   c c a t c t t t g g   g t c c t t a g t g   c a a t a c c t g g   c a g c t a g c c a
2461 g t g c t c a g c t   a a a t a t t t g t   t g a c t g a a t a   a a t g a a t g c a   c a a c c a a a a a   a a a a a a a a a a
2521 a a a a a a a a a a   a a a a a a a a a a   a a

```

IL1RL1 cDNA Sequence 3 (SEQ ID NO: 4)

NM_173459 Homo sapiens interleukin 1 receptor-like 1 (IL1RL1), transcript variant 3, mRNA

```

1 g a g g a g g g a c   c t a c a a a g a c   t g g a a a c t a t   t c t t a g c t c c   g t c a c t g a c t   c c a a g t t c a t
61 c c c c t c t g t c   t t t c a g t t t g   g t t g a g a t a t   a g g c t a c t c t   t c c c a a c t c a   g t c t t g a a g a
121 g t a t c a c c a a   c t g c c t c a t g   t g t g g t g a c c   t t c a c t g t c g   t a t g c c a g t g   a c t c a t c t g g
181 a g t a a t c t c a   a c a a c a g a g t   a c c a a t a c t t   g c t c t t g a t t   g a t a a a c a g a   a t g g g g t t t t
241 g g a t c t t a g c   a a t t c t c a c a   a t t c t c a t g t   a t t c c a c a g c   a g c a a a g t t t   a g t a a a c a a t
301 c a t g g g g c c t   g g a a a a t g a g   g c t t t a a t t g   t a a g a t g t c c   t a g a c a a g g a   a a a c c t a g t t
361 a c a c c g t g g a   t t g g t a t t a c   t c a c a a a c a a   a c a a a a g t a t   t c c c a c t c a g   g a a a g a a a t c
421 g t g t g t t t g c   c t c a g g c c a a   c t t c t g a a g t   t t c t a c c a g c   t g c a g t t g c t   g a t t c t g g t a
481 t t t a t a c c t g   t a t t g t c a g a   a g t c c c a c a t   t c a a t a g g a c   t g g a t a t g c g   a a t g t c a c c a
541 t a t a t a a a a a   a c a a t c a g a t   t g c a a t g t t c   c a g a t t a t t t   g a t g t a t t c a   a c a g t a t c t g
601 g a t c a g a a a a   a a a t t c c a a a   a t t t a t t g t c   c t a c c a t t g a   c c t c t a c a a c   t g g a c a g c a c
661 c t c t t g a g t g   g t t t a a g a a t   t g t c a g g c t c   t t c a a g g a t c   a a g g t a c a g g   g c g c a c a a g t
721 c a t t t t t g g t   c a t t g a t a a t   g t g a t g a c t g   a g g a c g c a g g   t g a t t a c a c c   t g t a a a t t t a
781 t a c a c a a t g a   a a a t g g a g c c   a a t t a t a g t g   t g a c g g c g a c   c a g g t c c t t c   a c g g t c a a g g
841 t t t g g t g t c a   g a g t t t c t g c   a a a t t a a a a a   a g a g c t t a a t   c t t t a g t a a t   a c t c a t t g g a
901 t t c a a a g t c t   a a t g a g a g g c   t t t g t g a t g g   t a t a c t a t g g   t g t a c a t a a a   t g t t g t c g a g
961 t g g t t t t t a a   t c t t t g t t t g   c a a t a c t t t c   a a c a t c a t c a   a t g g c c t t g a   a t g a g c a a g g
1021 c t t t t c t c t g   t t t c c a g t a a   t c g g a g c c c c   t g c a c a a a a t   g a a a t a a a g g   a a g t g g a a a t
1081 t g g a a a a a a c   g c a a a c c t a a   c t t g c t c t g c   t t g t t t t g g a   a a a g g c a c t c   a g t t c t t g g c
1141 t g c c g t c c t g   t g g c a g c t t a   a t g g a a c a a a   a a t t a c a g a c   t t t g g t g a a c   c a a g a a t t c a
1201 a c a a g a g g a a   g g g c a a a a t c   a a a g t t t c a g   c a a t g g g c t g   g c t t g t c t a g   a c a t g g t t t t
1261 a a g a a t a g c t   g a c g t g a a g g   a a g a g g a t t t   a t t g c t g c a g   t a c g a c t g t c   t g g c c c t g a a
1321 t t t g c a t g g c   t t g a g a a g g c   a c a c c g t a a g   a c t a a g t a g g   a a a a a t c c a a   g t a a g g a g t g
1381 t t t c t g a g a c   t t t g a t c a c c   t g a a c t t t c t   c t a g c a a g t g   t a a g c a g a a t   g g a g t g t g g t
1441 t c c a a g a g a t   c c a t c a a g a c   a a t g g g a a t g   g c c t g t g c c a   t a a a a t g t g c   t t c t c t t c t t
1501 c g g g a t g t g   t t t g c t g t c t   g a t c t t t g t a   g a c t g t t c c t   g t t t g c t g g g   a g c t t c t c t g
1561 c t g c t t a a a t   t g t t c g t c c t   c c c c c a c t c c   c t c c t a t c g t   t g g t t t g t c t   a g a a c a c t c a
1621 g c t g c t t c t t   t g g t c a t c c t   t g t t t t c t a a   c t t t a t g a a c   t c c c t c t g t g   t c a c t g t a t g
1681 t g a a a g g a a a   t g c a c c a a c a   a c c g t a a a c t   g a a c g t g t t c   t t t t g t g c t c   t t t t a t a a c t
1741 t g c a t t a c a t   g t t g t a a g c a   t g g t c c g t t c   t a t a c c t t t t   t c t g g t c a t a   a t g a a c a c t c
1801 a t t t t g t t a g   c g a g g g t g g t   a a a g t g a a c a   a a a a g g g g a a   g t a t c a a a c t   a c t g c c a t t t
1861 c a g t g a g a a a   a t c c t a g g t g   c t a c t t t t a t   a t a a g a c a t t   t g t t a g g c c a   t t c t t g c a t t
1921 g a t a t a a a g a   a a t a c c t g a g   a c t g g g t g a t   t t a t a t g a a a   a g a g g t t t a a   t t g g c t c a c a
1981 g t t c t g c a g g   c t g t a t g g g a   a g c a t g g c g g   c a t c t g c t t c   t g g g g a c a c c   t c a g g a g c t t
2041 t a c t c a t g g c   a g a a g g c a a a   g c a a a g g c a g   g c a c t t c a c a   c a g t a a a a g c   a g g a g c g a g a
2101 g a g a g g t g c c   a c a c t g a a a c   a g c c a g a t c t   c a t g a g a a g t   c a c t c a c t a t   t g c a a g g a c a
2161 g c a t c a a a g a   g a t g g t g c t a   a a c c a t t c a t   g a t g a a c t c a   c c c c c a t g a t   c c a a t c a c c t
2221 c c c a c c a g g c   t c c a c c t c g a   a t a c t g g g g a   t t a c c a t t c a   g c a t g a g a t t   t g g g c a g g a a

```

```

2281 cacagaccca aaccatacca cacacattat cattgttaaa ctttgtaaag tatttaaggt
2341 acatggaaca cacgggaagt ctggtagctc agccatttc tttattgcat ctgttattca
2401 ccatgtaatt caggtaccac gtattccagg gagcctttct tggccctcag tttgcagtat
2461 acacactttc caagtactct tgtagcatcc tgtttgatc atagcactgg tcacattgcc
2521 ttacctaaat ctgtttgaca gtctgctcaa cacgactgca agctccatga gggcagggac
2581 atcatctctt ccatctttgg gtccttagtg caatacctgg cagctagcca gtgctcagct
2641 aaatatttgt tgactgaata aatgaatgca caacaaaaaa aaaaaaaaaa aaaaaaaaaa
2701 aaaaaaaaaa aa

```

[0252] Following are show human amino acid sequences for isoform 1, isoform 2 and isoform 3 of IL1RL1.

IL1RL1 Amino Acid Sequence 1 (SEQ ID NO: 5)

NP_057316 interleukin 1 receptor-like 1 isoform 1 precursor; interleukin 1 receptor-related protein; homolog of mouse growth stimulation-expressed gene; ST2 protein [Homo sapiens]

MGFWILAILTILMYSTAAKFSKQSWGLENEALIVRCPRQGKPSYTVDWYYSQTNKSIPT
QERNRVFASGQLLKFLPAAVADSGIYTCIVRSPTFNRTGYANVTIYKKQSDCNVPDYLM
YSTVSGSEKNSKIYCPTIDLYNWTAPLEWFKNCQALQGSRYRAHKSFLVIDNVMTEDA
GDYTCKFIHNENGANYSVTATRSFTVKDEQGFSLPVIGAPAQNEIKEVEIGKNANLTCS
ACFGKGTQFLAAVLWQLNGTKITDFGEPRIQQEEGQNQSFSNGLACLDMLVRIADVKE
EDLLLQYDCLALNLHGLRRHTVRLSRKNPIDHHSIYCHAVCSVFLMLINVLVIILKMFWI
EATLLWRDIAKPYKTRNDGKLYDAYVVYPRNYKSSTDGASRVEHFVHQILPDVLENKC
GYTLCIYGRDMLPGEDVVTAVETNIRKSRRHIFILTPQITHNKEFAYEQEVALHICALIQN
DAKVILIEMEALSELDMLQAEALQDSLQHLMKVQGTIKWREDHIANKRSLNSKFWKHV
RYQMPVPSKIPRKASSLTPLAAQKQ

IL1RL1 Amino Acid Sequence 2 (SEQ ID NO: 6)

NP_003847 interleukin 1 receptor-like 1 isoform 2 precursor; interleukin 1 receptor-related protein; homolog of mouse growth stimulation-expressed gene; ST2 protein [Homo sapiens]

MGFWILAILTILMYSTAAKFSKQSWGLENEALIVRCPRQGKPSYTVDWYYSQTNKSIPT
QERNRVFASGQLLKFLPAAVADSGIYTCIVRSPTFNRTGYANVTIYKKQSDCNVPDYLM
YSTVSGSEKNSKIYCPTIDLYNWTAPLEWFKNCQALQGSRYRAHKSFLVIDNVMTEDA
GDYTCKFIHNENGANYSVTATRSFTVKDEQGFSLPVIGAPAQNEIKEVEIGKNANLTCS
ACFGKGTQFLAAVLWQLNGTKITDFGEPRIQQEEGQNQSFSNGLACLDMLVRIADVKE
EDLLLQYDCLALNLHGLRRHTVRLSRKNPSKECF

IL1RL1 Amino Acid Sequence 3 (SEQ ID NO: 7)

NP_775661 interleukin 1 receptor-like 1 isoform 3 precursor; interleukin 1 receptor-related protein; homolog of mouse growth stimulation-expressed gene; ST2 protein [Homo sapiens]

MGFWILAILTILMYSTAAKFSKQSWGLENEALIVRCPRQGKPSYTVDWYYSQTNKSIPT
QERNRVFASGQLLKFLPAAVADSGIYTCIVRSPTFNRTGYANVTIYKKQSDCNVPDYLM
YSTVSGSEKNSKIYCPTIDLYNWTAPLEWFKNCQALQGSRYRAHKSFLVIDNVMTEDA

GDYTCKFIHNENGANYSVTATRSFTVKVWCQSFCCLKKSLIFSNTHWIQSLMRGFVMV
YYGVHKCCRNVFNLCLQYFQHHQWP

[0253] Modifications may be made to the foregoing without departing from the basic aspects of the invention. Although the invention has been described in substantial detail with reference to one or more specific embodiments, those of skill in the art will recognize that changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the invention, as set forth in the aspects which follow. All publications or patent documents cited in this specification are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference.

[0254] Citation of the above publications or documents is not intended as an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents. U.S. patents and other publications referenced herein are hereby incorporated by reference.



17236 U.S. PTO

040204

PTO/SB/16 (08-03)

Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EL 961008095 US

22151 U.S. PTO

60/559275



040204

INVENTOR(S)					
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)			
Steven	MAH	San Diego, California			
Andreas	BRAUN	San Diego, California			
Stefan M.	KAMMERER	San Diego, California			
Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number:		25225			
OR					
<input type="checkbox"/> Firm or Individual Name					
Address					
City		State		Zip	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/>	Specification Number of Pages	121	<input type="checkbox"/>	CD(s), Number	
<input checked="" type="checkbox"/>	Drawing(s) Number of Sheets	3	<input checked="" type="checkbox"/>	Other	Return Receipt Postcard
<input checked="" type="checkbox"/>	Application Data Sheet. See 37 CFR 1.76 (4 pages) (specify):				
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/>	Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$) 80.00
<input type="checkbox"/>	A check or money order is enclosed to cover the filing fees.				
<input checked="" type="checkbox"/>	The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 03-1952				
<input type="checkbox"/>	Payment by credit card. Form PTO-2038 is attached.				
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/>	No	<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:			

[Page 1 of 2]

Respectfully submitted,

Date April 1, 2004

SIGNATURE

TYPED OR

PRINTED NAME

Bruce D. Grant

REGISTRATION NO.

(if appropriate)

47,608

TELEPHONE

(858) 720-7962

Docket Number:

524593009000

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL 961008095 US, in an envelope addressed to: Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 4/1/04

Signature:

Deborah Wykes

(Deborah Wykes)

SD-189456

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (08-03)

Approved for use through 07/31/06. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number 524593009000

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Matthew Roberts	NELSON	San Marcos, California
Rikard Henry	RENELAND	San Diego, California
Maria L.	LANGDOWN	San Diego, California

[Page 2 of 2]